{"PMC5727246": [["IntroductionDecitabine is a cytosine analog with S\u2010phase\u2010dependent pharmacokinetics that is incorporated into DNA, but cannot be methylated 1, 2, 3.", [["IntroductionDecitabine", "CHEMICAL", 0, 22], ["cytosine", "CHEMICAL", 28, 36], ["S\u2010phase\u2010dependent", "CHEMICAL", 49, 66], ["IntroductionDecitabine", "CHEMICAL", 0, 22], ["cytosine", "CHEMICAL", 28, 36], ["IntroductionDecitabine", "SIMPLE_CHEMICAL", 0, 22], ["cytosine", "SIMPLE_CHEMICAL", 28, 36], ["S\u2010phase\u2010dependent", "SIMPLE_CHEMICAL", 49, 66], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["IntroductionDecitabine", "TREATMENT", 0, 22], ["a cytosine analog", "TREATMENT", 26, 43], ["S\u2010phase\u2010dependent pharmacokinetics", "TREATMENT", 49, 83]]], ["Historically, it has yielded clinical responses in ~25% of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) across diverse clinical trials, although response rates may be higher using a 10\u2010day versus 5\u2010day approach 4, 5, 6.", [["acute myeloid leukemia", "ANATOMY", 73, 95], ["AML", "ANATOMY", 97, 100], ["acute myeloid leukemia", "DISEASE", 73, 95], ["AML", "DISEASE", 97, 100], ["myelodysplastic syndromes", "DISEASE", 105, 130], ["MDS", "DISEASE", 132, 135], ["patients", "ORGANISM", 59, 67], ["acute myeloid leukemia", "CANCER", 73, 95], ["AML", "CANCER", 97, 100], ["patients", "SPECIES", 59, 67], ["acute myeloid leukemia", "PROBLEM", 73, 95], ["AML)", "PROBLEM", 97, 101], ["myelodysplastic syndromes", "PROBLEM", 105, 130], ["MDS)", "PROBLEM", 132, 136], ["response rates", "TEST", 178, 192], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["myeloid leukemia", "OBSERVATION", 79, 95], ["myelodysplastic syndromes", "OBSERVATION", 105, 130]]], ["In general, decitabine is well tolerated and can be given in the outpatient setting.IntroductionDecitabine treatment is associated with infection complications and readmission for neutropenic fevers 5, 7, 8.", [["decitabine", "CHEMICAL", 12, 22], ["IntroductionDecitabine", "CHEMICAL", 84, 106], ["infection", "DISEASE", 136, 145], ["fevers", "DISEASE", 192, 198], ["decitabine", "CHEMICAL", 12, 22], ["decitabine", "SIMPLE_CHEMICAL", 12, 22], ["decitabine", "TREATMENT", 12, 22], ["IntroductionDecitabine treatment", "TREATMENT", 84, 116], ["infection complications", "PROBLEM", 136, 159], ["neutropenic fevers", "PROBLEM", 180, 198], ["associated with", "UNCERTAINTY", 120, 135], ["infection", "OBSERVATION", 136, 145]]], ["Limited data exist concerning the types of infections that occur in AML and MDS patients treated with decitabine.IntroductionWe recently completed a study of AML and MDS patients treated with decitabine administered in 10 daily doses per cycle 5.", [["AML", "ANATOMY", 68, 71], ["AML", "ANATOMY", 158, 161], ["infections", "DISEASE", 43, 53], ["AML", "DISEASE", 68, 71], ["MDS", "DISEASE", 76, 79], ["decitabine", "CHEMICAL", 102, 112], ["AML", "DISEASE", 158, 161], ["MDS", "DISEASE", 166, 169], ["decitabine", "CHEMICAL", 192, 202], ["decitabine", "CHEMICAL", 102, 112], ["decitabine", "CHEMICAL", 192, 202], ["AML", "CANCER", 68, 71], ["patients", "ORGANISM", 80, 88], ["decitabine", "SIMPLE_CHEMICAL", 102, 112], ["AML", "CANCER", 158, 161], ["patients", "ORGANISM", 170, 178], ["decitabine", "SIMPLE_CHEMICAL", 192, 202], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 170, 178], ["infections", "PROBLEM", 43, 53], ["AML", "PROBLEM", 68, 71], ["decitabine", "TREATMENT", 102, 112], ["a study", "TEST", 147, 154], ["AML", "PROBLEM", 158, 161], ["decitabine", "TREATMENT", 192, 202], ["infections", "OBSERVATION", 43, 53]]], ["Similar to others 6, we observed modestly higher response rates using the 10\u2010day regimen (46%) versus published results from 5\u2010day regimens (17\u201332%) 8, 9, 10, 11, and the majority of Common Terminology Criteria for Adverse Events (CTCAE)\u2010defined significant adverse events (SAEs) we observed were associated with infectious complications and readmission for neutropenic fevers 5.", [["fevers", "DISEASE", 370, 376], ["the 10\u2010day regimen", "TREATMENT", 70, 88], ["Adverse Events", "PROBLEM", 215, 229], ["significant adverse events", "PROBLEM", 246, 272], ["infectious complications", "PROBLEM", 313, 337], ["neutropenic fevers", "PROBLEM", 358, 376], ["significant", "OBSERVATION_MODIFIER", 246, 257], ["infectious", "OBSERVATION_MODIFIER", 313, 323]]], ["We also observed that response correlated with the presence of mutations in TP535.IntroductionAntibiotic prophylaxis has been controversial during AML chemotherapy (for both decitabine and cytarabine\u2010based treatments), and the benefits of prophylaxis are unclear.IntroductionIn this study, we reviewed each infection\u2010related SAE observed among 85 patients to determine whether the infectious complications observed during decitabine treatment might be different from the complications of more intensive regimens, and whether specific bacteria were commonly observed that might be amenable to alternative prophylaxis.Study design ::: Patients and MethodsWe reviewed all CTCAE (version 4.0) grade 3\u20135 SAEs associated with infectious complications in 85 patients with AML or MDS who were enrolled between April 2013 and November 2015 on a clinical study at Washington University School of Medicine (NCT01687400) 5.", [["AML", "ANATOMY", 147, 150], ["AML", "ANATOMY", 765, 768], ["AML", "DISEASE", 147, 150], ["decitabine", "CHEMICAL", 174, 184], ["cytarabine", "CHEMICAL", 189, 199], ["SAE", "DISEASE", 325, 328], ["decitabine", "CHEMICAL", 422, 432], ["infectious complications", "DISEASE", 720, 744], ["AML", "DISEASE", 765, 768], ["MDS", "DISEASE", 772, 775], ["decitabine", "CHEMICAL", 174, 184], ["cytarabine", "CHEMICAL", 189, 199], ["decitabine", "CHEMICAL", 422, 432], ["TP535", "GENE_OR_GENE_PRODUCT", 76, 81], ["AML", "CANCER", 147, 150], ["decitabine", "SIMPLE_CHEMICAL", 174, 184], ["cytarabine", "SIMPLE_CHEMICAL", 189, 199], ["patients", "ORGANISM", 347, 355], ["decitabine", "SIMPLE_CHEMICAL", 422, 432], ["Patients", "ORGANISM", 633, 641], ["patients", "ORGANISM", 751, 759], ["AML", "CANCER", 765, 768], ["TP535", "PROTEIN", 76, 81], ["patients", "SPECIES", 347, 355], ["Patients", "SPECIES", 633, 641], ["patients", "SPECIES", 751, 759], ["mutations in TP535", "PROBLEM", 63, 81], ["IntroductionAntibiotic prophylaxis", "TREATMENT", 82, 116], ["AML chemotherapy", "TREATMENT", 147, 163], ["both decitabine", "TREATMENT", 169, 184], ["cytarabine\u2010based treatments", "TREATMENT", 189, 216], ["prophylaxis", "TREATMENT", 239, 250], ["this study", "TEST", 278, 288], ["the infectious complications", "PROBLEM", 377, 405], ["decitabine treatment", "TREATMENT", 422, 442], ["intensive regimens", "TREATMENT", 493, 511], ["specific bacteria", "PROBLEM", 525, 542], ["alternative prophylaxis", "TREATMENT", 592, 615], ["grade 3\u20135 SAEs", "PROBLEM", 689, 703], ["infectious complications", "PROBLEM", 720, 744], ["AML", "PROBLEM", 765, 768], ["MDS", "PROBLEM", 772, 775], ["infectious", "OBSERVATION_MODIFIER", 381, 391], ["infectious", "OBSERVATION_MODIFIER", 720, 730]]], ["Of these, 70 patients had infection\u2010related events with documented culture results that could be retrospectively evaluated.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["infection\u2010related events", "PROBLEM", 26, 50], ["documented culture", "TEST", 56, 74]]], ["This study was approved by our institutional review board and conducted in accordance with the provisions of the Declaration of Helsinki.", [["This study", "TEST", 0, 10]]], ["Response evaluation and molecular end\u2010points have been previously published 5.Treatment ::: Patients and MethodsDecitabine was administered intravenously at a dose of 20 mg/m2 of body surface area per day in 28\u2010day cycles.", [["intravenously", "ANATOMY", 140, 153], ["body surface area", "ANATOMY", 179, 196], ["MethodsDecitabine", "CHEMICAL", 105, 122], ["Patients", "ORGANISM", 92, 100], ["MethodsDecitabine", "SIMPLE_CHEMICAL", 105, 122], ["body", "ORGANISM_SUBDIVISION", 179, 183], ["Patients", "SPECIES", 92, 100], ["Response evaluation", "TEST", 0, 19], ["MethodsDecitabine", "TREATMENT", 105, 122]]], ["Once patients achieved blasts <5%, they could reduce the dosing to days 1\u20135.", [["blasts", "ANATOMY", 23, 29], ["patients", "ORGANISM", 5, 13], ["blasts", "CELL", 23, 29], ["blasts", "CELL_TYPE", 23, 29], ["patients", "SPECIES", 5, 13], ["blasts", "TEST", 23, 29]]], ["After two cycles with dosing on days 1\u20135, the dose could be reduced further to days 1\u20133.Antimicrobial therapy ::: Patients and MethodsProphylactic antimicrobial therapy was recommended, but not stipulated as part of the study.", [["Patients", "ORGANISM", 114, 122], ["Patients", "SPECIES", 114, 122], ["Antimicrobial therapy", "TREATMENT", 88, 109], ["MethodsProphylactic antimicrobial therapy", "TREATMENT", 127, 168], ["the study", "TEST", 216, 225]]], ["Recommended prophylaxis consisted of acyclovir, ciprofloxacin, and fluconazole.", [["acyclovir", "CHEMICAL", 37, 46], ["ciprofloxacin", "CHEMICAL", 48, 61], ["fluconazole", "CHEMICAL", 67, 78], ["acyclovir", "CHEMICAL", 37, 46], ["ciprofloxacin", "CHEMICAL", 48, 61], ["fluconazole", "CHEMICAL", 67, 78], ["acyclovir", "SIMPLE_CHEMICAL", 37, 46], ["ciprofloxacin", "SIMPLE_CHEMICAL", 48, 61], ["fluconazole", "SIMPLE_CHEMICAL", 67, 78], ["prophylaxis", "TREATMENT", 12, 23], ["acyclovir", "TREATMENT", 37, 46], ["ciprofloxacin", "TREATMENT", 48, 61], ["fluconazole", "TREATMENT", 67, 78]]], ["Patients who developed infection\u2010related complications were treated with antimicrobial and supportive therapy according to commonly accepted guidelines.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["infection\u2010related complications", "PROBLEM", 23, 54], ["antimicrobial", "TREATMENT", 73, 86], ["supportive therapy", "TREATMENT", 91, 109]]], ["The diagnostic work\u2010up in case of fever included collection of blood cultures from central venous catheters and peripheral vein and collection of nasal, pharyngeal, and anal swab.", [["blood", "ANATOMY", 63, 68], ["central venous", "ANATOMY", 83, 97], ["peripheral vein", "ANATOMY", 112, 127], ["nasal", "ANATOMY", 146, 151], ["pharyngeal", "ANATOMY", 153, 163], ["anal swab", "ANATOMY", 169, 178], ["fever", "DISEASE", 34, 39], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["central venous catheters", "MULTI-TISSUE_STRUCTURE", 83, 107], ["peripheral vein", "MULTI-TISSUE_STRUCTURE", 112, 127], ["nasal", "ORGANISM_SUBDIVISION", 146, 151], ["pharyngeal", "ORGANISM_SUBDIVISION", 153, 163], ["anal swab", "ORGAN", 169, 178], ["The diagnostic work\u2010up", "TEST", 0, 22], ["fever", "PROBLEM", 34, 39], ["collection of blood cultures", "TEST", 49, 77], ["central venous catheters", "TREATMENT", 83, 107], ["peripheral vein", "TREATMENT", 112, 127], ["collection of nasal, pharyngeal, and anal swab", "TEST", 132, 178], ["central", "ANATOMY_MODIFIER", 83, 90], ["venous", "ANATOMY", 91, 97], ["catheters", "OBSERVATION", 98, 107], ["peripheral vein", "ANATOMY", 112, 127], ["nasal", "ANATOMY", 146, 151], ["pharyngeal", "ANATOMY", 153, 163], ["anal swab", "ANATOMY", 169, 178]]], ["Standard chest radiographs were obtained at hospital admission and if clinically indicated.", [["chest", "ANATOMY", 9, 14], ["Standard chest radiographs", "TEST", 0, 26], ["chest", "ANATOMY", 9, 14]]], ["Cytomegalovirus (CMV) reactivation was not routinely tested.", [["Cytomegalovirus (CMV) reactivation", "DISEASE", 0, 34], ["Cytomegalovirus", "ORGANISM", 0, 15], ["CMV", "ORGANISM", 17, 20], ["CMV", "SPECIES", 17, 20], ["Cytomegalovirus (CMV) reactivation", "PROBLEM", 0, 34]]], ["Prompt empiric first\u2010line therapies consisted of cephalosporin, penicillin, or carbapenem antibiotics.", [["cephalosporin", "CHEMICAL", 49, 62], ["penicillin", "CHEMICAL", 64, 74], ["carbapenem", "CHEMICAL", 79, 89], ["cephalosporin", "CHEMICAL", 49, 62], ["penicillin", "CHEMICAL", 64, 74], ["carbapenem", "CHEMICAL", 79, 89], ["cephalosporin", "SIMPLE_CHEMICAL", 49, 62], ["penicillin", "SIMPLE_CHEMICAL", 64, 74], ["carbapenem antibiotics", "SIMPLE_CHEMICAL", 79, 101], ["Prompt empiric first\u2010line therapies", "TREATMENT", 0, 35], ["cephalosporin", "TREATMENT", 49, 62], ["penicillin", "TREATMENT", 64, 74], ["carbapenem antibiotics", "TREATMENT", 79, 101]]], ["Vancomycin was added if fever persisted for 48\u201372 h and at least one of the following clinical findings was met: clinically suspected serious catheter\u2010related infections, known colonization with penicillin\u2010 and cephalosporin\u2010resistant pneumococci or methicillin\u2010resistant Staphylococcus aureus, positive blood cultures for gram\u2010positive bacteria before the final identification, hypotension or other evidence of cardiovascular impairment.", [["blood", "ANATOMY", 304, 309], ["cardiovascular", "ANATOMY", 412, 426], ["Vancomycin", "CHEMICAL", 0, 10], ["fever", "DISEASE", 24, 29], ["infections", "DISEASE", 159, 169], ["penicillin\u2010", "CHEMICAL", 195, 206], ["Staphylococcus aureus", "DISEASE", 272, 293], ["hypotension", "DISEASE", 379, 390], ["cardiovascular impairment", "DISEASE", 412, 437], ["Vancomycin", "CHEMICAL", 0, 10], ["penicillin\u2010", "CHEMICAL", 195, 206], ["Vancomycin", "SIMPLE_CHEMICAL", 0, 10], ["penicillin\u2010", "SIMPLE_CHEMICAL", 195, 206], ["methicillin\u2010resistant Staphylococcus aureus", "ORGANISM", 250, 293], ["blood", "ORGANISM_SUBSTANCE", 304, 309], ["cardiovascular", "ANATOMICAL_SYSTEM", 412, 426], ["Staphylococcus aureus", "SPECIES", 272, 293], ["Staphylococcus aureus", "SPECIES", 272, 293], ["Vancomycin", "TREATMENT", 0, 10], ["fever", "PROBLEM", 24, 29], ["serious catheter\u2010related infections", "PROBLEM", 134, 169], ["known colonization", "PROBLEM", 171, 189], ["penicillin\u2010", "TREATMENT", 195, 206], ["cephalosporin\u2010resistant pneumococci", "PROBLEM", 211, 246], ["methicillin\u2010resistant Staphylococcus aureus", "PROBLEM", 250, 293], ["positive blood cultures", "PROBLEM", 295, 318], ["gram\u2010positive bacteria", "PROBLEM", 323, 345], ["the final identification", "TEST", 353, 377], ["hypotension", "PROBLEM", 379, 390], ["cardiovascular impairment", "PROBLEM", 412, 437], ["infections", "OBSERVATION", 159, 169], ["Staphylococcus aureus", "OBSERVATION", 272, 293], ["cardiovascular", "ANATOMY", 412, 426], ["impairment", "OBSERVATION", 427, 437]]], ["An azole or echinocandin was given empirically if the patient did not respond to antibiotic therapy within 5\u20137 days.", [["azole", "CHEMICAL", 3, 8], ["echinocandin", "CHEMICAL", 12, 24], ["azole", "CHEMICAL", 3, 8], ["echinocandin", "CHEMICAL", 12, 24], ["azole", "SIMPLE_CHEMICAL", 3, 8], ["echinocandin", "SIMPLE_CHEMICAL", 12, 24], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["An azole", "TREATMENT", 0, 8], ["echinocandin", "TREATMENT", 12, 24], ["antibiotic therapy", "TREATMENT", 81, 99]]], ["Modifications of the antibiotic therapy were made on the basis of results of cultures and susceptibilities of microorganisms to antimicrobial agents.Assessment of infection incidence and outcome ::: Patients and MethodsEach recorded infection\u2010related serious adverse event was reviewed.", [["infection", "DISEASE", 163, 172], ["Patients", "ORGANISM", 199, 207], ["Patients", "SPECIES", 199, 207], ["the antibiotic therapy", "TREATMENT", 17, 39], ["cultures", "TEST", 77, 85], ["microorganisms", "PROBLEM", 110, 124], ["antimicrobial agents", "TREATMENT", 128, 148], ["serious adverse event", "PROBLEM", 251, 272], ["infection", "OBSERVATION", 163, 172]]], ["Fever was considered as a single temperature measurement of 38.4\u00b0C or 38.0\u00b0C over at least 1 h, in the absence of obvious environmental causes.Assessment of infection incidence and outcome ::: Patients and MethodsNeutropenia was defined as an absolute neutrophil count (ANC) less than 1.0 \u00d7 109/L. ANC was further categorized according to whether they were <0.5 \u00d7 109/L or <0.1 \u00d7 109/L at the onset of febrile episodes.Assessment of infection incidence and outcome ::: Patients and MethodsThe causative agent, when identified, was classified as bacterial (gram\u2010positive, gram\u2010negative, or mycobacterial), fungal (Candida species, Aspergillus species, or other), or viral (varicella zoster virus, herpes simplex virus [HSV]).Assessment of infection incidence and outcome ::: Patients and MethodsThe site of infection was classified as blood (bacteremia), skin and/or soft tissues, catheter\u2010related blood stream infection, gastrointestinal (GI) tract, upper respiratory tract (pharyngitis, sinusitis, rhinitis), lower respiratory tract (pneumonia or bronchitis), urinary tract or joint/bone (septic arthritis, osteomyelitis).Assessment of infection incidence and outcome ::: Patients and MethodsThe outcome of infections for each patient was determined at the completion of the antimicrobial therapy.", [["neutrophil", "ANATOMY", 252, 262], ["blood", "ANATOMY", 834, 839], ["skin", "ANATOMY", 854, 858], ["soft tissues", "ANATOMY", 866, 878], ["blood", "ANATOMY", 897, 902], ["gastrointestinal", "ANATOMY", 921, 937], ["GI", "ANATOMY", 939, 941], ["upper respiratory tract", "ANATOMY", 950, 973], ["lower respiratory tract", "ANATOMY", 1010, 1033], ["urinary tract", "ANATOMY", 1061, 1074], ["joint", "ANATOMY", 1078, 1083], ["bone", "ANATOMY", 1084, 1088], ["Fever", "DISEASE", 0, 5], ["infection", "DISEASE", 157, 166], ["Neutropenia", "DISEASE", 213, 224], ["febrile episodes", "DISEASE", 402, 418], ["infection", "DISEASE", 433, 442], ["varicella zoster", "DISEASE", 672, 688], ["herpes simplex virus", "DISEASE", 696, 716], ["infection", "DISEASE", 738, 747], ["infection", "DISEASE", 806, 815], ["bacteremia", "DISEASE", 841, 851], ["blood stream infection", "DISEASE", 897, 919], ["gastrointestinal (GI) tract, upper respiratory tract", "DISEASE", 921, 973], ["pharyngitis", "DISEASE", 975, 986], ["sinusitis", "DISEASE", 988, 997], ["rhinitis", "DISEASE", 999, 1007], ["lower respiratory tract", "DISEASE", 1010, 1033], ["pneumonia", "DISEASE", 1035, 1044], ["bronchitis", "DISEASE", 1048, 1058], ["septic arthritis", "DISEASE", 1090, 1106], ["osteomyelitis", "DISEASE", 1108, 1121], ["infection", "DISEASE", 1137, 1146], ["infections", "DISEASE", 1208, 1218], ["Patients", "ORGANISM", 193, 201], ["neutrophil", "CELL", 252, 262], ["Patients", "ORGANISM", 469, 477], ["Candida species", "ORGANISM", 613, 628], ["Aspergillus species", "ORGANISM", 630, 649], ["varicella zoster virus", "ORGANISM", 672, 694], ["herpes simplex virus", "ORGANISM", 696, 716], ["HSV", "ORGANISM", 718, 721], ["Patients", "ORGANISM", 774, 782], ["blood", "ORGANISM_SUBSTANCE", 834, 839], ["skin", "ORGAN", 854, 858], ["soft tissues", "TISSUE", 866, 878], ["blood", "ORGANISM_SUBSTANCE", 897, 902], ["gastrointestinal", "ORGANISM_SUBDIVISION", 921, 937], ["tract", "ORGANISM_SUBDIVISION", 943, 948], ["upper respiratory", "ORGANISM_SUBDIVISION", 950, 967], ["tract", "ORGANISM_SUBDIVISION", 968, 973], ["lower", "ORGANISM_SUBDIVISION", 1010, 1015], ["respiratory tract", "ORGANISM_SUBDIVISION", 1016, 1033], ["urinary tract", "ORGANISM_SUBDIVISION", 1061, 1074], ["joint", "MULTI-TISSUE_STRUCTURE", 1078, 1083], ["bone", "TISSUE", 1084, 1088], ["Patients", "ORGANISM", 1173, 1181], ["patient", "ORGANISM", 1228, 1235], ["Patients", "SPECIES", 193, 201], ["Patients", "SPECIES", 469, 477], ["varicella zoster virus", "SPECIES", 672, 694], ["herpes simplex virus", "SPECIES", 696, 716], ["Patients", "SPECIES", 774, 782], ["Patients", "SPECIES", 1173, 1181], ["patient", "SPECIES", 1228, 1235], ["varicella zoster virus", "SPECIES", 672, 694], ["herpes simplex virus", "SPECIES", 696, 716], ["HSV", "SPECIES", 718, 721], ["Fever", "PROBLEM", 0, 5], ["a single temperature measurement", "TEST", 24, 56], ["MethodsNeutropenia", "PROBLEM", 206, 224], ["an absolute neutrophil count", "TEST", 240, 268], ["ANC", "TEST", 270, 273], ["ANC", "TEST", 298, 301], ["febrile episodes", "PROBLEM", 402, 418], ["bacterial (gram\u2010positive, gram\u2010negative", "PROBLEM", 545, 584], ["mycobacterial)", "PROBLEM", 589, 603], ["fungal (Candida species", "PROBLEM", 605, 628], ["Aspergillus species", "PROBLEM", 630, 649], ["viral (varicella zoster virus", "PROBLEM", 665, 694], ["herpes simplex virus", "PROBLEM", 696, 716], ["infection", "PROBLEM", 806, 815], ["blood (bacteremia", "PROBLEM", 834, 851], ["skin and/or soft tissues", "PROBLEM", 854, 878], ["catheter\u2010related blood stream infection", "PROBLEM", 880, 919], ["gastrointestinal (GI) tract", "PROBLEM", 921, 948], ["upper respiratory tract", "PROBLEM", 950, 973], ["pharyngitis", "PROBLEM", 975, 986], ["sinusitis", "PROBLEM", 988, 997], ["rhinitis", "PROBLEM", 999, 1007], ["lower respiratory tract (pneumonia", "PROBLEM", 1010, 1044], ["bronchitis", "PROBLEM", 1048, 1058], ["urinary tract", "PROBLEM", 1061, 1074], ["joint/bone (septic arthritis", "PROBLEM", 1078, 1106], ["osteomyelitis", "PROBLEM", 1108, 1121], ["infections", "PROBLEM", 1208, 1218], ["the antimicrobial therapy", "TREATMENT", 1272, 1297], ["obvious", "OBSERVATION_MODIFIER", 114, 121], ["environmental causes", "OBSERVATION", 122, 142], ["infection", "OBSERVATION", 157, 166], ["Neutropenia", "OBSERVATION", 213, 224], ["neutrophil count", "OBSERVATION", 252, 268], ["febrile", "OBSERVATION_MODIFIER", 402, 409], ["infection", "OBSERVATION", 433, 442], ["varicella zoster", "OBSERVATION", 672, 688], ["infection", "OBSERVATION", 738, 747], ["infection", "OBSERVATION", 806, 815], ["bacteremia", "OBSERVATION", 841, 851], ["skin", "ANATOMY", 854, 858], ["soft tissues", "ANATOMY", 866, 878], ["stream", "OBSERVATION_MODIFIER", 903, 909], ["infection", "OBSERVATION", 910, 919], ["gastrointestinal", "ANATOMY", 921, 937], ["upper", "ANATOMY_MODIFIER", 950, 955], ["respiratory tract", "ANATOMY", 956, 973], ["pharyngitis", "OBSERVATION", 975, 986], ["sinusitis", "OBSERVATION", 988, 997], ["rhinitis", "OBSERVATION", 999, 1007], ["lower", "ANATOMY_MODIFIER", 1010, 1015], ["respiratory tract", "ANATOMY", 1016, 1033], ["pneumonia", "OBSERVATION", 1035, 1044], ["bronchitis", "OBSERVATION", 1048, 1058], ["urinary tract", "ANATOMY", 1061, 1074], ["joint", "ANATOMY", 1078, 1083], ["bone", "ANATOMY", 1084, 1088], ["septic arthritis", "OBSERVATION", 1090, 1106], ["osteomyelitis", "OBSERVATION", 1108, 1121], ["infection", "OBSERVATION", 1137, 1146], ["infections", "OBSERVATION", 1208, 1218]]], ["All patients who died of infection were considered a failure.Statistical analysis ::: Patients and MethodsData were analyzed through November 2016.", [["infection", "DISEASE", 25, 34], ["patients", "ORGANISM", 4, 12], ["Patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 4, 12], ["Patients", "SPECIES", 86, 94], ["infection", "PROBLEM", 25, 34], ["a failure", "PROBLEM", 51, 60], ["infection", "OBSERVATION", 25, 34], ["failure", "OBSERVATION", 53, 60]]], ["Statistical analysis was performed using SPSS program, version 24 (IBM, Chicago, IL).", [["Statistical analysis", "TEST", 0, 20], ["SPSS program", "TEST", 41, 53], ["version", "TEST", 55, 62]]], ["Univariate analysis (Fisher exact test and Pearson chi\u2010square T\u2010test) was used for assessment of infection incidence.", [["infection", "DISEASE", 97, 106], ["Univariate analysis", "TEST", 0, 19], ["Fisher exact test", "TEST", 21, 38], ["infection incidence", "PROBLEM", 97, 116], ["infection", "OBSERVATION", 97, 106]]], ["The distribution of overall survival was described using Kaplan\u2013Meier curves and compared by log\u2010rank test.", [["Meier curves", "TEST", 64, 76], ["log\u2010rank test", "TEST", 93, 106], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["overall", "OBSERVATION_MODIFIER", 20, 27], ["survival", "OBSERVATION", 28, 36]]], ["Survival analysis was performed using Prism 5 (GraphPad, San Diego, CA).Patients ::: ResultsA total number of 282 cycles of decitabine were administered to 85 patients with AML or MDS (Table 1).", [["AML", "ANATOMY", 173, 176], ["decitabine", "CHEMICAL", 124, 134], ["AML", "DISEASE", 173, 176], ["MDS", "DISEASE", 180, 183], ["decitabine", "CHEMICAL", 124, 134], ["Patients", "ORGANISM", 72, 80], ["decitabine", "SIMPLE_CHEMICAL", 124, 134], ["patients", "ORGANISM", 159, 167], ["AML", "CANCER", 173, 176], ["Patients", "SPECIES", 72, 80], ["patients", "SPECIES", 159, 167], ["Survival analysis", "TEST", 0, 17], ["Prism", "TEST", 38, 43], ["decitabine", "TREATMENT", 124, 134], ["AML", "PROBLEM", 173, 176]]], ["Fifty patients were males (58.8%) and 35 were females (41.2%).", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["The median age of the patient population was 74 years (range: 31\u201389 years).", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29]]], ["The median number of cycles received was 2 (range 0.5\u201317).", [["median", "OBSERVATION_MODIFIER", 4, 10]]], ["Two hundred and forty\u2010eight hospital admissions following the administration of decitabine were reviewed.", [["decitabine", "CHEMICAL", 80, 90], ["decitabine", "CHEMICAL", 80, 90], ["decitabine", "SIMPLE_CHEMICAL", 80, 90], ["decitabine", "TREATMENT", 80, 90]]], ["Of these admissions, 65.7% were for febrile episodes or infections (total of 163 admissions).", [["febrile episodes", "DISEASE", 36, 52], ["infections", "DISEASE", 56, 66], ["febrile episodes", "PROBLEM", 36, 52], ["infections", "PROBLEM", 56, 66]]], ["The clinical features of patients with and without infection\u2010related events are shown in Table 1.Effect of clinical factors ::: ResultsClinical features were correlated with the incidence of infection\u2010related SAEs (gender, age, performance status, disease, response, and cycles completed).", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["infection\u2010related events", "PROBLEM", 51, 75], ["infection\u2010related SAEs", "PROBLEM", 191, 213], ["disease", "PROBLEM", 248, 255]]], ["The median and the mode number of infection\u2010related SAEs per patient in each subgroup was 1 (Table 1).Effect of clinical factors ::: ResultsThe incidence of infection\u2010related SAEs was correlated with the cycle number (Fig. 1A).", [["SAEs", "DISEASE", 52, 56], ["SAEs", "DISEASE", 175, 179], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["infection\u2010related SAEs", "PROBLEM", 34, 56], ["infection\u2010related SAEs", "PROBLEM", 157, 179], ["mode", "OBSERVATION_MODIFIER", 19, 23], ["number", "OBSERVATION_MODIFIER", 24, 30]]], ["On average, within each cycle, approximately one third of patients receiving that cycle experienced an infection\u2010related SAE, and we observed no consistent reduction in incidence during higher numbered cycles (i.e., cycles 4\u20139).", [["SAE", "DISEASE", 121, 124], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["an infection\u2010related SAE", "PROBLEM", 100, 124], ["average", "OBSERVATION_MODIFIER", 3, 10], ["no consistent", "UNCERTAINTY", 142, 155], ["reduction", "OBSERVATION_MODIFIER", 156, 165]]], ["Counterintuitively, patients without an infection\u2010related SAE had shorter survival (median 104 days vs. 446, 354, and 318 days for patients with 0, 1, 2, or 3 or more SAEs, respectively), perhaps because they did not remain on therapy long enough to experience a complication (Fig. 1B).Effect of clinical factors ::: ResultsIn a univariate analysis comparing patients who had no infections versus those who had one or more, patients with younger age (age <70) tended to have a higher incidence of infections.", [["SAE", "DISEASE", 58, 61], ["infections", "DISEASE", 379, 389], ["infections", "DISEASE", 497, 507], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 359, 367], ["patients", "ORGANISM", 424, 432], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 359, 367], ["patients", "SPECIES", 424, 432], ["an infection\u2010related SAE", "PROBLEM", 37, 61], ["therapy", "TREATMENT", 227, 234], ["a complication", "PROBLEM", 261, 275], ["a univariate analysis", "TEST", 327, 348], ["infections", "PROBLEM", 379, 389], ["infections", "PROBLEM", 497, 507], ["infections", "OBSERVATION", 497, 507]]], ["However, older patients had shorter survival, and this may account for the disproportionate number of older patients without an infection\u2010related event (Fig. 1C).", [["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 108, 116], ["an infection\u2010related event", "PROBLEM", 125, 151], ["may account for", "UNCERTAINTY", 55, 70]]], ["Nevertheless, the difference in infection incidence between the two groups (>70 vs. <70) did not reach a statistical significance (P = 0.129).", [["infection", "DISEASE", 32, 41], ["infection", "PROBLEM", 32, 41], ["infection", "OBSERVATION", 32, 41]]], ["Likewise, compared to infections incidence in AML patients (77.5%), a higher incidence of infections was noted in MDS patients (96.3%, P = 0.032).", [["AML", "ANATOMY", 46, 49], ["infections", "DISEASE", 22, 32], ["AML", "DISEASE", 46, 49], ["infections", "DISEASE", 90, 100], ["MDS", "DISEASE", 114, 117], ["AML", "CANCER", 46, 49], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 118, 126], ["infections", "PROBLEM", 90, 100], ["P", "TEST", 135, 136], ["AML", "OBSERVATION", 46, 49], ["infections", "OBSERVATION", 90, 100]]], ["However, AML patients also had shorter survival compared with MDS patients (Fig. 1D).", [["AML", "ANATOMY", 9, 12], ["AML", "DISEASE", 9, 12], ["MDS", "DISEASE", 62, 65], ["AML", "CANCER", 9, 12], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 66, 74], ["AML", "OBSERVATION", 9, 12]]], ["Therefore, patients who lived longer and had more therapy tended to have more infection episodes, although developing multiple infections did not affect the overall survival compared to patients who only experienced one or two infections (Fig. 1B).Effect of clinical factors ::: ResultsBlood count results were prospectively recorded on day 0, cycle 1 day 10 (C1D10), cycle 1 day 28 (C1D28), and at the end of even cycles.", [["Blood", "ANATOMY", 286, 291], ["infection", "DISEASE", 78, 87], ["infections", "DISEASE", 127, 137], ["infections", "DISEASE", 227, 237], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 186, 194], ["Blood", "ORGANISM_SUBSTANCE", 286, 291], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 186, 194], ["more infection episodes", "PROBLEM", 73, 96], ["multiple infections", "PROBLEM", 118, 137], ["two infections", "PROBLEM", 223, 237], ["Blood count", "TEST", 286, 297], ["infection", "OBSERVATION", 78, 87], ["multiple", "OBSERVATION_MODIFIER", 118, 126], ["infections", "OBSERVATION", 127, 137], ["infections", "OBSERVATION", 227, 237]]], ["Neutropenia was common across all time\u2010points (Fig. 1E).", [["Neutropenia", "DISEASE", 0, 11], ["Neutropenia", "PROBLEM", 0, 11]]], ["In total, 23%, 60%, and 69% of patients had an ANC <0.1, <0.5, and <1.0 at two or more measurements, respectively.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["an ANC", "TEST", 44, 50]]], ["At the time of each infection\u2010related SAE, the ANC was retrospectively assessed.", [["SAE", "DISEASE", 38, 41], ["the ANC", "TEST", 43, 50]]], ["The majority of patients had neutropenia with ANC <1.0 \u00d7 109/L (88.6%), or ANC <0.5 \u00d7 109/L (83%) at the onset of infection, and more than half of the patients (60.3%) presented with ANC <0.1 \u00d7 109/L (Fig. 1F).Effect of clinical factors ::: ResultsFor each event, the recorded admission for antibacterial, antiviral, and antifungal prophylactic agents were reviewed (Table 2).", [["neutropenia", "DISEASE", 29, 40], ["infection", "DISEASE", 114, 123], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 151, 159], ["neutropenia", "PROBLEM", 29, 40], ["ANC", "TEST", 46, 49], ["ANC", "TEST", 75, 78], ["infection", "PROBLEM", 114, 123], ["ANC", "TEST", 183, 186], ["antibacterial", "TREATMENT", 291, 304], ["antiviral", "TREATMENT", 306, 315], ["antifungal prophylactic agents", "TREATMENT", 321, 351], ["neutropenia", "OBSERVATION", 29, 40], ["infection", "OBSERVATION", 114, 123]]], ["In the majority of admissions (74.8%, 122 of 163), the patients were documented as receiving antiviral prophylaxis.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["antiviral prophylaxis", "TREATMENT", 93, 114], ["antiviral prophylaxis", "OBSERVATION", 93, 114]]], ["Fewer patients were documented as receiving antibacterial (54%) or antifungal prophylaxis (41.7%).", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["antibacterial", "TREATMENT", 44, 57], ["antifungal prophylaxis", "TREATMENT", 67, 89]]], ["Of the admissions where patients were already receiving antibacterial prophylaxis, only 30% (27 of 90) had positive cultures for bacteria.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["antibacterial prophylaxis", "TREATMENT", 56, 81], ["positive cultures", "PROBLEM", 107, 124], ["bacteria", "PROBLEM", 129, 137]]], ["In contrast, positive cultures were noted in 42.8% (33 of 77) of the admissions of patients with no antibacterial prophylaxis (P value: 0.08).", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["positive cultures", "TEST", 13, 30], ["antibacterial prophylaxis", "TREATMENT", 100, 125], ["P value", "TEST", 127, 134]]], ["Furthermore, two of the six positive cultures for fungi occurred in the setting of antifungal prophylaxis and five of the eight viral infections occurred in patients receiving antiviral prophylaxis (parainfluenza, HSV and rhinovirus/enterovirus).Causative agent ::: ResultsIn 55.2% of the admissions (90 of 163), a clinically suspected infection was associated with negative culture results.", [["viral infections", "DISEASE", 128, 144], ["parainfluenza, HSV and rhinovirus/enterovirus)", "DISEASE", 199, 245], ["infection", "DISEASE", 336, 345], ["patients", "ORGANISM", 157, 165], ["parainfluenza", "ORGANISM", 199, 212], ["HSV", "ORGANISM", 214, 217], ["rhinovirus", "ORGANISM", 222, 232], ["enterovirus", "ORGANISM", 233, 244], ["patients", "SPECIES", 157, 165], ["parainfluenza", "SPECIES", 199, 212], ["HSV", "SPECIES", 214, 217], ["the six positive cultures", "TEST", 20, 45], ["fungi", "PROBLEM", 50, 55], ["antifungal prophylaxis", "TREATMENT", 83, 105], ["the eight viral infections", "PROBLEM", 118, 144], ["antiviral prophylaxis", "TREATMENT", 176, 197], ["parainfluenza", "PROBLEM", 199, 212], ["HSV", "PROBLEM", 214, 217], ["rhinovirus", "PROBLEM", 222, 232], ["enterovirus", "PROBLEM", 233, 244], ["ResultsIn", "TEST", 266, 275], ["a clinically suspected infection", "PROBLEM", 313, 345], ["antifungal prophylaxis", "OBSERVATION", 83, 105], ["infections", "OBSERVATION", 134, 144], ["infection", "OBSERVATION", 336, 345]]], ["A causative agent of infection was documented in 73 (44.8%) of 163 admissions: gram\u2010positive infections in 32 (19.6% of total admissions), 20 (12.3%) were gram\u2010negative, 12 (7.4%) of admissions were associated with mixed infections (two or more different pathogens), 6 (3.7%) were viral, two (1.2%) were fungal, and 1 (0.6%) was mycobacterial.", [["infection", "DISEASE", 21, 30], ["infections", "DISEASE", 93, 103], ["infections", "DISEASE", 221, 231], ["A causative agent of infection", "PROBLEM", 0, 30], ["gram\u2010positive infections", "PROBLEM", 79, 103], ["gram\u2010negative", "TEST", 155, 168], ["mixed infections", "PROBLEM", 215, 231], ["viral", "TEST", 281, 286], ["fungal", "TEST", 304, 310], ["mycobacterial", "PROBLEM", 329, 342], ["infection", "OBSERVATION", 21, 30], ["infections", "OBSERVATION", 93, 103], ["mixed", "OBSERVATION_MODIFIER", 215, 220], ["infections", "OBSERVATION", 221, 231]]], ["A total number of 91 pathogens were retrieved from the infectious diagnostic workups (cultures, swabs, etc. that were performed in these 73 admissions) (Table 3).", [["swabs", "ANATOMY", 96, 101], ["91 pathogens", "PROBLEM", 18, 30], ["the infectious diagnostic workups", "TEST", 51, 84], ["cultures", "TEST", 86, 94], ["swabs", "TEST", 96, 101], ["total", "OBSERVATION_MODIFIER", 2, 7], ["infectious", "OBSERVATION_MODIFIER", 55, 65]]], ["Gram\u2010positive bacteria represented 56% of the total isolated pathogens: coagulase\u2010negative staphylococci including Staphylococcus epidermidis represented the most common gram\u2010positive organisms (23/91: 25.3%) followed by vancomycin\u2010resistant enterococcus (VRE) (10/91: 11%).", [["coagulase\u2010negative staphylococci", "DISEASE", 72, 104], ["Staphylococcus epidermidis", "DISEASE", 115, 141], ["vancomycin\u2010resistant enterococcus", "DISEASE", 221, 254], ["coagulase\u2010negative staphylococci", "ORGANISM", 72, 104], ["Staphylococcus epidermidis", "ORGANISM", 115, 141], ["vancomycin\u2010resistant enterococcus", "SIMPLE_CHEMICAL", 221, 254], ["Staphylococcus epidermidis", "SPECIES", 115, 141], ["Staphylococcus epidermidis", "SPECIES", 115, 141], ["Gram\u2010positive bacteria", "PROBLEM", 0, 22], ["the total isolated pathogens", "PROBLEM", 42, 70], ["coagulase\u2010negative staphylococci", "PROBLEM", 72, 104], ["Staphylococcus epidermidis", "PROBLEM", 115, 141], ["the most common gram\u2010positive organisms", "PROBLEM", 154, 193], ["vancomycin\u2010resistant enterococcus (VRE", "PROBLEM", 221, 259], ["Staphylococcus epidermidis", "OBSERVATION", 115, 141]]], ["Pseudomonas species (8/91: 8.8%) followed by Escherichia coli (6/91: 6.6%) were the most frequent gram\u2010negative pathogens.", [["Pseudomonas species", "ORGANISM", 0, 19], ["Escherichia coli", "ORGANISM", 45, 61], ["Escherichia coli", "SPECIES", 45, 61], ["Escherichia coli", "SPECIES", 45, 61], ["Pseudomonas species", "PROBLEM", 0, 19], ["Escherichia coli", "PROBLEM", 45, 61], ["the most frequent gram\u2010negative pathogens", "PROBLEM", 80, 121], ["Escherichia coli", "OBSERVATION", 45, 61], ["most frequent", "OBSERVATION_MODIFIER", 84, 97], ["gram\u2010negative pathogens", "OBSERVATION", 98, 121]]], ["In the study population, 6 (6.6%) and 8 (8.8%) of the microbiology\u2010documented infections were caused by fungal and viral agents respectively.Site of infection ::: ResultsLower respiratory tract infections were the most common site for infection (28 events: 17.2% of all admissions).", [["respiratory tract", "ANATOMY", 176, 193], ["infections", "DISEASE", 78, 88], ["infection", "DISEASE", 149, 158], ["respiratory tract infections", "DISEASE", 176, 204], ["infection", "DISEASE", 235, 244], ["tract", "ORGANISM_SUBDIVISION", 188, 193], ["the study population", "TEST", 3, 23], ["the microbiology", "TEST", 50, 66], ["documented infections", "PROBLEM", 67, 88], ["fungal", "PROBLEM", 104, 110], ["viral agents", "TREATMENT", 115, 127], ["infection", "PROBLEM", 149, 158], ["ResultsLower respiratory tract infections", "PROBLEM", 163, 204], ["infection", "PROBLEM", 235, 244], ["infections", "OBSERVATION", 78, 88], ["viral agents", "OBSERVATION", 115, 127], ["infection", "OBSERVATION", 149, 158], ["respiratory tract", "ANATOMY", 176, 193], ["infections", "OBSERVATION", 194, 204], ["infection", "OBSERVATION", 235, 244]]], ["This was followed by bacteremia (27 events: 16.6% of all admissions) (Table 4).Type of catheter ::: ResultsTo understand whether indwelling catheters might influence the frequency and types of infections, we reviewed admission chest X\u2010rays and procedure notes associated with all 163 hospitalizations.", [["chest", "ANATOMY", 227, 232], ["bacteremia", "DISEASE", 21, 31], ["infections", "DISEASE", 193, 203], ["bacteremia", "PROBLEM", 21, 31], ["indwelling catheters", "TREATMENT", 129, 149], ["infections", "PROBLEM", 193, 203], ["chest X\u2010rays", "TEST", 227, 239], ["bacteremia", "OBSERVATION", 21, 31], ["catheter", "OBSERVATION", 87, 95], ["catheters", "OBSERVATION", 140, 149], ["infections", "OBSERVATION", 193, 203], ["chest", "ANATOMY", 227, 232]]], ["In 101 of the 163 hospitalizations (62%), the patients had a central venous catheter (Hohn).", [["venous", "ANATOMY", 69, 75], ["patients", "ORGANISM", 46, 54], ["venous catheter", "MULTI-TISSUE_STRUCTURE", 69, 84], ["patients", "SPECIES", 46, 54], ["a central venous catheter", "TREATMENT", 59, 84], ["central", "ANATOMY_MODIFIER", 61, 68], ["venous", "ANATOMY", 69, 75], ["catheter", "OBSERVATION", 76, 84]]], ["Twenty (12%) had implanted port, 20 (12%) had peripherally inserted central catheters (PICC), and 22 (14%) had peripheral access.", [["peripherally", "ANATOMY", 46, 58], ["implanted port", "TREATMENT", 17, 31], ["peripherally inserted central catheters (PICC", "TREATMENT", 46, 91], ["peripheral access", "TREATMENT", 111, 128], ["central catheters", "OBSERVATION", 68, 85]]], ["Patients who had Hohn or PICC catheters tended to have more gram\u2010positive infections compared to patients with other types of access (port and peripheral access).", [["infections", "DISEASE", 74, 84], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 97, 105], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 97, 105], ["PICC catheters", "TREATMENT", 25, 39], ["more gram\u2010positive infections", "PROBLEM", 55, 84], ["access (port and peripheral access", "TREATMENT", 126, 160], ["infections", "OBSERVATION", 74, 84]]], ["However, this correlation did not reach statistical significance (P = 0.47).Infection susceptibility ::: ResultsOf the gram\u2010positive organisms identified, vancomycin and linezolid were most frequently associated with susceptibility.", [["vancomycin", "CHEMICAL", 155, 165], ["linezolid", "CHEMICAL", 170, 179], ["vancomycin", "CHEMICAL", 155, 165], ["linezolid", "CHEMICAL", 170, 179], ["vancomycin", "SIMPLE_CHEMICAL", 155, 165], ["linezolid", "SIMPLE_CHEMICAL", 170, 179], ["P", "TEST", 66, 67], ["the gram\u2010positive organisms", "PROBLEM", 115, 142], ["vancomycin", "TREATMENT", 155, 165], ["linezolid", "TREATMENT", 170, 179]]], ["In contrast, gram\u2010negative organisms were most frequently susceptible to cefepime, meropenem, and gentamycin.", [["cefepime", "CHEMICAL", 73, 81], ["meropenem", "CHEMICAL", 83, 92], ["gentamycin", "CHEMICAL", 98, 108], ["cefepime", "CHEMICAL", 73, 81], ["meropenem", "CHEMICAL", 83, 92], ["gentamycin", "CHEMICAL", 98, 108], ["cefepime", "SIMPLE_CHEMICAL", 73, 81], ["meropenem", "SIMPLE_CHEMICAL", 83, 92], ["gentamycin", "SIMPLE_CHEMICAL", 98, 108], ["gram\u2010negative organisms", "PROBLEM", 13, 36], ["cefepime", "TREATMENT", 73, 81], ["meropenem", "TREATMENT", 83, 92], ["gentamycin", "TREATMENT", 98, 108]]], ["Cefepime and vancomycin were the most commonly used empiric antibiotics overall (56.25% of the admissions).", [["Cefepime", "CHEMICAL", 0, 8], ["vancomycin", "CHEMICAL", 13, 23], ["Cefepime", "CHEMICAL", 0, 8], ["vancomycin", "CHEMICAL", 13, 23], ["Cefepime", "SIMPLE_CHEMICAL", 0, 8], ["vancomycin", "SIMPLE_CHEMICAL", 13, 23], ["Cefepime", "TREATMENT", 0, 8], ["vancomycin", "TREATMENT", 13, 23], ["empiric antibiotics", "TREATMENT", 52, 71]]], ["Ten of the Enterococcus cases (out of 12: 83.3%) were VRE.", [["VRE", "DISEASE", 54, 57], ["the Enterococcus cases", "TEST", 7, 29], ["VRE", "PROBLEM", 54, 57], ["Enterococcus", "OBSERVATION", 11, 23], ["VRE", "OBSERVATION", 54, 57]]], ["Two of the Staphylococcus cases (out of 25: 8%) were methicillin resistant (MRSA).", [["methicillin", "CHEMICAL", 53, 64], ["MRSA", "DISEASE", 76, 80], ["methicillin", "CHEMICAL", 53, 64], ["Staphylococcus cases", "ORGANISM", 11, 31], ["MRSA", "SPECIES", 76, 80], ["MRSA", "SPECIES", 76, 80], ["the Staphylococcus cases", "TEST", 7, 31], ["methicillin resistant (MRSA", "PROBLEM", 53, 80], ["Staphylococcus", "OBSERVATION", 11, 25]]], ["One of the E. coli infections was caused by extended\u2010spectrum beta\u2010lactamase (ESBL)\u2010producing organism.", [["infections", "DISEASE", 19, 29], ["E. coli", "ORGANISM", 11, 18], ["extended\u2010spectrum beta\u2010lactamase", "GENE_OR_GENE_PRODUCT", 44, 76], ["ESBL", "PROTEIN", 78, 82], ["E. coli", "SPECIES", 11, 18], ["E. coli", "SPECIES", 11, 18], ["the E. coli infections", "PROBLEM", 7, 29], ["extended\u2010spectrum beta\u2010lactamase (ESBL)\u2010producing organism", "PROBLEM", 44, 102], ["E. coli", "OBSERVATION_MODIFIER", 11, 18], ["infections", "OBSERVATION", 19, 29]]], ["A prophylactic antibacterial (ciprofloxacin 500 BID) was being administrated in five cases (38.5%) of the 13 cases of resistant microorganisms (MRSA, VRE, and ESBL) prior to admission.", [["ciprofloxacin", "CHEMICAL", 30, 43], ["MRSA", "CHEMICAL", 144, 148], ["ciprofloxacin", "CHEMICAL", 30, 43], ["BID", "CHEMICAL", 48, 51], ["ciprofloxacin", "SIMPLE_CHEMICAL", 30, 43], ["BID", "SIMPLE_CHEMICAL", 48, 51], ["MRSA", "SPECIES", 144, 148], ["MRSA", "SPECIES", 144, 148], ["A prophylactic antibacterial (ciprofloxacin", "TREATMENT", 0, 43], ["resistant microorganisms", "PROBLEM", 118, 142], ["MRSA", "PROBLEM", 144, 148], ["VRE", "PROBLEM", 150, 153], ["ESBL", "PROBLEM", 159, 163]]], ["All the Pseudomonas infections were sensitive to carbapenems.Infection outcome ::: ResultsComplete recovery from infectious complications was observed in the majority of patients.", [["Pseudomonas infections", "DISEASE", 8, 30], ["carbapenems", "CHEMICAL", 49, 60], ["infectious complications", "DISEASE", 113, 137], ["carbapenems", "CHEMICAL", 49, 60], ["carbapenems", "SIMPLE_CHEMICAL", 49, 60], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["All the Pseudomonas infections", "PROBLEM", 0, 30], ["carbapenems", "TREATMENT", 49, 60], ["infectious complications", "PROBLEM", 113, 137], ["Pseudomonas", "OBSERVATION_MODIFIER", 8, 19], ["infections", "OBSERVATION", 20, 30], ["infectious", "OBSERVATION_MODIFIER", 113, 123]]], ["The patients were discharged on a prophylactic antibiotic (ciprofloxacin 500 mg BID) in 37.5% of the admissions.", [["ciprofloxacin", "CHEMICAL", 59, 72], ["ciprofloxacin", "CHEMICAL", 59, 72], ["BID", "CHEMICAL", 80, 83], ["patients", "ORGANISM", 4, 12], ["ciprofloxacin", "SIMPLE_CHEMICAL", 59, 72], ["patients", "SPECIES", 4, 12], ["a prophylactic antibiotic", "TREATMENT", 32, 57], ["ciprofloxacin", "TREATMENT", 59, 72]]], ["The length of prophylaxis was indefinite in almost half of these cases.Infection outcome ::: ResultsDuring the study period, 10 (31.2%) of the gram\u2010positive and 3 (15%) of the gram\u2010negative infections required readmission within 6 weeks.", [["infections", "DISEASE", 190, 200], ["The length of prophylaxis", "TREATMENT", 0, 25], ["the study", "TEST", 107, 116], ["the gram\u2010negative infections", "PROBLEM", 172, 200], ["length", "OBSERVATION_MODIFIER", 4, 10], ["infections", "OBSERVATION", 190, 200]]], ["A total of seven deaths were attributed to infection\u2010related complications, with an overall incidence of 8.2% (7 of 85 patients).", [["deaths", "DISEASE", 17, 23], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["infection\u2010related complications", "PROBLEM", 43, 74], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Three deaths were due to gram\u2010negative bacteremia/sepsis (caused by Pseudomonas and ESBL\u2010producing E. coli), two due to pneumonia and acute respiratory failure, one due to mixed bacteremia (Mycobacterium abscessus and VRE), and one due to pneumonia associated with disseminated fusarium.", [["respiratory", "ANATOMY", 140, 151], ["deaths", "DISEASE", 6, 12], ["bacteremia", "DISEASE", 39, 49], ["sepsis", "DISEASE", 50, 56], ["pneumonia", "DISEASE", 120, 129], ["acute respiratory failure", "DISEASE", 134, 159], ["bacteremia", "DISEASE", 178, 188], ["Mycobacterium abscessus and VRE)", "DISEASE", 190, 222], ["pneumonia", "DISEASE", 239, 248], ["E. coli", "ORGANISM", 99, 106], ["Mycobacterium abscessus", "ORGANISM", 190, 213], ["E. coli", "SPECIES", 99, 106], ["Mycobacterium abscessus", "SPECIES", 190, 213], ["E. coli", "SPECIES", 99, 106], ["Mycobacterium abscessus", "SPECIES", 190, 213], ["gram\u2010negative bacteremia", "PROBLEM", 25, 49], ["sepsis", "PROBLEM", 50, 56], ["Pseudomonas", "PROBLEM", 68, 79], ["ESBL", "PROBLEM", 84, 88], ["E. coli", "PROBLEM", 99, 106], ["pneumonia", "PROBLEM", 120, 129], ["acute respiratory failure", "PROBLEM", 134, 159], ["mixed bacteremia", "PROBLEM", 172, 188], ["Mycobacterium abscessus", "PROBLEM", 190, 213], ["VRE", "PROBLEM", 218, 221], ["pneumonia", "PROBLEM", 239, 248], ["disseminated fusarium", "PROBLEM", 265, 286], ["bacteremia", "OBSERVATION", 39, 49], ["sepsis", "OBSERVATION", 50, 56], ["E. coli", "OBSERVATION_MODIFIER", 99, 106], ["pneumonia", "OBSERVATION", 120, 129], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["respiratory failure", "OBSERVATION", 140, 159], ["mixed", "OBSERVATION_MODIFIER", 172, 177], ["bacteremia", "OBSERVATION", 178, 188], ["Mycobacterium abscessus", "OBSERVATION", 190, 213], ["pneumonia", "OBSERVATION", 239, 248], ["disseminated fusarium", "OBSERVATION", 265, 286]]], ["Only one of these seven cases was on prophylactic antibiotics prior to admission.Effect of quinolone prophylaxis ::: ResultsPatients who were receiving quinolone prophylaxis at the time of the SAE tended to have fewer positive cultures compared to those who were not receiving prophylaxis (43% vs. 57%); although this did not reach a statistical significance (P = 0.084).", [["quinolone", "CHEMICAL", 91, 100], ["quinolone", "CHEMICAL", 152, 161], ["quinolone", "CHEMICAL", 91, 100], ["quinolone", "CHEMICAL", 152, 161], ["quinolone", "SIMPLE_CHEMICAL", 91, 100], ["quinolone", "SIMPLE_CHEMICAL", 152, 161], ["prophylactic antibiotics", "TREATMENT", 37, 61], ["quinolone prophylaxis", "TREATMENT", 91, 112], ["quinolone prophylaxis", "TREATMENT", 152, 173], ["fewer positive cultures", "PROBLEM", 212, 235], ["prophylaxis", "TREATMENT", 277, 288]]], ["The presence of antibiotics prophylaxis at the time of admission was not associated with statistically significant higher rates of resistant microorganisms (P = 0.087) or lower rates of mortality (P = 0.705).", [["antibiotics prophylaxis", "TREATMENT", 16, 39], ["resistant microorganisms", "PROBLEM", 131, 155], ["P", "TEST", 157, 158], ["lower rates of mortality", "PROBLEM", 171, 195], ["P", "TEST", 197, 198], ["antibiotics prophylaxis", "OBSERVATION", 16, 39]]], ["Two of the cases of Clostridium difficile colitis occurred in the setting of prophylactic ciprofloxacin treatment, and one did not.DiscussionRelatively few precise data are available on the incidence and characteristics of bacterial, fungal, and viral causes of infections in AML and MDS patients treated with decitabine 12, 13.", [["AML", "ANATOMY", 276, 279], ["Clostridium difficile colitis", "DISEASE", 20, 49], ["ciprofloxacin", "CHEMICAL", 90, 103], ["infections", "DISEASE", 262, 272], ["AML", "DISEASE", 276, 279], ["MDS", "DISEASE", 284, 287], ["decitabine", "CHEMICAL", 310, 320], ["ciprofloxacin", "CHEMICAL", 90, 103], ["decitabine", "CHEMICAL", 310, 320], ["Clostridium difficile", "ORGANISM", 20, 41], ["colitis", "PATHOLOGICAL_FORMATION", 42, 49], ["ciprofloxacin", "SIMPLE_CHEMICAL", 90, 103], ["AML", "CANCER", 276, 279], ["patients", "ORGANISM", 288, 296], ["decitabine", "SIMPLE_CHEMICAL", 310, 320], ["Clostridium difficile colitis", "SPECIES", 20, 49], ["patients", "SPECIES", 288, 296], ["Clostridium difficile", "SPECIES", 20, 41], ["Clostridium difficile colitis", "PROBLEM", 20, 49], ["prophylactic ciprofloxacin treatment", "TREATMENT", 77, 113], ["bacterial, fungal", "PROBLEM", 223, 240], ["infections", "PROBLEM", 262, 272], ["AML", "PROBLEM", 276, 279], ["decitabine", "TREATMENT", 310, 320], ["Clostridium", "OBSERVATION_MODIFIER", 20, 31], ["difficile", "OBSERVATION_MODIFIER", 32, 41], ["colitis", "OBSERVATION", 42, 49], ["bacterial", "OBSERVATION", 223, 232], ["fungal", "OBSERVATION", 234, 240], ["infections", "OBSERVATION", 262, 272]]], ["In this study, we investigated retrospectively the infectious complications that occurred in 85 patients with AML or MDS enrolled in NCT01687400.", [["AML", "ANATOMY", 110, 113], ["AML", "DISEASE", 110, 113], ["MDS", "DISEASE", 117, 120], ["patients", "ORGANISM", 96, 104], ["AML", "CANCER", 110, 113], ["patients", "SPECIES", 96, 104], ["this study", "TEST", 3, 13], ["the infectious complications", "PROBLEM", 47, 75], ["AML", "PROBLEM", 110, 113], ["MDS", "PROBLEM", 117, 120], ["infectious", "OBSERVATION_MODIFIER", 51, 61]]], ["In this study, we have described the prevalence and characteristics of clinically and microbiologically defined infections and infection\u2010related mortality, and the relationship between number of cycles and infection\u2010related events as well as the effect of prophylaxis on the positivity of cultures and susceptibility of microorganisms.DiscussionNeutropenia was common across all cycles of therapy (Fig. 1E).", [["infections", "DISEASE", 112, 122], ["Neutropenia", "DISEASE", 345, 356], ["this study", "TEST", 3, 13], ["microbiologically defined infections", "PROBLEM", 86, 122], ["infection\u2010related mortality", "PROBLEM", 127, 154], ["infection\u2010related events", "PROBLEM", 206, 230], ["prophylaxis", "TREATMENT", 256, 267], ["cultures", "TEST", 289, 297], ["susceptibility of microorganisms", "PROBLEM", 302, 334], ["Neutropenia", "PROBLEM", 345, 356], ["therapy", "TREATMENT", 389, 396], ["infections", "OBSERVATION", 112, 122]]], ["Based on the frequency and duration of neutropenia observed in this cohort, current guidelines would recommend consistent quinolone prophylaxis and consideration of antifungal prophylaxis 14, 15.DiscussionInfection\u2010related grade 3\u20135 SAEs occurred in 70 of 85 patients (82%) during therapy, and were observed in approximately one third of patients during each cycle.", [["neutropenia", "DISEASE", 39, 50], ["quinolone", "CHEMICAL", 122, 131], ["SAEs", "DISEASE", 233, 237], ["quinolone", "CHEMICAL", 122, 131], ["quinolone", "SIMPLE_CHEMICAL", 122, 131], ["patients", "ORGANISM", 259, 267], ["patients", "ORGANISM", 338, 346], ["patients", "SPECIES", 259, 267], ["patients", "SPECIES", 338, 346], ["neutropenia", "PROBLEM", 39, 50], ["consistent quinolone prophylaxis", "TREATMENT", 111, 143], ["antifungal prophylaxis", "TREATMENT", 165, 187], ["Infection\u2010related grade 3\u20135 SAEs", "PROBLEM", 205, 237], ["therapy", "TREATMENT", 281, 288]]], ["When compared to the incidence of infections when using a 5\u2010day decitabine regimen (29%) 9, longer courses of therapy (10\u2010day) were associated with more infections: 82% in this study and 68% reported by Blum et al. 6.", [["infections", "DISEASE", 34, 44], ["decitabine", "CHEMICAL", 64, 74], ["infections", "DISEASE", 153, 163], ["decitabine", "CHEMICAL", 64, 74], ["decitabine", "SIMPLE_CHEMICAL", 64, 74], ["infections", "PROBLEM", 34, 44], ["a 5\u2010day decitabine regimen", "TREATMENT", 56, 82], ["therapy", "TREATMENT", 110, 117], ["this study", "TEST", 172, 182], ["infections", "OBSERVATION", 34, 44]]], ["However, 30\u2010day mortality and 6\u2010month survival remained comparable (2.4% vs. 7% and 63.5% vs. 60% in this cohort and a cohort treated with the 5\u2010day regimen, respectively) 9.DiscussionFever and infections were the most frequent cause of hospitalization in our patient population.", [["infections", "DISEASE", 194, 204], ["patient", "ORGANISM", 260, 267], ["patient", "SPECIES", 260, 267], ["the 5\u2010day regimen", "TREATMENT", 139, 156], ["infections", "PROBLEM", 194, 204], ["infections", "OBSERVATION", 194, 204]]], ["The majority of these events were not associated with a causative agent; an identifiable organism was isolated in 45% of admissions and bacteria represented the most commonly identified source of infection.", [["infection", "DISEASE", 196, 205], ["a causative agent", "PROBLEM", 54, 71], ["an identifiable organism", "PROBLEM", 73, 97], ["bacteria", "PROBLEM", 136, 144], ["infection", "PROBLEM", 196, 205], ["infection", "OBSERVATION", 196, 205]]], ["Microbiologically or clinically documented fungal or viral infections were diagnosed in less than 5% of hospitalizations.", [["fungal or viral infections", "DISEASE", 43, 69], ["fungal", "PROBLEM", 43, 49], ["viral infections", "PROBLEM", 53, 69], ["fungal", "OBSERVATION_MODIFIER", 43, 49], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infections", "OBSERVATION", 59, 69]]], ["In our study, the ratio of gram\u2010positive to gram\u2010negative bacteria approached 2:1.", [["our study", "TEST", 3, 12], ["the ratio", "TEST", 14, 23], ["gram\u2010negative bacteria", "PROBLEM", 44, 66]]], ["Gram\u2010positive cocci (predominantly coagulase\u2010negative staphylococci) represented the most frequently isolated microorganisms.", [["Gram\u2010positive cocci", "PROBLEM", 0, 19], ["predominantly coagulase\u2010negative staphylococci", "PROBLEM", 21, 67], ["cocci", "OBSERVATION", 14, 19], ["predominantly", "OBSERVATION_MODIFIER", 21, 34], ["coagulase\u2010negative staphylococci", "OBSERVATION", 35, 67]]], ["This finding is not surprising, and consistent with the literature of other chemotherapeutic agents in hematological malignancies as well as solid cancers 16, 17.", [["hematological malignancies", "ANATOMY", 103, 129], ["solid cancers", "ANATOMY", 141, 154], ["hematological malignancies", "DISEASE", 103, 129], ["cancers", "DISEASE", 147, 154], ["hematological malignancies", "CANCER", 103, 129], ["solid cancers", "CANCER", 141, 154], ["other chemotherapeutic agents", "TREATMENT", 70, 99], ["hematological malignancies", "PROBLEM", 103, 129], ["solid cancers", "PROBLEM", 141, 154], ["consistent with", "UNCERTAINTY", 36, 51], ["hematological malignancies", "OBSERVATION", 103, 129], ["cancers", "OBSERVATION", 147, 154]]], ["This dominant gram\u2010positive pattern can be attributed to the widespread use of indwelling intravascular catheters and the use of prophylaxis targeted against gram\u2010negative organisms (e.g., ciprofloxacin).", [["intravascular", "ANATOMY", 90, 103], ["ciprofloxacin", "CHEMICAL", 189, 202], ["ciprofloxacin", "CHEMICAL", 189, 202], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 103], ["ciprofloxacin", "SIMPLE_CHEMICAL", 189, 202], ["This dominant gram\u2010positive pattern", "PROBLEM", 0, 35], ["indwelling intravascular catheters", "TREATMENT", 79, 113], ["prophylaxis", "TREATMENT", 129, 140], ["gram\u2010negative organisms", "PROBLEM", 158, 181], ["ciprofloxacin", "TREATMENT", 189, 202], ["widespread", "OBSERVATION_MODIFIER", 61, 71], ["indwelling intravascular catheters", "OBSERVATION", 79, 113]]], ["Surgically implanted tunneled catheters have been associated with lower rates of bloodstream infections than percutaneously inserted catheters 18, 19.", [["bloodstream", "ANATOMY", 81, 92], ["bloodstream infections", "DISEASE", 81, 103], ["Surgically implanted tunneled catheters", "TREATMENT", 0, 39], ["bloodstream infections", "PROBLEM", 81, 103], ["percutaneously inserted catheters", "TREATMENT", 109, 142], ["implanted", "OBSERVATION_MODIFIER", 11, 20], ["tunneled catheters", "OBSERVATION", 21, 39], ["lower", "OBSERVATION_MODIFIER", 66, 71], ["rates", "OBSERVATION_MODIFIER", 72, 77], ["bloodstream", "OBSERVATION_MODIFIER", 81, 92], ["infections", "OBSERVATION", 93, 103], ["catheters", "OBSERVATION_MODIFIER", 133, 142]]], ["In this study, we observed a nonsignificant trend toward greater numbers of gram\u2010positive infections in patients with Hohn and PICC catheters, as might be expected.", [["infections", "DISEASE", 90, 100], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["this study", "TEST", 3, 13], ["a nonsignificant trend", "PROBLEM", 27, 49], ["gram\u2010positive infections", "PROBLEM", 76, 100], ["Hohn and PICC catheters", "TREATMENT", 118, 141], ["gram\u2010positive", "OBSERVATION_MODIFIER", 76, 89], ["infections", "OBSERVATION", 90, 100], ["PICC catheters", "OBSERVATION", 127, 141]]], ["AML and MDS patients receiving decitabine frequently present with cytopenias and are unable to obtain a surgically implanted catheter until they achieve remission.", [["AML", "ANATOMY", 0, 3], ["AML", "DISEASE", 0, 3], ["MDS", "DISEASE", 8, 11], ["decitabine", "CHEMICAL", 31, 41], ["cytopenias", "DISEASE", 66, 76], ["decitabine", "CHEMICAL", 31, 41], ["AML", "CANCER", 0, 3], ["patients", "ORGANISM", 12, 20], ["decitabine", "SIMPLE_CHEMICAL", 31, 41], ["patients", "SPECIES", 12, 20], ["AML", "PROBLEM", 0, 3], ["MDS", "PROBLEM", 8, 11], ["decitabine", "TREATMENT", 31, 41], ["cytopenias", "PROBLEM", 66, 76], ["a surgically implanted catheter", "TREATMENT", 102, 133], ["cytopenias", "OBSERVATION", 66, 76], ["catheter", "OBSERVATION", 125, 133]]], ["This limits this opportunity for alternative access, and physicians should be cognizant of the risks and opportunities posed by different forms of percutaneous access.", [["percutaneous", "ANATOMY", 147, 159], ["percutaneous access", "TREATMENT", 147, 166]]], ["Enterococcal species, especially vancomycin\u2010resistant bacteria, represented the second most common gram\u2010positive isolates in our population, causing mainly bacteremia and urinary tract infections.", [["urinary tract", "ANATOMY", 171, 184], ["bacteremia", "DISEASE", 156, 166], ["urinary tract infections", "DISEASE", 171, 195], ["Enterococcal species", "ORGANISM", 0, 20], ["urinary tract", "ORGANISM_SUBDIVISION", 171, 184], ["Enterococcal species", "PROBLEM", 0, 20], ["vancomycin\u2010resistant bacteria", "PROBLEM", 33, 62], ["mainly bacteremia", "PROBLEM", 149, 166], ["urinary tract infections", "PROBLEM", 171, 195], ["species", "OBSERVATION", 13, 20], ["mainly", "OBSERVATION_MODIFIER", 149, 155], ["bacteremia", "OBSERVATION", 156, 166], ["urinary tract", "ANATOMY", 171, 184], ["infections", "OBSERVATION", 185, 195]]], ["Nevertheless, the rate of VRE infections appears to be similar in our patients compared to patients undergoing induction with more intensive chemotherapy (11% compared to 10%) 20, 21.", [["infections", "DISEASE", 30, 40], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 91, 99], ["VRE infections", "PROBLEM", 26, 40], ["more intensive chemotherapy", "TREATMENT", 126, 153], ["VRE", "OBSERVATION", 26, 29]]], ["Although colonization is far more frequent than true infection even in immunocompromised patients, bacteremia with VRE has been involved in outbreaks among oncology patients treated with chemotherapy and can be associated with increased mortality rates 20, 22.DiscussionViridans group streptococci are other important pathogens that are classically seen in patients undergoing induction with high\u2010dose intensive chemotherapy associated with neutropenia and oropharyngeal mucositis 23, 24, 25, 26.", [["oropharyngeal", "ANATOMY", 457, 470], ["infection", "DISEASE", 53, 62], ["bacteremia", "DISEASE", 99, 109], ["VRE", "CHEMICAL", 115, 118], ["neutropenia", "DISEASE", 441, 452], ["oropharyngeal mucositis", "DISEASE", 457, 480], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 165, 173], ["DiscussionViridans group streptococci", "ORGANISM", 260, 297], ["patients", "ORGANISM", 357, 365], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 357, 365], ["colonization", "PROBLEM", 9, 21], ["true infection", "PROBLEM", 48, 62], ["bacteremia", "PROBLEM", 99, 109], ["VRE", "PROBLEM", 115, 118], ["chemotherapy", "TREATMENT", 187, 199], ["increased mortality rates", "PROBLEM", 227, 252], ["DiscussionViridans group streptococci", "TREATMENT", 260, 297], ["high\u2010dose intensive chemotherapy", "TREATMENT", 392, 424], ["neutropenia", "PROBLEM", 441, 452], ["oropharyngeal mucositis", "PROBLEM", 457, 480], ["colonization", "OBSERVATION", 9, 21], ["infection", "OBSERVATION", 53, 62], ["bacteremia", "OBSERVATION", 99, 109], ["oropharyngeal mucositis", "ANATOMY", 457, 480]]], ["Four cases of this type of bacteremia have been isolated in our patient group (2.5%).", [["bacteremia", "DISEASE", 27, 37], ["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["bacteremia", "PROBLEM", 27, 37], ["bacteremia", "OBSERVATION", 27, 37]]], ["Only one case had mucositis (rare with decitabine) at the time of bacteremia.", [["mucositis", "DISEASE", 18, 27], ["decitabine", "CHEMICAL", 39, 49], ["bacteremia", "DISEASE", 66, 76], ["decitabine", "CHEMICAL", 39, 49], ["decitabine", "SIMPLE_CHEMICAL", 39, 49], ["mucositis", "PROBLEM", 18, 27], ["decitabine", "TREATMENT", 39, 49], ["bacteremia", "PROBLEM", 66, 76], ["mucositis", "OBSERVATION", 18, 27], ["bacteremia", "OBSERVATION", 66, 76]]], ["Therefore, other ports of entry, such as GI mucosa or central venous lines, may represent potential sources for these infections in these patients.DiscussionInfection\u2010related mortality in our cohort was associated with gram\u2010negative bacteremia, pneumonia, and one case of disseminated Fusarium.", [["GI mucosa", "ANATOMY", 41, 50], ["central venous lines", "ANATOMY", 54, 74], ["infections", "DISEASE", 118, 128], ["bacteremia", "DISEASE", 233, 243], ["pneumonia", "DISEASE", 245, 254], ["Fusarium", "DISEASE", 285, 293], ["mucosa", "MULTI-TISSUE_STRUCTURE", 44, 50], ["central venous lines", "CELL", 54, 74], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["entry", "TREATMENT", 26, 31], ["central venous lines", "TREATMENT", 54, 74], ["these infections", "PROBLEM", 112, 128], ["gram\u2010negative bacteremia", "PROBLEM", 219, 243], ["pneumonia", "PROBLEM", 245, 254], ["disseminated Fusarium", "PROBLEM", 272, 293], ["ports", "OBSERVATION_MODIFIER", 17, 22], ["entry", "OBSERVATION", 26, 31], ["central", "ANATOMY_MODIFIER", 54, 61], ["venous", "ANATOMY", 62, 68], ["lines", "OBSERVATION", 69, 74], ["may represent", "UNCERTAINTY", 76, 89], ["infections", "OBSERVATION", 118, 128], ["bacteremia", "OBSERVATION", 233, 243], ["pneumonia", "OBSERVATION", 245, 254], ["disseminated Fusarium", "OBSERVATION", 272, 293]]], ["These data are consistent with historical outcomes of aerobic gram\u2010negative bacilli (E. coli and Pseudomonas aeruginosa) 27, 28, and the focus of our antibacterial prophylaxis targeted these bacteria.", [["E. coli", "ORGANISM", 85, 92], ["Pseudomonas aeruginosa", "ORGANISM", 97, 119], ["E. coli", "SPECIES", 85, 92], ["Pseudomonas aeruginosa", "SPECIES", 97, 119], ["E. coli", "SPECIES", 85, 92], ["Pseudomonas aeruginosa", "SPECIES", 97, 119], ["These data", "TEST", 0, 10], ["aerobic gram\u2010negative bacilli", "PROBLEM", 54, 83], ["E. coli", "PROBLEM", 85, 92], ["Pseudomonas aeruginosa", "PROBLEM", 97, 119], ["our antibacterial prophylaxis", "TREATMENT", 146, 175], ["these bacteria", "PROBLEM", 185, 199], ["consistent with", "UNCERTAINTY", 15, 30], ["antibacterial prophylaxis", "OBSERVATION", 150, 175]]], ["Primary prophylaxis with fluoroquinolones in our patient population was associated with a trend toward fewer positive blood cultures (P = 0.084), but was not associated with higher rates of resistant microorganisms or lower rates of mortality.DiscussionFungal infections are an infrequent, but recurrent cause of morbidity and mortality.", [["blood cultures", "ANATOMY", 118, 132], ["fluoroquinolones", "CHEMICAL", 25, 41], ["DiscussionFungal infections", "DISEASE", 243, 270], ["fluoroquinolones", "CHEMICAL", 25, 41], ["fluoroquinolones", "SIMPLE_CHEMICAL", 25, 41], ["patient", "ORGANISM", 49, 56], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["patient", "SPECIES", 49, 56], ["Primary prophylaxis", "TREATMENT", 0, 19], ["fluoroquinolones", "TREATMENT", 25, 41], ["fewer positive blood cultures", "PROBLEM", 103, 132], ["P", "TEST", 134, 135], ["resistant microorganisms", "PROBLEM", 190, 214], ["lower rates of mortality", "PROBLEM", 218, 242], ["DiscussionFungal infections", "PROBLEM", 243, 270], ["morbidity", "PROBLEM", 313, 322], ["mortality", "PROBLEM", 327, 336], ["morbidity", "OBSERVATION", 313, 322]]], ["We observed an incidence of probable/proven invasive fungal infections of 7% including the mixed infections.", [["fungal infections", "DISEASE", 53, 70], ["infections", "DISEASE", 97, 107], ["invasive fungal infections", "PROBLEM", 44, 70], ["the mixed infections", "PROBLEM", 87, 107], ["probable", "UNCERTAINTY", 28, 36], ["/proven", "OBSERVATION_MODIFIER", 36, 43], ["invasive", "OBSERVATION_MODIFIER", 44, 52], ["fungal", "OBSERVATION_MODIFIER", 53, 59], ["infections", "OBSERVATION", 60, 70], ["mixed", "OBSERVATION_MODIFIER", 91, 96], ["infections", "OBSERVATION", 97, 107]]], ["Although the spectrum of the fungal pathogens is similar (commonly, Aspergillus species and Candida species), the incidence may be modestly lower than the reported 12% incidence rate of IFIs in AML patient treated with more intensive cytotoxic therapy 29.", [["AML", "ANATOMY", 194, 197], ["fungal pathogens", "DISEASE", 29, 45], ["IFIs", "DISEASE", 186, 190], ["AML", "DISEASE", 194, 197], ["Aspergillus species", "ORGANISM", 68, 87], ["Candida species", "ORGANISM", 92, 107], ["IFIs", "PATHOLOGICAL_FORMATION", 186, 190], ["AML", "CANCER", 194, 197], ["patient", "ORGANISM", 198, 205], ["patient", "SPECIES", 198, 205], ["the fungal pathogens", "PROBLEM", 25, 45], ["Aspergillus species", "PROBLEM", 68, 87], ["Candida species", "PROBLEM", 92, 107], ["IFIs", "PROBLEM", 186, 190], ["AML", "PROBLEM", 194, 197], ["more intensive cytotoxic therapy", "TREATMENT", 219, 251], ["fungal", "OBSERVATION_MODIFIER", 29, 35], ["pathogens", "OBSERVATION", 36, 45], ["Candida species", "OBSERVATION", 92, 107], ["modestly", "OBSERVATION_MODIFIER", 131, 139], ["lower", "OBSERVATION_MODIFIER", 140, 145], ["IFIs", "OBSERVATION", 186, 190], ["AML", "OBSERVATION", 194, 197]]], ["Nevertheless, considering the high number of observed clinically suspected infections with negative cultures, we cannot exclude that the incidence of invasive fungal infections might be higher.DiscussionSimilar patterns of infectious complications have been reported in AML patients during intensive chemotherapy.", [["AML", "ANATOMY", 270, 273], ["infections", "DISEASE", 75, 85], ["fungal infections", "DISEASE", 159, 176], ["infectious complications", "DISEASE", 223, 247], ["AML", "DISEASE", 270, 273], ["AML", "CANCER", 270, 273], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 274, 282], ["invasive fungal infections", "PROBLEM", 150, 176], ["infectious complications", "PROBLEM", 223, 247], ["intensive chemotherapy", "TREATMENT", 290, 312], ["infections", "OBSERVATION", 75, 85], ["invasive", "OBSERVATION_MODIFIER", 150, 158], ["fungal", "OBSERVATION_MODIFIER", 159, 165], ["infections", "OBSERVATION", 166, 176], ["higher", "OBSERVATION_MODIFIER", 186, 192], ["infectious", "OBSERVATION", 223, 233]]], ["A review of 747 adults with AML treated with conventional chemotherapy identified a source organism in 56.6% of the febrile episodes 30.", [["AML", "ANATOMY", 28, 31], ["AML", "DISEASE", 28, 31], ["febrile", "DISEASE", 116, 123], ["adults", "ORGANISM", 16, 22], ["AML", "CANCER", 28, 31], ["AML", "PROBLEM", 28, 31], ["conventional chemotherapy", "TREATMENT", 45, 70], ["a source organism", "PROBLEM", 82, 99], ["the febrile episodes", "PROBLEM", 112, 132], ["AML", "OBSERVATION", 28, 31]]], ["Although bacterial infections were also the most frequent cause of infectious complications (38.4%), more gram\u2010negative infections were observed (ratio 1:1), and a modestly higher incidence of fungal infections was observed (13.8%) 29, 30.DiscussionIn sum, we found that infection\u2010related SAEs were common in AML and MDS patients undergoing a 10\u2010day decitabine regimen.", [["AML", "ANATOMY", 309, 312], ["bacterial infections", "DISEASE", 9, 29], ["infections", "DISEASE", 120, 130], ["fungal infections", "DISEASE", 193, 210], ["SAEs", "DISEASE", 289, 293], ["AML", "DISEASE", 309, 312], ["MDS", "DISEASE", 317, 320], ["decitabine", "CHEMICAL", 350, 360], ["decitabine", "CHEMICAL", 350, 360], ["AML", "CANCER", 309, 312], ["patients", "ORGANISM", 321, 329], ["decitabine", "SIMPLE_CHEMICAL", 350, 360], ["patients", "SPECIES", 321, 329], ["bacterial infections", "PROBLEM", 9, 29], ["infectious complications", "PROBLEM", 67, 91], ["more gram\u2010negative infections", "PROBLEM", 101, 130], ["fungal infections", "PROBLEM", 193, 210], ["infection\u2010related SAEs", "PROBLEM", 271, 293], ["AML", "PROBLEM", 309, 312], ["a 10\u2010day decitabine regimen", "TREATMENT", 341, 368], ["bacterial", "OBSERVATION_MODIFIER", 9, 18], ["infections", "OBSERVATION", 19, 29], ["infectious", "OBSERVATION_MODIFIER", 67, 77], ["infections", "OBSERVATION", 120, 130], ["modestly", "OBSERVATION_MODIFIER", 164, 172], ["higher", "OBSERVATION_MODIFIER", 173, 179], ["incidence", "OBSERVATION_MODIFIER", 180, 189], ["fungal infections", "OBSERVATION", 193, 210]]], ["In this cohort, admission to the hospital for evaluation of neutropenic fever occurred in the majority of patients at some point during treatment, and occurred in nearly one third of patients during each cycle of treatment.", [["fever", "DISEASE", 72, 77], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 183, 191], ["evaluation", "TEST", 46, 56], ["neutropenic fever", "PROBLEM", 60, 77], ["treatment", "TREATMENT", 136, 145], ["treatment", "TREATMENT", 213, 222], ["neutropenic", "OBSERVATION", 60, 71]]], ["A causative agent was identified in less than half of admissions, and gram\u2010positive bacteria were the most frequent agents identified.", [["A causative agent", "PROBLEM", 0, 17], ["gram\u2010positive bacteria", "PROBLEM", 70, 92]]], ["However, gram\u2010negative infections were associated with mortality.", [["infections", "DISEASE", 23, 33], ["gram\u2010negative infections", "PROBLEM", 9, 33], ["infections", "OBSERVATION", 23, 33]]], ["Although expanding antimicrobial prophylaxis to include better gram\u2010positive coverage (e.g., ampicillin or augmentin) could reduce the incidence of hospital admissions, this is unlikely to have an impact on overall survival.", [["ampicillin", "CHEMICAL", 93, 103], ["augmentin", "CHEMICAL", 107, 116], ["ampicillin", "CHEMICAL", 93, 103], ["augmentin", "CHEMICAL", 107, 116], ["ampicillin", "SIMPLE_CHEMICAL", 93, 103], ["augmentin", "SIMPLE_CHEMICAL", 107, 116], ["expanding antimicrobial prophylaxis", "TREATMENT", 9, 44], ["better gram\u2010positive coverage", "TREATMENT", 56, 85], ["ampicillin", "TREATMENT", 93, 103], ["augmentin", "TREATMENT", 107, 116], ["antimicrobial prophylaxis", "OBSERVATION", 19, 44]]], ["Furthermore, the downsides of this approach including toxicities and the potential for promoting resistance should be considered.", [["toxicities", "DISEASE", 54, 64], ["this approach", "TREATMENT", 30, 43], ["toxicities", "PROBLEM", 54, 64], ["promoting resistance", "TREATMENT", 87, 107]]], ["Prospective studies are needed to determine whether the benefit of antibacterial prophylaxis outweighs the risks.Conflict of InterestThe authors declare no conflicts of interest.", [["Prospective studies", "TEST", 0, 19], ["antibacterial prophylaxis", "TREATMENT", 67, 92]]]], "07d115c9506263813b374bac29c74009dde267d4": [["INTRODUCTIONThe spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) during the ongoing coronavirus disease 2019 (COVID-19) pandemic has been particularly high in Italy.", [["acute respiratory syndrome coronavirus", "DISEASE", 33, 71], ["coronavirus disease", "DISEASE", 106, 125], ["COVID-19", "CHEMICAL", 132, 140], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 26, 73], ["SARS-CoV-2", "ORGANISM", 75, 85], ["severe acute respiratory syndrome coronavirus", "SPECIES", 26, 71], ["SARS-CoV-2", "SPECIES", 75, 85], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 26, 71], ["SARS-CoV", "TEST", 75, 83], ["the ongoing coronavirus disease", "PROBLEM", 94, 125], ["COVID", "TEST", 132, 137], ["pandemic", "PROBLEM", 142, 150], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory syndrome coronavirus", "OBSERVATION", 39, 71], ["coronavirus disease", "OBSERVATION", 106, 125], ["high", "OBSERVATION_MODIFIER", 173, 177]]], ["In Italy, as in the rest of the world, extremely rare cases of infection have been seen in the pediatric population.", [["infection", "DISEASE", 63, 72], ["infection", "PROBLEM", 63, 72], ["infection", "OBSERVATION", 63, 72]]], ["In a study carried out in China involving more than 44,000 cases of COVID-19, 0.9% of patients were between 0 and 10 years of age and 1.2% ranged in age from 10 to 19 years [1] .", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["a study", "TEST", 3, 10], ["COVID", "TEST", 68, 73]]], ["The absence of evident symptoms in children has reduced the need for nasopharyngeal and oropharyngeal swab screening in this age group [2] , with the result that little information is currently available on this segment of the population.", [["nasopharyngeal", "ANATOMY", 69, 83], ["oropharyngeal swab", "ANATOMY", 88, 106], ["children", "ORGANISM", 35, 43], ["nasopharyngeal", "CANCER", 69, 83], ["oropharyngeal swab", "MULTI-TISSUE_STRUCTURE", 88, 106], ["children", "SPECIES", 35, 43], ["evident symptoms", "PROBLEM", 15, 31], ["nasopharyngeal and oropharyngeal swab screening", "TEST", 69, 116]]], ["During the pandemic period in Italy, we observed more than ten pediatric patients who tested IgG positive for Sars-CoV-2 with painful vasculitic skin lesions on the feet that required modest pain relief therapy.", [["skin lesions", "ANATOMY", 145, 157], ["feet", "ANATOMY", 165, 169], ["pain", "DISEASE", 191, 195], ["patients", "ORGANISM", 73, 81], ["IgG", "GENE_OR_GENE_PRODUCT", 93, 96], ["skin lesions", "PATHOLOGICAL_FORMATION", 145, 157], ["feet", "ORGANISM_SUBDIVISION", 165, 169], ["IgG", "PROTEIN", 93, 96], ["patients", "SPECIES", 73, 81], ["Sars-CoV", "SPECIES", 110, 118], ["IgG", "TEST", 93, 96], ["Sars-CoV", "TEST", 110, 118], ["painful vasculitic skin lesions on the feet", "PROBLEM", 126, 169], ["modest pain relief therapy", "TREATMENT", 184, 210], ["painful", "OBSERVATION_MODIFIER", 126, 133], ["vasculitic", "OBSERVATION_MODIFIER", 134, 144], ["skin", "ANATOMY", 145, 149], ["lesions", "OBSERVATION", 150, 157], ["feet", "ANATOMY", 165, 169], ["modest", "OBSERVATION_MODIFIER", 184, 190]]], ["Here, we describe the case history of one of these patients and present pictures of her condition.CASE: 11-YEAR-OLD GIRLAt the first observation, the patient had erythematous chilblain-like skin lesions on her feet and several ulcerative lesions with dyschromia of the nails (Fig. 1a) ; the erythematous areas did not disappear with finger pressure.", [["skin lesions", "ANATOMY", 190, 202], ["feet", "ANATOMY", 210, 214], ["ulcerative lesions", "ANATOMY", 227, 245], ["erythematous areas", "ANATOMY", 291, 309], ["finger", "ANATOMY", 333, 339], ["skin lesions", "DISEASE", 190, 202], ["ulcerative lesions", "DISEASE", 227, 245], ["dyschromia of the nails", "DISEASE", 251, 274], ["patients", "ORGANISM", 51, 59], ["patient", "ORGANISM", 150, 157], ["skin lesions", "PATHOLOGICAL_FORMATION", 190, 202], ["ulcerative lesions", "PATHOLOGICAL_FORMATION", 227, 245], ["finger", "ORGANISM_SUBDIVISION", 333, 339], ["patients", "SPECIES", 51, 59], ["patient", "SPECIES", 150, 157], ["erythematous chilblain", "PROBLEM", 162, 184], ["skin lesions on her feet", "PROBLEM", 190, 214], ["several ulcerative lesions", "PROBLEM", 219, 245], ["dyschromia of the nails", "PROBLEM", 251, 274], ["the erythematous areas", "PROBLEM", 287, 309], ["finger pressure", "TEST", 333, 348], ["erythematous", "OBSERVATION_MODIFIER", 162, 174], ["chilblain", "OBSERVATION", 175, 184], ["skin", "ANATOMY", 190, 194], ["lesions", "OBSERVATION", 195, 202], ["feet", "ANATOMY", 210, 214], ["several", "OBSERVATION_MODIFIER", 219, 226], ["ulcerative", "OBSERVATION_MODIFIER", 227, 237], ["lesions", "OBSERVATION", 238, 245], ["dyschromia", "OBSERVATION", 251, 261], ["nails", "ANATOMY", 269, 274], ["erythematous", "OBSERVATION_MODIFIER", 291, 303], ["pressure", "OBSERVATION_MODIFIER", 340, 348]]], ["In the previous 6 weeks she had not shown fever, cough, malaise or asthenia.", [["fever", "DISEASE", 42, 47], ["cough", "DISEASE", 49, 54], ["asthenia", "DISEASE", 67, 75], ["fever", "PROBLEM", 42, 47], ["cough", "PROBLEM", 49, 54], ["malaise", "PROBLEM", 56, 63], ["asthenia", "PROBLEM", 67, 75]]], ["Her medical history was negative for vascular and/or inflammatory conditions.", [["vascular", "ANATOMY", 37, 45], ["vascular", "MULTI-TISSUE_STRUCTURE", 37, 45], ["vascular and/or inflammatory conditions", "PROBLEM", 37, 76], ["vascular", "ANATOMY", 37, 45], ["inflammatory", "OBSERVATION", 53, 65]]], ["She reported mild to moderate pain and itching.", [["pain", "DISEASE", 30, 34], ["itching", "DISEASE", 39, 46], ["mild to moderate pain", "PROBLEM", 13, 34], ["itching", "PROBLEM", 39, 46], ["mild", "OBSERVATION_MODIFIER", 13, 17], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["pain", "OBSERVATION", 30, 34], ["itching", "OBSERVATION", 39, 46]]], ["All blood tests were negative (complete blood count, ESR, PCR analysis, D-dimer, creatinine, AST, ALT, C3, C4, IL-6 and 25-hydroxyvitamin D).", [["blood", "ANATOMY", 4, 9], ["blood", "ANATOMY", 40, 45], ["creatinine", "CHEMICAL", 81, 91], ["25-hydroxyvitamin D", "CHEMICAL", 120, 139], ["creatinine", "CHEMICAL", 81, 91], ["25-hydroxyvitamin D", "CHEMICAL", 120, 139], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["D-dimer", "GENE_OR_GENE_PRODUCT", 72, 79], ["creatinine", "SIMPLE_CHEMICAL", 81, 91], ["AST", "SIMPLE_CHEMICAL", 93, 96], ["ALT", "SIMPLE_CHEMICAL", 98, 101], ["C3", "SIMPLE_CHEMICAL", 103, 105], ["C4", "SIMPLE_CHEMICAL", 107, 109], ["IL-6", "SIMPLE_CHEMICAL", 111, 115], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 120, 139], ["AST", "PROTEIN", 93, 96], ["ALT", "PROTEIN", 98, 101], ["C3", "PROTEIN", 103, 105], ["C4", "PROTEIN", 107, 109], ["All blood tests", "TEST", 0, 15], ["complete blood count", "TEST", 31, 51], ["ESR", "TEST", 53, 56], ["PCR analysis", "TEST", 58, 70], ["D", "TEST", 72, 73], ["creatinine", "TEST", 81, 91], ["AST", "TEST", 93, 96], ["ALT", "TEST", 98, 101], ["C3", "TEST", 103, 105], ["C4", "TEST", 107, 109], ["IL", "TEST", 111, 113]]], ["No Sars-CoV-2 virus was detected on the nose and oropharyngeal swab, while serologic testing for Sars-CoV-2 antibodies revealed Sars-CoV-2 IgG at 5.2 AU/ml (normal range [ 1 AU/ml) and Sars-CoV-2 IgM at 0.8 AU/ml (normal range [ 1 AU/ml).CASE: 11-YEAR-OLD GIRLThe pain measured using the Oucher scale, with the results indicating a score of 2 (range 0-5).CASE: 11-YEAR-OLD GIRLThe patients was immediately treated with paracetamol 750 mg 4 times/day.", [["nose", "ANATOMY", 40, 44], ["oropharyngeal swab", "ANATOMY", 49, 67], ["pain", "DISEASE", 264, 268], ["paracetamol", "CHEMICAL", 419, 430], ["paracetamol", "CHEMICAL", 419, 430], ["Sars-CoV-2 virus", "ORGANISM", 3, 19], ["nose", "ORGANISM_SUBDIVISION", 40, 44], ["oropharyngeal swab", "ORGAN", 49, 67], ["Sars-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 97, 118], ["Sars-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 128, 142], ["Sars-CoV-2 IgM", "GENE_OR_GENE_PRODUCT", 185, 199], ["patients", "ORGANISM", 381, 389], ["paracetamol", "SIMPLE_CHEMICAL", 419, 430], ["Sars-CoV-2 antibodies", "PROTEIN", 97, 118], ["Sars-CoV-2 IgG", "PROTEIN", 128, 142], ["IgM", "PROTEIN", 196, 199], ["CoV-2 virus", "SPECIES", 8, 19], ["patients", "SPECIES", 381, 389], ["Sars-CoV-2 virus", "SPECIES", 3, 19], ["Sars-CoV", "SPECIES", 97, 105], ["Sars-CoV", "SPECIES", 128, 136], ["Sars-CoV-2 virus", "PROBLEM", 3, 19], ["the nose", "TEST", 36, 44], ["oropharyngeal swab", "TEST", 49, 67], ["serologic testing", "TEST", 75, 92], ["Sars", "TEST", 97, 101], ["CoV", "TEST", 102, 105], ["antibodies", "TEST", 108, 118], ["Sars", "TEST", 128, 132], ["CoV", "TEST", 133, 136], ["IgG", "TEST", 139, 142], ["Sars", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["IgM", "TEST", 196, 199], ["OLD GIRLThe pain", "PROBLEM", 252, 268], ["the Oucher scale", "TEST", 284, 300], ["paracetamol", "TREATMENT", 419, 430], ["Sars", "OBSERVATION", 3, 7], ["CoV", "OBSERVATION", 8, 11], ["nose", "ANATOMY", 40, 44], ["oropharyngeal swab", "ANATOMY", 49, 67]]], ["Some of these lesions became purulent in the following days and was treated with Mupirocin 2% Ointment 3 time per day.CASE: 11-YEAR-OLD GIRLAfter 7 days the analgesic therapy was discontinued (Fig. 1b, c) , and after 15 days the skin lesions were completely resolved (Fig. 1d) .CONCLUSIONThe lack of finger pressure clearing of the eritematous lesions suggests that the vasculitis in our patient was of an ischemic hemorrhagic nature.", [["lesions", "ANATOMY", 14, 21], ["skin lesions", "ANATOMY", 229, 241], ["finger", "ANATOMY", 300, 306], ["eritematous lesions", "ANATOMY", 332, 351], ["Mupirocin", "CHEMICAL", 81, 90], ["vasculitis", "DISEASE", 370, 380], ["hemorrhagic", "DISEASE", 415, 426], ["Mupirocin", "CHEMICAL", 81, 90], ["lesions", "PATHOLOGICAL_FORMATION", 14, 21], ["skin lesions", "CANCER", 229, 241], ["finger", "ORGANISM_SUBDIVISION", 300, 306], ["eritematous lesions", "PATHOLOGICAL_FORMATION", 332, 351], ["patient", "ORGANISM", 388, 395], ["patient", "SPECIES", 388, 395], ["these lesions", "PROBLEM", 8, 21], ["purulent", "PROBLEM", 29, 37], ["Mupirocin", "TREATMENT", 81, 90], ["the analgesic therapy", "TREATMENT", 153, 174], ["the skin lesions", "PROBLEM", 225, 241], ["finger pressure", "TEST", 300, 315], ["the eritematous lesions", "PROBLEM", 328, 351], ["the vasculitis", "PROBLEM", 366, 380], ["an ischemic hemorrhagic nature", "PROBLEM", 403, 433], ["lesions", "OBSERVATION", 14, 21], ["purulent", "OBSERVATION", 29, 37], ["skin", "ANATOMY", 229, 233], ["lesions", "OBSERVATION", 234, 241], ["finger", "OBSERVATION_MODIFIER", 300, 306], ["pressure", "OBSERVATION_MODIFIER", 307, 315], ["clearing", "OBSERVATION_MODIFIER", 316, 324], ["eritematous", "OBSERVATION_MODIFIER", 332, 343], ["lesions", "OBSERVATION", 344, 351], ["vasculitis", "OBSERVATION", 370, 380], ["ischemic", "OBSERVATION_MODIFIER", 406, 414], ["hemorrhagic", "OBSERVATION", 415, 426]]], ["In the pediatric population there are numerous clinical conditions of a predominantly infectious or immune-mediated origin that can be associated with hemorrhagic ischemic vasculitis.", [["hemorrhagic ischemic vasculitis", "DISEASE", 151, 182], ["numerous clinical conditions", "PROBLEM", 38, 66], ["hemorrhagic ischemic vasculitis", "PROBLEM", 151, 182], ["numerous", "OBSERVATION_MODIFIER", 38, 46], ["predominantly", "OBSERVATION_MODIFIER", 72, 85], ["infectious", "OBSERVATION", 86, 96], ["can be associated with", "UNCERTAINTY", 128, 150], ["hemorrhagic", "OBSERVATION_MODIFIER", 151, 162], ["ischemic", "OBSERVATION_MODIFIER", 163, 171], ["vasculitis", "OBSERVATION", 172, 182]]], ["One of the most of these, Kawasaki disease, has already been correlated with COVID-19 [3] .", [["Kawasaki disease", "DISEASE", 26, 42], ["COVID-19", "CHEMICAL", 77, 85], ["Kawasaki disease", "PROBLEM", 26, 42], ["COVID", "TEST", 77, 82], ["Kawasaki disease", "OBSERVATION", 26, 42]]], ["Although it is not possible to correlate our patient case with the presence of SARS-COV-2 due to the swab negativity, we believe that the positive result for SARS-COV-2 IgG antibodies does correlate the skin lesion with COVID-19.", [["swab", "ANATOMY", 101, 105], ["skin lesion", "ANATOMY", 203, 214], ["SARS", "DISEASE", 79, 83], ["SARS", "DISEASE", 158, 162], ["patient", "ORGANISM", 45, 52], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 158, 168], ["skin", "ORGAN", 203, 207], ["SARS-COV-2 IgG antibodies", "PROTEIN", 158, 183], ["patient", "SPECIES", 45, 52], ["SARS", "PROBLEM", 79, 83], ["the swab negativity", "TEST", 97, 116], ["SARS", "TEST", 158, 162], ["COV", "TEST", 163, 166], ["2 IgG antibodies", "TEST", 167, 183], ["the skin lesion", "PROBLEM", 199, 214], ["COVID", "TEST", 220, 225], ["not possible", "UNCERTAINTY", 15, 27], ["skin", "ANATOMY", 203, 207], ["lesion", "OBSERVATION", 208, 214]]], ["This belief is reinforced by the fact that similar vasculitic manifestations associated with coagulation disorders, cyanosis and gangrene have been reported as late manifestations in severe COVID-19 cases in adults [4] [5] [6] .CONCLUSIONFunding.", [["coagulation disorders", "DISEASE", 93, 114], ["cyanosis", "DISEASE", 116, 124], ["gangrene", "DISEASE", 129, 137], ["COVID", "DISEASE", 190, 195], ["similar vasculitic manifestations", "PROBLEM", 43, 76], ["coagulation disorders", "PROBLEM", 93, 114], ["cyanosis", "PROBLEM", 116, 124], ["gangrene", "PROBLEM", 129, 137], ["late manifestations in severe COVID", "PROBLEM", 160, 195], ["vasculitic", "OBSERVATION", 51, 61], ["gangrene", "OBSERVATION", 129, 137]]], ["No funding or sponsorship was received for this study or publication of this article.CONCLUSIONAuthorship.", [["this study", "TEST", 43, 53], ["funding", "OBSERVATION", 3, 10]]], ["All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.CONCLUSIONDisclosures.", [["this version", "TREATMENT", 224, 236]]], ["Giustino Varrassi is a member of the journal's Editorial Board.CONCLUSIONCompliance with Ethics Guidelines.", [["Giustino", "CHEMICAL", 0, 8]]], ["Informed consent for publication was obtained from the patient's parents.CONCLUSIONData Availability.", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62]]], ["The datasets during and/ or analyzed during the current study are available from the corresponding author on reasonable request.CONCLUSIONOpen Access.", [["the current study", "TEST", 44, 61]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "79be2bad7d0442947cec07b060a5b21f8eff7c72": [["IntroductionParkinson's disease (PD) is a recognized progressive neurodegenerative disorder which is caused by a decrease in the number of dopaminergic neurons located in the substantia nigra (1, 2) .", [["dopaminergic neurons", "ANATOMY", 139, 159], ["substantia nigra", "ANATOMY", 175, 191], ["IntroductionParkinson's disease", "DISEASE", 0, 31], ["PD", "DISEASE", 33, 35], ["neurodegenerative disorder", "DISEASE", 65, 91], ["dopaminergic neurons", "CELL", 139, 159], ["dopaminergic neurons", "CELL_TYPE", 139, 159], ["IntroductionParkinson's disease", "PROBLEM", 0, 31], ["a recognized progressive neurodegenerative disorder", "PROBLEM", 40, 91], ["a decrease in the number of dopaminergic neurons", "PROBLEM", 111, 159], ["progressive", "OBSERVATION_MODIFIER", 53, 64], ["neurodegenerative disorder", "OBSERVATION", 65, 91], ["decrease", "OBSERVATION_MODIFIER", 113, 121], ["dopaminergic neurons", "OBSERVATION", 139, 159], ["substantia", "ANATOMY_MODIFIER", 175, 185], ["nigra", "ANATOMY_MODIFIER", 186, 191]]], ["Although the etiology of the disease remains unknown, postmortem studies have indicated that dying cells not only bear signs of necrosis, but also of apoptosis, in particular chromatin condensation, DNA fragmentation, oxidative damage, mitochondrial dysfunction and caspase activation (3, 4) .", [["cells", "ANATOMY", 99, 104], ["chromatin", "ANATOMY", 175, 184], ["mitochondrial", "ANATOMY", 236, 249], ["necrosis", "DISEASE", 128, 136], ["mitochondrial dysfunction", "DISEASE", 236, 261], ["cells", "CELL", 99, 104], ["chromatin", "CELLULAR_COMPONENT", 175, 184], ["DNA", "CELLULAR_COMPONENT", 199, 202], ["mitochondrial", "CELLULAR_COMPONENT", 236, 249], ["caspase", "GENE_OR_GENE_PRODUCT", 266, 273], ["dying cells", "CELL_TYPE", 93, 104], ["chromatin", "DNA", 175, 184], ["caspase", "PROTEIN", 266, 273], ["the disease", "PROBLEM", 25, 36], ["postmortem studies", "TEST", 54, 72], ["dying cells", "PROBLEM", 93, 104], ["necrosis", "PROBLEM", 128, 136], ["apoptosis", "PROBLEM", 150, 159], ["chromatin condensation", "PROBLEM", 175, 197], ["DNA fragmentation", "PROBLEM", 199, 216], ["oxidative damage", "PROBLEM", 218, 234], ["mitochondrial dysfunction", "PROBLEM", 236, 261], ["caspase activation", "TREATMENT", 266, 284], ["disease", "OBSERVATION", 29, 36], ["necrosis", "OBSERVATION", 128, 136], ["apoptosis", "OBSERVATION", 150, 159], ["chromatin condensation", "OBSERVATION", 175, 197], ["DNA fragmentation", "OBSERVATION", 199, 216], ["oxidative damage", "OBSERVATION", 218, 234], ["mitochondrial dysfunction", "OBSERVATION", 236, 261], ["caspase activation", "OBSERVATION", 266, 284]]], ["1-Methyl-4-phenylpyridinium (MPP + ) is commonly used in vitro and in vivo to produce models of PD (5, 6) .", [["1-Methyl-4-phenylpyridinium", "CHEMICAL", 0, 27], ["MPP", "CHEMICAL", 29, 32], ["PD", "DISEASE", 96, 98], ["1-Methyl-4-phenylpyridinium", "CHEMICAL", 0, 27], ["MPP +", "CHEMICAL", 29, 34], ["1-Methyl-4-phenylpyridinium", "SIMPLE_CHEMICAL", 0, 27], ["MPP +", "SIMPLE_CHEMICAL", 29, 34], ["Methyl", "TREATMENT", 2, 8], ["phenylpyridinium (MPP + )", "TREATMENT", 11, 36]]], ["Similar to other dopaminergic toxins, MPP + causes oxidative stress and the selective death of dopaminerigic neuronal cells, such as PC12 (7) and SH-SY5Y cells (8) .IntroductionA number of studies have reported that herbal preparations and their natural compounds display broad protective effects against neurotoxicity in various neurodegenerative diseases (9, 10) .", [["neuronal cells", "ANATOMY", 109, 123], ["PC12", "ANATOMY", 133, 137], ["SH-SY5Y cells", "ANATOMY", 146, 159], ["MPP", "CHEMICAL", 38, 41], ["death", "DISEASE", 86, 91], ["neurotoxicity", "DISEASE", 305, 318], ["neurodegenerative diseases", "DISEASE", 330, 356], ["MPP +", "CHEMICAL", 38, 43], ["MPP +", "SIMPLE_CHEMICAL", 38, 43], ["dopaminerigic neuronal cells", "CELL", 95, 123], ["PC12", "CELL", 133, 137], ["SH-SY5Y cells", "CELL", 146, 159], ["dopaminerigic neuronal cells", "CELL_TYPE", 95, 123], ["PC12", "CELL_LINE", 133, 137], ["SH-SY5Y cells", "CELL_LINE", 146, 159], ["other dopaminergic toxins", "TEST", 11, 36], ["MPP", "TEST", 38, 41], ["oxidative stress", "PROBLEM", 51, 67], ["the selective death of dopaminerigic neuronal cells", "PROBLEM", 72, 123], ["PC12", "TEST", 133, 137], ["SH-SY5Y cells", "TEST", 146, 159], ["studies", "TEST", 189, 196], ["herbal preparations", "TREATMENT", 216, 235], ["neurotoxicity", "PROBLEM", 305, 318], ["various neurodegenerative diseases", "PROBLEM", 322, 356], ["oxidative stress", "OBSERVATION", 51, 67], ["neuronal cells", "OBSERVATION", 109, 123], ["various", "OBSERVATION_MODIFIER", 322, 329], ["neurodegenerative diseases", "OBSERVATION", 330, 356]]], ["Glycyrrhizic acid (GA), a major active ingredient separated from Radix Glycyrrhizae, possesses anti-inflammatory and anti-viral effects (11, 12) .", [["Glycyrrhizic acid", "CHEMICAL", 0, 17], ["GA", "CHEMICAL", 19, 21], ["Radix Glycyrrhizae", "CHEMICAL", 65, 83], ["Glycyrrhizic acid", "CHEMICAL", 0, 17], ["Glycyrrhizic acid", "SIMPLE_CHEMICAL", 0, 17], ["GA", "SIMPLE_CHEMICAL", 19, 21], ["Radix Glycyrrhizae", "ORGANISM", 65, 83], ["Radix Glycyrrhizae", "SPECIES", 65, 83], ["Radix Glycyrrhizae", "SPECIES", 65, 83], ["Glycyrrhizic acid (GA)", "TREATMENT", 0, 22], ["a major active ingredient", "TREATMENT", 24, 49], ["Radix Glycyrrhizae", "TREATMENT", 65, 83], ["possesses anti-inflammatory", "TREATMENT", 85, 112], ["anti-viral effects", "TREATMENT", 117, 135], ["anti-inflammatory", "OBSERVATION_MODIFIER", 95, 112]]], ["It has been well documented that GA exerts marked neuroprotective effects against 6-hydroxydopamine-or glutamate-induced damage to neuronal cells (13, 14) .", [["neuronal cells", "ANATOMY", 131, 145], ["GA", "CHEMICAL", 33, 35], ["6-hydroxydopamine", "CHEMICAL", 82, 99], ["glutamate", "CHEMICAL", 103, 112], ["6-hydroxydopamine", "CHEMICAL", 82, 99], ["glutamate", "CHEMICAL", 103, 112], ["GA", "SIMPLE_CHEMICAL", 33, 35], ["6-hydroxydopamine", "SIMPLE_CHEMICAL", 82, 99], ["glutamate", "SIMPLE_CHEMICAL", 103, 112], ["neuronal cells", "CELL", 131, 145], ["neuronal cells", "CELL_TYPE", 131, 145], ["hydroxydopamine", "TREATMENT", 84, 99], ["glutamate", "PROBLEM", 103, 112], ["induced damage to neuronal cells", "PROBLEM", 113, 145], ["marked", "OBSERVATION_MODIFIER", 43, 49], ["neuronal cells", "OBSERVATION", 131, 145]]], ["However, the contribution of GA toward MPP + -induced cell damage and the underlying mechanisms have not yet been fully elucidated.IntroductionIt is well known that extracellular signal-regulated kinase (ERK) plays a key role in cell proliferation, differentiation, survival and apoptosis (15) .", [["cell", "ANATOMY", 54, 58], ["cell", "ANATOMY", 229, 233], ["GA", "CHEMICAL", 29, 31], ["MPP", "CHEMICAL", 39, 42], ["MPP +", "CHEMICAL", 39, 44], ["GA", "SIMPLE_CHEMICAL", 29, 31], ["MPP +", "SIMPLE_CHEMICAL", 39, 44], ["cell", "CELL", 54, 58], ["extracellular signal-regulated kinase", "GENE_OR_GENE_PRODUCT", 165, 202], ["ERK", "GENE_OR_GENE_PRODUCT", 204, 207], ["cell", "CELL", 229, 233], ["extracellular signal-regulated kinase", "PROTEIN", 165, 202], ["ERK", "PROTEIN", 204, 207], ["induced cell damage", "PROBLEM", 46, 65], ["extracellular signal", "TEST", 165, 185], ["apoptosis", "TEST", 279, 288], ["induced cell damage", "OBSERVATION", 46, 65], ["cell proliferation", "OBSERVATION", 229, 247]]], ["The phosphorylation of ERK has been shown to be critical for mediating the neuroprotectives effects of leptin (16) .", [["leptin", "CHEMICAL", 103, 109], ["ERK", "GENE_OR_GENE_PRODUCT", 23, 26], ["leptin", "GENE_OR_GENE_PRODUCT", 103, 109], ["ERK", "PROTEIN", 23, 26], ["The phosphorylation of ERK", "TEST", 0, 26], ["the neuroprotectives effects of leptin", "TREATMENT", 71, 109]]], ["Combined with the activation of ERK, mitochondrial depolarization is associated with apoptotic cell death (17) .", [["mitochondrial", "ANATOMY", 37, 50], ["cell", "ANATOMY", 95, 99], ["ERK", "GENE_OR_GENE_PRODUCT", 32, 35], ["mitochondrial", "CELLULAR_COMPONENT", 37, 50], ["cell", "CELL", 95, 99], ["ERK", "PROTEIN", 32, 35], ["mitochondrial depolarization", "PROBLEM", 37, 65], ["apoptotic cell death", "PROBLEM", 85, 105], ["mitochondrial depolarization", "OBSERVATION", 37, 65], ["associated with", "UNCERTAINTY", 69, 84], ["apoptotic cell death", "OBSERVATION", 85, 105]]], ["Another pathway involved in this process is the PI3K/AKT signaling pathway, which is essential for rescuing neuronal cells from oxidative stress (18) .IntroductionWe therefore hypothesized that GA exerts neuroprotective effects against MPP + -induced cell damage.", [["neuronal cells", "ANATOMY", 108, 122], ["cell", "ANATOMY", 251, 255], ["GA", "CHEMICAL", 194, 196], ["MPP", "CHEMICAL", 236, 239], ["MPP +", "CHEMICAL", 236, 241], ["PI3K", "GENE_OR_GENE_PRODUCT", 48, 52], ["AKT", "GENE_OR_GENE_PRODUCT", 53, 56], ["neuronal cells", "CELL", 108, 122], ["GA", "SIMPLE_CHEMICAL", 194, 196], ["MPP +", "SIMPLE_CHEMICAL", 236, 241], ["cell", "CELL", 251, 255], ["PI3K", "PROTEIN", 48, 52], ["AKT", "PROTEIN", 53, 56], ["neuronal cells", "CELL_TYPE", 108, 122], ["oxidative stress", "TEST", 128, 144], ["MPP", "PROBLEM", 236, 239], ["induced cell damage", "PROBLEM", 243, 262], ["induced cell damage", "OBSERVATION", 243, 262]]], ["To examine this hypothesis, in this study, we investigated the inhibitory effects of GA on MPP + cytotoxicity and the underlying mechanisms.", [["GA", "CHEMICAL", 85, 87], ["MPP", "CHEMICAL", 91, 94], ["GA", "SIMPLE_CHEMICAL", 85, 87], ["MPP +", "SIMPLE_CHEMICAL", 91, 96], ["this study", "TEST", 31, 41], ["MPP + cytotoxicity", "TREATMENT", 91, 109]]], ["Our data revealed that GA attenuated MPP + -induced cell death, the high apoptotic rate, the intracellular Ca 2+ overload, the overproduction of lactate dehydrogenase (LDH), as well as mitochondrial dysfunction.", [["cell", "ANATOMY", 52, 56], ["intracellular", "ANATOMY", 93, 106], ["mitochondrial", "ANATOMY", 185, 198], ["GA", "CHEMICAL", 23, 25], ["MPP", "CHEMICAL", 37, 40], ["Ca", "CHEMICAL", 107, 109], ["lactate", "CHEMICAL", 145, 152], ["mitochondrial dysfunction", "DISEASE", 185, 210], ["MPP +", "CHEMICAL", 37, 42], ["Ca 2+", "CHEMICAL", 107, 112], ["lactate", "CHEMICAL", 145, 152], ["GA", "SIMPLE_CHEMICAL", 23, 25], ["MPP +", "SIMPLE_CHEMICAL", 37, 42], ["cell", "CELL", 52, 56], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 93, 106], ["Ca 2+", "SIMPLE_CHEMICAL", 107, 112], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 145, 166], ["LDH", "GENE_OR_GENE_PRODUCT", 168, 171], ["mitochondrial", "CELLULAR_COMPONENT", 185, 198], ["lactate dehydrogenase", "PROTEIN", 145, 166], ["LDH", "PROTEIN", 168, 171], ["Our data", "TEST", 0, 8], ["GA attenuated MPP", "PROBLEM", 23, 40], ["induced cell death", "PROBLEM", 44, 62], ["the high apoptotic rate", "PROBLEM", 64, 87], ["the intracellular Ca", "PROBLEM", 89, 109], ["overload", "PROBLEM", 113, 121], ["lactate dehydrogenase (LDH)", "PROBLEM", 145, 172], ["mitochondrial dysfunction", "PROBLEM", 185, 210], ["cell death", "OBSERVATION", 52, 62], ["high", "OBSERVATION_MODIFIER", 68, 72], ["apoptotic rate", "OBSERVATION", 73, 87], ["overload", "OBSERVATION", 113, 121], ["mitochondrial dysfunction", "OBSERVATION", 185, 210]]], ["Further experiments indicated that the activation of ERK contributes to the GA-mediated neuroprotection of dopaminergic neuronal cells.", [["dopaminergic neuronal cells", "ANATOMY", 107, 134], ["GA", "CHEMICAL", 76, 78], ["ERK", "GENE_OR_GENE_PRODUCT", 53, 56], ["GA", "SIMPLE_CHEMICAL", 76, 78], ["dopaminergic neuronal cells", "CELL", 107, 134], ["ERK", "PROTEIN", 53, 56], ["dopaminergic neuronal cells", "CELL_TYPE", 107, 134], ["Further experiments", "TEST", 0, 19], ["the activation of ERK", "PROBLEM", 35, 56], ["the GA", "PROBLEM", 72, 78], ["dopaminergic neuronal cells", "PROBLEM", 107, 134], ["dopaminergic neuronal cells", "OBSERVATION", 107, 134]]], ["Briefly, the neurons were dissociated from the cerebral cortex of embryonic rats and were plated in 96-well culture plates which had been previously coated with poly-D-lysine (Invitrogen).", [["neurons", "ANATOMY", 13, 20], ["cerebral cortex", "ANATOMY", 47, 62], ["embryonic", "ANATOMY", 66, 75], ["poly-D-lysine", "CHEMICAL", 161, 174], ["poly-D-lysine", "CHEMICAL", 161, 174], ["neurons", "CELL", 13, 20], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 47, 62], ["rats", "ORGANISM", 76, 80], ["poly-D-lysine", "SIMPLE_CHEMICAL", 161, 174], ["Invitrogen", "SIMPLE_CHEMICAL", 176, 186], ["rats", "SPECIES", 76, 80], ["culture plates", "TEST", 108, 122], ["poly-D-lysine (Invitrogen", "TREATMENT", 161, 186], ["neurons", "ANATOMY", 13, 20], ["cerebral cortex", "ANATOMY", 47, 62], ["embryonic rats", "OBSERVATION", 66, 80]]], ["The cells were maintained in neurobasal medium supplemented with 2% B27 and 1% GlutaMAX (both from Invitrogen).", [["cells", "ANATOMY", 4, 9], ["GlutaMAX", "CHEMICAL", 79, 87], ["GlutaMAX", "CHEMICAL", 79, 87], ["cells", "CELL", 4, 9], ["GlutaMAX", "SIMPLE_CHEMICAL", 79, 87], ["neurobasal medium", "TREATMENT", 29, 46], ["2% B27", "TREATMENT", 65, 71], ["1% GlutaMAX", "TREATMENT", 76, 87]]], ["The purity of the primary cortical neuronal cells was 88.1\u00b15.6% ( Fig. 2A) which was determined by \u03b23-tubulin (red fluorescence) staining using ImageJ software.Involvement of the ERK pathway in the protective effects of glycyrrhizic acid against the MPP + -induced apoptosis of dopaminergic neuronal cellsAnalysis of cell viability and cellular morphology.", [["primary cortical neuronal cells", "ANATOMY", 18, 49], ["dopaminergic neuronal cells", "ANATOMY", 278, 305], ["cell", "ANATOMY", 317, 321], ["cellular", "ANATOMY", 336, 344], ["glycyrrhizic acid", "CHEMICAL", 220, 237], ["MPP", "CHEMICAL", 250, 253], ["glycyrrhizic acid", "CHEMICAL", 220, 237], ["MPP +", "CHEMICAL", 250, 255], ["cortical neuronal cells", "CELL", 26, 49], ["\u03b23-tubulin", "GENE_OR_GENE_PRODUCT", 99, 109], ["ERK", "GENE_OR_GENE_PRODUCT", 179, 182], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 220, 237], ["MPP +", "SIMPLE_CHEMICAL", 250, 255], ["dopaminergic neuronal cells", "CELL", 278, 305], ["cell", "CELL", 317, 321], ["cellular", "CELL", 336, 344], ["primary cortical neuronal cells", "CELL_TYPE", 18, 49], ["\u03b23", "PROTEIN", 99, 101], ["ERK", "PROTEIN", 179, 182], ["dopaminergic neuronal cells", "CELL_TYPE", 278, 305], ["the primary cortical neuronal cells", "TEST", 14, 49], ["red fluorescence", "TEST", 111, 127], ["ImageJ software", "TEST", 144, 159], ["the ERK pathway", "TEST", 175, 190], ["glycyrrhizic acid", "TREATMENT", 220, 237], ["the MPP", "TEST", 246, 253], ["dopaminergic neuronal cells", "PROBLEM", 278, 305], ["cell viability", "TEST", 317, 331], ["cortical", "ANATOMY_MODIFIER", 26, 34], ["neuronal cells", "ANATOMY", 35, 49], ["dopaminergic neuronal cells", "OBSERVATION", 278, 305], ["cell viability", "OBSERVATION", 317, 331], ["cellular morphology", "OBSERVATION", 336, 355]]], ["Cell viability was measured by a quantitative colorimetric assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) as described in a previous study (20) .", [["Cell", "ANATOMY", 0, 4], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 70, 130], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 70, 130], ["MTT", "CHEMICAL", 132, 135], ["Cell", "CELL", 0, 4], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 70, 130], ["MTT", "SIMPLE_CHEMICAL", 132, 135], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 137, 150], ["Cell viability", "TEST", 0, 14], ["a quantitative colorimetric assay", "TEST", 31, 64], ["dimethylthiazol", "TREATMENT", 77, 92], ["diphenyltetrazolium bromide", "TREATMENT", 103, 130], ["a previous study", "TEST", 168, 184]]], ["Briefly, the differentiated PC12 (DPC12) cells and primary neurons were seeded into 96-well plates at 5x10 4 cells per well.", [["PC12 (DPC12) cells", "ANATOMY", 28, 46], ["primary neurons", "ANATOMY", 51, 66], ["5x10 4 cells", "ANATOMY", 102, 114], ["PC12 (DPC12) cells", "CELL", 28, 46], ["neurons", "CELL", 59, 66], ["5x10 4 cells", "CELL", 102, 114], ["differentiated PC12 (DPC12) cells", "CELL_LINE", 13, 46], ["primary neurons", "CELL_TYPE", 51, 66], ["5x10 4 cells", "CELL_LINE", 102, 114], ["primary neurons", "TEST", 51, 66]]], ["The cells were pre-treated with 5-100 \u00b5M GA for 3 h, co-treated with 0.5 or 4 mM MPP + for 24 h, and then incubated with MTT solution (5 mg/ml) for a further 4 h.", [["cells", "ANATOMY", 4, 9], ["GA", "CHEMICAL", 41, 43], ["MPP", "CHEMICAL", 81, 84], ["MTT", "CHEMICAL", 121, 124], ["MPP", "CHEMICAL", 81, 84], ["MTT", "CHEMICAL", 121, 124], ["cells", "CELL", 4, 9], ["GA", "SIMPLE_CHEMICAL", 41, 43], ["MTT", "SIMPLE_CHEMICAL", 121, 124], ["MTT solution", "TREATMENT", 121, 133]]], ["A total of 100 \u00b5l dimethyl sulfoxide (DMSO) was added to each well and then the absorbance was measured using a microplate reader (Bio-Rad, Berkeley, CA, USA) at 540 nm.", [["\u00b5l dimethyl sulfoxide", "CHEMICAL", 15, 36], ["DMSO", "CHEMICAL", 38, 42], ["dimethyl sulfoxide", "CHEMICAL", 18, 36], ["DMSO", "CHEMICAL", 38, 42], ["\u00b5l dimethyl sulfoxide", "SIMPLE_CHEMICAL", 15, 36], ["DMSO", "SIMPLE_CHEMICAL", 38, 42], ["A total of 100 \u00b5l dimethyl sulfoxide (DMSO)", "TREATMENT", 0, 43], ["a microplate reader", "TREATMENT", 110, 129]]], ["Cell viability was expressed as a percentage of the value in the control group (untreated cells).", [["Cell", "ANATOMY", 0, 4], ["cells", "ANATOMY", 90, 95], ["Cell", "CELL", 0, 4], ["cells", "CELL", 90, 95], ["untreated cells", "CELL_TYPE", 80, 95], ["Cell viability", "TEST", 0, 14]]], ["Prior to MTT assay, the morphology of the primary neurons was detected by normal photography (10' , Axio Observer Z1; Carl Zeiss, Inc., Oberkochen, Germany).Involvement of the ERK pathway in the protective effects of glycyrrhizic acid against the MPP + -induced apoptosis of dopaminergic neuronal cellsMeasurement of LDH release.", [["primary neurons", "ANATOMY", 42, 57], ["dopaminergic neuronal cells", "ANATOMY", 275, 302], ["glycyrrhizic acid", "CHEMICAL", 217, 234], ["MPP", "CHEMICAL", 247, 250], ["MTT", "CHEMICAL", 9, 12], ["glycyrrhizic acid", "CHEMICAL", 217, 234], ["MPP +", "CHEMICAL", 247, 252], ["neurons", "CELL", 50, 57], ["ERK", "GENE_OR_GENE_PRODUCT", 176, 179], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 217, 234], ["MPP +", "SIMPLE_CHEMICAL", 247, 252], ["dopaminergic neuronal cells", "CELL", 275, 302], ["LDH", "GENE_OR_GENE_PRODUCT", 317, 320], ["primary neurons", "CELL_TYPE", 42, 57], ["ERK", "PROTEIN", 176, 179], ["dopaminergic neuronal cells", "CELL_TYPE", 275, 302], ["LDH", "PROTEIN", 317, 320], ["MTT assay", "TEST", 9, 18], ["the ERK pathway", "TEST", 172, 187], ["glycyrrhizic acid", "TREATMENT", 217, 234], ["the MPP", "TEST", 243, 250], ["dopaminergic neuronal cells", "PROBLEM", 275, 302], ["Measurement of LDH release", "TEST", 302, 328], ["dopaminergic neuronal cells", "OBSERVATION", 275, 302], ["LDH", "ANATOMY", 317, 320]]], ["The release of LDH into the culture medium was measured using an In Vitro Toxicology Assay kit (Sigma-Aldrich).", [["LDH", "CHEMICAL", 15, 18], ["LDH", "GENE_OR_GENE_PRODUCT", 15, 18], ["LDH", "PROTEIN", 15, 18], ["LDH", "TEST", 15, 18], ["the culture medium", "TEST", 24, 42]]], ["Briefly, the PC12 cells were seeded into 96-well plates at 2x10 4 cells per well.", [["PC12 cells", "ANATOMY", 13, 23], ["2x10 4 cells", "ANATOMY", 59, 71], ["PC12 cells", "CELL", 13, 23], ["2x10 4 cells", "CELL", 59, 71], ["PC12 cells", "CELL_LINE", 13, 23], ["the PC12 cells", "TREATMENT", 9, 23]]], ["Following differentiation, the cells were pre-treated with 25 \u00b5M GA for 3 h and co-treated with 4 mM MPP + for 24 h.", [["cells", "ANATOMY", 31, 36], ["GA", "CHEMICAL", 65, 67], ["MPP", "CHEMICAL", 101, 104], ["MPP", "CHEMICAL", 101, 104], ["cells", "CELL", 31, 36], ["GA", "SIMPLE_CHEMICAL", 65, 67], ["MPP +", "SIMPLE_CHEMICAL", 101, 106], ["25 \u00b5M GA", "TREATMENT", 59, 67]]], ["A total of 60 \u00b5l mixed assay solution was added into 30 \u00b5l culture medium collected from each group.", [["A total of 60 \u00b5l mixed assay solution", "TREATMENT", 0, 37]]], ["Following 30 min of incubation at room temperature in the dark, 10 \u00b5l 1 N HCl were added to terminate the reaction.", [["1 N HCl", "CHEMICAL", 70, 77], ["HCl", "CHEMICAL", 74, 77], ["incubation", "TREATMENT", 20, 30], ["the reaction", "PROBLEM", 102, 114]]], ["The absorbance was measured at a wavelength of 490 nm using a microplate reader (Bio-Rad).", [["a microplate reader", "TREATMENT", 60, 79], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["The values of the treated cells were expressed as a percentage of the corresponding untreated cells.Involvement of the ERK pathway in the protective effects of glycyrrhizic acid against the MPP + -induced apoptosis of dopaminergic neuronal cellsMitochondrial membrane potential (MMP) analysis.", [["cells", "ANATOMY", 26, 31], ["cells", "ANATOMY", 94, 99], ["dopaminergic neuronal cells", "ANATOMY", 218, 245], ["Mitochondrial membrane", "ANATOMY", 245, 267], ["glycyrrhizic acid", "CHEMICAL", 160, 177], ["MPP", "CHEMICAL", 190, 193], ["glycyrrhizic acid", "CHEMICAL", 160, 177], ["MPP +", "CHEMICAL", 190, 195], ["cells", "CELL", 26, 31], ["cells", "CELL", 94, 99], ["ERK", "GENE_OR_GENE_PRODUCT", 119, 122], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 160, 177], ["MPP +", "SIMPLE_CHEMICAL", 190, 195], ["dopaminergic neuronal cells", "CELL", 218, 245], ["Mitochondrial membrane", "CELLULAR_COMPONENT", 245, 267], ["treated cells", "CELL_LINE", 18, 31], ["untreated cells", "CELL_TYPE", 84, 99], ["ERK", "PROTEIN", 119, 122], ["dopaminergic neuronal cells", "CELL_TYPE", 218, 245], ["the ERK pathway", "TEST", 115, 130], ["glycyrrhizic acid", "TREATMENT", 160, 177], ["the MPP", "TEST", 186, 193], ["dopaminergic neuronal cells", "PROBLEM", 218, 245], ["Mitochondrial membrane potential (MMP) analysis", "TEST", 245, 292], ["untreated cells", "OBSERVATION", 84, 99], ["dopaminergic neuronal cells", "OBSERVATION", 218, 245]]], ["5,5' ,6,6'-Tetrachloro-1,1' ,3,3' tetraethylbenzimidazolylcarbocyanine iodide (JC-1; Sigma-Aldrich) was used to measure changes in MMP.", [["5,5' ,6,6'-Tetrachloro-1,1' ,3,3' tetraethylbenzimidazolylcarbocyanine iodide", "CHEMICAL", 0, 77], ["JC-1", "CHEMICAL", 79, 83], ["5,5' ,6,6'-Tetrachloro-1,1' ,3,3' tetraethylbenzimidazolylcarbocyanine iodide", "CHEMICAL", 0, 77], ["JC-1", "CHEMICAL", 79, 83], ["5,5' ,6,6'-Tetrachloro-1,1' ,3,3' tetraethylbenzimidazolylcarbocyanine iodide", "SIMPLE_CHEMICAL", 0, 77], ["JC-1", "SIMPLE_CHEMICAL", 79, 83], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 85, 98], ["MMP", "PROTEIN", 131, 134], ["Tetrachloro", "TREATMENT", 11, 22], ["3,3' tetraethylbenzimidazolylcarbocyanine iodide", "TREATMENT", 29, 77], ["Sigma-Aldrich)", "TREATMENT", 85, 99]]], ["The PC12 cells (1x10 5 ) were seeded in 12-well plates and allowed to differentiate.", [["PC12 cells", "ANATOMY", 4, 14], ["PC12 cells", "CELL", 4, 14], ["1x10 5", "CELL", 16, 22], ["PC12 cells", "CELL_LINE", 4, 14], ["1x10 5", "CELL_LINE", 16, 22], ["The PC12 cells", "TREATMENT", 0, 14], ["PC12 cells", "OBSERVATION", 4, 14]]], ["The cells were pre-treated with 25 \u00b5M GA for 3 h and co-treated with 4 mM MPP + for 24 h.", [["cells", "ANATOMY", 4, 9], ["GA", "CHEMICAL", 38, 40], ["MPP", "CHEMICAL", 74, 77], ["MPP", "CHEMICAL", 74, 77], ["cells", "CELL", 4, 9], ["GA", "SIMPLE_CHEMICAL", 38, 40], ["MPP +", "SIMPLE_CHEMICAL", 74, 79], ["25 \u00b5M GA", "TREATMENT", 32, 40]]], ["The treated DPC12 cells were incubated with 2 \u00b5M JC-1 at 37\u030aC for 10 min.", [["DPC12 cells", "ANATOMY", 12, 23], ["DPC12 cells", "CELL", 12, 23], ["DPC12 cells", "CELL_LINE", 12, 23], ["The treated DPC12 cells", "TREATMENT", 0, 23], ["2 \u00b5M JC", "TREATMENT", 44, 51]]], ["After 3 washes with phosphate-buffered saline (PBS), the changes in MMP of the DPC12 cells were analyzed using a fluorescence microscope (x20 magnification; Axio Observer Z1, CCD camera; Carl Zeiss, Inc.).Measurement of intracellular Ca 2+ concentration.Fluo-4 AM (Invitrogen) staining was used to measure the intracellular Ca 2+ concentration.", [["DPC12 cells", "ANATOMY", 79, 90], ["intracellular", "ANATOMY", 220, 233], ["intracellular", "ANATOMY", 310, 323], ["phosphate", "CHEMICAL", 20, 29], ["Ca", "CHEMICAL", 234, 236], ["Fluo-4 AM", "CHEMICAL", 254, 263], ["Ca", "CHEMICAL", 324, 326], ["phosphate", "CHEMICAL", 20, 29], ["Ca 2+", "CHEMICAL", 234, 239], ["Fluo-4 AM", "CHEMICAL", 254, 263], ["Ca 2+", "CHEMICAL", 324, 329], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 20, 45], ["DPC12 cells", "CELL", 79, 90], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 220, 233], ["Ca 2+", "SIMPLE_CHEMICAL", 234, 239], ["Fluo-4 AM", "SIMPLE_CHEMICAL", 254, 263], ["Invitrogen", "SIMPLE_CHEMICAL", 265, 275], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 310, 323], ["Ca 2+", "SIMPLE_CHEMICAL", 324, 329], ["MMP", "PROTEIN", 68, 71], ["DPC12 cells", "CELL_LINE", 79, 90], ["phosphate-buffered saline (PBS", "TREATMENT", 20, 50], ["MMP of the DPC12 cells", "TREATMENT", 68, 90], ["a fluorescence microscope", "TREATMENT", 111, 136], ["intracellular Ca", "TREATMENT", 220, 236], ["Fluo", "TEST", 254, 258], ["the intracellular Ca", "TREATMENT", 306, 326]]], ["The DPC12 cells were pre-treated with 25 \u00b5M GA for 3 h and then co-treated with 4 mM MPP + for a further 3 h.", [["DPC12 cells", "ANATOMY", 4, 15], ["GA", "CHEMICAL", 44, 46], ["MPP", "CHEMICAL", 85, 88], ["MPP", "CHEMICAL", 85, 88], ["DPC12 cells", "CELL", 4, 15], ["MPP +", "SIMPLE_CHEMICAL", 85, 90], ["DPC12 cells", "CELL_LINE", 4, 15], ["The DPC12 cells", "TREATMENT", 0, 15], ["25 \u00b5M GA", "TREATMENT", 38, 46]]], ["The cells were incubated with Fluo-4 AM (final concentration, 5 \u00b5M) at 37\u030aC for 30 min, and washed 3 times to remove the excess probe.", [["cells", "ANATOMY", 4, 9], ["Fluo-4 AM", "CHEMICAL", 30, 39], ["cells", "CELL", 4, 9], ["Fluo-4 AM", "SIMPLE_CHEMICAL", 30, 39]]], ["The fluorescence intensity was determined using a fluorescence microscope (x40 magnification; Axio Observer Z1, CCD camera; Carl Zeiss).", [["The fluorescence intensity", "TEST", 0, 26], ["a fluorescence microscope", "TEST", 48, 73]]], ["The experiment was repeated 3 times and the average fluorescence intensity for each cell was calculated using ImageJ software.Measurement of intracellular Ca 2+ concentration.Flow cytometric analysis of apoptosis.", [["cell", "ANATOMY", 84, 88], ["intracellular", "ANATOMY", 141, 154], ["Ca", "CHEMICAL", 155, 157], ["Ca 2+", "CHEMICAL", 155, 160], ["cell", "CELL", 84, 88], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 141, 154], ["Ca 2+", "SIMPLE_CHEMICAL", 155, 160], ["ImageJ software", "TEST", 110, 125], ["intracellular Ca", "TREATMENT", 141, 157], ["Flow cytometric analysis", "TEST", 175, 199], ["apoptosis", "PROBLEM", 203, 212], ["apoptosis", "OBSERVATION", 203, 212]]], ["Flow cytometric analysis was used to assess the membrane and nuclear events during apoptosis, as previously described (7).", [["membrane", "ANATOMY", 48, 56], ["nuclear", "ANATOMY", 61, 68], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["nuclear", "CELLULAR_COMPONENT", 61, 68], ["Flow cytometric analysis", "TEST", 0, 24]]], ["The assay was performed with a two-color analysis of fluorescein isothiocyanate (FITC)-labeled Annexin V binding propidium iodide (PI) (Becton-Dickinson Co., Miami, FL, USA).", [["fluorescein isothiocyanate", "CHEMICAL", 53, 79], ["Annexin V", "CHEMICAL", 95, 104], ["propidium iodide", "CHEMICAL", 113, 129], ["fluorescein isothiocyanate", "CHEMICAL", 53, 79], ["FITC", "CHEMICAL", 81, 85], ["propidium iodide", "CHEMICAL", 113, 129], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 53, 79], ["FITC", "SIMPLE_CHEMICAL", 81, 85], ["Annexin V binding propidium iodide", "SIMPLE_CHEMICAL", 95, 129], ["PI", "SIMPLE_CHEMICAL", 131, 133], ["The assay", "TEST", 0, 9], ["fluorescein isothiocyanate", "TREATMENT", 53, 79]]], ["The DPC12 cells were pre-treated with 25 \u00b5M GA for 3 h and then co-treated with 4 mM MPP + for a further 12 h.", [["DPC12 cells", "ANATOMY", 4, 15], ["GA", "CHEMICAL", 44, 46], ["MPP", "CHEMICAL", 85, 88], ["MPP", "CHEMICAL", 85, 88], ["DPC12 cells", "CELL", 4, 15], ["MPP +", "SIMPLE_CHEMICAL", 85, 90], ["DPC12 cells", "CELL_LINE", 4, 15], ["The DPC12 cells", "TREATMENT", 0, 15], ["25 \u00b5M GA", "TREATMENT", 38, 46]]], ["The cells were suspended (1x10 6 /ml) in binding buffer and incubated for 10 min with 5 \u00b5l Anexin V-FITC (20 \u00b5g/ml) and 10 \u00b5l PI (50 \u00b5g/ml) at room temperature in the dark.", [["cells", "ANATOMY", 4, 9], ["Anexin V-FITC", "CHEMICAL", 91, 104], ["FITC", "CHEMICAL", 100, 104], ["cells", "CELL", 4, 9], ["Anexin V-FITC", "SIMPLE_CHEMICAL", 91, 104], ["The cells", "TREATMENT", 0, 9], ["5 \u00b5l Anexin V-FITC", "TREATMENT", 86, 104]]], ["The level of fluorescence was analyzed using a flow cytometer (Cytomics\u2122 FC 500; Beckman Coulter, Inc., Brea, CA, USA).", [["a flow cytometer", "TEST", 45, 61], ["Beckman Coulter", "TEST", 81, 96]]], ["The experiment was repeated 3 times.Measurement of intracellular Ca 2+ concentration.Western blot analysis.", [["intracellular", "ANATOMY", 51, 64], ["Ca", "CHEMICAL", 65, 67], ["Ca 2+", "CHEMICAL", 65, 70], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 64], ["Ca 2+", "SIMPLE_CHEMICAL", 65, 70], ["intracellular Ca", "TREATMENT", 51, 67], ["blot analysis", "TEST", 93, 106]]], ["The treated cells were lysed with RIPA buffer containing 1% protease inhibitor cocktails and 2% phenylmethanesulfonyl fluoride (PMSF) (all from Sigma-Aldrich).", [["cells", "ANATOMY", 12, 17], ["phenylmethanesulfonyl fluoride", "CHEMICAL", 96, 126], ["phenylmethanesulfonyl fluoride", "CHEMICAL", 96, 126], ["PMSF", "CHEMICAL", 128, 132], ["cells", "CELL", 12, 17], ["phenylmethanesulfonyl fluoride", "SIMPLE_CHEMICAL", 96, 126], ["PMSF", "SIMPLE_CHEMICAL", 128, 132], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 144, 157], ["treated cells", "CELL_LINE", 4, 17], ["The treated cells", "TREATMENT", 0, 17], ["RIPA buffer", "TREATMENT", 34, 45], ["1% protease inhibitor cocktails", "TREATMENT", 57, 88], ["2% phenylmethanesulfonyl fluoride", "TREATMENT", 93, 126]]], ["For the detection of ERK translocation, the preparation of cytoplasmic and nuclear extracts was carried out as described in a previous study by Yang et al (21) .", [["cytoplasmic", "ANATOMY", 59, 70], ["nuclear extracts", "ANATOMY", 75, 91], ["ERK", "GENE_OR_GENE_PRODUCT", 21, 24], ["cytoplasmic", "ORGANISM_SUBSTANCE", 59, 70], ["nuclear extracts", "ORGANISM_SUBSTANCE", 75, 91], ["ERK", "PROTEIN", 21, 24], ["ERK translocation", "PROBLEM", 21, 38], ["a previous study", "TEST", 124, 140], ["ERK translocation", "OBSERVATION", 21, 38]]], ["After the supernatant collection, the protein concentration was determined using the Bradford method.", [["supernatant", "ANATOMY", 10, 21], ["the supernatant collection", "TREATMENT", 6, 32], ["the protein concentration", "TEST", 34, 59], ["the Bradford method", "TREATMENT", 81, 100], ["supernatant", "OBSERVATION_MODIFIER", 10, 21], ["collection", "OBSERVATION", 22, 32]]], ["Proteins were separated on a 10% SDS-PAGE gel and transferred electrophoretically onto nitrocellulose membranes (Bio Basic, Inc., Markham, Ontario, Canada).", [["Proteins", "ANATOMY", 0, 8], ["membranes", "ANATOMY", 102, 111], ["nitrocellulose", "CHEMICAL", 87, 101], ["membranes", "CELLULAR_COMPONENT", 102, 111], ["a 10% SDS-PAGE gel", "TREATMENT", 27, 45], ["nitrocellulose membranes", "TREATMENT", 87, 111]]], ["The transferred membranes were then blotted with primary antibodies (dilution of 1:1,000) to: phosphorylated ERK (p-ERKs), total ERK (t-ERKs), phosphorylated AKT (p-AKT), total AKT (t-AKT), cleaved poly(ADP-ribose) polymerase (PARP), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and lamin B (Cell Signaling Technology, Inc., Danvers, MA, USA) at 4\u030aC overnight, followed by treatment with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc., Dallas, TX, USA).", [["membranes", "ANATOMY", 16, 25], ["poly(ADP-ribose", "CHEMICAL", 198, 213], ["glyceraldehyde 3-phosphate", "CHEMICAL", 234, 260], ["poly(ADP-ribose)", "CHEMICAL", 198, 214], ["glyceraldehyde 3-phosphate", "CHEMICAL", 234, 260], ["membranes", "CELLULAR_COMPONENT", 16, 25], ["ERK", "GENE_OR_GENE_PRODUCT", 109, 112], ["p-ERKs", "GENE_OR_GENE_PRODUCT", 114, 120], ["ERK", "GENE_OR_GENE_PRODUCT", 129, 132], ["t-ERKs", "GENE_OR_GENE_PRODUCT", 134, 140], ["AKT", "GENE_OR_GENE_PRODUCT", 158, 161], ["p-AKT", "GENE_OR_GENE_PRODUCT", 163, 168], ["AKT", "GENE_OR_GENE_PRODUCT", 177, 180], ["t-AKT", "GENE_OR_GENE_PRODUCT", 182, 187], ["poly(ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 198, 225], ["PARP", "GENE_OR_GENE_PRODUCT", 227, 231], ["glyceraldehyde 3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 234, 274], ["GAPDH", "GENE_OR_GENE_PRODUCT", 276, 281], ["lamin B", "GENE_OR_GENE_PRODUCT", 287, 294], ["Cell", "CELL", 296, 300], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 392, 414], ["primary antibodies", "PROTEIN", 49, 67], ["phosphorylated ERK", "PROTEIN", 94, 112], ["p-ERKs", "PROTEIN", 114, 120], ["ERK", "PROTEIN", 129, 132], ["t-ERKs", "PROTEIN", 134, 140], ["phosphorylated AKT", "PROTEIN", 143, 161], ["AKT", "PROTEIN", 165, 168], ["total AKT", "PROTEIN", 171, 180], ["t-AKT", "PROTEIN", 182, 187], ["cleaved poly(ADP-ribose) polymerase", "PROTEIN", 190, 225], ["PARP", "PROTEIN", 227, 231], ["glyceraldehyde 3-phosphate dehydrogenase", "PROTEIN", 234, 274], ["GAPDH", "PROTEIN", 276, 281], ["lamin B", "PROTEIN", 287, 294], ["horseradish peroxidase", "PROTEIN", 392, 414], ["conjugated secondary antibodies", "PROTEIN", 415, 446], ["Santa Cruz Biotechnology", "PROTEIN", 448, 472], ["horseradish", "SPECIES", 392, 403], ["phosphorylated ERK", "TEST", 94, 112], ["ERKs", "TEST", 116, 120], ["total ERK", "TEST", 123, 132], ["ERKs", "TEST", 136, 140], ["phosphorylated AKT", "TEST", 143, 161], ["AKT", "TEST", 165, 168], ["total AKT", "TEST", 171, 180], ["AKT", "TEST", 184, 187], ["cleaved poly(ADP-ribose) polymerase", "TEST", 190, 225], ["PARP", "TEST", 227, 231], ["glyceraldehyde", "TEST", 234, 248], ["phosphate dehydrogenase (GAPDH)", "PROBLEM", 251, 282], ["lamin B (Cell Signaling Technology", "TREATMENT", 287, 321], ["horseradish peroxidase", "TREATMENT", 392, 414]]], ["Chemiluminescence was detected using ECL detection kits (GE Healthcare, Buckinghamshire, UK).", [["Chemiluminescence", "TEST", 0, 17]]], ["The intensity of the bands was quantified by scanning densitometry using Quantity One 4.5.0 software (Bio Basic, Inc.).Measurement of intracellular Ca 2+ concentration.Statistical analysis.", [["intracellular", "ANATOMY", 134, 147], ["Ca", "CHEMICAL", 148, 150], ["Ca 2+", "CHEMICAL", 148, 153], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 134, 147], ["Ca 2+", "SIMPLE_CHEMICAL", 148, 153], ["the bands", "PROBLEM", 17, 26], ["scanning densitometry", "TEST", 45, 66], ["intracellular Ca", "TREATMENT", 134, 150], ["Statistical analysis", "TEST", 168, 188], ["intensity", "OBSERVATION_MODIFIER", 4, 13]]], ["One-way ANOVA was applied to determine the statistical significance, followed by post-hoc multiple comparisons (Dunn's test).", [["Dunn's test", "TEST", 112, 123]]], ["A value of P<0.05 was considered to indicate a statistically significant difference.", [["A value", "TEST", 0, 7], ["a statistically significant difference", "PROBLEM", 45, 83], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["difference", "OBSERVATION", 73, 83]]], ["Moreover, double-staining with Annexin V-FITC and PI was used to detect the apoptotic rate of DPC12 cells following treatment.", [["DPC12 cells", "ANATOMY", 94, 105], ["Annexin V", "CHEMICAL", 31, 40], ["FITC", "CHEMICAL", 41, 45], ["Annexin V-FITC", "GENE_OR_GENE_PRODUCT", 31, 45], ["PI", "SIMPLE_CHEMICAL", 50, 52], ["DPC12 cells", "CELL", 94, 105], ["DPC12 cells", "CELL_LINE", 94, 105], ["Annexin V", "TREATMENT", 31, 40], ["FITC and PI", "TREATMENT", 41, 52], ["DPC12 cells", "TREATMENT", 94, 105], ["treatment", "TREATMENT", 116, 125], ["DPC12 cells", "OBSERVATION", 94, 105]]], ["The increase in the apoptotic rate of the MPP + -exposed cells was reversed by pre-treatment with 25 \u00b5M GA (7.2 vs. 19.1%; Fig. 1C ).", [["MPP + -exposed cells", "ANATOMY", 42, 62], ["GA", "CHEMICAL", 104, 106], ["cells", "CELL", 57, 62], ["MPP + -exposed cells", "CELL_LINE", 42, 62], ["The increase", "PROBLEM", 0, 12], ["-exposed cells", "PROBLEM", 48, 62], ["\u00b5M GA", "TEST", 101, 106], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["apoptotic", "OBSERVATION_MODIFIER", 20, 29], ["-exposed cells", "OBSERVATION", 48, 62]]], ["The morphological changes in the primary cortical neurons were visualized by phase-contrast imaging.", [["primary cortical neurons", "ANATOMY", 33, 57], ["cortical neurons", "CELL", 41, 57], ["primary cortical neurons", "CELL_TYPE", 33, 57], ["phase-contrast imaging", "TEST", 77, 99], ["morphological", "OBSERVATION_MODIFIER", 4, 17], ["cortical neurons", "ANATOMY", 41, 57]]], ["Compared with the untreated cells, shrinkage and detachment were observed following exposure to MPP + .", [["cells", "ANATOMY", 28, 33], ["MPP", "CHEMICAL", 96, 99], ["MPP", "CHEMICAL", 96, 99], ["cells", "CELL", 28, 33], ["MPP +", "SIMPLE_CHEMICAL", 96, 101], ["the untreated cells", "PROBLEM", 14, 33], ["shrinkage", "PROBLEM", 35, 44], ["detachment", "PROBLEM", 49, 59], ["MPP", "TEST", 96, 99], ["shrinkage", "OBSERVATION_MODIFIER", 35, 44], ["detachment", "OBSERVATION", 49, 59]]], ["Pre-treatment with 25 \u00b5M GA markedly reversed the morphological damage caused by MPP + (Fig. 2C) .EffectsEffects of GA on mitochondrial dysfunction, intracellular Ca 2+ overload and the expression of cleaved PARP.", [["mitochondrial", "ANATOMY", 122, 135], ["intracellular", "ANATOMY", 149, 162], ["GA", "CHEMICAL", 25, 27], ["MPP", "CHEMICAL", 81, 84], ["GA", "CHEMICAL", 116, 118], ["mitochondrial dysfunction", "DISEASE", 122, 147], ["Ca", "CHEMICAL", 163, 165], ["MPP", "CHEMICAL", 81, 84], ["Ca 2+", "CHEMICAL", 163, 168], ["GA", "SIMPLE_CHEMICAL", 25, 27], ["MPP +", "SIMPLE_CHEMICAL", 81, 86], ["GA", "SIMPLE_CHEMICAL", 116, 118], ["mitochondrial", "CELLULAR_COMPONENT", 122, 135], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 149, 162], ["Ca 2+", "SIMPLE_CHEMICAL", 163, 168], ["PARP", "GENE_OR_GENE_PRODUCT", 208, 212], ["cleaved PARP", "PROTEIN", 200, 212], ["Pre-treatment", "TREATMENT", 0, 13], ["25 \u00b5M GA", "TREATMENT", 19, 27], ["the morphological damage", "PROBLEM", 46, 70], ["MPP", "TEST", 81, 84], ["mitochondrial dysfunction", "PROBLEM", 122, 147], ["intracellular Ca", "PROBLEM", 149, 165], ["overload", "PROBLEM", 169, 177], ["PARP", "PROBLEM", 208, 212], ["GA", "OBSERVATION", 116, 118], ["mitochondrial dysfunction", "OBSERVATION", 122, 147], ["intracellular", "OBSERVATION_MODIFIER", 149, 162], ["Ca", "OBSERVATION", 163, 165], ["overload", "OBSERVATION", 169, 177]]], ["MMP related to mitochondrial permeability plays an important role in the cell apoptotic pathway.", [["mitochondrial", "ANATOMY", 15, 28], ["cell", "ANATOMY", 73, 77], ["MMP", "GENE_OR_GENE_PRODUCT", 0, 3], ["mitochondrial", "CELLULAR_COMPONENT", 15, 28], ["cell", "CELL", 73, 77], ["MMP", "PROTEIN", 0, 3], ["MMP", "PROBLEM", 0, 3], ["mitochondrial permeability", "PROBLEM", 15, 41], ["mitochondrial permeability", "OBSERVATION", 15, 41]]], ["Compared with the MPP + -exposed cells, after 12 h of co-treatment, 25 \u00b5M GA restored the dissipation of MMP indicated by an increase in the emission of red fluorescence (Fig. 3A) .EffectsThe results from Fluo-4 AM staining showed that after 3 h of incubation of the PC12 cells, GA mitigated the calcium overload caused by MPP + , indicated by a reduction in the emission of green fluorescence (Fig. 3B) .EffectsFurthermore, the level of cleaved PARP, a hallmark of apoptosis, was determined by western blot analysis.", [["MPP + -exposed cells", "ANATOMY", 18, 38], ["PC12 cells", "ANATOMY", 267, 277], ["GA", "CHEMICAL", 74, 76], ["Fluo-4", "CHEMICAL", 205, 211], ["GA", "CHEMICAL", 279, 281], ["calcium", "CHEMICAL", 296, 303], ["MPP", "CHEMICAL", 323, 326], ["calcium", "CHEMICAL", 296, 303], ["MPP +", "CHEMICAL", 323, 328], ["cells", "CELL", 33, 38], ["GA", "SIMPLE_CHEMICAL", 74, 76], ["Fluo-4 AM", "GENE_OR_GENE_PRODUCT", 205, 214], ["PC12 cells", "CELL", 267, 277], ["GA", "SIMPLE_CHEMICAL", 279, 281], ["calcium", "SIMPLE_CHEMICAL", 296, 303], ["MPP +", "SIMPLE_CHEMICAL", 323, 328], ["PARP", "GENE_OR_GENE_PRODUCT", 446, 450], ["MPP + -exposed cells", "CELL_LINE", 18, 38], ["MMP", "PROTEIN", 105, 108], ["PC12 cells", "CELL_LINE", 267, 277], ["cleaved PARP", "PROTEIN", 438, 450], ["the MPP", "TEST", 14, 21], ["co-treatment", "TREATMENT", 54, 66], ["MMP", "PROBLEM", 105, 108], ["red fluorescence", "TEST", 153, 169], ["Fluo-4 AM staining", "TEST", 205, 223], ["the PC12 cells", "TREATMENT", 263, 277], ["the calcium overload", "PROBLEM", 292, 312], ["MPP", "TEST", 323, 326], ["PARP", "PROBLEM", 446, 450], ["apoptosis", "PROBLEM", 466, 475], ["blot analysis", "TEST", 503, 516], ["-exposed cells", "OBSERVATION", 24, 38], ["increase", "OBSERVATION_MODIFIER", 125, 133], ["PC12 cells", "OBSERVATION", 267, 277], ["hallmark", "OBSERVATION_MODIFIER", 454, 462], ["apoptosis", "OBSERVATION", 466, 475]]], ["A significant enhancement in the expression of cleaved PARP was observed in the DPC12 cells exposed to 4 mM MPP + for 24 h.", [["DPC12 cells", "ANATOMY", 80, 91], ["MPP", "CHEMICAL", 108, 111], ["MPP", "CHEMICAL", 108, 111], ["PARP", "GENE_OR_GENE_PRODUCT", 55, 59], ["DPC12 cells", "CELL", 80, 91], ["MPP +", "SIMPLE_CHEMICAL", 108, 113], ["cleaved PARP", "PROTEIN", 47, 59], ["DPC12 cells", "CELL_LINE", 80, 91], ["A significant enhancement", "PROBLEM", 0, 25], ["cleaved PARP", "PROBLEM", 47, 59], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["enhancement", "OBSERVATION", 14, 25], ["cleaved", "OBSERVATION_MODIFIER", 47, 54], ["PARP", "OBSERVATION", 55, 59]]], ["Conversely, pre-treatment with 25 \u00b5M GA reduced the overexpression of cleaved PARP (P<0.05; Fig. 4 ).EffectsThe ERK, but not the AKT pathway contributes to the GA-mediated neuroprotective effects.", [["GA", "CHEMICAL", 37, 39], ["GA", "CHEMICAL", 160, 162], ["GA", "SIMPLE_CHEMICAL", 37, 39], ["PARP", "GENE_OR_GENE_PRODUCT", 78, 82], ["ERK", "GENE_OR_GENE_PRODUCT", 112, 115], ["AKT", "GENE_OR_GENE_PRODUCT", 129, 132], ["GA", "SIMPLE_CHEMICAL", 160, 162], ["cleaved PARP", "PROTEIN", 70, 82], ["ERK", "PROTEIN", 112, 115], ["AKT", "PROTEIN", 129, 132], ["25 \u00b5M GA", "TREATMENT", 31, 39], ["cleaved PARP", "PROBLEM", 70, 82], ["The ERK", "TEST", 108, 115], ["the GA-mediated neuroprotective effects", "PROBLEM", 156, 195]]], ["Exposure to MPP + significantly suppressed the expression of p-ERK, but not that of t-ERK (Fig. 5A) .", [["MPP", "CHEMICAL", 12, 15], ["MPP +", "CHEMICAL", 12, 17], ["MPP +", "SIMPLE_CHEMICAL", 12, 17], ["p-ERK", "GENE_OR_GENE_PRODUCT", 61, 66], ["t-ERK", "GENE_OR_GENE_PRODUCT", 84, 89], ["Fig. 5A", "GENE_OR_GENE_PRODUCT", 91, 98], ["p", "PROTEIN", 61, 62], ["ERK", "PROTEIN", 63, 66], ["t-ERK", "PROTEIN", 84, 89], ["Fig. 5A", "PROTEIN", 91, 98]]], ["Treatment with GA (25 \u00b5M) alone increased the phosphorylation of ERK after 30 min of incubation (P<0.01; Fig. 5B ).Pre-treatment with GA (25 \u00b5M) markedly reversed the decrease in the expression of p-ERK caused by MPP + at 10 and 30 min of treatment (Fig. 5C) .", [["GA", "CHEMICAL", 15, 17], ["GA", "CHEMICAL", 134, 136], ["MPP", "CHEMICAL", 213, 216], ["GA", "SIMPLE_CHEMICAL", 15, 17], ["ERK", "GENE_OR_GENE_PRODUCT", 65, 68], ["GA", "SIMPLE_CHEMICAL", 134, 136], ["p-ERK", "GENE_OR_GENE_PRODUCT", 197, 202], ["MPP +", "SIMPLE_CHEMICAL", 213, 218], ["ERK", "PROTEIN", 65, 68], ["ERK", "PROTEIN", 199, 202], ["MPP", "PROTEIN", 213, 216], ["GA (25 \u00b5M)", "TREATMENT", 15, 25], ["the phosphorylation of ERK", "TREATMENT", 42, 68], ["MPP", "TEST", 213, 216], ["treatment (Fig. 5C", "TREATMENT", 239, 257], ["decrease", "OBSERVATION_MODIFIER", 167, 175]]], ["Furthermore, the translocation of activated ERK from the cytoplasm to the nucleus was determined.", [["cytoplasm", "ANATOMY", 57, 66], ["nucleus", "ANATOMY", 74, 81], ["ERK", "GENE_OR_GENE_PRODUCT", 44, 47], ["cytoplasm", "ORGANISM_SUBSTANCE", 57, 66], ["nucleus", "CELLULAR_COMPONENT", 74, 81], ["ERK", "PROTEIN", 44, 47], ["activated ERK", "PROBLEM", 34, 47], ["nucleus", "ANATOMY", 74, 81]]], ["Following exposure to 4 mM MPP + for 60 min, the expression of p-ERK in the nucleus was reduced; by contrast, pre-treatment with GA for 3 h significantly reversed the MPP + -induced suppression of the translocation of ERK to the nucleus (Fig. 5E) .EffectsAdditionally, treatment with MPP + alone, GA alone and MPP + plus GA had no effects on the expression of p-AKT and t-AKT (Fig. 6A-D) .", [["nucleus", "ANATOMY", 76, 83], ["nucleus", "ANATOMY", 229, 236], ["MPP", "CHEMICAL", 27, 30], ["GA", "CHEMICAL", 129, 131], ["MPP", "CHEMICAL", 167, 170], ["MPP", "CHEMICAL", 284, 287], ["GA", "CHEMICAL", 297, 299], ["MPP", "CHEMICAL", 310, 313], ["GA", "CHEMICAL", 321, 323], ["MPP", "CHEMICAL", 27, 30], ["MPP +", "CHEMICAL", 167, 172], ["MPP", "CHEMICAL", 284, 287], ["MPP +", "SIMPLE_CHEMICAL", 27, 32], ["p-ERK", "GENE_OR_GENE_PRODUCT", 63, 68], ["nucleus", "CELLULAR_COMPONENT", 76, 83], ["GA", "SIMPLE_CHEMICAL", 129, 131], ["MPP +", "SIMPLE_CHEMICAL", 167, 172], ["ERK", "GENE_OR_GENE_PRODUCT", 218, 221], ["nucleus", "CELLULAR_COMPONENT", 229, 236], ["MPP +", "SIMPLE_CHEMICAL", 284, 289], ["GA", "SIMPLE_CHEMICAL", 297, 299], ["MPP +", "SIMPLE_CHEMICAL", 310, 315], ["GA", "SIMPLE_CHEMICAL", 321, 323], ["p-AKT", "GENE_OR_GENE_PRODUCT", 360, 365], ["t-AKT", "GENE_OR_GENE_PRODUCT", 370, 375], ["Fig. 6A-D", "GENE_OR_GENE_PRODUCT", 377, 386], ["p", "PROTEIN", 63, 64], ["ERK", "PROTEIN", 65, 68], ["ERK", "PROTEIN", 218, 221], ["p", "PROTEIN", 360, 361], ["AKT", "PROTEIN", 362, 365], ["t-AKT", "PROTEIN", 370, 375], ["Fig. 6A-D", "PROTEIN", 377, 386], ["the MPP", "TEST", 163, 170], ["MPP", "TREATMENT", 284, 287], ["MPP", "TEST", 310, 313], ["nucleus", "ANATOMY", 76, 83], ["nucleus", "ANATOMY", 229, 236]]], ["Further experiments revealed that the GA-induced increase in the phosphorylation of ERK and the improvement in cell viability were markedly abrogated by pre-treatment with 10 \u00b5M PD98059, an ERK inhibitor (Fig. 7A and B) .", [["cell", "ANATOMY", 111, 115], ["GA", "CHEMICAL", 38, 40], ["PD98059", "CHEMICAL", 178, 185], ["PD98059", "CHEMICAL", 178, 185], ["GA", "SIMPLE_CHEMICAL", 38, 40], ["ERK", "GENE_OR_GENE_PRODUCT", 84, 87], ["cell", "CELL", 111, 115], ["PD98059", "SIMPLE_CHEMICAL", 178, 185], ["ERK", "GENE_OR_GENE_PRODUCT", 190, 193], ["B", "GENE_OR_GENE_PRODUCT", 217, 218], ["ERK", "PROTEIN", 84, 87], ["Further experiments", "TEST", 0, 19], ["the GA", "PROBLEM", 34, 40], ["the phosphorylation of ERK", "PROBLEM", 61, 87], ["cell viability", "PROBLEM", 111, 125], ["an ERK inhibitor", "TREATMENT", 187, 203], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["cell viability", "OBSERVATION", 111, 125]]], ["Collectively, our data suggest that the ERK, but not the AKT signaling pathway contributes to the GA-mediated neuroprotective effects against MPP + -induced DPC12 cell damage.DiscussionPC12 cells, which possess a dopamine synthesis, metabolism and transporting system (22) , can shift their phenotype, changing from proliferating, undifferentiated cells into postmitotic, differentiated, neurite-bearing neurons following incubation with NGF (23) .", [["DPC12 cell", "ANATOMY", 157, 167], ["DiscussionPC12 cells", "ANATOMY", 175, 195], ["cells", "ANATOMY", 348, 353], ["neurite", "ANATOMY", 388, 395], ["neurons", "ANATOMY", 404, 411], ["GA", "CHEMICAL", 98, 100], ["MPP", "CHEMICAL", 142, 145], ["dopamine", "CHEMICAL", 213, 221], ["dopamine", "CHEMICAL", 213, 221], ["ERK", "GENE_OR_GENE_PRODUCT", 40, 43], ["AKT", "GENE_OR_GENE_PRODUCT", 57, 60], ["GA", "SIMPLE_CHEMICAL", 98, 100], ["MPP +", "SIMPLE_CHEMICAL", 142, 147], ["DPC12 cell", "CELL", 157, 167], ["DiscussionPC12 cells", "CELL", 175, 195], ["dopamine", "SIMPLE_CHEMICAL", 213, 221], ["cells", "CELL", 348, 353], ["postmitotic", "CELL", 359, 370], ["neurite", "CELL", 388, 395], ["neurons", "CELL", 404, 411], ["NGF", "GENE_OR_GENE_PRODUCT", 438, 441], ["ERK", "PROTEIN", 40, 43], ["AKT", "PROTEIN", 57, 60], ["DiscussionPC12 cells", "CELL_LINE", 175, 195], ["proliferating, undifferentiated cells", "CELL_TYPE", 316, 353], ["postmitotic, differentiated, neurite-bearing neurons", "CELL_TYPE", 359, 411], ["NGF", "PROTEIN", 438, 441], ["the ERK", "TEST", 36, 43], ["the AKT signaling pathway", "PROBLEM", 53, 78], ["the GA", "PROBLEM", 94, 100], ["MPP", "PROBLEM", 142, 145], ["-induced DPC12 cell damage", "PROBLEM", 148, 174], ["a dopamine synthesis", "TREATMENT", 211, 231], ["DPC12 cell damage", "OBSERVATION", 157, 174], ["undifferentiated cells", "OBSERVATION", 331, 353]]], ["Studies have demonstrated that DPC12 cells are more sensitive to neurotoxins (24) .", [["DPC12 cells", "ANATOMY", 31, 42], ["DPC12 cells", "CELL", 31, 42], ["DPC12 cells", "CELL_LINE", 31, 42], ["Studies", "TEST", 0, 7], ["DPC12 cells", "PROBLEM", 31, 42], ["neurotoxins", "TEST", 65, 76], ["DPC12 cells", "OBSERVATION", 31, 42]]], ["The present study clearly confirms that GA exerts marked neuroprotective effects, as evidenced by our results: GA greatly ameliorated the MPP + -induced reduction in cell viability, the increased apoptotic rate, the intracellular Ca 2+ overload and the dissipation in MMP in the DPC12 cells.", [["cell", "ANATOMY", 166, 170], ["intracellular", "ANATOMY", 216, 229], ["DPC12 cells", "ANATOMY", 279, 290], ["GA", "CHEMICAL", 40, 42], ["GA", "CHEMICAL", 111, 113], ["MPP", "CHEMICAL", 138, 141], ["Ca", "CHEMICAL", 230, 232], ["MPP +", "CHEMICAL", 138, 143], ["Ca 2+", "CHEMICAL", 230, 235], ["GA", "SIMPLE_CHEMICAL", 40, 42], ["GA", "SIMPLE_CHEMICAL", 111, 113], ["MPP +", "SIMPLE_CHEMICAL", 138, 143], ["cell", "CELL", 166, 170], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 216, 229], ["Ca 2+", "SIMPLE_CHEMICAL", 230, 235], ["DPC12 cells", "CELL", 279, 290], ["MMP", "PROTEIN", 268, 271], ["DPC12 cells", "CELL_LINE", 279, 290], ["The present study", "TEST", 0, 17], ["the MPP", "TEST", 134, 141], ["induced reduction in cell viability", "PROBLEM", 145, 180], ["the increased apoptotic rate", "PROBLEM", 182, 210], ["the intracellular Ca", "PROBLEM", 212, 232], ["overload", "PROBLEM", 236, 244], ["the dissipation in MMP in the DPC12 cells", "PROBLEM", 249, 290], ["marked", "OBSERVATION_MODIFIER", 50, 56], ["neuroprotective effects", "OBSERVATION", 57, 80], ["reduction", "OBSERVATION_MODIFIER", 153, 162], ["cell viability", "OBSERVATION", 166, 180], ["increased", "OBSERVATION_MODIFIER", 186, 195], ["apoptotic rate", "OBSERVATION", 196, 210], ["overload", "OBSERVATION", 236, 244]]], ["GA also exerted suppressive effects on the overproduction of intracellular LDH caused by MPP + .", [["intracellular", "ANATOMY", 61, 74], ["GA", "CHEMICAL", 0, 2], ["MPP", "CHEMICAL", 89, 92], ["GA", "SIMPLE_CHEMICAL", 0, 2], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["LDH", "SIMPLE_CHEMICAL", 75, 78], ["MPP +", "SIMPLE_CHEMICAL", 89, 94], ["intracellular LDH", "PROTEIN", 61, 78], ["MPP", "PROTEIN", 89, 92], ["intracellular LDH", "TEST", 61, 78], ["suppressive", "OBSERVATION_MODIFIER", 16, 27], ["intracellular LDH", "OBSERVATION", 61, 78]]], ["Consistent with the results of previous studies (25, 26) , this suppressive effect on the LDH level is a consequence of the protective effects of GA against neurotoxicity.", [["GA", "CHEMICAL", 146, 148], ["neurotoxicity", "DISEASE", 157, 170], ["LDH", "GENE_OR_GENE_PRODUCT", 90, 93], ["GA", "SIMPLE_CHEMICAL", 146, 148], ["LDH", "PROTEIN", 90, 93], ["previous studies", "TEST", 31, 47], ["this suppressive effect", "PROBLEM", 59, 82], ["the LDH level", "TEST", 86, 99], ["neurotoxicity", "PROBLEM", 157, 170]]], ["PARP is a family of proteins involved in a number of cellular processes, including DNA repair and programmed cell death (27) .", [["cellular", "ANATOMY", 53, 61], ["cell", "ANATOMY", 109, 113], ["PARP", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 53, 61], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["cell", "CELL", 109, 113], ["PARP", "PROTEIN", 0, 4], ["PARP", "PROBLEM", 0, 4], ["DNA repair", "TREATMENT", 83, 93], ["programmed cell death", "PROBLEM", 98, 119], ["cellular processes", "OBSERVATION", 53, 71]]], ["GA markedly suppressed the enhanced expression of cleaved PARP caused by MPP + .DiscussionThe pro-survival activation of ERK is well known in dopaminergic neurons (16, 28) .", [["dopaminergic neurons", "ANATOMY", 142, 162], ["GA", "CHEMICAL", 0, 2], ["MPP", "CHEMICAL", 73, 76], ["GA", "SIMPLE_CHEMICAL", 0, 2], ["PARP", "GENE_OR_GENE_PRODUCT", 58, 62], ["MPP +", "SIMPLE_CHEMICAL", 73, 78], ["ERK", "GENE_OR_GENE_PRODUCT", 121, 124], ["dopaminergic neurons", "CELL", 142, 162], ["cleaved PARP", "PROTEIN", 50, 62], ["MPP", "PROTEIN", 73, 76], ["ERK", "PROTEIN", 121, 124], ["dopaminergic neurons", "CELL_TYPE", 142, 162], ["MPP", "TEST", 73, 76]]], ["The phosphorylation of ERK in SH-SY5Y cells has been shown to be suppressed after 4 h of exposure to MPP + (29) .", [["SH-SY5Y cells", "ANATOMY", 30, 43], ["MPP", "CHEMICAL", 101, 104], ["MPP", "CHEMICAL", 101, 104], ["ERK", "GENE_OR_GENE_PRODUCT", 23, 26], ["SH-SY5Y cells", "CELL", 30, 43], ["ERK", "PROTEIN", 23, 26], ["SH-SY5Y cells", "CELL_LINE", 30, 43], ["The phosphorylation of ERK in SH-SY5Y cells", "TEST", 0, 43], ["MPP", "TEST", 101, 104]]], ["Our study confirmed that MPP + reduced the phosporylation of ERK; by contrast, GA reversed the MPP + -mediated inhibition of ERK activation.", [["MPP", "CHEMICAL", 25, 28], ["GA", "CHEMICAL", 79, 81], ["MPP", "CHEMICAL", 95, 98], ["MPP +", "CHEMICAL", 25, 30], ["MPP +", "SIMPLE_CHEMICAL", 25, 30], ["ERK", "GENE_OR_GENE_PRODUCT", 61, 64], ["GA", "SIMPLE_CHEMICAL", 79, 81], ["MPP +", "SIMPLE_CHEMICAL", 95, 100], ["ERK", "GENE_OR_GENE_PRODUCT", 125, 128], ["ERK", "PROTEIN", 61, 64], ["MPP", "PROTEIN", 95, 98], ["ERK", "PROTEIN", 125, 128], ["Our study", "TEST", 0, 9], ["MPP", "TEST", 25, 28], ["the MPP", "TEST", 91, 98], ["ERK activation", "PROBLEM", 125, 139], ["reduced", "OBSERVATION_MODIFIER", 31, 38], ["ERK activation", "OBSERVATION", 125, 139]]], ["Additionally, the presence of PD98059 eradicated the effects of GA on ERK activation and protection of cell viability.", [["cell", "ANATOMY", 103, 107], ["PD98059", "CHEMICAL", 30, 37], ["GA", "CHEMICAL", 64, 66], ["PD98059", "CHEMICAL", 30, 37], ["PD98059", "SIMPLE_CHEMICAL", 30, 37], ["GA", "SIMPLE_CHEMICAL", 64, 66], ["ERK", "GENE_OR_GENE_PRODUCT", 70, 73], ["cell", "CELL", 103, 107], ["ERK", "PROTEIN", 70, 73], ["PD98059", "TREATMENT", 30, 37], ["ERK activation", "TREATMENT", 70, 84], ["cell viability", "PROBLEM", 103, 117], ["cell viability", "OBSERVATION", 103, 117]]], ["Compared with the MPP + -treated cells, treatment with GA resulted in an increase in p-ERK nuclear migration.", [["cells", "ANATOMY", 33, 38], ["nuclear", "ANATOMY", 91, 98], ["MPP", "CHEMICAL", 18, 21], ["GA", "CHEMICAL", 55, 57], ["MPP +", "CHEMICAL", 18, 23], ["MPP +", "SIMPLE_CHEMICAL", 18, 23], ["cells", "CELL", 33, 38], ["GA", "SIMPLE_CHEMICAL", 55, 57], ["ERK", "GENE_OR_GENE_PRODUCT", 87, 90], ["MPP + -treated cells", "CELL_LINE", 18, 38], ["ERK", "PROTEIN", 87, 90], ["the MPP", "TEST", 14, 21], ["treatment", "TREATMENT", 40, 49], ["GA", "TREATMENT", 55, 57], ["an increase in p-ERK nuclear migration", "PROBLEM", 70, 108], ["increase", "OBSERVATION_MODIFIER", 73, 81], ["nuclear migration", "OBSERVATION", 91, 108]]], ["It has previously been demonstrated that activated ERK migrates to the nucleus where it regulates transcription factors, leading to changes in gene expression and cell proliferation (30) .", [["nucleus", "ANATOMY", 71, 78], ["cell", "ANATOMY", 163, 167], ["ERK", "GENE_OR_GENE_PRODUCT", 51, 54], ["nucleus", "CELLULAR_COMPONENT", 71, 78], ["cell", "CELL", 163, 167], ["ERK", "PROTEIN", 51, 54], ["transcription factors", "PROTEIN", 98, 119], ["activated ERK", "PROBLEM", 41, 54], ["changes in gene expression", "PROBLEM", 132, 158], ["cell proliferation", "TEST", 163, 181], ["nucleus", "ANATOMY_MODIFIER", 71, 78], ["cell proliferation", "OBSERVATION", 163, 181]]], ["Collectively, our data indicate that the ERK signaling pathway contributes to the GA-mediated protective effects against MPP + -induced DPC12 cell damage.DiscussionOur data further indicated that pre-treatment with GA markedly blocked the calcium influx caused by MPP + .", [["cell", "ANATOMY", 142, 146], ["GA", "CHEMICAL", 82, 84], ["MPP", "CHEMICAL", 121, 124], ["GA", "CHEMICAL", 215, 217], ["calcium", "CHEMICAL", 239, 246], ["MPP", "CHEMICAL", 264, 267], ["calcium", "CHEMICAL", 239, 246], ["ERK", "GENE_OR_GENE_PRODUCT", 41, 44], ["GA", "SIMPLE_CHEMICAL", 82, 84], ["MPP +", "SIMPLE_CHEMICAL", 121, 126], ["DPC12 cell", "CELL", 136, 146], ["GA", "SIMPLE_CHEMICAL", 215, 217], ["calcium", "SIMPLE_CHEMICAL", 239, 246], ["MPP +", "SIMPLE_CHEMICAL", 264, 269], ["ERK", "PROTEIN", 41, 44], ["our data", "TEST", 14, 22], ["the ERK signaling pathway", "PROBLEM", 37, 62], ["the GA", "PROBLEM", 78, 84], ["MPP", "PROBLEM", 121, 124], ["-induced DPC12 cell damage", "PROBLEM", 127, 153], ["pre-treatment with GA", "TREATMENT", 196, 217], ["the calcium influx", "TEST", 235, 253], ["MPP", "TEST", 264, 267], ["DPC12 cell damage", "OBSERVATION", 136, 153]]], ["Excessive cytosolic calcium causes a wide range of subcellular pathological responses, in particular the dysfunction of mitochondrial membrane permeability (31) .", [["cytosolic", "ANATOMY", 10, 19], ["subcellular", "ANATOMY", 51, 62], ["mitochondrial membrane", "ANATOMY", 120, 142], ["calcium", "CHEMICAL", 20, 27], ["calcium", "CHEMICAL", 20, 27], ["cytosolic", "ORGANISM_SUBSTANCE", 10, 19], ["calcium", "SIMPLE_CHEMICAL", 20, 27], ["mitochondrial membrane", "CELLULAR_COMPONENT", 120, 142], ["Excessive cytosolic calcium", "PROBLEM", 0, 27], ["the dysfunction of mitochondrial membrane permeability", "PROBLEM", 101, 155], ["cytosolic calcium", "OBSERVATION", 10, 27], ["wide range", "OBSERVATION_MODIFIER", 37, 47], ["subcellular pathological responses", "OBSERVATION", 51, 85], ["dysfunction", "OBSERVATION", 105, 116], ["mitochondrial membrane permeability", "OBSERVATION", 120, 155]]], ["Growing experimental evidence suggests that the mitochondrial-dependent pathway plays a central role in cell apoptosis (17) .", [["mitochondrial", "ANATOMY", 48, 61], ["cell", "ANATOMY", 104, 108], ["mitochondrial", "CELLULAR_COMPONENT", 48, 61], ["cell", "CELL", 104, 108], ["the mitochondrial-dependent pathway", "PROBLEM", 44, 79], ["central", "OBSERVATION_MODIFIER", 88, 95], ["cell apoptosis", "OBSERVATION", 104, 118]]], ["A key feature of mitochondrial apoptosis is the disruption of the membrane potential, mainly caused by increased membrane permeability (32) .", [["mitochondrial", "ANATOMY", 17, 30], ["membrane", "ANATOMY", 66, 74], ["membrane", "ANATOMY", 113, 121], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["membrane", "CELLULAR_COMPONENT", 66, 74], ["membrane", "CELLULAR_COMPONENT", 113, 121], ["mitochondrial apoptosis", "PROBLEM", 17, 40], ["increased membrane permeability", "PROBLEM", 103, 134], ["mitochondrial apoptosis", "OBSERVATION", 17, 40], ["membrane", "OBSERVATION_MODIFIER", 66, 74], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["membrane permeability", "OBSERVATION", 113, 134]]], ["The present study demonstrated that GA restored the dissipation of MMP and promoted the activation of ERK.", [["GA", "CHEMICAL", 36, 38], ["GA", "SIMPLE_CHEMICAL", 36, 38], ["MMP", "GENE_OR_GENE_PRODUCT", 67, 70], ["ERK", "GENE_OR_GENE_PRODUCT", 102, 105], ["MMP", "PROTEIN", 67, 70], ["ERK", "PROTEIN", 102, 105], ["The present study", "TEST", 0, 17], ["MMP", "PROBLEM", 67, 70]]], ["As reported previously, the activation of ERK regulates mitochondrial function (33, 34) .", [["mitochondrial", "ANATOMY", 56, 69], ["ERK", "GENE_OR_GENE_PRODUCT", 42, 45], ["mitochondrial", "CELLULAR_COMPONENT", 56, 69], ["ERK", "PROTEIN", 42, 45], ["mitochondrial function", "TEST", 56, 78]]], ["Previous studies have demonstrated that ERK inhibitors downregulate the expression of B-cell lymphoma-2 (Bcl-2) and Bcl-extra large (Bcl-xL) (33) , which are located in the outer membrane of the mitochondria and regulate mitochondrial function (35) .", [["outer membrane", "ANATOMY", 173, 187], ["mitochondria", "ANATOMY", 195, 207], ["mitochondrial", "ANATOMY", 221, 234], ["ERK", "GENE_OR_GENE_PRODUCT", 40, 43], ["B-cell lymphoma-2", "GENE_OR_GENE_PRODUCT", 86, 103], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 105, 110], ["Bcl-extra large (Bcl-xL) (33)", "GENE_OR_GENE_PRODUCT", 116, 145], ["outer membrane", "CELLULAR_COMPONENT", 173, 187], ["mitochondria", "CELLULAR_COMPONENT", 195, 207], ["mitochondrial", "CELLULAR_COMPONENT", 221, 234], ["ERK", "PROTEIN", 40, 43], ["Bcl-xL", "PROTEIN", 133, 139], ["Previous studies", "TEST", 0, 16], ["ERK inhibitors", "TEST", 40, 54], ["B-cell lymphoma", "PROBLEM", 86, 101], ["Bcl", "TEST", 105, 108], ["Bcl-extra large (Bcl-xL)", "PROBLEM", 116, 140], ["B-cell lymphoma", "OBSERVATION", 86, 101], ["large", "OBSERVATION_MODIFIER", 126, 131], ["outer membrane", "ANATOMY_MODIFIER", 173, 187], ["mitochondria", "ANATOMY", 195, 207], ["mitochondrial function", "OBSERVATION", 221, 243]]], ["However, the association between the activation of ERK and mitochondrial function and their involvement in the GA-mediated neuroprotective effects require further investigation.DiscussionIt has been demonstrated that GA exerts neuroprotective effects against 6-hydroxydopamine-induced cytotoxicity in PC12 cells via PI3K/AKT pathway (13) ; however, in our study, we did not observe any significant effects on the activation of AKT following treatment with GA or MPP + .", [["mitochondrial", "ANATOMY", 59, 72], ["PC12 cells", "ANATOMY", 301, 311], ["GA", "CHEMICAL", 111, 113], ["GA", "CHEMICAL", 217, 219], ["6-hydroxydopamine", "CHEMICAL", 259, 276], ["GA", "CHEMICAL", 456, 458], ["MPP", "CHEMICAL", 462, 465], ["6-hydroxydopamine", "CHEMICAL", 259, 276], ["ERK", "GENE_OR_GENE_PRODUCT", 51, 54], ["mitochondrial", "CELLULAR_COMPONENT", 59, 72], ["GA", "SIMPLE_CHEMICAL", 111, 113], ["GA", "SIMPLE_CHEMICAL", 217, 219], ["6-hydroxydopamine", "SIMPLE_CHEMICAL", 259, 276], ["PC12 cells", "CELL", 301, 311], ["PI3K", "GENE_OR_GENE_PRODUCT", 316, 320], ["AKT", "GENE_OR_GENE_PRODUCT", 321, 324], ["AKT", "GENE_OR_GENE_PRODUCT", 427, 430], ["GA", "SIMPLE_CHEMICAL", 456, 458], ["MPP +", "SIMPLE_CHEMICAL", 462, 467], ["ERK", "PROTEIN", 51, 54], ["PC12 cells", "CELL_LINE", 301, 311], ["PI3K", "PROTEIN", 316, 320], ["AKT", "PROTEIN", 321, 324], ["AKT", "PROTEIN", 427, 430], ["mitochondrial function", "TEST", 59, 81], ["further investigation", "TEST", 155, 176], ["hydroxydopamine", "TREATMENT", 261, 276], ["induced cytotoxicity in PC12 cells", "PROBLEM", 277, 311], ["PI3K/AKT pathway", "TEST", 316, 332], ["our study", "TEST", 352, 361], ["treatment", "TREATMENT", 441, 450], ["mitochondrial function", "OBSERVATION", 59, 81], ["PC12 cells", "OBSERVATION", 301, 311]]], ["In another separate experiment, GA did not exert any effects on the glutamateinduced decrease in the level of p-AKT.", [["GA", "CHEMICAL", 32, 34], ["glutamateinduced", "CHEMICAL", 68, 84], ["GA", "SIMPLE_CHEMICAL", 32, 34], ["glutamateinduced", "SIMPLE_CHEMICAL", 68, 84], ["p-AKT", "GENE_OR_GENE_PRODUCT", 110, 115], ["p-AKT", "PROTEIN", 110, 115], ["the glutamateinduced decrease", "PROBLEM", 64, 93], ["p-AKT", "OBSERVATION", 110, 115]]], ["The different results noted in our study may due to the different microenvironmental system.", [["our study", "TEST", 31, 40]]], ["Furthermore, the accumulation of cells in the G1 phase is considered one of the factors responsible for MPP + -induced cell damage (36) .", [["cells", "ANATOMY", 33, 38], ["cell", "ANATOMY", 119, 123], ["MPP", "CHEMICAL", 104, 107], ["MPP +", "CHEMICAL", 104, 109], ["cells", "CELL", 33, 38], ["MPP +", "SIMPLE_CHEMICAL", 104, 109], ["cell", "CELL", 119, 123], ["the accumulation of cells", "PROBLEM", 13, 38], ["MPP", "TEST", 104, 107], ["induced cell damage", "PROBLEM", 111, 130], ["accumulation of cells", "OBSERVATION", 17, 38], ["G1 phase", "OBSERVATION_MODIFIER", 46, 54], ["cell damage", "OBSERVATION", 119, 130]]], ["In our study, MPP + -induced G1 phase arrest was observed in the DPC12 cells; however, pre-treatment with GA failed to reverse this effect (data not shown).DiscussionIn conclusion, our data demonstrate that GA exerts significant protective effects on neuronal cells against MPP + neurotoxicity, as indicated by the suppression of the intracellular Ca 2+ overload, the restoration of mitochondrial dysfunction, and the increase in the expression and migration of p-ERK.", [["DPC12 cells", "ANATOMY", 65, 76], ["neuronal cells", "ANATOMY", 251, 265], ["intracellular", "ANATOMY", 334, 347], ["mitochondrial", "ANATOMY", 383, 396], ["MPP", "CHEMICAL", 14, 17], ["GA", "CHEMICAL", 106, 108], ["GA", "CHEMICAL", 207, 209], ["MPP", "CHEMICAL", 274, 277], ["neurotoxicity", "DISEASE", 280, 293], ["Ca", "CHEMICAL", 348, 350], ["mitochondrial dysfunction", "DISEASE", 383, 408], ["MPP", "CHEMICAL", 14, 17], ["Ca 2+", "CHEMICAL", 348, 353], ["MPP +", "SIMPLE_CHEMICAL", 14, 19], ["DPC12 cells", "CELL", 65, 76], ["GA", "SIMPLE_CHEMICAL", 106, 108], ["GA", "SIMPLE_CHEMICAL", 207, 209], ["neuronal cells", "CELL", 251, 265], ["MPP +", "SIMPLE_CHEMICAL", 274, 279], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 334, 347], ["Ca 2+", "SIMPLE_CHEMICAL", 348, 353], ["mitochondrial", "CELLULAR_COMPONENT", 383, 396], ["p-ERK", "GENE_OR_GENE_PRODUCT", 462, 467], ["MPP", "PROTEIN", 14, 17], ["DPC12 cells", "CELL_LINE", 65, 76], ["neuronal cells", "CELL_TYPE", 251, 265], ["p-ERK", "PROTEIN", 462, 467], ["our study", "TEST", 3, 12], ["MPP", "TEST", 14, 17], ["G1 phase arrest", "PROBLEM", 29, 44], ["GA", "TREATMENT", 106, 108], ["MPP", "PROBLEM", 274, 277], ["neurotoxicity", "PROBLEM", 280, 293], ["the intracellular Ca", "PROBLEM", 330, 350], ["overload", "PROBLEM", 354, 362], ["mitochondrial dysfunction", "PROBLEM", 383, 408], ["p-ERK", "TREATMENT", 462, 467], ["G1 phase", "OBSERVATION_MODIFIER", 29, 37], ["arrest", "OBSERVATION", 38, 44], ["significant", "OBSERVATION_MODIFIER", 217, 228], ["overload", "OBSERVATION", 354, 362], ["mitochondrial dysfunction", "OBSERVATION", 383, 408], ["increase", "OBSERVATION_MODIFIER", 418, 426], ["migration", "OBSERVATION_MODIFIER", 449, 458]]], ["The present findings provide pharmacological evidence to support the therapeutic application of GA in the treatment of neurodegenerative diseases.", [["GA", "CHEMICAL", 96, 98], ["neurodegenerative diseases", "DISEASE", 119, 145], ["GA", "SIMPLE_CHEMICAL", 96, 98], ["the therapeutic application of GA", "TREATMENT", 65, 98], ["neurodegenerative diseases", "PROBLEM", 119, 145], ["neurodegenerative", "OBSERVATION_MODIFIER", 119, 136], ["diseases", "OBSERVATION", 137, 145]]]], "1951cbe2ddd496f0b785a8c3edde16cb9bd6a206": [["Existe una gran diversidad de cuadros cl\u00ednicos asociados a estas infecciones, con distintos niveles de gravedad, desde resfriado com\u00fan hasta procesos con afectaci\u00f3n de v\u00edas respiratorias bajas, como la bronquioli-OBJETIVO.", [["una gran diversidad", "PROBLEM", 7, 26]]], ["En todas las muestras se realiz\u00f3 una t\u00e9cnica r\u00e1pida de detecci\u00f3n de ant\u00edgeno de virus respiratorio sincitial (VRS) y, en las que se obtuvo resultado negativo, inmunofluorescencia (IF) y cultivo celular (CC).", [["CC", "CHEMICAL", 203, 205]]], ["El VRS se detect\u00f3 en 769 ni\u00f1os (74,5%).", [["El VRS", "TEST", 0, 6]]], ["Los dem\u00e1s virus identificados, por orden de frecuencia, fueron: virus parainfluenza, rinovirus, adenovirus, virus de la gripe, enterovirus y coronavirus.", [["parainfluenza", "DISEASE", 70, 83], ["enterovirus y coronavirus", "DISEASE", 127, 152], ["virus parainfluenza", "ORGANISM", 64, 83], ["adenovirus", "ORGANISM", 96, 106], ["enterovirus y coronavirus", "ORGANISM", 127, 152], ["parainfluenza", "SPECIES", 70, 83], ["enterovirus y coronavirus", "SPECIES", 127, 152], ["Los dem\u00e1s virus identificados", "PROBLEM", 0, 29], ["virus parainfluenza", "PROBLEM", 64, 83], ["rinovirus", "TREATMENT", 85, 94], ["adenovirus", "PROBLEM", 96, 106], ["enterovirus y coronavirus", "PROBLEM", 127, 152]]], ["Se encontraron diferencias estad\u00edsticamente significativas al comparar la edad y el tipo de virus detectado: los adenovirus fueron responsables de cuadros en ni\u00f1os de mayor edad (mediana: 6 meses; intervalo: 1-74).", [["adenovirus", "ORGANISM", 113, 123], ["Se encontraron diferencias estad\u00edsticamente", "TEST", 0, 43]]], ["Los agentes etiol\u00f3gicos relacionados con dichos cuadros son el virus respiratorio sincitial (VRS), los virus parainfluenza (VPI), los virus de la gripe, los adenovirus, los rinovirus, los enterovirus, los coronavirus y los metaneumovirus humanos.Introducci\u00f3nLa presentaci\u00f3n cl\u00ednica suele ser similar en todos los virus implicados, pero puede variar ligeramente en funci\u00f3n del agente etiol\u00f3gico.", [["respiratorio sincitial", "DISEASE", 69, 91], ["parainfluenza", "DISEASE", 109, 122], ["enterovirus", "DISEASE", 188, 199], ["los virus parainfluenza", "ORGANISM", 99, 122], ["adenovirus", "ORGANISM", 157, 167], ["parainfluenza", "SPECIES", 109, 122], ["Los", "TEST", 0, 3], ["etiol\u00f3gicos", "TEST", 12, 23], ["relacionados", "TEST", 24, 36], ["dichos", "TEST", 41, 47], ["los virus parainfluenza (VPI", "PROBLEM", 99, 127], ["los virus de la gripe", "TEST", 130, 151], ["los adenovirus", "PROBLEM", 153, 167], ["los enterovirus", "PROBLEM", 184, 199], ["Introducci\u00f3nLa", "TREATMENT", 246, 260]]], ["Los virus de la gripe tienen un patr\u00f3n estacional similar al VRS.", [["Los virus", "PROBLEM", 0, 9]]], ["Los adenovirus producen infecciones en cualquier \u00e9poca del a\u00f1o, debido a la eliminaci\u00f3n fecal en ni\u00f1os sanos, y afectan en mayor medida a ni\u00f1os mayores de 6 meses 6,7 .", [["adenovirus", "ORGANISM", 4, 14], ["Los adenovirus", "TEST", 0, 14]]], ["La frecuencia del resto de los virus (rinovirus, coronavirus, enterovirus y el recientemente descrito metaneumovirus humano 8 ) en patolog\u00eda respiratoria no est\u00e1 adecuadamente descrita debido a las limitaciones para su detecci\u00f3n e identificaci\u00f3n.Introducci\u00f3nEl diagn\u00f3stico virol\u00f3gico convencional se basa en t\u00e9cnicas de detecci\u00f3n antig\u00e9nica y en el cultivo celular, aunque en los \u00faltimos a\u00f1os se est\u00e1n desarrollando m\u00e9todos de amplificaci\u00f3n gen\u00e9tica (reacci\u00f3n en cadena de la polimerasa [PCR] convencional, PCR en tiempo real) que complementan dicho diagn\u00f3stico 9-12 .Introducci\u00f3nEl objetivo de nuestro estudio fue conocer la etiolog\u00eda viral de las IRA que presentaron los ni\u00f1os atendidos en el servicio de urgencias de un hospital pedi\u00e1trico.", [["coronavirus", "SPECIES", 49, 60], ["La frecuencia del resto de los virus", "PROBLEM", 0, 36], ["coronavirus", "PROBLEM", 49, 60], ["enterovirus", "PROBLEM", 62, 73], ["PCR", "TEST", 488, 491], ["PCR", "TEST", 507, 510], ["los virus", "OBSERVATION", 27, 36]]], ["Adem\u00e1s, se compar\u00f3 la rentabilidad diagn\u00f3stica de la detecci\u00f3n de ant\u00edgeno por inmunofluorescencia y el cultivo celular para los virus de la gripe, los VPI y los adenovirus.Material y m\u00e9todos PacientesSe incluyeron en el estudio todos los ni\u00f1os menores de 14 a\u00f1os atendidos en el Hospital Universitario Materno Infantil de Gran Canaria, que cubre una poblaci\u00f3n de 126.806 ni\u00f1os, por sospecha cl\u00ednica de IRA desde mayo de 2002 a mayo de 2005.MuestrasSe recogieron 1.957 lavados nasofar\u00edngeos pertenecientes a 1.729 ni\u00f1os.", [["adenovirus", "ORGANISM", 162, 172], ["MuestrasSe recogieron", "TREATMENT", 441, 462]]], ["En las muestras en que se obtuvo resultado negativo o no interpretable se realiz\u00f3 la detecci\u00f3n de ant\u00edgenos de VRS, adenovirus, virus de la gripe A/B y VPI (1, 2 y 3) mediante una t\u00e9cnica de inmunofluorescencia (IF) indirecta con anticuerpos monoclonales espec\u00edficos (Viral Respiratory Panel 1, Screening and Identification IFA Kit, Light Diagnostics, Chemicon International, Temecula, EE.UU.).", [["adenovirus", "ORGANISM", 116, 126], ["adenovirus", "PROBLEM", 116, 126], ["mediante una t\u00e9cnica de inmunofluorescencia", "PROBLEM", 167, 210], ["indirecta", "PROBLEM", 216, 225], ["Viral Respiratory Panel", "TEST", 268, 291], ["Screening", "TEST", 295, 304], ["Identification", "TEST", 309, 323], ["IFA", "TEST", 324, 327], ["Light Diagnostics", "TEST", 333, 350]]], ["A partir de octubre de 2003 se ampli\u00f3 el estudio con la detecci\u00f3n antig\u00e9nica de los coronavirus (anticuerpo monoclonol Anti-Coronavirus OC-43, Chemicon International, Temecula, EE.UU.) y la tipificaci\u00f3n del VRS (anticuerpos monoclonales RSV/RSV A, Chemicon Internacional, Temecula, EE.UU.) b) Cultivo celular.", [["los coronavirus", "DISEASE", 80, 95], ["anticuerpo monoclonol Anti-Coronavirus OC-43", "SPECIES", 97, 141], ["RSV", "SPECIES", 241, 244], ["coronavirus (anticuerpo monoclonol Anti-Coronavirus OC", "TREATMENT", 84, 138], ["UU", "TEST", 180, 182], ["y la tipificaci\u00f3n del VRS", "TEST", 185, 210], ["anticuerpos", "TEST", 212, 223], ["RSV", "PROBLEM", 237, 240], ["RSV", "PROBLEM", 241, 244], ["Cultivo celular", "TREATMENT", 293, 308], ["Temecula", "ANATOMY", 167, 175], ["RSV", "ANATOMY", 241, 244]]], ["Se inocularon las muestras EIA-negativo en las l\u00edneas celulares HEp-2 (carcinoma epidermoide de laringe, Centro Nacional de Microbiolog\u00eda, Madrid) y MRC-5 (fibroblastos de pulm\u00f3n fetal humano, Vircell, Granada) mediante cultivo convencional: se incubaron a 37\u00b0C en rotaci\u00f3n continua y se observaron microsc\u00f3picamente durante un m\u00e1ximo de 2 semanas.", [["carcinoma epidermoide", "DISEASE", 71, 92], ["EIA", "TEST", 27, 30], ["negativo", "TEST", 31, 39], ["HEp", "TEST", 64, 67], ["C en rotaci\u00f3n", "TREATMENT", 260, 273]]], ["Los enterovirus se identificaron por IF (Monoclonal anti-Enterovirus, Dako, Glostrup, Dinamarca).", [["enterovirus", "ORGANISM", 4, 15], ["Monoclonal anti-Enterovirus", "PROTEIN", 41, 68], ["Los enterovirus", "PROBLEM", 0, 15], ["Monoclonal anti-Enterovirus", "PROBLEM", 41, 68]]], ["Los rinovirus se identificaron por su incapacidad para multiplicarse a pH \u00e1cido, con incubaci\u00f3n a 33\u00b0C. Adem\u00e1s, se inocularon las l\u00edneas celulares HEp-2, LLC-MK2 (ri\u00f1\u00f3n de mono Rhesus, Vircell, Granada) y MDCK (ri\u00f1\u00f3n de perro Madin-Darby, Centro Nacional de Microbiolog\u00eda, Madrid) por t\u00e9cnica de shell vial 13 .", [["a pH \u00e1cido", "TREATMENT", 69, 79], ["Adem\u00e1s", "TEST", 104, 110], ["HEp", "TEST", 147, 150], ["LLC", "TEST", 154, 157], ["LLC", "ANATOMY", 154, 157]]], ["Tras centrifugaci\u00f3n e incubaci\u00f3n a 37\u00b0C (33\u00b0C para la l\u00ednea MDCK) durante 48-72 h, se procedi\u00f3 a la tinci\u00f3n con anticuerpos monoclonales espec\u00edficos (descrito anteriormente).An\u00e1lisis estad\u00edsticoLas variables cuantitativas se presentaron mediante \u00edndices de centralizaci\u00f3n y dispersi\u00f3n: mediana e intervalo.", [["durante", "TEST", 66, 73], ["a la tinci\u00f3n", "TREATMENT", 95, 107], ["mediana e intervalo", "TREATMENT", 286, 305]]], ["Se contrast\u00f3 la hip\u00f3tesis de normalidad de dichas variables mediante el test de Kolmogorov-Smirnov para una sola muestra.", [["Se contrast\u00f3 la hip\u00f3tesis", "PROBLEM", 0, 25]]], ["En los pacientes con m\u00e1s de una muestra, s\u00f3lo se consider\u00f3 para el estudio la primera muestra recibida.ResultadosLa relaci\u00f3n var\u00f3n:mujer fue 1,45:1.", [["primera muestra recibida", "ORGANISM", 78, 102], ["primera muestra", "SPECIES", 78, 93]]], ["El 74,9% de los ni\u00f1os atendidos precis\u00f3 ingreso hospitalario.ResultadosSe detect\u00f3 el virus responsable del cuadro respiratorio en 1.032 ni\u00f1os (59,7%).", [["El", "TEST", 0, 2], ["ResultadosSe", "TEST", 61, 73]]], ["El virus identificado con m\u00e1s frecuencia fue el VRS, cuya distribuci\u00f3n mensual acumulada se muestra en la figura 1.", [["El virus identificado", "TEST", 0, 21], ["m\u00e1s", "TEST", 26, 29], ["fue el VRS", "TEST", 41, 51], ["cuya", "TEST", 53, 57], ["distribuci\u00f3n", "TEST", 58, 70]]], ["El 80,7% de los pacientes con VRS A precis\u00f3 ingreso, frente al 53,6% de los pacientes con VRS B (p < 0,001).", [["El", "TEST", 0, 2]]], ["La distribuci\u00f3n de los virus m\u00e1s frecuentes despu\u00e9s del VRS se muestra en la figura 2.", [["La distribuci\u00f3n de los virus m\u00e1s", "TEST", 0, 32], ["del VRS", "TEST", 52, 59], ["los virus", "OBSERVATION", 19, 28]]], ["En cuanto a los virus gripales, nuestros datos coinciden con los descritos en Espa\u00f1a en la temporada 2003-2004, caracterizada por una actividad gripal moderada, con un comienzo temprano de los casos y picos en las semanas epidemiol\u00f3gicas 46 y 47, con predominio de virus de la gripe A; y en la temporada 2004-2005, caracterizada por una actividad gripal alta, de comienzo m\u00e1s tard\u00edo, con picos en las semanas 2 y 3, y con predominio de virus de la gripe A y casos espor\u00e1dicos de virus de la gripe B 20, 21 .", [["con picos en las semanas", "TREATMENT", 384, 408], ["y con predominio de virus", "TREATMENT", 416, 441], ["los virus", "OBSERVATION", 12, 21]]], ["En circunstancias normales estos virus causan cuadros leves de v\u00edas altas, por lo que su tratamiento suele ser extrahospitalario.Discusi\u00f3nLos adenovirus se han presentado en ni\u00f1os con m\u00e1s meses de edad como se ha descrito previamente 6 .", [["adenovirus", "ORGANISM", 142, 152], ["En circunstancias", "TEST", 0, 17], ["adenovirus", "PROBLEM", 142, 152]]], ["En cualquier caso, no tenemos informaci\u00f3n sobre el criterio real de ingreso en los ni\u00f1os con infecci\u00f3n por adenovirus, por lo que no podemos establecer ninguna conclusi\u00f3n.Discusi\u00f3nLa identificaci\u00f3n de enterovirus y coronavirus ha sido muy baja en el conjunto de la serie, pero consideramos importante su investigaci\u00f3n como parte del protocolo de diagn\u00f3stico ya que pueden ser responsables de cuadros cl\u00ednicos graves.Discusi\u00f3nUna limitaci\u00f3n en nuestro estudio ha sido el desconocimiento de la incidencia de IRA producidas por metaneumovirus.", [["enterovirus y coronavirus", "DISEASE", 201, 226], ["adenovirus", "ORGANISM", 107, 117]]], ["Se sabe que su detecci\u00f3n en la actualidad precisa de t\u00e9cnicas de amplificaci\u00f3n gen\u00e9tica, por lo que deber\u00e1n incorporarse en el diagn\u00f3stico cotidiano.Discusi\u00f3nEn cuanto a la sensibilidad de la IF para la detecci\u00f3n r\u00e1pida de ant\u00edgenos de VPI, virus de la gripe y adenovirus, ha sido baja si la consideramos de manera global, sobre todo debido a la baja sensibilidad de la t\u00e9cnica para detectar los adenovirus.", [["adenovirus", "ORGANISM", 261, 271], ["adenovirus", "ORGANISM", 396, 406]]], ["Esto puede explicarse por la gran variedad de subtipos de adenovirus causantes de infecci\u00f3n respiratoria.", [["adenovirus", "ORGANISM", 58, 68]]], ["La especificidad ha sido muy alta para todos los virus.", [["La", "TEST", 0, 2], ["los virus", "OBSERVATION", 45, 54]]], ["El valor predictivo positivo global ha sido tambi\u00e9n bajo.Discusi\u00f3nEn cuanto a las infecciones mixtas, la tasa es menor a la descrita por otros autores 10, 22 , probablemente porque no hemos investigado otros virus respiratorios en las muestras con EIA positivo y porque no se han empleado t\u00e9cnicas de amplificaci\u00f3n gen\u00e9tica que aumentar\u00edan la sensibilidad diagn\u00f3stica.", [["hemos", "TEST", 184, 189]]], ["Para conocer con exactitud la relaci\u00f3n existente entre los agentes virales y el tipo de cuadro respiratorio que producen es necesaria la realizaci\u00f3n de estudios prospectivos en poblaci\u00f3n pedi\u00e1trica ambulatoria y hospitalizada 16, 22 , as\u00ed como evaluar en qu\u00e9 medida est\u00e1n presentes los virus descritos en este estudio en ni\u00f1os asintom\u00e1ticos.Discusi\u00f3nLas conclusiones principales de nuestro estudio han sido: a) en una proporci\u00f3n alta de casos de IRA se ha podido establecer la etiolog\u00eda por m\u00e9todos convencionales; b) la bronquiolitis ha sido el principal cuadro cl\u00ednico producido por todos los virus estudiados, y el VRS es el agente etiol\u00f3gico m\u00e1s frecuente; c) las infecciones producidas por adenovirus han ocurrido en ni\u00f1os de mayor edad; d) a pesar de que no hay diferencias importantes en el patr\u00f3n estacional de los virus estudiados con relaci\u00f3n a lo descrito en otras series, hemos constatado que los rinovirus y los virus parainfluenza son una causa importante de IRA en cualquier \u00e9poca del a\u00f1o, y e) la sensibilidad de la detecci\u00f3n de ant\u00edgeno por IF es baja para poder tomar decisiones en el tratamiento cl\u00ednico de los pacientes con IRA, en particular para los adenovirus.", [["adenovirus", "ORGANISM", 695, 705], ["parainfluenza", "ORGANISM", 931, 944], ["adenovirus", "ORGANISM", 1172, 1182], ["parainfluenza", "SPECIES", 931, 944], ["m\u00e9todos convencionales", "PROBLEM", 491, 513], ["la bronquiolitis", "PROBLEM", 518, 534], ["los virus estudiados", "PROBLEM", 591, 611], ["a lo descrito en otras series", "TREATMENT", 853, 882]]]], "PMC7333444": [["While my experience was somewhat impoverished as I did not have a residency there, it did offer me some insights regarding CRISPER-Cas9, and my participation occurred at the very same time that news came that a Chinese doctor, He Jiankul, had gene-edited two babies: Lulu and Nana.", [["CRISPER-Cas9", "GENE_OR_GENE_PRODUCT", 123, 135], ["babies", "ORGANISM", 259, 265], ["Nana", "OBSERVATION", 276, 280]]]], "ab8b03a08dc3caf7e74ebfa77ab2453409d8c699": [["Another study has evaluated the potential for domestic dissemination of SARS-CoV-2 from a particular US state, again using cell phone location data.", [["cell", "ANATOMY", 123, 127], ["SARS", "DISEASE", 72, 76], ["cell", "CELL", 123, 127], ["SARS-CoV", "SPECIES", 72, 80], ["Another study", "TEST", 0, 13], ["SARS", "PROBLEM", 72, 76]]]], "PMC7503179": [["IntroductionCoronavirus disease 2019 (COVID-19) is already considered a world pandemic which is starting to have dramatic effects in Europe, where, as of 27 of March, 265,421 cases have been reported1,2.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["dramatic", "OBSERVATION_MODIFIER", 113, 121]]], ["COVID-19 infection in Portugal has been growing exponentially with an average rate of 34\u00b113% new cases per day from 2 March and is far from reaching the peak by the end of March.", [["COVID-19", "CHEMICAL", 0, 8], ["infection", "DISEASE", 9, 18], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["infection", "OBSERVATION", 9, 18], ["growing", "OBSERVATION_MODIFIER", 40, 47], ["exponentially", "OBSERVATION_MODIFIER", 48, 61], ["average", "OBSERVATION_MODIFIER", 70, 77]]], ["As of March 27, 4268 infection cases and 76 deaths have been reported2.", [["infection", "DISEASE", 21, 30], ["deaths", "DISEASE", 44, 50]]], ["The highest infection burden is found in Porto (317 cases, 7.4%) and in Lisbon (284 cases, 6.7%) but the disease is present throughout the entire country.", [["infection", "DISEASE", 12, 21], ["The highest infection burden", "PROBLEM", 0, 28], ["cases", "TEST", 84, 89], ["the disease", "PROBLEM", 101, 112], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 12, 21], ["disease", "OBSERVATION", 105, 112]]], ["As in other countries, infection occurs mostly in individuals\u2019 with \u226540 years of age (71.9% males; 69.3% females).", [["infection", "DISEASE", 23, 32], ["infection", "PROBLEM", 23, 32], ["infection", "OBSERVATION", 23, 32]]], ["Death occurs mostly in males (64.5%) all with \u226550 years of age.IntroductionPredictive models estimate that the peak of SARS-CoV-2 infection globally would be between mid-April and May, with an estimated total of 48 million people infected3.", [["Death", "DISEASE", 0, 5], ["SARS", "DISEASE", 119, 123], ["infection", "DISEASE", 130, 139], ["SARS-CoV-2", "ORGANISM", 119, 129], ["people", "ORGANISM", 223, 229], ["people", "SPECIES", 223, 229], ["SARS-CoV", "SPECIES", 119, 127], ["Death", "PROBLEM", 0, 5], ["SARS", "PROBLEM", 119, 123], ["CoV", "TEST", 124, 127], ["2 infection", "PROBLEM", 128, 139], ["mid-April", "TREATMENT", 166, 175]]], ["As with most other countries, the Portuguese national health care system cannot deal with the increasing demand of care due to limited ventilators and care units3.", [["limited ventilators", "TREATMENT", 127, 146], ["care units3", "TREATMENT", 151, 162]]], ["Therefore, the Portuguese government together with the National Health Directorate (DGS) declared a state of emergency and adopted interventive populational measures through Government-Imposed Measures (GIM) on 18 March 2020 in an attempt to drop the peak of infections even if at the cost of prolonging the infection time.", [["infections", "DISEASE", 259, 269], ["infection", "DISEASE", 308, 317], ["infections", "PROBLEM", 259, 269], ["infections", "OBSERVATION", 259, 269], ["infection", "OBSERVATION", 308, 317]]], ["These measures are based on the lockdown of people at home, social distancing and adopting protective antiseptic policies such as the usage of masks.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["adopting protective antiseptic policies", "TREATMENT", 82, 121]]], ["Lockdown was implemented to assure compliance of the population, expect for people that maintain basic services such as medical and food distribution staff.IntroductionMost forecasting models are based on the number of cases reported and do not take into account the effects of these government-imposed measures and behavioral change.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["these government", "TREATMENT", 278, 294], ["behavioral change", "PROBLEM", 316, 333]]], ["Thus, accessing the compliance degree and predicting how much is necessary for the control of SARS-CoV2 infection would be a useful tool for fighting COVID-19 pandemic.", [["SARS", "DISEASE", 94, 98], ["infection", "DISEASE", 104, 113], ["SARS-CoV2", "ORGANISM", 94, 103], ["COVID-19", "ORGANISM", 150, 158], ["SARS", "PROBLEM", 94, 98], ["CoV2 infection", "PROBLEM", 99, 113], ["fighting COVID", "TEST", 141, 155], ["pandemic", "PROBLEM", 159, 167]]], ["Recently published mathematical modelling studies of COVID-19 transmission have already provided useful insights that can be used to guide public health measures and resource allocation to better control this pandemic4\u20137 .", [["COVID", "TEST", 53, 58], ["public health measures", "TREATMENT", 139, 161], ["resource allocation", "TREATMENT", 166, 185]]], ["However, most parameters of statistical models have been estimated with high degree of uncertainty, resulting in predictions with wide intervals of confidence4,6.", [["high degree", "OBSERVATION_MODIFIER", 72, 83]]], ["Compartmental models such as susceptible, infected and resistant (SIR) models are deterministic approaches based on solving nonlinear systems of Ordinary Differential Equations (ODE) that have been successful in describing complex dynamics of virus infection in populations, including COVID-19 in several countries7\u201311.", [["infection", "DISEASE", 249, 258], ["Compartmental models", "TEST", 0, 20], ["susceptible, infected and resistant (SIR) models", "PROBLEM", 29, 77], ["virus infection", "PROBLEM", 243, 258], ["COVID", "TEST", 285, 290], ["susceptible", "OBSERVATION_MODIFIER", 29, 40], ["infected", "OBSERVATION", 42, 50], ["virus infection", "OBSERVATION", 243, 258]]], ["Here, we provide a simple SI model that describe the dynamics of transition of COVID-19 in Portugal during the first 21 days, explain the evolution of SARS-CoV-2 infection dynamics up to 19 of August and predicts the degree of compliance of GIM by the Portuguese population.MethodsBasic transmission dynamics of COVID-19 was modelled using a simple mathematical model based on a system of two ordinary differential equations (ODE) developed specifically for this purpose (Equation 1 andEquation 2).", [["SARS", "DISEASE", 151, 155], ["infection", "DISEASE", 162, 171], ["COVID-19", "CHEMICAL", 312, 320], ["CoV-2", "ORGANISM", 156, 161], ["COVID-19", "DNA", 312, 320], ["SARS-CoV", "SPECIES", 151, 159], ["a simple SI model", "TREATMENT", 17, 34], ["COVID", "TREATMENT", 79, 84], ["SARS", "PROBLEM", 151, 155], ["CoV", "PROBLEM", 156, 159], ["2 infection dynamics", "PROBLEM", 160, 180], ["COVID", "TEST", 312, 317]]], ["The equations reflect the number of people infected (I) and susceptible (S) to infection per unit of time (dI/dt anddS/dt).", [["infection", "DISEASE", 79, 88], ["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["infection", "PROBLEM", 79, 88], ["infection", "OBSERVATION", 79, 88]]], ["In this model, we accounted for the reported average time of duration of infection (\u03c4) of 14 days4,11.", [["infection", "DISEASE", 73, 82], ["infection", "PROBLEM", 73, 82]]], ["The model was calibrated by adjusting the rate constant (k) to approximate the total infection value reported by the DGS at 17 March.", [["infection", "DISEASE", 85, 94], ["the total infection value", "PROBLEM", 75, 100], ["infection", "OBSERVATION", 85, 94]]], ["The compliance of GIM by different fractions of the population was modelled through the variation of parameter\u03b1 inEquation 1 andEquation 2.", [["GIM", "SIMPLE_CHEMICAL", 18, 21], ["GIM", "PROTEIN", 18, 21]]], ["We considered that these protective measures (GIM) were 97% effective based on recent meta-analysis estimates, accounted through model parameter\u03b212.", [["these protective measures", "TREATMENT", 19, 44], ["recent meta-analysis estimates", "TEST", 79, 109]]], ["The ODEs were encoded and solved usingPLAS software version 1.2.0.120, where a series of simulations were carried scanning various values of the \u03b1 parameter13.", [["\u03b1 parameter13", "PROTEIN", 145, 158]]], ["Simulations were carried with the initial two cases reported by the DGS and considering only the population of the grand Lisbon and Porto areas (total of 6.5 \u00d7 106) since they represent most of the susceptible population (seeFigure 2).", [["Porto", "ANATOMY_MODIFIER", 132, 137]]], ["For simulations, we used the numerical solver based on the Adams/BDF method, implemented in the LSODA routine of PLAS software.", [["the numerical solver", "TREATMENT", 25, 45], ["the Adams/BDF method", "TREATMENT", 55, 75]]], ["Because a serological screening study made by the Portuguese Nacional Institute of Health (http://www.insa.pt/) found a 6-fold higher infected due to untested asymptomatic exposed to SARS-CoV-2, we have considered this ratio to estimate the reported symptomatic infected by the DGS.", [["SARS", "DISEASE", 183, 187], ["DGS", "DISEASE", 278, 281], ["SARS-CoV-2", "ORGANISM", 183, 193], ["SARS-CoV", "SPECIES", 183, 191], ["a serological screening study", "TEST", 8, 37], ["CoV", "TEST", 188, 191], ["this ratio", "PROBLEM", 214, 224], ["symptomatic", "OBSERVATION_MODIFIER", 250, 261], ["infected", "OBSERVATION", 262, 270]]], ["Further analysis, computations and plots were conducted using Python 3 in the Jupiter Notebook ipython 7.8.0 programing environment under Anaconda distribution version 4.7.12.", [["Further analysis", "TEST", 0, 16]]], ["Data regarding the daily evolution of number of total infected in Portugal by COVID-19 was collected from the DGS web site (https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/) from 2 March to 19 August 2020 (seeSource data, Table S1 and Figure S1)14.", [["DGS web site", "DNA", 110, 122], ["COVID", "TEST", 78, 83], ["total", "OBSERVATION_MODIFIER", 48, 53], ["infected", "OBSERVATION", 54, 62]]], ["The model is available asExtended data.Methods", [["Methods", "TREATMENT", 39, 46]]]], "4cc337b9ce1fbaae39f2cb2a83505907ce155ea0": [["IntroductionAvermectins are a group of drugs with a multiple treatment target.", [["IntroductionAvermectins", "CHEMICAL", 0, 23], ["IntroductionAvermectins", "SIMPLE_CHEMICAL", 0, 23], ["drugs", "TREATMENT", 39, 44], ["a multiple treatment target", "TREATMENT", 50, 77]]], ["They are generally used as a pesticide for the treatment of pests and parasitic worms as a result of their anthelmintic and insecticidal properties [1] .", [["parasitic worms", "DISEASE", 70, 85], ["worms", "SPECIES", 80, 85], ["the treatment of pests", "TREATMENT", 43, 65], ["parasitic worms", "PROBLEM", 70, 85]]], ["The compounds are derived from a 16-membered lactone ring.", [["lactone", "CHEMICAL", 45, 52], ["16-membered lactone", "SIMPLE_CHEMICAL", 33, 52], ["a 16-membered lactone ring", "TREATMENT", 31, 57]]], ["Avermectins occur avermectin synthesis pathway [8] .", [["Avermectins", "CHEMICAL", 0, 11], ["Avermectins", "CHEMICAL", 0, 11], ["avermectin", "CHEMICAL", 18, 28], ["Avermectins", "SIMPLE_CHEMICAL", 0, 11], ["avermectin", "SIMPLE_CHEMICAL", 18, 28], ["Avermectins occur avermectin synthesis pathway", "TREATMENT", 0, 46]]], ["The first step is the synthesis of avermectin aglycone catalyzed by polyketide synthases, followed by aglycone modification, synthesis of modified sugar and the avermectin aglycone is glycosylated with the modified sugar.", [["avermectin aglycone", "CHEMICAL", 35, 54], ["aglycone", "CHEMICAL", 102, 110], ["avermectin aglycone", "CHEMICAL", 161, 180], ["avermectin", "CHEMICAL", 35, 45], ["sugar", "CHEMICAL", 147, 152], ["avermectin", "CHEMICAL", 161, 171], ["sugar", "CHEMICAL", 215, 220], ["avermectin aglycone", "SIMPLE_CHEMICAL", 35, 54], ["polyketide synthases", "SIMPLE_CHEMICAL", 68, 88], ["aglycone", "SIMPLE_CHEMICAL", 102, 110], ["sugar", "SIMPLE_CHEMICAL", 147, 152], ["avermectin aglycone", "SIMPLE_CHEMICAL", 161, 180], ["sugar", "SIMPLE_CHEMICAL", 215, 220], ["avermectin aglycone", "TREATMENT", 35, 54], ["polyketide synthases", "TREATMENT", 68, 88], ["aglycone modification", "TREATMENT", 102, 123], ["modified sugar", "TREATMENT", 138, 152], ["the avermectin aglycone", "TREATMENT", 157, 180]]], ["Eight different types of avermectins are synthesized from these clusters of gene [16] .", [["avermectins", "CHEMICAL", 25, 36], ["avermectins", "CHEMICAL", 25, 36], ["avermectins", "SIMPLE_CHEMICAL", 25, 36], ["avermectins", "TREATMENT", 25, 36]]], ["The polyketide synthase complex activity requires four proteins (AVES 1, AVES 2, AVES 3, and AVES 4) for the synthesis of the initial avermectin aglycone.", [["polyketide", "CHEMICAL", 4, 14], ["avermectin aglycone", "CHEMICAL", 134, 153], ["avermectin", "CHEMICAL", 134, 144], ["polyketide synthase", "GENE_OR_GENE_PRODUCT", 4, 23], ["AVES 3", "GENE_OR_GENE_PRODUCT", 81, 87], ["avermectin aglycone", "SIMPLE_CHEMICAL", 134, 153], ["polyketide synthase complex", "PROTEIN", 4, 31], ["AVES 1", "PROTEIN", 65, 71], ["AVES 2", "PROTEIN", 73, 79], ["AVES 3", "PROTEIN", 81, 87], ["AVES 4", "PROTEIN", 93, 99], ["The polyketide synthase complex activity", "PROBLEM", 0, 40], ["AVES", "TEST", 65, 69], ["AVES", "TEST", 73, 77], ["AVES", "TEST", 81, 85], ["the initial avermectin aglycone", "TREATMENT", 122, 153], ["complex", "OBSERVATION_MODIFIER", 24, 31], ["activity", "OBSERVATION_MODIFIER", 32, 40]]], ["There is a strong similarity between the activity of the enzyme and type I polyketide synthases [16] .", [["type I polyketide synthases", "GENE_OR_GENE_PRODUCT", 68, 95], ["enzyme", "PROTEIN", 57, 63], ["type I polyketide synthases", "PROTEIN", 68, 95], ["the enzyme", "TEST", 53, 63], ["type I polyketide synthases", "TREATMENT", 68, 95], ["strong", "OBSERVATION_MODIFIER", 11, 17]]], ["The enzyme uses either isobutyrl CoA 2-methylbutyrl CoA as a substrate, after which seven acetate units and five propionate units are added to produce avermectin \"A\" or \"B\" series, respectively [16] .", [["isobutyrl CoA 2-methylbutyrl CoA", "CHEMICAL", 23, 55], ["acetate", "CHEMICAL", 90, 97], ["propionate", "CHEMICAL", 113, 123], ["isobutyrl CoA 2-methylbutyrl CoA", "CHEMICAL", 23, 55], ["acetate", "CHEMICAL", 90, 97], ["propionate", "CHEMICAL", 113, 123], ["avermectin", "CHEMICAL", 151, 161], ["isobutyrl CoA 2-methylbutyrl CoA", "SIMPLE_CHEMICAL", 23, 55], ["acetate", "SIMPLE_CHEMICAL", 90, 97], ["propionate", "SIMPLE_CHEMICAL", 113, 123], ["avermectin", "SIMPLE_CHEMICAL", 151, 161], ["The enzyme", "TEST", 0, 10], ["seven acetate units", "TREATMENT", 84, 103], ["five propionate units", "TREATMENT", 108, 129]]], ["The first substrate is now removed from the enzyme complex (thioesterase domain of AVES4), via the cyclization to form cyclic esters.", [["cyclic esters", "CHEMICAL", 119, 132], ["cyclic esters", "CHEMICAL", 119, 132], ["AVES4", "GENE_OR_GENE_PRODUCT", 83, 88], ["cyclic esters", "SIMPLE_CHEMICAL", 119, 132], ["enzyme complex", "PROTEIN", 44, 58], ["thioesterase domain", "PROTEIN", 60, 79], ["AVES4", "PROTEIN", 83, 88], ["the cyclization", "TREATMENT", 95, 110], ["cyclic esters", "PROBLEM", 119, 132]]], ["The other enzymatic activity involved the modification of the avermectin aglycone includes: (1) AveE which contains a Cyt P450 monooxygenase activity and catalyzes the cyclization between C6 and C8 to form a furan ring, (2) AveF which has a keto reductase activity that catalyzes the reduction of keto group on C5 to a hydroxyl group, using NAD(P)H as an electron donor, (3) The mechanism by which AveC acts as a dehydratase between C22-C23 in module 2 is not well understood, AveD possesses a methyltransferase activity that requires SAM [17, 18] .", [["avermectin aglycone", "CHEMICAL", 62, 81], ["furan", "CHEMICAL", 208, 213], ["AveF", "CHEMICAL", 224, 228], ["keto", "CHEMICAL", 297, 301], ["hydroxyl", "CHEMICAL", 319, 327], ["NAD", "CHEMICAL", 341, 344], ["AveC", "CHEMICAL", 398, 402], ["C22-C23", "CHEMICAL", 433, 440], ["avermectin aglycone", "CHEMICAL", 62, 81], ["furan", "CHEMICAL", 208, 213], ["keto", "CHEMICAL", 241, 245], ["keto", "CHEMICAL", 297, 301], ["hydroxyl", "CHEMICAL", 319, 327], ["NAD(P)H", "CHEMICAL", 341, 348], ["C22-C23", "CHEMICAL", 433, 440], ["SAM", "CHEMICAL", 535, 538], ["avermectin aglycone", "SIMPLE_CHEMICAL", 62, 81], ["(1) AveE", "SIMPLE_CHEMICAL", 92, 100], ["Cyt P450", "GENE_OR_GENE_PRODUCT", 118, 126], ["C6", "SIMPLE_CHEMICAL", 188, 190], ["(2) AveF", "SIMPLE_CHEMICAL", 220, 228], ["C5", "SIMPLE_CHEMICAL", 311, 313], ["hydroxyl", "SIMPLE_CHEMICAL", 319, 327], ["NAD(P)H", "SIMPLE_CHEMICAL", 341, 348], ["AveC", "GENE_OR_GENE_PRODUCT", 398, 402], ["C22-C23", "SIMPLE_CHEMICAL", 433, 440], ["AveD", "SIMPLE_CHEMICAL", 477, 481], ["Cyt P450 monooxygenase", "PROTEIN", 118, 140], ["keto reductase", "PROTEIN", 241, 255], ["NAD(P)H", "PROTEIN", 341, 348], ["AveC", "PROTEIN", 398, 402], ["dehydratase", "PROTEIN", 413, 424], ["AveD", "PROTEIN", 477, 481], ["methyltransferase", "PROTEIN", 494, 511], ["a Cyt P450 monooxygenase activity", "TEST", 116, 149], ["the cyclization between C6 and C8", "TREATMENT", 164, 197], ["a furan ring", "TREATMENT", 206, 218], ["a keto reductase activity", "PROBLEM", 239, 264], ["a dehydratase between C22", "PROBLEM", 411, 436], ["enzymatic activity", "OBSERVATION", 10, 28], ["avermectin aglycone", "OBSERVATION", 62, 81], ["C8", "ANATOMY", 195, 197], ["furan ring", "OBSERVATION", 208, 218], ["methyltransferase activity", "OBSERVATION", 494, 520]]], ["Whether AveC or AveD acts on the aglycone determines whether the resulting avermectin aglycone produces avermectin series \"A\" or \"B\" and series 1 or 2, respectively.", [["AveC", "CHEMICAL", 8, 12], ["AveD", "CHEMICAL", 16, 20], ["aglycone", "CHEMICAL", 33, 41], ["avermectin aglycone", "CHEMICAL", 75, 94], ["avermectin", "CHEMICAL", 75, 85], ["avermectin", "CHEMICAL", 104, 114], ["AveC", "GENE_OR_GENE_PRODUCT", 8, 12], ["AveD", "GENE_OR_GENE_PRODUCT", 16, 20], ["aglycone", "SIMPLE_CHEMICAL", 33, 41], ["avermectin aglycone", "SIMPLE_CHEMICAL", 75, 94], ["avermectin", "SIMPLE_CHEMICAL", 104, 114], ["AveC", "PROTEIN", 8, 12], ["AveD", "PROTEIN", 16, 20]]], ["Downstream of AveA4 are none open reading frames (orf1, aveB-BVIII) that are involved in the synthesis of the sugar and glycosylation [17] .", [["sugar", "CHEMICAL", 110, 115], ["AveA4", "GENE_OR_GENE_PRODUCT", 14, 19], ["orf1", "GENE_OR_GENE_PRODUCT", 50, 54], ["aveB-BVIII", "GENE_OR_GENE_PRODUCT", 56, 66], ["sugar", "SIMPLE_CHEMICAL", 110, 115], ["AveA4", "DNA", 14, 19], ["open reading frames", "DNA", 29, 48], ["orf1", "DNA", 50, 54], ["aveB", "DNA", 56, 60], ["BVIII", "DNA", 61, 66], ["orf1", "TEST", 50, 54]]], ["Analysis of orf1 sequence shows that it might probably possess a reductase activity that is active but might not be needed in the avermectin synthesis.", [["avermectin", "CHEMICAL", 130, 140], ["avermectin", "CHEMICAL", 130, 140], ["orf1", "GENE_OR_GENE_PRODUCT", 12, 16], ["avermectin", "SIMPLE_CHEMICAL", 130, 140], ["orf1 sequence", "DNA", 12, 25], ["reductase", "PROTEIN", 65, 74], ["Analysis of orf1 sequence", "TEST", 0, 25], ["a reductase activity", "PROBLEM", 63, 83], ["the avermectin synthesis", "TREATMENT", 126, 150], ["reductase activity", "OBSERVATION", 65, 83]]], ["AveBI is involved in avermectin aglycone glycosylation with an activated sugar (dTDP-sugar).", [["AveBI", "CHEMICAL", 0, 5], ["avermectin aglycone", "CHEMICAL", 21, 40], ["dTDP-sugar", "CHEMICAL", 80, 90], ["sugar", "CHEMICAL", 73, 78], ["dTDP-sugar", "CHEMICAL", 80, 90], ["AveBI", "GENE_OR_GENE_PRODUCT", 0, 5], ["avermectin aglycone", "SIMPLE_CHEMICAL", 21, 40], ["sugar", "SIMPLE_CHEMICAL", 73, 78], ["dTDP-sugar", "SIMPLE_CHEMICAL", 80, 90], ["AveBI", "PROTEIN", 0, 5], ["avermectin aglycone glycosylation", "TREATMENT", 21, 54], ["an activated sugar", "TEST", 60, 78]]], ["AveBII-BVIII are involved in the synthesis of dTDP-L-oleandrose [19] .", [["dTDP-L-oleandrose", "CHEMICAL", 46, 63], ["dTDP-L-oleandrose", "CHEMICAL", 46, 63], ["AveBII-BVIII", "GENE_OR_GENE_PRODUCT", 0, 12], ["dTDP-L-oleandrose", "SIMPLE_CHEMICAL", 46, 63], ["AveBII", "PROTEIN", 0, 6], ["BVIII", "DNA", 7, 12], ["AveBII", "TEST", 0, 6], ["dTDP", "TEST", 46, 50]]], ["The summary of avermectin biosynthesis has been shown in Figure 1 .IvermectinIvermectin is the most common avermectin derivative.", [["avermectin", "CHEMICAL", 15, 25], ["IvermectinIvermectin", "CHEMICAL", 67, 87], ["avermectin", "CHEMICAL", 107, 117], ["avermectin", "CHEMICAL", 15, 25], ["IvermectinIvermectin", "CHEMICAL", 67, 87], ["avermectin", "CHEMICAL", 107, 117], ["avermectin", "SIMPLE_CHEMICAL", 15, 25], ["IvermectinIvermectin", "SIMPLE_CHEMICAL", 67, 87], ["avermectin derivative", "SIMPLE_CHEMICAL", 107, 128], ["avermectin biosynthesis", "TREATMENT", 15, 38], ["IvermectinIvermectin", "TREATMENT", 67, 87]]], ["It is used by humans to treat gastrointestinal strongyloidiasis in the United States and other countries and has been used to treat onchocerciasis and strongyloidosis [10] .", [["gastrointestinal", "ANATOMY", 30, 46], ["gastrointestinal strongyloidiasis", "DISEASE", 30, 63], ["onchocerciasis", "DISEASE", 132, 146], ["strongyloidosis", "DISEASE", 151, 166], ["humans", "ORGANISM", 14, 20], ["humans", "SPECIES", 14, 20], ["humans", "SPECIES", 14, 20], ["gastrointestinal strongyloidiasis", "PROBLEM", 30, 63], ["onchocerciasis and strongyloidosis", "PROBLEM", 132, 166], ["gastrointestinal", "ANATOMY", 30, 46], ["strongyloidiasis", "OBSERVATION", 47, 63]]], ["In animals, it is used to prevent heartworm, treat ectoparasite, and as a microfilaricide.", [["heartworm", "DISEASE", 34, 43], ["heartworm", "ORGANISM", 34, 43], ["heartworm", "PROBLEM", 34, 43], ["ectoparasite", "PROBLEM", 51, 63], ["a microfilaricide", "TREATMENT", 72, 89]]], ["Its dosage is dependent on the kind of treatment, i.e., 0.006 to 0.012 mg/kg has been used for heartworm prevention in dogs and 0.024 mg/kg in cats, 0.05 to 0.2 mg/kg as a macrofilaricide in dogs and 0.3 to 0.6 mg/kg to treat ectoparasites [20] .", [["macrofilaricide", "CHEMICAL", 172, 187], ["heartworm", "ORGANISM", 95, 104], ["dogs", "ORGANISM", 119, 123], ["cats", "ORGANISM", 143, 147], ["dogs", "ORGANISM", 191, 195], ["dogs", "SPECIES", 119, 123], ["cats", "SPECIES", 143, 147], ["dogs", "SPECIES", 191, 195], ["treatment", "TREATMENT", 39, 48], ["heartworm prevention", "TREATMENT", 95, 115], ["a macrofilaricide in dogs", "TREATMENT", 170, 195], ["ectoparasites", "PROBLEM", 226, 239], ["dependent", "OBSERVATION_MODIFIER", 14, 23]]], ["It is administered at high concentration in animals (10-18.7 mg/mL) that may lead to overdose due to wrong calculation or exposure [10] .", [["overdose", "DISEASE", 85, 93], ["overdose", "PROBLEM", 85, 93], ["wrong calculation", "PROBLEM", 101, 118]]], ["Exposure may also be from the remnants of the de-wormer or drippings or droplets of the horse's mouth when dewormed, or from the excreta of treated animals.", [["mouth", "ANATOMY", 96, 101], ["horse", "ORGANISM_SUBDIVISION", 88, 93], ["mouth", "ORGANISM_SUBDIVISION", 96, 101], ["excreta", "ORGANISM_SUBDIVISION", 129, 136], ["horse", "SPECIES", 88, 93], ["may also be", "UNCERTAINTY", 9, 20]]], ["For example, a study showed that the peak amount of ivermectin was 2.5 mg/kg of horse excreta after 2.5 days post-exposure [21] .", [["ivermectin", "CHEMICAL", 52, 62], ["ivermectin", "CHEMICAL", 52, 62], ["ivermectin", "SIMPLE_CHEMICAL", 52, 62], ["horse", "ORGANISM", 80, 85], ["excreta", "ORGANISM_SUBSTANCE", 86, 93], ["horse", "SPECIES", 80, 85], ["horse", "SPECIES", 80, 85], ["a study", "TEST", 13, 20], ["ivermectin", "TREATMENT", 52, 62]]], ["This meant that for a collie to be exposed to a mild toxic level of ivermectin (0.1 mg/kg), a 27.3 kg (60 lb) collie homozygous for ABCB1-1\u2206 would ingest about 1.1 kg (2.4lb) of excreta [22] .", [["ivermectin", "CHEMICAL", 68, 78], ["ivermectin", "CHEMICAL", 68, 78], ["ivermectin", "SIMPLE_CHEMICAL", 68, 78], ["ABCB1-1", "GENE_OR_GENE_PRODUCT", 132, 139], ["ABCB1", "PROTEIN", 132, 137], ["a mild toxic level", "PROBLEM", 46, 64], ["ivermectin", "TREATMENT", 68, 78], ["ABCB1", "TEST", 132, 137]]], ["Some breeds of dogs have been shown to develop clinical symptoms following ivermectin ingestion.", [["ivermectin", "CHEMICAL", 75, 85], ["ivermectin", "CHEMICAL", 75, 85], ["dogs", "ORGANISM", 15, 19], ["ivermectin", "SIMPLE_CHEMICAL", 75, 85], ["dogs", "SPECIES", 15, 19], ["Some breeds of dogs", "PROBLEM", 0, 19], ["clinical symptoms", "PROBLEM", 47, 64], ["ivermectin ingestion", "PROBLEM", 75, 95]]], ["However, it was not known whether dogs have defects in the ABCB1 gene, particularly when the dose was between 0.08-0.34 mg/kg [23] .", [["dogs", "ORGANISM", 34, 38], ["ABCB1", "GENE_OR_GENE_PRODUCT", 59, 64], ["ABCB1 gene", "DNA", 59, 69], ["dogs", "SPECIES", 34, 38], ["defects in the ABCB1 gene", "PROBLEM", 44, 69], ["defects", "OBSERVATION", 44, 51]]], ["It was also shown that dose higher than 0.2 mg/kg resulted in mild symptoms in normal animals and developed severe signs when the dose was above 1 mg/kg [23, 24] .", [["mild symptoms", "PROBLEM", 62, 75], ["severe signs", "PROBLEM", 108, 120], ["mild", "OBSERVATION_MODIFIER", 62, 66], ["symptoms", "OBSERVATION", 67, 75], ["severe", "OBSERVATION_MODIFIER", 108, 114]]], ["The study also found that German shepherds are sensitive to low doses of ivermectin, with a small percentage having a defect in ABCB1 gene, which could be correlated with clinical signs observed in normal dogs at low doses [25] .", [["ivermectin", "CHEMICAL", 73, 83], ["ivermectin", "CHEMICAL", 73, 83], ["ivermectin", "SIMPLE_CHEMICAL", 73, 83], ["ABCB1", "GENE_OR_GENE_PRODUCT", 128, 133], ["dogs", "ORGANISM", 205, 209], ["ABCB1 gene", "DNA", 128, 138], ["The study", "TEST", 0, 9], ["ivermectin", "TREATMENT", 73, 83], ["a defect in ABCB1 gene", "PROBLEM", 116, 138], ["clinical signs", "TEST", 171, 185], ["low doses", "OBSERVATION_MODIFIER", 60, 69], ["small", "OBSERVATION_MODIFIER", 92, 97], ["percentage", "OBSERVATION_MODIFIER", 98, 108], ["defect", "OBSERVATION", 118, 124]]], ["However, these problems have not been encountered with therapeutic doses to avoid heartworm in normal or ABCB1 gene defective dogs.", [["heartworm", "ORGANISM_SUBDIVISION", 82, 91], ["ABCB1", "GENE_OR_GENE_PRODUCT", 105, 110], ["ABCB1 gene", "DNA", 105, 115], ["dogs", "SPECIES", 126, 130], ["therapeutic doses", "TREATMENT", 55, 72], ["heartworm", "PROBLEM", 82, 91], ["ABCB1 gene defective dogs", "PROBLEM", 105, 130], ["defective dogs", "OBSERVATION", 116, 130]]], ["No clinical signs were observed when collies sensitive to ivermectin administered at a high dose of 0.06 mg/kg [26] .", [["ivermectin", "CHEMICAL", 58, 68], ["ivermectin", "CHEMICAL", 58, 68], ["ivermectin", "SIMPLE_CHEMICAL", 58, 68], ["clinical signs", "PROBLEM", 3, 17], ["ivermectin", "TREATMENT", 58, 68]]], ["Patients with ABCB1 gene defect can develop clinical signs when administered a high dose of ivermectin as a microfilaricide or for demodicosis.", [["ivermectin", "CHEMICAL", 92, 102], ["microfilaricide", "CHEMICAL", 108, 123], ["demodicosis", "DISEASE", 131, 142], ["ivermectin", "CHEMICAL", 92, 102], ["Patients", "ORGANISM", 0, 8], ["ABCB1", "GENE_OR_GENE_PRODUCT", 14, 19], ["ivermectin", "SIMPLE_CHEMICAL", 92, 102], ["ABCB1 gene", "DNA", 14, 24], ["Patients", "SPECIES", 0, 8], ["ABCB1 gene defect", "PROBLEM", 14, 31], ["clinical signs", "PROBLEM", 44, 58], ["a high dose of ivermectin", "TREATMENT", 77, 102], ["a microfilaricide", "TREATMENT", 106, 123], ["demodicosis", "PROBLEM", 131, 142], ["defect", "OBSERVATION", 25, 31]]], ["Sometimes dogs with normal ABCB1 genotype can develop clinical signs when administered a high dose of ivermectin.", [["ivermectin", "CHEMICAL", 102, 112], ["ivermectin", "CHEMICAL", 102, 112], ["dogs", "ORGANISM", 10, 14], ["ABCB1", "GENE_OR_GENE_PRODUCT", 27, 32], ["ivermectin", "SIMPLE_CHEMICAL", 102, 112], ["ABCB1", "PROTEIN", 27, 32], ["dogs", "SPECIES", 10, 14], ["clinical signs", "PROBLEM", 54, 68], ["a high dose of ivermectin", "TREATMENT", 87, 112]]], ["Other clinical symptoms have been observed including bradycardia, tremors, hypersalivation, lethargy, ataxia, and blindness [26, 27] .", [["bradycardia", "DISEASE", 53, 64], ["tremors", "DISEASE", 66, 73], ["hypersalivation", "DISEASE", 75, 90], ["lethargy", "DISEASE", 92, 100], ["ataxia", "DISEASE", 102, 108], ["blindness", "DISEASE", 114, 123], ["Other clinical symptoms", "PROBLEM", 0, 23], ["bradycardia", "PROBLEM", 53, 64], ["tremors", "PROBLEM", 66, 73], ["hypersalivation", "PROBLEM", 75, 90], ["lethargy", "PROBLEM", 92, 100], ["ataxia", "PROBLEM", 102, 108], ["blindness", "PROBLEM", 114, 123]]], ["Several derivatives were developed including eprinomectin, which shows prolonged activity and no milk withdrawal and selamectin with a greater margin of safety than IVM in MDR1 mutated dogs [28] .MoxidectinMoxidectin is an example of avermectin that is used in horses and ruminants at high concentrations to prevent heartworms.", [["milk", "ANATOMY", 97, 101], ["heartworms", "ANATOMY", 316, 326], ["eprinomectin", "CHEMICAL", 45, 57], ["selamectin", "CHEMICAL", 117, 127], ["IVM", "CHEMICAL", 165, 168], ["MoxidectinMoxidectin", "CHEMICAL", 196, 216], ["avermectin", "CHEMICAL", 234, 244], ["heartworms", "DISEASE", 316, 326], ["eprinomectin", "CHEMICAL", 45, 57], ["selamectin", "CHEMICAL", 117, 127], ["IVM", "CHEMICAL", 165, 168], ["MoxidectinMoxidectin", "CHEMICAL", 196, 216], ["avermectin", "CHEMICAL", 234, 244], ["eprinomectin", "SIMPLE_CHEMICAL", 45, 57], ["milk", "ORGANISM_SUBSTANCE", 97, 101], ["selamectin", "SIMPLE_CHEMICAL", 117, 127], ["MDR1", "GENE_OR_GENE_PRODUCT", 172, 176], ["MoxidectinMoxidectin", "SIMPLE_CHEMICAL", 196, 216], ["avermectin", "SIMPLE_CHEMICAL", 234, 244], ["horses", "ORGANISM", 261, 267], ["MDR1", "PROTEIN", 172, 176], ["dogs", "SPECIES", 185, 189], ["horses", "SPECIES", 261, 267], ["Several derivatives", "PROBLEM", 0, 19], ["eprinomectin", "TREATMENT", 45, 57], ["prolonged activity", "PROBLEM", 71, 89], ["milk withdrawal", "PROBLEM", 97, 112], ["selamectin", "TREATMENT", 117, 127], ["MoxidectinMoxidectin", "TREATMENT", 196, 216], ["avermectin", "TREATMENT", 234, 244], ["heartworms", "PROBLEM", 316, 326]]], ["It is administered through different routes such as topical, subcutaneous, oral route.", [["subcutaneous", "ANATOMY", 61, 73], ["oral", "ANATOMY", 75, 79], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["topical, subcutaneous, oral route", "TREATMENT", 52, 85]]], ["A study documented that dogs can be exposed to moxidectin through horse dungs, with as much as 2.6 mg/kg of moxidectin measured after 2.5 days treatment [21] .", [["moxidectin", "CHEMICAL", 47, 57], ["moxidectin", "CHEMICAL", 108, 118], ["moxidectin", "CHEMICAL", 47, 57], ["moxidectin", "CHEMICAL", 108, 118], ["dogs", "ORGANISM", 24, 28], ["moxidectin", "SIMPLE_CHEMICAL", 47, 57], ["horse", "ORGANISM", 66, 71], ["dungs", "ORGANISM_SUBDIVISION", 72, 77], ["moxidectin", "SIMPLE_CHEMICAL", 108, 118], ["dogs", "SPECIES", 24, 28], ["horse", "SPECIES", 66, 71], ["horse", "SPECIES", 66, 71], ["A study", "TEST", 0, 7], ["moxidectin", "TREATMENT", 47, 57], ["moxidectin", "TREATMENT", 108, 118]]], ["Moxidectin is also administered to cats to prevent heartworm [20] .", [["Moxidectin", "CHEMICAL", 0, 10], ["Moxidectin", "CHEMICAL", 0, 10], ["Moxidectin", "SIMPLE_CHEMICAL", 0, 10], ["cats", "ORGANISM", 35, 39], ["cats", "SPECIES", 35, 39], ["Moxidectin", "TREATMENT", 0, 10], ["heartworm", "PROBLEM", 51, 60]]], ["Some of the adverse effects of moxidectin administration in dogs include bradycardia, blindness, hypersalivation, hyperthermia, ataxia, respiratory depression, and coma [29] .SelamectinSelamectin is another type of avermectin that is used topically for preventing and killing heartworm and ear mites in cats and dogs, respectively [30] .", [["respiratory", "ANATOMY", 136, 147], ["heartworm", "ANATOMY", 276, 285], ["ear mites", "ANATOMY", 290, 299], ["moxidectin", "CHEMICAL", 31, 41], ["bradycardia", "DISEASE", 73, 84], ["blindness", "DISEASE", 86, 95], ["hypersalivation", "DISEASE", 97, 112], ["hyperthermia", "DISEASE", 114, 126], ["ataxia", "DISEASE", 128, 134], ["respiratory depression", "DISEASE", 136, 158], ["coma", "DISEASE", 164, 168], ["SelamectinSelamectin", "CHEMICAL", 175, 195], ["avermectin", "CHEMICAL", 215, 225], ["moxidectin", "CHEMICAL", 31, 41], ["SelamectinSelamectin", "CHEMICAL", 175, 195], ["avermectin", "CHEMICAL", 215, 225], ["moxidectin", "SIMPLE_CHEMICAL", 31, 41], ["dogs", "ORGANISM", 60, 64], ["SelamectinSelamectin", "SIMPLE_CHEMICAL", 175, 195], ["avermectin", "SIMPLE_CHEMICAL", 215, 225], ["heartworm", "ORGANISM", 276, 285], ["ear mites", "ORGAN", 290, 299], ["cats", "ORGANISM", 303, 307], ["dogs", "ORGANISM", 312, 316], ["dogs", "SPECIES", 60, 64], ["cats", "SPECIES", 303, 307], ["dogs", "SPECIES", 312, 316], ["moxidectin administration", "TREATMENT", 31, 56], ["bradycardia", "PROBLEM", 73, 84], ["blindness", "PROBLEM", 86, 95], ["hypersalivation", "PROBLEM", 97, 112], ["hyperthermia", "PROBLEM", 114, 126], ["ataxia", "PROBLEM", 128, 134], ["respiratory depression", "PROBLEM", 136, 158], ["coma", "PROBLEM", 164, 168], ["SelamectinSelamectin", "TREATMENT", 175, 195], ["avermectin", "TREATMENT", 215, 225], ["blindness", "OBSERVATION", 86, 95], ["respiratory depression", "OBSERVATION", 136, 158], ["ear", "ANATOMY", 290, 293]]], ["Other treatment includes sarcoptic mange and tick infestation in dogs and ascarids and hookworms in cats.", [["ascarids", "ANATOMY", 74, 82], ["tick infestation", "DISEASE", 45, 61], ["dogs", "ORGANISM", 65, 69], ["ascarids", "CANCER", 74, 82], ["cats", "ORGANISM", 100, 104], ["dogs", "SPECIES", 65, 69], ["cats", "SPECIES", 100, 104], ["Other treatment", "TREATMENT", 0, 15], ["sarcoptic mange", "PROBLEM", 25, 40], ["tick infestation", "PROBLEM", 45, 61]]], ["Adverse reactions were reported following oral exposure to selamectin, including vomiting, drooling, retching, licking of lips, lethargy, agitation, anorexia, and ataxia [31] .", [["oral", "ANATOMY", 42, 46], ["lips", "ANATOMY", 122, 126], ["selamectin", "CHEMICAL", 59, 69], ["vomiting", "DISEASE", 81, 89], ["drooling", "DISEASE", 91, 99], ["retching", "DISEASE", 101, 109], ["lethargy", "DISEASE", 128, 136], ["agitation", "DISEASE", 138, 147], ["anorexia", "DISEASE", 149, 157], ["ataxia", "DISEASE", 163, 169], ["selamectin", "CHEMICAL", 59, 69], ["oral", "ORGANISM_SUBDIVISION", 42, 46], ["selamectin", "SIMPLE_CHEMICAL", 59, 69], ["lips", "ORGANISM_SUBDIVISION", 122, 126], ["Adverse reactions", "PROBLEM", 0, 17], ["selamectin", "TREATMENT", 59, 69], ["vomiting", "PROBLEM", 81, 89], ["drooling", "PROBLEM", 91, 99], ["retching", "PROBLEM", 101, 109], ["licking of lips", "PROBLEM", 111, 126], ["lethargy", "PROBLEM", 128, 136], ["agitation", "PROBLEM", 138, 147], ["anorexia", "PROBLEM", 149, 157], ["ataxia", "PROBLEM", 163, 169], ["lips", "ANATOMY", 122, 126]]], ["Abamectin, also known as avermectin B1 is used to regulate insects such as mites and cockroaches.", [["Abamectin", "CHEMICAL", 0, 9], ["avermectin B1", "CHEMICAL", 25, 38], ["Abamectin", "CHEMICAL", 0, 9], ["avermectin B1", "CHEMICAL", 25, 38], ["Abamectin", "SIMPLE_CHEMICAL", 0, 9], ["avermectin B1", "GENE_OR_GENE_PRODUCT", 25, 38], ["avermectin B1", "PROTEIN", 25, 38], ["Abamectin", "TREATMENT", 0, 9], ["avermectin B1", "TREATMENT", 25, 38]]], ["Their low concentration makes it rare to observe signs and symptoms.", [["signs and symptoms", "PROBLEM", 49, 67], ["low concentration", "OBSERVATION_MODIFIER", 6, 23]]], ["Some experiments involving sub-chronic toxicity of abamectin in rats, dogs, and mice have shown that it is slightly more toxic than ivermectin.", [["toxicity", "DISEASE", 39, 47], ["abamectin", "CHEMICAL", 51, 60], ["ivermectin", "CHEMICAL", 132, 142], ["abamectin", "CHEMICAL", 51, 60], ["ivermectin", "CHEMICAL", 132, 142], ["abamectin", "SIMPLE_CHEMICAL", 51, 60], ["rats", "ORGANISM", 64, 68], ["dogs", "ORGANISM", 70, 74], ["mice", "ORGANISM", 80, 84], ["ivermectin", "SIMPLE_CHEMICAL", 132, 142], ["rats", "SPECIES", 64, 68], ["dogs", "SPECIES", 70, 74], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["Some experiments", "PROBLEM", 0, 16], ["chronic toxicity", "PROBLEM", 31, 47], ["slightly more toxic", "PROBLEM", 107, 126], ["ivermectin", "TREATMENT", 132, 142], ["sub", "OBSERVATION_MODIFIER", 27, 30], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["toxicity", "OBSERVATION", 39, 47], ["slightly", "OBSERVATION_MODIFIER", 107, 115], ["more toxic", "OBSERVATION_MODIFIER", 116, 126]]], ["Some of the clinical symptoms in dogs exposed to abamectin includes vomiting, ataxia, hypersalivation, lethargy, mydriasis, diarrhea, and gastrointestinal disturbance [33] .MilbemycinMilbemycin is another type of avermectin that is also used to prevent heartworms in dogs and cats and in a 0.1% otic solution for the treatment of ear mites [22] .", [["gastrointestinal", "ANATOMY", 138, 154], ["heartworms", "ANATOMY", 253, 263], ["otic", "ANATOMY", 295, 299], ["ear", "ANATOMY", 330, 333], ["abamectin", "CHEMICAL", 49, 58], ["vomiting", "DISEASE", 68, 76], ["ataxia", "DISEASE", 78, 84], ["hypersalivation", "DISEASE", 86, 101], ["lethargy", "DISEASE", 103, 111], ["mydriasis", "DISEASE", 113, 122], ["diarrhea", "DISEASE", 124, 132], ["gastrointestinal disturbance", "DISEASE", 138, 166], ["MilbemycinMilbemycin", "CHEMICAL", 173, 193], ["avermectin", "CHEMICAL", 213, 223], ["heartworms", "DISEASE", 253, 263], ["abamectin", "CHEMICAL", 49, 58], ["MilbemycinMilbemycin", "CHEMICAL", 173, 193], ["avermectin", "CHEMICAL", 213, 223], ["dogs", "ORGANISM", 33, 37], ["gastrointestinal", "ORGANISM_SUBDIVISION", 138, 154], ["MilbemycinMilbemycin", "SIMPLE_CHEMICAL", 173, 193], ["avermectin", "SIMPLE_CHEMICAL", 213, 223], ["dogs", "ORGANISM", 267, 271], ["cats", "ORGANISM", 276, 280], ["ear", "ORGAN", 330, 333], ["dogs", "SPECIES", 33, 37], ["dogs", "SPECIES", 267, 271], ["cats", "SPECIES", 276, 280], ["the clinical symptoms", "PROBLEM", 8, 29], ["abamectin", "TREATMENT", 49, 58], ["vomiting", "PROBLEM", 68, 76], ["ataxia", "PROBLEM", 78, 84], ["hypersalivation", "PROBLEM", 86, 101], ["lethargy", "PROBLEM", 103, 111], ["mydriasis", "PROBLEM", 113, 122], ["diarrhea", "PROBLEM", 124, 132], ["gastrointestinal disturbance", "PROBLEM", 138, 166], ["MilbemycinMilbemycin", "TREATMENT", 173, 193], ["avermectin", "TREATMENT", 213, 223], ["a 0.1% otic solution", "TREATMENT", 288, 308], ["the treatment of ear mites", "TREATMENT", 313, 339], ["diarrhea", "OBSERVATION", 124, 132], ["gastrointestinal", "ANATOMY", 138, 154], ["ear", "ANATOMY", 330, 333]]], ["The low concentration makes it difficult for overdose.", [["overdose", "DISEASE", 45, 53], ["The low concentration", "TREATMENT", 0, 21], ["overdose", "PROBLEM", 45, 53], ["low concentration", "OBSERVATION_MODIFIER", 4, 21]]], ["It is administered at a dose of 0.5 mg/kg and 2 mg/kg to dogs and cats, respectively to prevent heartworm.", [["heartworm", "DISEASE", 96, 105], ["dogs", "ORGANISM", 57, 61], ["cats", "ORGANISM", 66, 70], ["heartworm", "ORGANISM", 96, 105], ["dogs", "SPECIES", 57, 61], ["cats", "SPECIES", 66, 70], ["heartworm", "PROBLEM", 96, 105], ["heartworm", "ANATOMY", 96, 105]]], ["Dogs sensitive to ivermectin have been shown to develop mild symptoms including lethargy, hypersalivation, ataxia, and mydriasis when administered at a high dose ranging between 5 to 10 mg/kg [22] .Doramectin, Eprinomectin, and NemadectinDoramectin has been used as an injectable (10 mg/mL) or topical form (5 mg/mL) in ruminants, pigs, and cattle [34, 35] .", [["ivermectin", "CHEMICAL", 18, 28], ["lethargy", "DISEASE", 80, 88], ["hypersalivation", "DISEASE", 90, 105], ["ataxia", "DISEASE", 107, 113], ["mydriasis", "DISEASE", 119, 128], ["Doramectin", "CHEMICAL", 198, 208], ["Eprinomectin", "CHEMICAL", 210, 222], ["NemadectinDoramectin", "CHEMICAL", 228, 248], ["ivermectin", "CHEMICAL", 18, 28], ["Doramectin", "CHEMICAL", 198, 208], ["Eprinomectin", "CHEMICAL", 210, 222], ["NemadectinDoramectin", "CHEMICAL", 228, 248], ["Dogs", "ORGANISM", 0, 4], ["ivermectin", "SIMPLE_CHEMICAL", 18, 28], ["Doramectin", "SIMPLE_CHEMICAL", 198, 208], ["Eprinomectin", "SIMPLE_CHEMICAL", 210, 222], ["NemadectinDoramectin", "SIMPLE_CHEMICAL", 228, 248], ["pigs", "ORGANISM", 331, 335], ["pigs", "SPECIES", 331, 335], ["cattle", "SPECIES", 341, 347], ["ruminants", "SPECIES", 320, 329], ["pigs", "SPECIES", 331, 335], ["cattle", "SPECIES", 341, 347], ["ivermectin", "TREATMENT", 18, 28], ["mild symptoms", "PROBLEM", 56, 69], ["lethargy", "PROBLEM", 80, 88], ["hypersalivation", "PROBLEM", 90, 105], ["ataxia", "PROBLEM", 107, 113], ["mydriasis", "PROBLEM", 119, 128], ["Doramectin", "TREATMENT", 198, 208], ["Eprinomectin", "TREATMENT", 210, 222], ["NemadectinDoramectin", "TREATMENT", 228, 248]]], ["Eprinomectin is poured on cattle at a concentration of 5 mg/mL and for treating Toxocara canis in dogs at a dose of 0.1 mg/kg [36] .", [["Eprinomectin", "CHEMICAL", 0, 12], ["Toxocara canis", "DISEASE", 80, 94], ["Eprinomectin", "CHEMICAL", 0, 12], ["Eprinomectin", "SIMPLE_CHEMICAL", 0, 12], ["cattle", "ORGANISM", 26, 32], ["Toxocara canis", "ORGANISM", 80, 94], ["dogs", "ORGANISM", 98, 102], ["cattle", "SPECIES", 26, 32], ["Toxocara canis", "SPECIES", 80, 94], ["dogs", "SPECIES", 98, 102], ["cattle", "SPECIES", 26, 32], ["Toxocara canis", "SPECIES", 80, 94], ["Eprinomectin", "TREATMENT", 0, 12], ["Toxocara canis", "PROBLEM", 80, 94]]], ["Nemadectin is used to treat gastrointestinal helminths in dogs at doses of 0.2 to 0.6 mg/kg [37] .", [["gastrointestinal", "ANATOMY", 28, 44], ["Nemadectin", "CHEMICAL", 0, 10], ["gastrointestinal helminths", "DISEASE", 28, 54], ["Nemadectin", "CHEMICAL", 0, 10], ["Nemadectin", "SIMPLE_CHEMICAL", 0, 10], ["dogs", "ORGANISM", 58, 62], ["dogs", "SPECIES", 58, 62], ["Nemadectin", "TREATMENT", 0, 10], ["gastrointestinal helminths", "PROBLEM", 28, 54]]], ["Animals with ABCB1 gene defect have been shown to develop hypersalivation, bradycardia, slow mobility, restlessness, blindness, and depression.", [["hypersalivation", "DISEASE", 58, 73], ["bradycardia", "DISEASE", 75, 86], ["blindness", "DISEASE", 117, 126], ["depression", "DISEASE", 132, 142], ["Animals", "ORGANISM", 0, 7], ["ABCB1", "GENE_OR_GENE_PRODUCT", 13, 18], ["ABCB1 gene", "DNA", 13, 23], ["ABCB1 gene defect", "PROBLEM", 13, 30], ["hypersalivation", "PROBLEM", 58, 73], ["bradycardia", "PROBLEM", 75, 86], ["slow mobility", "PROBLEM", 88, 101], ["restlessness", "PROBLEM", 103, 115], ["blindness", "PROBLEM", 117, 126], ["depression", "PROBLEM", 132, 142], ["slow", "OBSERVATION_MODIFIER", 88, 92], ["mobility", "OBSERVATION_MODIFIER", 93, 101], ["blindness", "OBSERVATION", 117, 126]]], ["In normal animals, similar clinical signs for epinomectrin and nemadectin overdose are expected.", [["epinomectrin", "CHEMICAL", 46, 58], ["nemadectin", "CHEMICAL", 63, 73], ["overdose", "DISEASE", 74, 82], ["epinomectrin", "CHEMICAL", 46, 58], ["nemadectin", "CHEMICAL", 63, 73], ["epinomectrin", "SIMPLE_CHEMICAL", 46, 58], ["nemadectin", "SIMPLE_CHEMICAL", 63, 73], ["epinomectrin and nemadectin overdose", "PROBLEM", 46, 82], ["normal animals", "OBSERVATION_MODIFIER", 3, 17]]], ["However, the particular dose to be termed overdose has not been determined [38] .", [["overdose", "DISEASE", 42, 50]]], ["The chemical structures, synonyms, IUPAC name, and molecular formula of ivermectin, selamectin, moxidectin, moxidectin, eprinomectin, nemadectin, abamectin, milbemycin and doramectin are shown in Table 1 .", [["ivermectin", "CHEMICAL", 72, 82], ["selamectin", "CHEMICAL", 84, 94], ["moxidectin", "CHEMICAL", 96, 106], ["moxidectin", "CHEMICAL", 108, 118], ["eprinomectin", "CHEMICAL", 120, 132], ["nemadectin", "CHEMICAL", 134, 144], ["abamectin", "CHEMICAL", 146, 155], ["milbemycin", "CHEMICAL", 157, 167], ["doramectin", "CHEMICAL", 172, 182], ["ivermectin", "CHEMICAL", 72, 82], ["selamectin", "CHEMICAL", 84, 94], ["moxidectin", "CHEMICAL", 96, 106], ["moxidectin", "CHEMICAL", 108, 118], ["eprinomectin", "CHEMICAL", 120, 132], ["nemadectin", "CHEMICAL", 134, 144], ["abamectin", "CHEMICAL", 146, 155], ["milbemycin", "CHEMICAL", 157, 167], ["doramectin", "CHEMICAL", 172, 182], ["ivermectin", "SIMPLE_CHEMICAL", 72, 82], ["selamectin", "SIMPLE_CHEMICAL", 84, 94], ["moxidectin", "SIMPLE_CHEMICAL", 96, 106], ["moxidectin", "SIMPLE_CHEMICAL", 108, 118], ["eprinomectin", "SIMPLE_CHEMICAL", 120, 132], ["nemadectin", "SIMPLE_CHEMICAL", 134, 144], ["abamectin", "SIMPLE_CHEMICAL", 146, 155], ["milbemycin", "SIMPLE_CHEMICAL", 157, 167], ["doramectin", "SIMPLE_CHEMICAL", 172, 182], ["ivermectin", "TREATMENT", 72, 82], ["selamectin", "TREATMENT", 84, 94], ["moxidectin", "TREATMENT", 96, 106], ["moxidectin", "TREATMENT", 108, 118], ["eprinomectin", "TREATMENT", 120, 132], ["nemadectin", "TREATMENT", 134, 144], ["abamectin", "TREATMENT", 146, 155], ["milbemycin", "TREATMENT", 157, 167], ["doramectin", "TREATMENT", 172, 182], ["chemical structures", "ANATOMY", 4, 23]]], ["Pharmaceuticals 2020, 13, 196DosingA commonly used therapy in recent times has been based on oral, parenteral, topical, or spot topical (as in veterinary flea repellant \"drops\") administration of avermectin.", [["oral", "ANATOMY", 93, 97], ["avermectin", "CHEMICAL", 196, 206], ["avermectin", "CHEMICAL", 196, 206], ["oral", "ORGANISM_SUBDIVISION", 93, 97], ["avermectin", "SIMPLE_CHEMICAL", 196, 206], ["Pharmaceuticals", "TREATMENT", 0, 15], ["therapy", "TREATMENT", 51, 58], ["oral, parenteral", "TREATMENT", 93, 109], ["topical", "TREATMENT", 111, 118], ["spot topical", "TREATMENT", 123, 135], ["veterinary flea repellant \"drops", "TREATMENT", 143, 175], ["avermectin", "TREATMENT", 196, 206]]], ["They show activity against a broad range of nematodes and arthropod parasites of domestic animals at doses of 300 \u00b5g/kg or less than 200 \u00b5g/kg of ivermectin appears to be the common interspecies standard, from humans to horses to house pets, unless otherwise indicated.", [["ivermectin", "CHEMICAL", 146, 156], ["ivermectin", "CHEMICAL", 146, 156], ["arthropod parasites", "ORGANISM", 58, 77], ["ivermectin", "SIMPLE_CHEMICAL", 146, 156], ["humans", "ORGANISM", 210, 216], ["humans", "SPECIES", 210, 216], ["humans", "SPECIES", 210, 216], ["ivermectin", "TREATMENT", 146, 156], ["activity", "OBSERVATION_MODIFIER", 10, 18]]], ["Unlike the macrolide or polyene antibiotics, they lack significant antibacterial or antifungal activity [40] .", [["macrolide", "CHEMICAL", 11, 20], ["polyene", "CHEMICAL", 24, 31], ["macrolide", "CHEMICAL", 11, 20], ["polyene", "CHEMICAL", 24, 31], ["macrolide", "SIMPLE_CHEMICAL", 11, 20], ["polyene antibiotics", "SIMPLE_CHEMICAL", 24, 43], ["the macrolide", "TREATMENT", 7, 20], ["polyene antibiotics", "TREATMENT", 24, 43], ["significant antibacterial or antifungal activity", "PROBLEM", 55, 103]]], ["Taylor et al. [41] illustrated an annual single oral dose of 150 \u00b5g/kg of ivermectin was given to prevent microfilarial production and inhibit disease progression.", [["oral", "ANATOMY", 48, 52], ["ivermectin", "CHEMICAL", 74, 84], ["ivermectin", "CHEMICAL", 74, 84], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["ivermectin", "SIMPLE_CHEMICAL", 74, 84], ["ivermectin", "TREATMENT", 74, 84], ["microfilarial production", "PROBLEM", 106, 130], ["disease progression", "PROBLEM", 143, 162], ["microfilarial production", "OBSERVATION", 106, 130]]], ["In humans, the most commonly used dose of ivermectin varies from 150 to 200 \u00b5g/kg for the treatment of enterobiasis onchocerciasis, and strongyloidiasis, while a higher dose of 400 \u00b5g/kg was used for lymphatic filariasis.", [["lymphatic", "ANATOMY", 200, 209], ["ivermectin", "CHEMICAL", 42, 52], ["enterobiasis onchocerciasis", "DISEASE", 103, 130], ["strongyloidiasis", "DISEASE", 136, 152], ["lymphatic filariasis", "DISEASE", 200, 220], ["ivermectin", "CHEMICAL", 42, 52], ["humans", "ORGANISM", 3, 9], ["ivermectin", "SIMPLE_CHEMICAL", 42, 52], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["ivermectin", "TREATMENT", 42, 52], ["enterobiasis onchocerciasis", "PROBLEM", 103, 130], ["strongyloidiasis", "PROBLEM", 136, 152], ["lymphatic filariasis", "PROBLEM", 200, 220], ["enterobiasis", "OBSERVATION", 103, 115], ["strongyloidiasis", "OBSERVATION", 136, 152], ["lymphatic", "ANATOMY", 200, 209], ["filariasis", "OBSERVATION", 210, 220]]], ["It is worth noting that ivermectin was administered twice a week, up to 1.6 mg/kg subcutaneously, for patients with spinal damage and muscle spasms, for 12 weeks [42] .", [["subcutaneously", "ANATOMY", 82, 96], ["spinal", "ANATOMY", 116, 122], ["muscle", "ANATOMY", 134, 140], ["ivermectin", "CHEMICAL", 24, 34], ["spinal damage", "DISEASE", 116, 129], ["muscle spasms", "DISEASE", 134, 147], ["ivermectin", "CHEMICAL", 24, 34], ["ivermectin", "SIMPLE_CHEMICAL", 24, 34], ["patients", "ORGANISM", 102, 110], ["spinal", "ORGANISM_SUBDIVISION", 116, 122], ["muscle", "ORGAN", 134, 140], ["patients", "SPECIES", 102, 110], ["ivermectin", "TREATMENT", 24, 34], ["spinal damage", "PROBLEM", 116, 129], ["muscle spasms", "PROBLEM", 134, 147], ["spinal", "ANATOMY", 116, 122], ["damage", "OBSERVATION", 123, 129], ["muscle", "ANATOMY", 134, 140], ["spasms", "OBSERVATION", 141, 147]]], ["Avermectin IB1 demonstrated the potential to minimize tumor growth at a dose of 1 mg/kg in SHK male mice with a strong Ehrlich carcinoma as well as human acute myeloblastic leukemia, breast and colon carcinoma, glioblastoma, and murine lymphosarcoma cell line.", [["tumor", "ANATOMY", 54, 59], ["Ehrlich carcinoma", "ANATOMY", 119, 136], ["acute myeloblastic leukemia", "ANATOMY", 154, 181], ["breast", "ANATOMY", 183, 189], ["colon carcinoma", "ANATOMY", 194, 209], ["glioblastoma", "ANATOMY", 211, 223], ["lymphosarcoma cell line", "ANATOMY", 236, 259], ["Avermectin IB1", "CHEMICAL", 0, 14], ["tumor", "DISEASE", 54, 59], ["Ehrlich carcinoma", "DISEASE", 119, 136], ["acute myeloblastic leukemia", "DISEASE", 154, 181], ["breast and colon carcinoma", "DISEASE", 183, 209], ["glioblastoma", "DISEASE", 211, 223], ["lymphosarcoma", "DISEASE", 236, 249], ["Avermectin IB1", "SIMPLE_CHEMICAL", 0, 14], ["tumor", "CANCER", 54, 59], ["mice", "ORGANISM", 100, 104], ["Ehrlich carcinoma", "CANCER", 119, 136], ["human", "ORGANISM", 148, 153], ["acute myeloblastic leukemia", "CANCER", 154, 181], ["breast", "CANCER", 183, 189], ["colon carcinoma", "CANCER", 194, 209], ["glioblastoma", "CANCER", 211, 223], ["murine", "ORGANISM", 229, 235], ["lymphosarcoma cell line", "CELL", 236, 259], ["murine lymphosarcoma cell line", "CELL_LINE", 229, 259], ["mice", "SPECIES", 100, 104], ["human", "SPECIES", 148, 153], ["murine", "SPECIES", 229, 235], ["mice", "SPECIES", 100, 104], ["human", "SPECIES", 148, 153], ["Avermectin IB1", "TREATMENT", 0, 14], ["tumor growth", "PROBLEM", 54, 66], ["a strong Ehrlich carcinoma", "PROBLEM", 110, 136], ["human acute myeloblastic leukemia", "PROBLEM", 148, 181], ["breast and colon carcinoma", "PROBLEM", 183, 209], ["glioblastoma", "PROBLEM", 211, 223], ["murine lymphosarcoma cell line", "TREATMENT", 229, 259], ["tumor", "OBSERVATION", 54, 59], ["Ehrlich carcinoma", "OBSERVATION", 119, 136], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["myeloblastic leukemia", "OBSERVATION", 160, 181], ["breast", "ANATOMY", 183, 189], ["colon", "ANATOMY", 194, 199], ["carcinoma", "OBSERVATION", 200, 209], ["glioblastoma", "OBSERVATION", 211, 223], ["murine", "OBSERVATION_MODIFIER", 229, 235], ["lymphosarcoma cell line", "OBSERVATION", 236, 259]]], ["The median dose used was 5 mg/kg (2.4-40 mg/kg), equivalent to 0.40 mg/kg in humans [43] [44] [45] [46] .", [["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["The median dose", "TREATMENT", 0, 15]]], ["A dose of 150 \u00b5g/kg of ivermectin was reported to be linked to reduce mortality rates and lower healthcare resource use in COVID-19 patients.", [["ivermectin", "CHEMICAL", 23, 33], ["ivermectin", "CHEMICAL", 23, 33], ["ivermectin", "SIMPLE_CHEMICAL", 23, 33], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["ivermectin", "TREATMENT", 23, 33]]], ["Laing et al. documented that a single dose of 30 \u00b5g/kg of ivermectin significantly reduced the number of skin microfilariae, and that effect continued for at least 6 months without any significant adverse effects [49] .Mechanism of ActionAvermectin generally works by preventing the transmission of electrical impulses in the muscles and nerves of invertebrates by amplifying the glutamate effects on the invertebrates-specific gated chloride channel [50, 51] .", [["skin microfilariae", "ANATOMY", 105, 123], ["muscles", "ANATOMY", 326, 333], ["nerves", "ANATOMY", 338, 344], ["ivermectin", "CHEMICAL", 58, 68], ["ActionAvermectin", "CHEMICAL", 232, 248], ["glutamate", "CHEMICAL", 380, 389], ["chloride", "CHEMICAL", 434, 442], ["ivermectin", "CHEMICAL", 58, 68], ["glutamate", "CHEMICAL", 380, 389], ["chloride", "CHEMICAL", 434, 442], ["ivermectin", "SIMPLE_CHEMICAL", 58, 68], ["skin", "ORGAN", 105, 109], ["microfilariae", "ORGANISM_SUBSTANCE", 110, 123], ["ActionAvermectin", "SIMPLE_CHEMICAL", 232, 248], ["muscles", "ORGAN", 326, 333], ["nerves", "ANATOMICAL_SYSTEM", 338, 344], ["glutamate", "SIMPLE_CHEMICAL", 380, 389], ["chloride", "SIMPLE_CHEMICAL", 434, 442], ["ivermectin", "TREATMENT", 58, 68], ["skin microfilariae", "PROBLEM", 105, 123], ["any significant adverse effects", "PROBLEM", 181, 212], ["the glutamate effects", "PROBLEM", 376, 397], ["skin", "ANATOMY", 105, 109], ["microfilariae", "OBSERVATION", 110, 123], ["muscles", "ANATOMY", 326, 333], ["nerves", "ANATOMY", 338, 344]]], ["This allows more chloride ions to enter the cells, causing hyperpolarization and culminating in paralysis of the invertebrate neuromuscular systems.", [["cells", "ANATOMY", 44, 49], ["neuromuscular systems", "ANATOMY", 126, 147], ["chloride", "CHEMICAL", 17, 25], ["paralysis", "DISEASE", 96, 105], ["chloride", "CHEMICAL", 17, 25], ["chloride ions", "SIMPLE_CHEMICAL", 17, 30], ["cells", "CELL", 44, 49], ["neuromuscular systems", "MULTI-TISSUE_STRUCTURE", 126, 147], ["more chloride ions", "TREATMENT", 12, 30], ["hyperpolarization", "PROBLEM", 59, 76], ["paralysis of the invertebrate neuromuscular systems", "PROBLEM", 96, 147], ["hyperpolarization", "OBSERVATION_MODIFIER", 59, 76], ["paralysis", "OBSERVATION", 96, 105], ["neuromuscular systems", "ANATOMY", 126, 147]]], ["The administered doses that lead to this damage are not toxic to mammals, the reason being that they lack the glutamate-gated chloride channel [52] (Figure 2 ).", [["glutamate", "CHEMICAL", 110, 119], ["chloride", "CHEMICAL", 126, 134], ["glutamate", "CHEMICAL", 110, 119], ["chloride", "CHEMICAL", 126, 134], ["glutamate", "SIMPLE_CHEMICAL", 110, 119], ["chloride", "SIMPLE_CHEMICAL", 126, 134], ["The administered doses", "TREATMENT", 0, 22], ["this damage", "PROBLEM", 36, 47], ["toxic", "PROBLEM", 56, 61]]], ["Pharmaceuticals 2020, 13, x FOR PEER REVIEW 9 of 38DosingA commonly used therapy in recent times has been based on oral, parenteral, topical, or spot topical (as in veterinary flea repellant \"drops\") administration of avermectin.", [["oral", "ANATOMY", 115, 119], ["avermectin", "CHEMICAL", 218, 228], ["avermectin", "CHEMICAL", 218, 228], ["oral", "ORGANISM_SUBDIVISION", 115, 119], ["avermectin", "SIMPLE_CHEMICAL", 218, 228], ["therapy", "TREATMENT", 73, 80], ["oral, parenteral", "TREATMENT", 115, 131], ["topical", "TREATMENT", 133, 140], ["spot topical", "TREATMENT", 145, 157], ["veterinary flea repellant \"drops", "TREATMENT", 165, 197], ["avermectin", "TREATMENT", 218, 228]]], ["They show activity against a broad range of nematodes and arthropod parasites of domestic animals at doses of 300 \u03bcg/kg or less than 200 \u03bcg/kg of ivermectin appears to be the common interspecies standard, from humans to horses to house pets, unless otherwise indicated.", [["ivermectin", "CHEMICAL", 146, 156], ["ivermectin", "CHEMICAL", 146, 156], ["arthropod parasites", "ORGANISM", 58, 77], ["ivermectin", "SIMPLE_CHEMICAL", 146, 156], ["humans", "ORGANISM", 210, 216], ["humans", "SPECIES", 210, 216], ["humans", "SPECIES", 210, 216], ["ivermectin", "TREATMENT", 146, 156], ["activity", "OBSERVATION_MODIFIER", 10, 18]]], ["Unlike the macrolide or polyene antibiotics, they lack significant antibacterial or antifungal activity [40] .", [["macrolide", "CHEMICAL", 11, 20], ["polyene", "CHEMICAL", 24, 31], ["macrolide", "CHEMICAL", 11, 20], ["polyene", "CHEMICAL", 24, 31], ["macrolide", "SIMPLE_CHEMICAL", 11, 20], ["polyene antibiotics", "SIMPLE_CHEMICAL", 24, 43], ["the macrolide", "TREATMENT", 7, 20], ["polyene antibiotics", "TREATMENT", 24, 43], ["significant antibacterial or antifungal activity", "PROBLEM", 55, 103]]], ["Taylor et al. [41] illustrated an annual single oral dose of 150 \u03bcg/kg of ivermectin was given to prevent microfilarial production and inhibit disease progression.", [["oral", "ANATOMY", 48, 52], ["ivermectin", "CHEMICAL", 74, 84], ["ivermectin", "CHEMICAL", 74, 84], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["ivermectin", "SIMPLE_CHEMICAL", 74, 84], ["ivermectin", "TREATMENT", 74, 84], ["microfilarial production", "PROBLEM", 106, 130], ["disease progression", "PROBLEM", 143, 162], ["microfilarial production", "OBSERVATION", 106, 130]]], ["In humans, the most commonly used dose of ivermectin varies from 150 to 200 \u03bcg/kg for the treatment of enterobiasis onchocerciasis, and strongyloidiasis, while a higher dose of 400 \u03bcg/kg was used for lymphatic filariasis.", [["lymphatic", "ANATOMY", 200, 209], ["ivermectin", "CHEMICAL", 42, 52], ["enterobiasis onchocerciasis", "DISEASE", 103, 130], ["strongyloidiasis", "DISEASE", 136, 152], ["lymphatic filariasis", "DISEASE", 200, 220], ["ivermectin", "CHEMICAL", 42, 52], ["humans", "ORGANISM", 3, 9], ["ivermectin", "SIMPLE_CHEMICAL", 42, 52], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["ivermectin", "TREATMENT", 42, 52], ["enterobiasis onchocerciasis", "PROBLEM", 103, 130], ["strongyloidiasis", "PROBLEM", 136, 152], ["lymphatic filariasis", "PROBLEM", 200, 220], ["enterobiasis", "OBSERVATION", 103, 115], ["strongyloidiasis", "OBSERVATION", 136, 152], ["lymphatic", "ANATOMY", 200, 209], ["filariasis", "OBSERVATION", 210, 220]]], ["It is worth noting that ivermectin was administered twice a week, up to 1.6 mg/kg subcutaneously, for patients with spinal damage and muscle spasms, for 12 weeks.", [["subcutaneously", "ANATOMY", 82, 96], ["spinal", "ANATOMY", 116, 122], ["muscle", "ANATOMY", 134, 140], ["ivermectin", "CHEMICAL", 24, 34], ["spinal damage", "DISEASE", 116, 129], ["muscle spasms", "DISEASE", 134, 147], ["ivermectin", "CHEMICAL", 24, 34], ["ivermectin", "SIMPLE_CHEMICAL", 24, 34], ["patients", "ORGANISM", 102, 110], ["spinal", "ORGANISM_SUBDIVISION", 116, 122], ["muscle", "ORGAN", 134, 140], ["patients", "SPECIES", 102, 110], ["ivermectin", "TREATMENT", 24, 34], ["spinal damage", "PROBLEM", 116, 129], ["muscle spasms", "PROBLEM", 134, 147], ["spinal", "ANATOMY", 116, 122], ["damage", "OBSERVATION", 123, 129], ["muscle", "ANATOMY", 134, 140], ["spasms", "OBSERVATION", 141, 147]]], ["Avermectin IB1 demonstrated the potential to minimize tumor growth at a dose of 1 mg/kg in SHK male mice with a strong Ehrlich carcinoma as well as human acute myeloblastic leukemia, breast and colon carcinoma, glioblastoma, and murine lymphosarcoma cell line.", [["tumor", "ANATOMY", 54, 59], ["Ehrlich carcinoma", "ANATOMY", 119, 136], ["acute myeloblastic leukemia", "ANATOMY", 154, 181], ["breast", "ANATOMY", 183, 189], ["colon carcinoma", "ANATOMY", 194, 209], ["glioblastoma", "ANATOMY", 211, 223], ["lymphosarcoma cell line", "ANATOMY", 236, 259], ["Avermectin IB1", "CHEMICAL", 0, 14], ["tumor", "DISEASE", 54, 59], ["Ehrlich carcinoma", "DISEASE", 119, 136], ["acute myeloblastic leukemia", "DISEASE", 154, 181], ["breast and colon carcinoma", "DISEASE", 183, 209], ["glioblastoma", "DISEASE", 211, 223], ["lymphosarcoma", "DISEASE", 236, 249], ["Avermectin IB1", "SIMPLE_CHEMICAL", 0, 14], ["tumor", "CANCER", 54, 59], ["mice", "ORGANISM", 100, 104], ["Ehrlich carcinoma", "CANCER", 119, 136], ["human", "ORGANISM", 148, 153], ["acute myeloblastic leukemia", "CANCER", 154, 181], ["breast", "CANCER", 183, 189], ["colon carcinoma", "CANCER", 194, 209], ["glioblastoma", "CANCER", 211, 223], ["murine", "ORGANISM", 229, 235], ["lymphosarcoma cell line", "CELL", 236, 259], ["murine lymphosarcoma cell line", "CELL_LINE", 229, 259], ["mice", "SPECIES", 100, 104], ["human", "SPECIES", 148, 153], ["murine", "SPECIES", 229, 235], ["mice", "SPECIES", 100, 104], ["human", "SPECIES", 148, 153], ["Avermectin IB1", "TREATMENT", 0, 14], ["tumor growth", "PROBLEM", 54, 66], ["a strong Ehrlich carcinoma", "PROBLEM", 110, 136], ["human acute myeloblastic leukemia", "PROBLEM", 148, 181], ["breast and colon carcinoma", "PROBLEM", 183, 209], ["glioblastoma", "PROBLEM", 211, 223], ["murine lymphosarcoma cell line", "TREATMENT", 229, 259], ["tumor", "OBSERVATION", 54, 59], ["Ehrlich carcinoma", "OBSERVATION", 119, 136], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["myeloblastic leukemia", "OBSERVATION", 160, 181], ["breast", "ANATOMY", 183, 189], ["colon", "ANATOMY", 194, 199], ["carcinoma", "OBSERVATION", 200, 209], ["glioblastoma", "OBSERVATION", 211, 223], ["murine", "OBSERVATION_MODIFIER", 229, 235], ["lymphosarcoma cell line", "OBSERVATION", 236, 259]]], ["The median dose used was 5 mg/kg (2.4-40 mg/kg), equivalent to 0.40 mg/kg in humans [43] [44] [45] [46] .", [["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["The median dose", "TREATMENT", 0, 15]]], ["A dose of 150 \u03bcg/kg of ivermectin was reported to be linked to reduce mortality rates and lower healthcare resource use in COVID-19 patients.", [["ivermectin", "CHEMICAL", 23, 33], ["ivermectin", "CHEMICAL", 23, 33], ["ivermectin", "SIMPLE_CHEMICAL", 23, 33], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["ivermectin", "TREATMENT", 23, 33]]], ["Laing et al. documented that a single dose of 30 \u03bcg/kg of ivermectin significantly reduced the number of skin microfilariae, and that effect continued for at least 6 months without any significant adverse effects [49] .Mechanism of ActionAvermectin generally works by preventing the transmission of electrical impulses in the muscles and nerves of invertebrates by amplifying the glutamate effects on the invertebrates-specific gated chloride channel [50, 51] .", [["skin microfilariae", "ANATOMY", 105, 123], ["muscles", "ANATOMY", 326, 333], ["nerves", "ANATOMY", 338, 344], ["ivermectin", "CHEMICAL", 58, 68], ["ActionAvermectin", "CHEMICAL", 232, 248], ["glutamate", "CHEMICAL", 380, 389], ["chloride", "CHEMICAL", 434, 442], ["ivermectin", "CHEMICAL", 58, 68], ["glutamate", "CHEMICAL", 380, 389], ["chloride", "CHEMICAL", 434, 442], ["ivermectin", "SIMPLE_CHEMICAL", 58, 68], ["skin", "ORGAN", 105, 109], ["microfilariae", "ORGANISM_SUBSTANCE", 110, 123], ["ActionAvermectin", "SIMPLE_CHEMICAL", 232, 248], ["muscles", "ORGAN", 326, 333], ["nerves", "ANATOMICAL_SYSTEM", 338, 344], ["glutamate", "SIMPLE_CHEMICAL", 380, 389], ["chloride", "SIMPLE_CHEMICAL", 434, 442], ["ivermectin", "TREATMENT", 58, 68], ["skin microfilariae", "PROBLEM", 105, 123], ["any significant adverse effects", "PROBLEM", 181, 212], ["the glutamate effects", "PROBLEM", 376, 397], ["skin", "ANATOMY", 105, 109], ["microfilariae", "OBSERVATION", 110, 123], ["muscles", "ANATOMY", 326, 333], ["nerves", "ANATOMY", 338, 344]]], ["This allows more chloride ions to enter the cells, causing hyperpolarization and culminating in paralysis of the invertebrate neuromuscular systems.", [["cells", "ANATOMY", 44, 49], ["neuromuscular systems", "ANATOMY", 126, 147], ["chloride", "CHEMICAL", 17, 25], ["paralysis", "DISEASE", 96, 105], ["chloride", "CHEMICAL", 17, 25], ["chloride ions", "SIMPLE_CHEMICAL", 17, 30], ["cells", "CELL", 44, 49], ["neuromuscular systems", "MULTI-TISSUE_STRUCTURE", 126, 147], ["more chloride ions", "TREATMENT", 12, 30], ["hyperpolarization", "PROBLEM", 59, 76], ["paralysis of the invertebrate neuromuscular systems", "PROBLEM", 96, 147], ["hyperpolarization", "OBSERVATION_MODIFIER", 59, 76], ["paralysis", "OBSERVATION", 96, 105], ["neuromuscular systems", "ANATOMY", 126, 147]]], ["The administered doses that lead to this damage are not toxic to mammals, the reason being that they lack the glutamate-gated chloride channel [52] (Figure 2 ).", [["glutamate", "CHEMICAL", 110, 119], ["chloride", "CHEMICAL", 126, 134], ["glutamate", "CHEMICAL", 110, 119], ["chloride", "CHEMICAL", 126, 134], ["glutamate", "SIMPLE_CHEMICAL", 110, 119], ["chloride", "SIMPLE_CHEMICAL", 126, 134], ["The administered doses", "TREATMENT", 0, 22], ["this damage", "PROBLEM", 36, 47], ["toxic", "PROBLEM", 56, 61]]], ["Low concentration of ivermectin does not destroy the worms by its effect on GluCls expressed in the neurons, as hyperpolarization caused by ivermectin spreads through gap junctions encoded by unc-7 and unc-9 to other excitable cells important for the worm's activity.", [["worms", "ANATOMY", 53, 58], ["neurons", "ANATOMY", 100, 107], ["gap junctions", "ANATOMY", 167, 180], ["cells", "ANATOMY", 227, 232], ["worm", "ANATOMY", 251, 255], ["ivermectin", "CHEMICAL", 21, 31], ["ivermectin", "CHEMICAL", 140, 150], ["ivermectin", "CHEMICAL", 21, 31], ["ivermectin", "CHEMICAL", 140, 150], ["ivermectin", "SIMPLE_CHEMICAL", 21, 31], ["GluCls", "GENE_OR_GENE_PRODUCT", 76, 82], ["neurons", "CELL", 100, 107], ["ivermectin", "SIMPLE_CHEMICAL", 140, 150], ["gap junctions", "CELLULAR_COMPONENT", 167, 180], ["unc-7", "GENE_OR_GENE_PRODUCT", 192, 197], ["unc-9", "GENE_OR_GENE_PRODUCT", 202, 207], ["cells", "CELL", 227, 232], ["worm", "ORGAN", 251, 255], ["GluCls", "PROTEIN", 76, 82], ["unc-7 and unc-9", "PROTEIN", 192, 207], ["excitable cells", "CELL_TYPE", 217, 232], ["worms", "SPECIES", 53, 58], ["ivermectin", "TREATMENT", 21, 31], ["ivermectin spreads through gap junctions", "PROBLEM", 140, 180], ["unc", "TEST", 192, 195], ["unc", "TEST", 202, 205], ["neurons", "ANATOMY", 100, 107]]], ["A study in GluCl\u03b13 (AVR- 14) and GluCl\u03b11 (GLC-1) to confer sensitive gap junction to ivermectin has shown that it is important for hyperpolarization to spread from the extra pharyngeal nervous system to the pharynx [53] .", [["gap junction", "ANATOMY", 69, 81], ["pharyngeal nervous system", "ANATOMY", 174, 199], ["pharynx", "ANATOMY", 207, 214], ["ivermectin", "CHEMICAL", 85, 95], ["ivermectin", "CHEMICAL", 85, 95], ["GluCl\u03b13", "GENE_OR_GENE_PRODUCT", 11, 18], ["AVR- 14", "GENE_OR_GENE_PRODUCT", 20, 27], ["GluCl\u03b11", "GENE_OR_GENE_PRODUCT", 33, 40], ["GLC-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["ivermectin", "SIMPLE_CHEMICAL", 85, 95], ["pharyngeal nervous system", "ANATOMICAL_SYSTEM", 174, 199], ["pharynx", "ORGAN", 207, 214], ["GluCl\u03b13 (AVR- 14", "DNA", 11, 27], ["GluCl\u03b11 (GLC-1", "DNA", 33, 47], ["A study", "TEST", 0, 7], ["GluCl", "TEST", 11, 16], ["AVR", "TEST", 20, 23], ["GluCl\u03b11", "TEST", 33, 40], ["GLC", "TEST", 42, 45], ["ivermectin", "TREATMENT", 85, 95], ["hyperpolarization", "PROBLEM", 131, 148], ["extra", "ANATOMY_MODIFIER", 168, 173], ["pharyngeal nervous", "ANATOMY", 174, 192], ["pharynx", "ANATOMY", 207, 214]]], ["This process occurs by connecting neurons, such as I1 and RIP, which may not be expressed by GluCls [28, 54] .", [["neurons", "ANATOMY", 34, 41], ["neurons", "CELL", 34, 41], ["I1", "GENE_OR_GENE_PRODUCT", 51, 53], ["RIP", "GENE_OR_GENE_PRODUCT", 58, 61], ["GluCls", "GENE_OR_GENE_PRODUCT", 93, 99], ["I1", "PROTEIN", 51, 53], ["RIP", "PROTEIN", 58, 61]]], ["The information on the role of avermectins on chloride channels opening, decreasing muscle fiber's resistance to input, GABA-like effects, and nerve signal transmission has been well documented [55] .", [["muscle fiber", "ANATOMY", 84, 96], ["nerve", "ANATOMY", 143, 148], ["avermectins", "CHEMICAL", 31, 42], ["chloride", "CHEMICAL", 46, 54], ["GABA", "CHEMICAL", 120, 124], ["avermectins", "CHEMICAL", 31, 42], ["chloride", "CHEMICAL", 46, 54], ["GABA", "CHEMICAL", 120, 124], ["avermectins", "SIMPLE_CHEMICAL", 31, 42], ["chloride", "SIMPLE_CHEMICAL", 46, 54], ["muscle fiber", "TISSUE", 84, 96], ["GABA", "SIMPLE_CHEMICAL", 120, 124], ["chloride channels", "TREATMENT", 46, 63], ["GABA", "TEST", 120, 124], ["nerve signal transmission", "TEST", 143, 168], ["muscle", "ANATOMY", 84, 90], ["nerve", "ANATOMY", 143, 148]]], ["Some early results on different species, various model systems, and at varying concentrations are as follows: stimulation of high-affinity binding of GABA and benzodiazepine to rat brain membranes.", [["brain membranes", "ANATOMY", 181, 196], ["GABA", "CHEMICAL", 150, 154], ["benzodiazepine", "CHEMICAL", 159, 173], ["GABA", "CHEMICAL", 150, 154], ["benzodiazepine", "CHEMICAL", 159, 173], ["GABA", "SIMPLE_CHEMICAL", 150, 154], ["benzodiazepine", "SIMPLE_CHEMICAL", 159, 173], ["rat", "ORGANISM", 177, 180], ["brain membranes", "MULTI-TISSUE_STRUCTURE", 181, 196], ["rat", "SPECIES", 177, 180], ["benzodiazepine", "TREATMENT", 159, 173], ["early", "OBSERVATION_MODIFIER", 5, 10], ["brain membranes", "ANATOMY", 181, 196]]], ["A quick disabling of nematodes devoid of hypercontraction or soft disability.", [["hypercontraction", "DISEASE", 41, 57], ["soft disability", "DISEASE", 61, 76], ["A quick disabling of nematodes", "PROBLEM", 0, 30], ["hypercontraction", "PROBLEM", 41, 57], ["soft disability", "PROBLEM", 61, 76], ["soft disability", "OBSERVATION", 61, 76]]], ["A very low concentration of avermectin induced a quick and fast irreversible inhibition of inhibitory postsynaptic potential in the nerve of crustacean and delay reducing the excitatory potential amplitude and elevating the chloride ion entry.", [["nerve", "ANATOMY", 132, 137], ["avermectin", "CHEMICAL", 28, 38], ["chloride", "CHEMICAL", 224, 232], ["avermectin", "CHEMICAL", 28, 38], ["chloride", "CHEMICAL", 224, 232], ["avermectin", "SIMPLE_CHEMICAL", 28, 38], ["nerve", "MULTI-TISSUE_STRUCTURE", 132, 137], ["chloride ion", "SIMPLE_CHEMICAL", 224, 236], ["A very low concentration of avermectin", "PROBLEM", 0, 38], ["a quick and fast irreversible inhibition", "PROBLEM", 47, 87], ["the chloride ion entry", "TREATMENT", 220, 242], ["very", "OBSERVATION_MODIFIER", 2, 6], ["low concentration", "OBSERVATION_MODIFIER", 7, 24], ["nerve", "ANATOMY", 132, 137]]], ["High avermectin induced by membrane conduction was inhibited using GABA antagonists (e.g., bicuculline and picrotoxin) [56] .", [["membrane", "ANATOMY", 27, 35], ["avermectin", "CHEMICAL", 5, 15], ["GABA", "CHEMICAL", 67, 71], ["bicuculline", "CHEMICAL", 91, 102], ["picrotoxin", "CHEMICAL", 107, 117], ["avermectin", "CHEMICAL", 5, 15], ["GABA", "CHEMICAL", 67, 71], ["bicuculline", "CHEMICAL", 91, 102], ["picrotoxin", "CHEMICAL", 107, 117], ["avermectin", "SIMPLE_CHEMICAL", 5, 15], ["membrane", "CELLULAR_COMPONENT", 27, 35], ["GABA antagonists", "SIMPLE_CHEMICAL", 67, 83], ["bicuculline", "SIMPLE_CHEMICAL", 91, 102], ["picrotoxin", "SIMPLE_CHEMICAL", 107, 117], ["High avermectin", "TREATMENT", 0, 15], ["membrane conduction", "PROBLEM", 27, 46], ["GABA antagonists", "TREATMENT", 67, 83], ["bicuculline and picrotoxin", "TREATMENT", 91, 117], ["membrane conduction", "OBSERVATION", 27, 46]]], ["The signal transmission between ventral interneurons and motor neurons of Ascaris was blocked.", [["ventral interneurons", "ANATOMY", 32, 52], ["motor neurons", "ANATOMY", 57, 70], ["ventral interneurons", "MULTI-TISSUE_STRUCTURE", 32, 52], ["motor neurons", "CELL", 57, 70], ["Ascaris", "ORGANISM", 74, 81], ["motor neurons", "CELL_TYPE", 57, 70], ["ventral", "ANATOMY_MODIFIER", 32, 39], ["interneurons", "ANATOMY_MODIFIER", 40, 52], ["motor neurons", "ANATOMY", 57, 70], ["Ascaris", "OBSERVATION", 74, 81]]], ["The nanomolar concentration of avermectin in the extensor tibiae muscle of the locust Schistocerca gregaria has been reversibly increased by the chloride ion in the GABA sensitive fibers.", [["extensor tibiae muscle", "ANATOMY", 49, 71], ["fibers", "ANATOMY", 180, 186], ["avermectin", "CHEMICAL", 31, 41], ["chloride", "CHEMICAL", 145, 153], ["GABA", "CHEMICAL", 165, 169], ["avermectin", "CHEMICAL", 31, 41], ["chloride", "CHEMICAL", 145, 153], ["GABA", "CHEMICAL", 165, 169], ["avermectin", "SIMPLE_CHEMICAL", 31, 41], ["extensor tibiae", "ORGAN", 49, 64], ["muscle", "ORGAN", 65, 71], ["locust Schistocerca gregaria", "ORGANISM", 79, 107], ["chloride", "SIMPLE_CHEMICAL", 145, 153], ["GABA", "SIMPLE_CHEMICAL", 165, 169], ["fibers", "CELLULAR_COMPONENT", 180, 186], ["Schistocerca gregaria", "SPECIES", 86, 107], ["Schistocerca gregaria", "SPECIES", 86, 107], ["The nanomolar concentration of avermectin", "TREATMENT", 0, 41], ["nanomolar", "OBSERVATION_MODIFIER", 4, 13], ["concentration", "OBSERVATION_MODIFIER", 14, 27], ["avermectin", "OBSERVATION_MODIFIER", 31, 41], ["extensor", "ANATOMY_MODIFIER", 49, 57], ["tibiae muscle", "ANATOMY", 58, 71], ["locust", "ANATOMY_MODIFIER", 79, 85], ["Schistocerca gregaria", "OBSERVATION", 86, 107], ["reversibly", "OBSERVATION_MODIFIER", 117, 127], ["increased", "OBSERVATION_MODIFIER", 128, 137]]], ["Micromolar concentrations of avermectin also reversibly prevent muscle fibers from Schistocerca gregaria that are either sensitive or insensitive to GABA [57] .", [["muscle fibers", "ANATOMY", 64, 77], ["avermectin", "CHEMICAL", 29, 39], ["GABA", "CHEMICAL", 149, 153], ["avermectin", "CHEMICAL", 29, 39], ["GABA", "CHEMICAL", 149, 153], ["avermectin", "SIMPLE_CHEMICAL", 29, 39], ["muscle fibers", "TISSUE", 64, 77], ["Schistocerca gregaria", "ORGANISM", 83, 104], ["GABA [57]", "GENE_OR_GENE_PRODUCT", 149, 158], ["Schistocerca gregaria", "SPECIES", 83, 104], ["Schistocerca gregaria", "SPECIES", 83, 104], ["Micromolar concentrations of avermectin", "TREATMENT", 0, 39], ["muscle fibers", "PROBLEM", 64, 77], ["Schistocerca gregaria", "PROBLEM", 83, 104], ["muscle", "ANATOMY", 64, 70], ["fibers", "OBSERVATION", 71, 77], ["Schistocerca gregaria", "OBSERVATION", 83, 104]]], ["Another study showed that subpicomolar concentration of avermectin induced reversible opening of multi-transmitter-gated chloride channels isolated from the stomach muscle of crayfish using a patch-clamp technique.", [["stomach muscle", "ANATOMY", 157, 171], ["crayfish", "ANATOMY", 175, 183], ["avermectin", "CHEMICAL", 56, 66], ["chloride", "CHEMICAL", 121, 129], ["avermectin", "CHEMICAL", 56, 66], ["chloride", "CHEMICAL", 121, 129], ["avermectin", "SIMPLE_CHEMICAL", 56, 66], ["chloride", "SIMPLE_CHEMICAL", 121, 129], ["stomach muscle", "ORGAN", 157, 171], ["multi-transmitter-gated chloride channels", "PROTEIN", 97, 138], ["Another study", "TEST", 0, 13], ["avermectin", "TREATMENT", 56, 66], ["multi-transmitter-gated chloride channels", "TREATMENT", 97, 138], ["a patch-clamp technique", "TREATMENT", 190, 213], ["avermectin induced", "OBSERVATION", 56, 74], ["reversible opening", "OBSERVATION", 75, 93], ["stomach muscle", "ANATOMY", 157, 171]]], ["It should be noted that the chloride channel can be activated using GABA, glutamate, or acetylcholine [58] .", [["chloride", "CHEMICAL", 28, 36], ["GABA", "CHEMICAL", 68, 72], ["glutamate", "CHEMICAL", 74, 83], ["acetylcholine", "CHEMICAL", 88, 101], ["chloride", "CHEMICAL", 28, 36], ["GABA", "CHEMICAL", 68, 72], ["glutamate", "CHEMICAL", 74, 83], ["acetylcholine", "CHEMICAL", 88, 101], ["chloride", "SIMPLE_CHEMICAL", 28, 36], ["GABA", "SIMPLE_CHEMICAL", 68, 72], ["glutamate", "SIMPLE_CHEMICAL", 74, 83], ["acetylcholine", "SIMPLE_CHEMICAL", 88, 101], ["the chloride channel", "TREATMENT", 24, 44], ["GABA, glutamate", "TREATMENT", 68, 83], ["acetylcholine", "TREATMENT", 88, 101]]], ["This experimental design was able to distinguish between two different conductance states, the first being activated by carbachol, glutamate, ibotenic and quisqualic acid, while the second was activated by GABA and muscimol (a GABA agonist).", [["carbachol", "CHEMICAL", 120, 129], ["glutamate", "CHEMICAL", 131, 140], ["ibotenic", "CHEMICAL", 142, 150], ["quisqualic acid", "CHEMICAL", 155, 170], ["GABA", "CHEMICAL", 206, 210], ["muscimol", "CHEMICAL", 215, 223], ["GABA", "CHEMICAL", 227, 231], ["carbachol", "CHEMICAL", 120, 129], ["glutamate", "CHEMICAL", 131, 140], ["ibotenic", "CHEMICAL", 142, 150], ["quisqualic acid", "CHEMICAL", 155, 170], ["GABA", "CHEMICAL", 206, 210], ["muscimol", "CHEMICAL", 215, 223], ["GABA", "CHEMICAL", 227, 231], ["carbachol", "SIMPLE_CHEMICAL", 120, 129], ["glutamate", "SIMPLE_CHEMICAL", 131, 140], ["ibotenic", "SIMPLE_CHEMICAL", 142, 150], ["quisqualic acid", "SIMPLE_CHEMICAL", 155, 170], ["GABA", "SIMPLE_CHEMICAL", 206, 210], ["muscimol", "SIMPLE_CHEMICAL", 215, 223], ["GABA", "SIMPLE_CHEMICAL", 227, 231], ["carbachol", "TREATMENT", 120, 129], ["glutamate", "TREATMENT", 131, 140], ["quisqualic acid", "TEST", 155, 170], ["a GABA agonist", "TREATMENT", 225, 239]]], ["Avermectin was not effective in activating the second conductance like GABA.", [["Avermectin", "CHEMICAL", 0, 10], ["GABA", "CHEMICAL", 71, 75], ["Avermectin", "CHEMICAL", 0, 10], ["GABA", "CHEMICAL", 71, 75], ["Avermectin", "SIMPLE_CHEMICAL", 0, 10], ["GABA", "SIMPLE_CHEMICAL", 71, 75], ["Avermectin", "TREATMENT", 0, 10]]], ["This is because the effect is direct and thus it does not require a second messenger pathway.", [["a second messenger pathway", "TREATMENT", 66, 92]]], ["However, a huge non-reversible increase in the opening of chloride channels occurs when the avermectin concentration increased to or above 10 pmol and this reversible or nonreversible opening of the chloride channels was blocked by picrotoxin [58] .", [["chloride", "CHEMICAL", 58, 66], ["avermectin", "CHEMICAL", 92, 102], ["chloride", "CHEMICAL", 199, 207], ["picrotoxin", "CHEMICAL", 232, 242], ["chloride", "CHEMICAL", 58, 66], ["avermectin", "CHEMICAL", 92, 102], ["chloride", "CHEMICAL", 199, 207], ["picrotoxin", "CHEMICAL", 232, 242], ["chloride", "SIMPLE_CHEMICAL", 58, 66], ["avermectin", "SIMPLE_CHEMICAL", 92, 102], ["chloride", "SIMPLE_CHEMICAL", 199, 207], ["picrotoxin", "SIMPLE_CHEMICAL", 232, 242], ["chloride channels", "PROTEIN", 58, 75], ["a huge non-reversible increase", "PROBLEM", 9, 39], ["chloride channels", "TREATMENT", 58, 75], ["the avermectin concentration", "PROBLEM", 88, 116], ["this reversible", "PROBLEM", 151, 166], ["the chloride channels", "TREATMENT", 195, 216], ["picrotoxin", "TEST", 232, 242], ["huge", "OBSERVATION_MODIFIER", 11, 15], ["non-reversible", "OBSERVATION_MODIFIER", 16, 30], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["chloride channels", "OBSERVATION", 58, 75]]], ["Further studies were carried out on the effect of ivermectin on the electrophysiology of the oocytes obtained from Xenopus laevis.", [["oocytes", "ANATOMY", 93, 100], ["Xenopus laevis", "ANATOMY", 115, 129], ["ivermectin", "CHEMICAL", 50, 60], ["ivermectin", "CHEMICAL", 50, 60], ["ivermectin", "SIMPLE_CHEMICAL", 50, 60], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 93, 100], ["Xenopus laevis", "ORGANISM", 115, 129], ["Xenopus laevis", "SPECIES", 115, 129], ["Xenopus laevis", "SPECIES", 115, 129], ["Further studies", "TEST", 0, 15], ["ivermectin", "TREATMENT", 50, 60], ["Xenopus laevis", "OBSERVATION", 115, 129]]], ["A 1-2.5 kb size of poly (A+) RNA obtained from C. elegans was injected into the oocytes.", [["oocytes", "ANATOMY", 80, 87], ["poly", "CHEMICAL", 19, 23], ["poly (A+)", "CHEMICAL", 19, 28], ["poly (A+)", "GENE_OR_GENE_PRODUCT", 19, 28], ["C. elegans", "ORGANISM", 47, 57], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 80, 87], ["poly (A+) RNA", "RNA", 19, 32], ["C. elegans", "SPECIES", 47, 57], ["C. elegans", "SPECIES", 47, 57], ["poly (A+) RNA", "PROBLEM", 19, 32], ["C. elegans", "PROBLEM", 47, 57]]], ["The results showed that the induction of inner-bound membrane stream associated with high ivermectin concentration as well as increasing the entry of chloride ion across the membrane [59] .", [["inner-bound membrane", "ANATOMY", 41, 61], ["membrane", "ANATOMY", 174, 182], ["ivermectin", "CHEMICAL", 90, 100], ["chloride", "CHEMICAL", 150, 158], ["ivermectin", "CHEMICAL", 90, 100], ["chloride", "CHEMICAL", 150, 158], ["ivermectin", "SIMPLE_CHEMICAL", 90, 100], ["chloride", "SIMPLE_CHEMICAL", 150, 158], ["membrane", "CELLULAR_COMPONENT", 174, 182], ["the induction of inner-bound membrane stream", "TREATMENT", 24, 68], ["high ivermectin concentration", "TREATMENT", 85, 114]]], ["The result also shows that GABA, muscimol, benzodiazepam or bicuculline do not alter the effect of ivermectin, while picrotoxin does.", [["GABA", "CHEMICAL", 27, 31], ["muscimol", "CHEMICAL", 33, 41], ["benzodiazepam", "CHEMICAL", 43, 56], ["bicuculline", "CHEMICAL", 60, 71], ["ivermectin", "CHEMICAL", 99, 109], ["picrotoxin", "CHEMICAL", 117, 127], ["GABA", "CHEMICAL", 27, 31], ["muscimol", "CHEMICAL", 33, 41], ["benzodiazepam", "CHEMICAL", 43, 56], ["bicuculline", "CHEMICAL", 60, 71], ["ivermectin", "CHEMICAL", 99, 109], ["picrotoxin", "CHEMICAL", 117, 127], ["GABA", "SIMPLE_CHEMICAL", 27, 31], ["muscimol", "SIMPLE_CHEMICAL", 33, 41], ["benzodiazepam", "SIMPLE_CHEMICAL", 43, 56], ["bicuculline", "SIMPLE_CHEMICAL", 60, 71], ["ivermectin", "SIMPLE_CHEMICAL", 99, 109], ["picrotoxin", "SIMPLE_CHEMICAL", 117, 127], ["GABA", "TREATMENT", 27, 31], ["muscimol", "TREATMENT", 33, 41], ["benzodiazepam", "TREATMENT", 43, 56], ["bicuculline", "TREATMENT", 60, 71], ["ivermectin", "TREATMENT", 99, 109]]], ["Based on the above-mentioned results, it can be concluded that ivermectin can directly induce the GABA-insensitive chloride channels opening [59, 60] .", [["ivermectin", "CHEMICAL", 63, 73], ["GABA", "CHEMICAL", 98, 102], ["chloride", "CHEMICAL", 115, 123], ["ivermectin", "CHEMICAL", 63, 73], ["GABA", "CHEMICAL", 98, 102], ["chloride", "CHEMICAL", 115, 123], ["ivermectin", "SIMPLE_CHEMICAL", 63, 73], ["GABA", "SIMPLE_CHEMICAL", 98, 102], ["chloride", "SIMPLE_CHEMICAL", 115, 123], ["ivermectin", "TREATMENT", 63, 73], ["the GABA", "TEST", 94, 102]]], ["To understand the mechanism by which avermectin acts against different species of insects, arthropods, nematodes and immature worms such as flukes, tapeworms and filarial worms, couples with good tolerance by the host animals.", [["worms", "ANATOMY", 126, 131], ["flukes", "ANATOMY", 140, 146], ["avermectin", "CHEMICAL", 37, 47], ["filarial worms", "DISEASE", 162, 176], ["avermectin", "CHEMICAL", 37, 47], ["avermectin", "GENE_OR_GENE_PRODUCT", 37, 47], ["flukes", "ORGANISM_SUBDIVISION", 140, 146], ["filarial worms", "ORGANISM", 162, 176], ["worms", "SPECIES", 126, 131], ["worms", "SPECIES", 171, 176], ["immature worms", "PROBLEM", 117, 131], ["immature worms", "OBSERVATION", 117, 131]]], ["It is necessary to isolate the binding site of avermectin in various species and study how it induces the opening of chloride channels and increases hyperpolarization, since it has been established that its binding site is specific to other effector molecules [61] .Mode of Action of MilbemycinsThe mode of action of milbemycins is not well understood compared to avermectin although its anti-parasitic properties have been discovered and described more than two decades ago [62] .", [["avermectin", "CHEMICAL", 47, 57], ["chloride", "CHEMICAL", 117, 125], ["Milbemycins", "CHEMICAL", 284, 295], ["milbemycins", "CHEMICAL", 317, 328], ["avermectin", "CHEMICAL", 364, 374], ["avermectin", "CHEMICAL", 47, 57], ["chloride", "CHEMICAL", 117, 125], ["Milbemycins", "CHEMICAL", 284, 295], ["milbemycins", "CHEMICAL", 317, 328], ["avermectin", "CHEMICAL", 364, 374], ["avermectin", "SIMPLE_CHEMICAL", 47, 57], ["chloride", "SIMPLE_CHEMICAL", 117, 125], ["Milbemycins", "SIMPLE_CHEMICAL", 284, 295], ["milbemycins", "SIMPLE_CHEMICAL", 317, 328], ["avermectin", "SIMPLE_CHEMICAL", 364, 374], ["chloride channels", "PROTEIN", 117, 134], ["effector molecules", "PROTEIN", 241, 259], ["chloride channels", "TREATMENT", 117, 134], ["its binding site", "PROBLEM", 203, 219], ["Milbemycins", "TREATMENT", 284, 295], ["milbemycins", "TREATMENT", 317, 328], ["avermectin", "TREATMENT", 364, 374]]], ["Nemadectin is the most potent milbemycin that has unsaturated long-chain C at its 25-position.", [["Nemadectin", "CHEMICAL", 0, 10], ["milbemycin", "CHEMICAL", 30, 40], ["Nemadectin", "CHEMICAL", 0, 10], ["milbemycin", "CHEMICAL", 30, 40], ["Nemadectin", "SIMPLE_CHEMICAL", 0, 10], ["milbemycin", "SIMPLE_CHEMICAL", 30, 40], ["long-chain C", "SIMPLE_CHEMICAL", 62, 74], ["unsaturated long-chain C", "PROTEIN", 50, 74], ["Nemadectin", "TREATMENT", 0, 10], ["most potent", "OBSERVATION_MODIFIER", 18, 29], ["unsaturated", "OBSERVATION_MODIFIER", 50, 61]]], ["Nemadectin has been shown to possess insecticidal and nematocidal activities.", [["Nemadectin", "CHEMICAL", 0, 10], ["Nemadectin", "GENE_OR_GENE_PRODUCT", 0, 10], ["Nemadectin", "PROTEIN", 0, 10], ["Nemadectin", "TREATMENT", 0, 10]]], ["It also serves as a substrate for moxidectin (MOX) synthesis, a commercial endectocide [63] .", [["moxidectin", "CHEMICAL", 34, 44], ["MOX", "CHEMICAL", 46, 49], ["moxidectin", "CHEMICAL", 34, 44], ["MOX", "CHEMICAL", 46, 49], ["endectocide", "CHEMICAL", 75, 86], ["moxidectin", "SIMPLE_CHEMICAL", 34, 44], ["MOX", "SIMPLE_CHEMICAL", 46, 49], ["moxidectin (MOX) synthesis", "TREATMENT", 34, 60]]], ["As with other macrocyclic lactones, there is a high affinity for invertebrates-specific glutamate-gated ion channels.Mode of Action of MilbemycinsThe glutamate-gated binding site exists in juxtaposed to GABA-gated chloride channels, therefore, there is a possibility of macrolide endectocides enhancing GABA-gated chloride channels.", [["macrocyclic lactones", "CHEMICAL", 14, 34], ["glutamate", "CHEMICAL", 88, 97], ["Milbemycins", "CHEMICAL", 135, 146], ["glutamate", "CHEMICAL", 150, 159], ["GABA", "CHEMICAL", 203, 207], ["chloride", "CHEMICAL", 214, 222], ["macrolide", "CHEMICAL", 270, 279], ["GABA", "CHEMICAL", 303, 307], ["chloride", "CHEMICAL", 314, 322], ["lactones", "CHEMICAL", 26, 34], ["glutamate", "CHEMICAL", 88, 97], ["Milbemycins", "CHEMICAL", 135, 146], ["glutamate", "CHEMICAL", 150, 159], ["GABA", "CHEMICAL", 203, 207], ["chloride", "CHEMICAL", 214, 222], ["macrolide", "CHEMICAL", 270, 279], ["GABA", "CHEMICAL", 303, 307], ["chloride", "CHEMICAL", 314, 322], ["macrocyclic lactones", "SIMPLE_CHEMICAL", 14, 34], ["glutamate", "SIMPLE_CHEMICAL", 88, 97], ["Milbemycins", "SIMPLE_CHEMICAL", 135, 146], ["glutamate", "SIMPLE_CHEMICAL", 150, 159], ["GABA", "SIMPLE_CHEMICAL", 203, 207], ["chloride", "SIMPLE_CHEMICAL", 214, 222], ["macrolide endectocides", "SIMPLE_CHEMICAL", 270, 292], ["GABA", "SIMPLE_CHEMICAL", 303, 307], ["chloride", "SIMPLE_CHEMICAL", 314, 322], ["glutamate-gated ion channels", "PROTEIN", 88, 116], ["glutamate-gated binding site", "PROTEIN", 150, 178], ["GABA-gated chloride channels", "PROTEIN", 303, 331], ["other macrocyclic lactones", "TREATMENT", 8, 34], ["a high affinity", "PROBLEM", 45, 60], ["Milbemycins", "TREATMENT", 135, 146], ["The glutamate-gated binding site", "TREATMENT", 146, 178], ["gated chloride channels", "TREATMENT", 208, 231], ["macrolide endectocides", "PROBLEM", 270, 292]]], ["MOX also binds to the myroneural junctions of anthropoids and neuronal membrane of nematodes [64] .", [["myroneural junctions", "ANATOMY", 22, 42], ["anthropoids", "ANATOMY", 46, 57], ["neuronal membrane", "ANATOMY", 62, 79], ["MOX", "CHEMICAL", 0, 3], ["MOX", "CHEMICAL", 0, 3], ["MOX", "SIMPLE_CHEMICAL", 0, 3], ["myroneural junctions", "CELLULAR_COMPONENT", 22, 42], ["anthropoids", "CELLULAR_COMPONENT", 46, 57], ["neuronal membrane", "CELLULAR_COMPONENT", 62, 79], ["MOX", "PROTEIN", 0, 3], ["myroneural junctions", "ANATOMY", 22, 42], ["anthropoids", "ANATOMY_MODIFIER", 46, 57], ["neuronal membrane", "OBSERVATION", 62, 79], ["nematodes", "OBSERVATION", 83, 92]]], ["Hyperpolarization of the postsynaptic cells occurs as a result of the influx of chloride ion, which decreases the resistance of the cell membrane.", [["postsynaptic cells", "ANATOMY", 25, 43], ["cell membrane", "ANATOMY", 132, 145], ["chloride", "CHEMICAL", 80, 88], ["chloride", "CHEMICAL", 80, 88], ["cells", "CELL", 38, 43], ["chloride", "SIMPLE_CHEMICAL", 80, 88], ["cell membrane", "CELLULAR_COMPONENT", 132, 145], ["postsynaptic cells", "CELL_TYPE", 25, 43], ["Hyperpolarization of the postsynaptic cells", "PROBLEM", 0, 43], ["the influx of chloride ion", "PROBLEM", 66, 92], ["postsynaptic cells", "OBSERVATION", 25, 43], ["resistance", "OBSERVATION_MODIFIER", 114, 124], ["cell membrane", "OBSERVATION", 132, 145]]], ["This disrupts the neurotransmission processes, causing disability, death, and elimination of the parasite [65] .", [["disability", "DISEASE", 55, 65], ["death", "DISEASE", 67, 72], ["disability", "PROBLEM", 55, 65], ["death", "PROBLEM", 67, 72]]], ["It has also been reported that MOX inhibits the release of dopamine from the striatum due to the activation of the GABAergic system, leading to reduced motor coordination in rats [66] .Mode of Action of SpinosynsUnlike other avermectin compounds, spinosyns elicit its insecticidal activity through a different mechanism [67] .", [["striatum", "ANATOMY", 77, 85], ["GABAergic system", "ANATOMY", 115, 131], ["MOX", "CHEMICAL", 31, 34], ["dopamine", "CHEMICAL", 59, 67], ["spinosyns", "CHEMICAL", 247, 256], ["MOX", "CHEMICAL", 31, 34], ["dopamine", "CHEMICAL", 59, 67], ["SpinosynsUnlike", "CHEMICAL", 203, 218], ["avermectin", "CHEMICAL", 225, 235], ["spinosyns", "CHEMICAL", 247, 256], ["MOX", "SIMPLE_CHEMICAL", 31, 34], ["dopamine", "SIMPLE_CHEMICAL", 59, 67], ["striatum", "MULTI-TISSUE_STRUCTURE", 77, 85], ["rats", "ORGANISM", 174, 178], ["avermectin compounds", "SIMPLE_CHEMICAL", 225, 245], ["spinosyns", "SIMPLE_CHEMICAL", 247, 256], ["rats", "SPECIES", 174, 178], ["dopamine", "TREATMENT", 59, 67], ["reduced motor coordination in rats", "PROBLEM", 144, 178], ["SpinosynsUnlike other avermectin compounds", "TREATMENT", 203, 245], ["spinosyns", "TREATMENT", 247, 256], ["GABAergic system", "OBSERVATION", 115, 131], ["reduced", "OBSERVATION_MODIFIER", 144, 151], ["motor coordination", "OBSERVATION", 152, 170]]], ["Several reports suggested that spinosyns may alter neuronal function by affecting the function of the nicotinic receptor [68, 69] .", [["neuronal", "ANATOMY", 51, 59], ["spinosyns", "CHEMICAL", 31, 40], ["spinosyns", "CHEMICAL", 31, 40], ["spinosyns", "SIMPLE_CHEMICAL", 31, 40], ["neuronal", "CELL", 51, 59], ["nicotinic receptor", "PROTEIN", 102, 120]]], ["The nicotinic-receptor binding site for spinosyn A in insects, spinosad, has not been identified, including the GABA or nicotinic binding site for insecticide.", [["spinosyn A", "CHEMICAL", 40, 50], ["spinosad", "CHEMICAL", 63, 71], ["GABA", "CHEMICAL", 112, 116], ["spinosyn A", "CHEMICAL", 40, 50], ["spinosad", "CHEMICAL", 63, 71], ["GABA", "CHEMICAL", 112, 116], ["spinosyn A", "SIMPLE_CHEMICAL", 40, 50], ["spinosad", "SIMPLE_CHEMICAL", 63, 71], ["GABA", "SIMPLE_CHEMICAL", 112, 116], ["nicotinic-receptor binding site", "DNA", 4, 35], ["The nicotinic-receptor binding site", "TREATMENT", 0, 35]]], ["In addition, spinosyn does not interact with the binding site for avermectins [70] .", [["spinosyn", "CHEMICAL", 13, 21], ["avermectins", "CHEMICAL", 66, 77], ["spinosyn", "CHEMICAL", 13, 21], ["avermectins", "CHEMICAL", 66, 77], ["spinosyn", "SIMPLE_CHEMICAL", 13, 21]]], ["A study carried out by Robertson et al. [71] showed that spinosyn A induced nicotinic effect, suggesting an unknown mechanism by which it binds to the nicotinic receptor.", [["spinosyn A", "CHEMICAL", 57, 67], ["spinosyn A", "CHEMICAL", 57, 67], ["spinosyn A", "SIMPLE_CHEMICAL", 57, 67], ["nicotinic receptor", "PROTEIN", 151, 169], ["A study", "TEST", 0, 7], ["spinosyn A induced nicotinic effect", "PROBLEM", 57, 92]]], ["A new study using a knockout Drosophila melanogaster suggested that D\u03b16 subunit of the nicotinic receptor as a potential binding site for spinosyn [72] .Human Uses of IvermectinThe origin of ivermectin use in the treatment of human diseases started in 1985, in an effort by the united nation to tackle the challenges posed by tropical diseases, which have become endemic in various areas of Africa.", [["spinosyn", "CHEMICAL", 138, 146], ["Ivermectin", "CHEMICAL", 167, 177], ["ivermectin", "CHEMICAL", 191, 201], ["spinosyn", "CHEMICAL", 138, 146], ["Ivermectin", "CHEMICAL", 167, 177], ["ivermectin", "CHEMICAL", 191, 201], ["Drosophila melanogaster", "ORGANISM", 29, 52], ["D\u03b16", "GENE_OR_GENE_PRODUCT", 68, 71], ["nicotinic receptor", "GENE_OR_GENE_PRODUCT", 87, 105], ["Human", "ORGANISM", 153, 158], ["Ivermectin", "SIMPLE_CHEMICAL", 167, 177], ["ivermectin", "SIMPLE_CHEMICAL", 191, 201], ["human", "ORGANISM", 226, 231], ["D\u03b16 subunit", "PROTEIN", 68, 79], ["nicotinic receptor", "PROTEIN", 87, 105], ["Drosophila melanogaster", "SPECIES", 29, 52], ["Human", "SPECIES", 153, 158], ["human", "SPECIES", 226, 231], ["Drosophila melanogaster", "SPECIES", 29, 52], ["Human", "SPECIES", 153, 158], ["human", "SPECIES", 226, 231], ["A new study", "TEST", 0, 11], ["a knockout Drosophila melanogaster", "TREATMENT", 18, 52], ["the nicotinic receptor", "TREATMENT", 83, 105], ["Ivermectin", "TREATMENT", 167, 177], ["ivermectin use", "TREATMENT", 191, 205], ["human diseases", "PROBLEM", 226, 240], ["tropical diseases", "PROBLEM", 326, 343], ["Africa", "PROBLEM", 391, 397], ["ivermectin", "OBSERVATION", 191, 201], ["tropical diseases", "OBSERVATION", 326, 343], ["endemic", "OBSERVATION_MODIFIER", 363, 370], ["Africa", "OBSERVATION", 391, 397]]], ["Some of these diseases that are treated with ivermectin, including onchocerciasis, caused by a filarial nematode, Onchocerca volvulus [73] .", [["ivermectin", "CHEMICAL", 45, 55], ["onchocerciasis", "DISEASE", 67, 81], ["filarial nematode", "DISEASE", 95, 112], ["Onchocerca volvulus", "DISEASE", 114, 133], ["ivermectin", "CHEMICAL", 45, 55], ["ivermectin", "SIMPLE_CHEMICAL", 45, 55], ["filarial nematode", "ORGANISM", 95, 112], ["Onchocerca volvulus", "ORGANISM", 114, 133], ["Onchocerca volvulus", "SPECIES", 114, 133], ["Onchocerca volvulus", "SPECIES", 114, 133], ["these diseases", "PROBLEM", 8, 22], ["ivermectin", "TREATMENT", 45, 55], ["onchocerciasis", "PROBLEM", 67, 81], ["a filarial nematode", "PROBLEM", 93, 112], ["Onchocerca volvulus", "PROBLEM", 114, 133], ["diseases", "OBSERVATION", 14, 22], ["filarial nematode", "OBSERVATION", 95, 112]]], ["Presently ivermectin is used to treat strongyloidiasis, scabies, pediculosis, gnathostomiasis, myiasis, and leishmaniasis [74, 75] .", [["ivermectin", "CHEMICAL", 10, 20], ["strongyloidiasis", "DISEASE", 38, 54], ["scabies", "DISEASE", 56, 63], ["pediculosis", "DISEASE", 65, 76], ["gnathostomiasis", "DISEASE", 78, 93], ["myiasis", "DISEASE", 95, 102], ["leishmaniasis", "DISEASE", 108, 121], ["ivermectin", "CHEMICAL", 10, 20], ["ivermectin", "SIMPLE_CHEMICAL", 10, 20], ["ivermectin", "TREATMENT", 10, 20], ["strongyloidiasis", "PROBLEM", 38, 54], ["scabies", "PROBLEM", 56, 63], ["pediculosis", "PROBLEM", 65, 76], ["gnathostomiasis", "PROBLEM", 78, 93], ["myiasis", "PROBLEM", 95, 102], ["leishmaniasis", "PROBLEM", 108, 121], ["strongyloidiasis", "OBSERVATION", 38, 54], ["pediculosis", "OBSERVATION", 65, 76], ["leishmaniasis", "OBSERVATION", 108, 121]]], ["In addition, other studies have shown that ivermectin can be used to reduce the prevalence and spread of other infectious diseases linked to a helminthic parasites transmitted through soil such as strongyloidiasis, ascariasis, trichuriasis, and enterobiasis hookworm, Trichuris and Ascaris.", [["ivermectin", "CHEMICAL", 43, 53], ["infectious diseases", "DISEASE", 111, 130], ["helminthic parasites", "DISEASE", 143, 163], ["strongyloidiasis", "DISEASE", 197, 213], ["ascariasis", "DISEASE", 215, 225], ["trichuriasis", "DISEASE", 227, 239], ["enterobiasis hookworm", "DISEASE", 245, 266], ["Trichuris and Ascaris", "DISEASE", 268, 289], ["ivermectin", "CHEMICAL", 43, 53], ["ivermectin", "SIMPLE_CHEMICAL", 43, 53], ["enterobiasis hookworm", "ORGANISM", 245, 266], ["Trichuris", "ORGANISM", 268, 277], ["other studies", "TEST", 13, 26], ["ivermectin", "TREATMENT", 43, 53], ["other infectious diseases", "PROBLEM", 105, 130], ["a helminthic parasites", "PROBLEM", 141, 163], ["strongyloidiasis", "PROBLEM", 197, 213], ["ascariasis", "PROBLEM", 215, 225], ["trichuriasis", "PROBLEM", 227, 239], ["enterobiasis hookworm", "PROBLEM", 245, 266], ["Trichuris", "PROBLEM", 268, 277], ["Ascaris", "PROBLEM", 282, 289], ["infectious", "OBSERVATION", 111, 121], ["strongyloidiasis", "OBSERVATION", 197, 213], ["ascariasis", "OBSERVATION", 215, 225], ["enterobiasis hookworm", "OBSERVATION", 245, 266], ["Trichuris", "OBSERVATION", 268, 277], ["Ascaris", "OBSERVATION_MODIFIER", 282, 289]]], ["These diseases have been identified as major cause of death for underdeveloped children with poor nutrition and retarded growth [76, 77] .", [["death", "DISEASE", 54, 59], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["These diseases", "PROBLEM", 0, 14], ["death", "PROBLEM", 54, 59], ["retarded growth", "PROBLEM", 112, 127], ["diseases", "OBSERVATION", 6, 14]]], ["Topical administration of ivermectin to children also reduced the prevalence of head lice and scabies [78] .", [["head lice", "ANATOMY", 80, 89], ["ivermectin", "CHEMICAL", 26, 36], ["scabies", "DISEASE", 94, 101], ["ivermectin", "CHEMICAL", 26, 36], ["ivermectin", "SIMPLE_CHEMICAL", 26, 36], ["children", "ORGANISM", 40, 48], ["head", "ORGANISM_SUBDIVISION", 80, 84], ["lice", "ORGANISM_SUBSTANCE", 85, 89], ["children", "SPECIES", 40, 48], ["Topical administration", "TREATMENT", 0, 22], ["ivermectin", "TREATMENT", 26, 36], ["head lice", "PROBLEM", 80, 89], ["scabies", "PROBLEM", 94, 101], ["head", "ANATOMY", 80, 84]]], ["Moreover, ivermectin has also been shown to be effective in the treatment of Papulopustular rosacea (PPR), a human skin disease characterized by transient pustules and facial erythema [79] .", [["skin", "ANATOMY", 115, 119], ["pustules", "ANATOMY", 155, 163], ["facial", "ANATOMY", 168, 174], ["ivermectin", "CHEMICAL", 10, 20], ["Papulopustular rosacea", "DISEASE", 77, 99], ["skin disease", "DISEASE", 115, 127], ["pustules", "DISEASE", 155, 163], ["erythema", "DISEASE", 175, 183], ["ivermectin", "CHEMICAL", 10, 20], ["ivermectin", "SIMPLE_CHEMICAL", 10, 20], ["human", "ORGANISM", 109, 114], ["skin", "ORGAN", 115, 119], ["pustules", "PATHOLOGICAL_FORMATION", 155, 163], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["ivermectin", "TREATMENT", 10, 20], ["Papulopustular rosacea", "PROBLEM", 77, 99], ["a human skin disease", "PROBLEM", 107, 127], ["transient pustules", "PROBLEM", 145, 163], ["facial erythema", "PROBLEM", 168, 183], ["Papulopustular", "OBSERVATION_MODIFIER", 77, 91], ["rosacea", "OBSERVATION", 92, 99], ["skin", "ANATOMY", 115, 119], ["disease", "OBSERVATION", 120, 127], ["transient", "OBSERVATION_MODIFIER", 145, 154], ["pustules", "OBSERVATION", 155, 163], ["facial", "ANATOMY", 168, 174], ["erythema", "OBSERVATION", 175, 183]]], ["In order to enhance the efficacy of ivermectin in the treatment of infectious diseases in human, it has been administered with other drugs.", [["ivermectin", "CHEMICAL", 36, 46], ["infectious diseases", "DISEASE", 67, 86], ["ivermectin", "CHEMICAL", 36, 46], ["ivermectin", "SIMPLE_CHEMICAL", 36, 46], ["human", "ORGANISM", 90, 95], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["ivermectin", "TREATMENT", 36, 46], ["infectious diseases in human", "PROBLEM", 67, 95], ["other drugs", "TREATMENT", 127, 138], ["infectious", "OBSERVATION", 67, 77]]], ["For example, ivermectin is combined with doxycycline to inhibit onchocerciasis transmission in humans [80] .", [["ivermectin", "CHEMICAL", 13, 23], ["doxycycline", "CHEMICAL", 41, 52], ["onchocerciasis", "DISEASE", 64, 78], ["ivermectin", "CHEMICAL", 13, 23], ["doxycycline", "CHEMICAL", 41, 52], ["ivermectin", "SIMPLE_CHEMICAL", 13, 23], ["doxycycline", "SIMPLE_CHEMICAL", 41, 52], ["humans", "ORGANISM", 95, 101], ["humans", "SPECIES", 95, 101], ["humans", "SPECIES", 95, 101], ["ivermectin", "TREATMENT", 13, 23], ["doxycycline", "TREATMENT", 41, 52]]], ["Other study showed that ivermectin combined with doxycycline has also been shown to improve the efficacy of ivermectin in suppressing microfiladerma, as it has been shown to reduce the symbiotic endobacteria of filariae, Wolbachia spp. that is important for the reproduction and survival of mature female worms [81] .", [["ivermectin", "CHEMICAL", 24, 34], ["doxycycline", "CHEMICAL", 49, 60], ["ivermectin", "CHEMICAL", 108, 118], ["microfiladerma", "CHEMICAL", 134, 148], ["ivermectin", "CHEMICAL", 24, 34], ["doxycycline", "CHEMICAL", 49, 60], ["ivermectin", "CHEMICAL", 108, 118], ["ivermectin", "SIMPLE_CHEMICAL", 24, 34], ["doxycycline", "SIMPLE_CHEMICAL", 49, 60], ["ivermectin", "SIMPLE_CHEMICAL", 108, 118], ["microfiladerma", "SIMPLE_CHEMICAL", 134, 148], ["filariae", "ORGANISM", 211, 219], ["Wolbachia spp", "ORGANISM", 221, 234], ["worms", "SPECIES", 305, 310], ["Other study", "TEST", 0, 11], ["ivermectin", "TREATMENT", 24, 34], ["doxycycline", "TREATMENT", 49, 60], ["ivermectin", "TREATMENT", 108, 118], ["the symbiotic endobacteria of filariae", "PROBLEM", 181, 219], ["Wolbachia spp", "PROBLEM", 221, 234], ["symbiotic", "OBSERVATION_MODIFIER", 185, 194], ["endobacteria", "OBSERVATION", 195, 207], ["filariae", "OBSERVATION", 211, 219], ["Wolbachia spp", "OBSERVATION", 221, 234]]], ["Moreover, another study stated that the daily administration of ivermectin-antibiotic combination for six weeks was more effective in reducing the microfiladerma levels in infected patients than ivermectin alone.", [["ivermectin", "CHEMICAL", 64, 74], ["microfiladerma", "CHEMICAL", 147, 161], ["ivermectin", "CHEMICAL", 195, 205], ["ivermectin", "CHEMICAL", 64, 74], ["ivermectin", "CHEMICAL", 195, 205], ["ivermectin", "SIMPLE_CHEMICAL", 64, 74], ["microfiladerma", "SIMPLE_CHEMICAL", 147, 161], ["patients", "ORGANISM", 181, 189], ["ivermectin", "SIMPLE_CHEMICAL", 195, 205], ["patients", "SPECIES", 181, 189], ["another study", "TEST", 10, 23], ["ivermectin-antibiotic combination", "TREATMENT", 64, 97], ["ivermectin", "TREATMENT", 195, 205]]], ["The antiparasitic activity of ivermectin in the treatment of onchocerciasis was also improved when combined with amorcazine compared to ivermectin itself [82] .", [["ivermectin", "CHEMICAL", 30, 40], ["onchocerciasis", "DISEASE", 61, 75], ["amorcazine", "CHEMICAL", 113, 123], ["ivermectin", "CHEMICAL", 136, 146], ["ivermectin", "CHEMICAL", 30, 40], ["amorcazine", "CHEMICAL", 113, 123], ["ivermectin", "CHEMICAL", 136, 146], ["ivermectin", "SIMPLE_CHEMICAL", 30, 40], ["amorcazine", "SIMPLE_CHEMICAL", 113, 123], ["ivermectin", "SIMPLE_CHEMICAL", 136, 146], ["ivermectin", "TREATMENT", 30, 40], ["onchocerciasis", "PROBLEM", 61, 75], ["amorcazine", "TREATMENT", 113, 123], ["antiparasitic", "OBSERVATION_MODIFIER", 4, 17], ["activity", "OBSERVATION_MODIFIER", 18, 26], ["onchocerciasis", "OBSERVATION", 61, 75]]], ["The study also showed that ivermectin has the potential to be used in the treatment of mites and human lice infestation [83] .", [["ivermectin", "CHEMICAL", 27, 37], ["lice infestation", "DISEASE", 103, 119], ["ivermectin", "CHEMICAL", 27, 37], ["ivermectin", "SIMPLE_CHEMICAL", 27, 37], ["human", "ORGANISM", 97, 102], ["lice", "ORGANISM_SUBDIVISION", 103, 107], ["human", "SPECIES", 97, 102], ["human lice", "SPECIES", 97, 107], ["The study", "TEST", 0, 9], ["ivermectin", "TREATMENT", 27, 37], ["human lice infestation", "PROBLEM", 97, 119]]], ["Ivermectin has also been reported to possess other therapeutic properties such as filaricidal in the lymphatic system and as an anticonvulsant against lidocaine-and strychnine-induced convulsion [84] .", [["lymphatic system", "ANATOMY", 101, 117], ["Ivermectin", "CHEMICAL", 0, 10], ["lidocaine", "CHEMICAL", 151, 160], ["strychnine", "CHEMICAL", 165, 175], ["convulsion", "DISEASE", 184, 194], ["Ivermectin", "CHEMICAL", 0, 10], ["lidocaine", "CHEMICAL", 151, 160], ["strychnine", "CHEMICAL", 165, 175], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["filaricidal", "SIMPLE_CHEMICAL", 82, 93], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 101, 117], ["lidocaine", "SIMPLE_CHEMICAL", 151, 160], ["strychnine", "SIMPLE_CHEMICAL", 165, 175], ["Ivermectin", "TREATMENT", 0, 10], ["filaricidal in the lymphatic system", "TREATMENT", 82, 117], ["an anticonvulsant against lidocaine", "TREATMENT", 125, 160], ["strychnine", "TREATMENT", 165, 175], ["convulsion", "PROBLEM", 184, 194], ["lymphatic system", "ANATOMY", 101, 117]]], ["The anticonvulsant properties of ivermectin is linked to the activation of a receptor-ion channel that is independent in the glycine and strychnine Pharmaceuticals 2020, 13, 196 11 of 37 pathway [85] .", [["ivermectin", "CHEMICAL", 33, 43], ["glycine", "CHEMICAL", 125, 132], ["strychnine", "CHEMICAL", 137, 147], ["ivermectin", "CHEMICAL", 33, 43], ["glycine", "CHEMICAL", 125, 132], ["strychnine", "CHEMICAL", 137, 147], ["ivermectin", "SIMPLE_CHEMICAL", 33, 43], ["glycine", "SIMPLE_CHEMICAL", 125, 132], ["strychnine", "SIMPLE_CHEMICAL", 137, 147], ["ivermectin", "TREATMENT", 33, 43], ["a receptor-ion channel", "TREATMENT", 75, 97]]], ["Moreover, Kane et al. [86] revealed that the anticonvulsant effect of ivermectin is mediated by GABAA receptors.", [["ivermectin", "CHEMICAL", 70, 80], ["GABAA", "CHEMICAL", 96, 101], ["ivermectin", "CHEMICAL", 70, 80], ["ivermectin", "SIMPLE_CHEMICAL", 70, 80], ["GABAA receptors", "GENE_OR_GENE_PRODUCT", 96, 111], ["GABAA receptors", "PROTEIN", 96, 111], ["ivermectin", "TREATMENT", 70, 80]]], ["The summary of human uses of ivermectin is shown in Table 2 .Efficacy against Plant Parasitic NematodesOne of the commercially available forms of avermectin is abamectin, which contains 80% avermectin B1a and 20% avermectin B1b.", [["ivermectin", "CHEMICAL", 29, 39], ["Parasitic Nematodes", "DISEASE", 84, 103], ["avermectin", "CHEMICAL", 146, 156], ["abamectin", "CHEMICAL", 160, 169], ["avermectin", "CHEMICAL", 190, 200], ["avermectin B1b", "CHEMICAL", 213, 227], ["ivermectin", "CHEMICAL", 29, 39], ["avermectin", "CHEMICAL", 146, 156], ["abamectin", "CHEMICAL", 160, 169], ["avermectin B1b", "CHEMICAL", 213, 227], ["human", "ORGANISM", 15, 20], ["ivermectin", "SIMPLE_CHEMICAL", 29, 39], ["avermectin", "SIMPLE_CHEMICAL", 146, 156], ["abamectin", "SIMPLE_CHEMICAL", 160, 169], ["avermectin", "SIMPLE_CHEMICAL", 190, 200], ["B1a", "SIMPLE_CHEMICAL", 201, 204], ["avermectin B1b", "SIMPLE_CHEMICAL", 213, 227], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["ivermectin", "TREATMENT", 29, 39], ["Plant Parasitic Nematodes", "PROBLEM", 78, 103], ["Parasitic", "OBSERVATION_MODIFIER", 84, 93]]], ["It is reportedly to be used either as an insecticide or acaricide in several countries, mostly in countries that depend on agriculture and animal husbandry for preservation and protection, respectively [87, 88] .", [["acaricide", "TREATMENT", 56, 65]]], ["In addition, Khalil et al. [32] reported its use as a protective agent against plant nematodes that feed on the roots, during seed germination, coupled with its long shelf-life, while Hussein and Sabry [89] reported its molluscicides activity against matured E. vermiculata in the growth of wheat.", [["roots", "ANATOMY", 112, 117], ["seed", "ANATOMY", 126, 130], ["roots", "ORGAN", 112, 117], ["seed", "DEVELOPING_ANATOMICAL_STRUCTURE", 126, 130], ["molluscicides", "GENE_OR_GENE_PRODUCT", 220, 233], ["E. vermiculata", "ORGANISM", 259, 273], ["wheat", "ORGANISM", 291, 296], ["E. vermiculata", "SPECIES", 259, 273], ["wheat", "SPECIES", 291, 296], ["E. vermiculata", "SPECIES", 259, 273], ["wheat", "SPECIES", 291, 296], ["a protective agent", "TREATMENT", 52, 70], ["plant nematodes", "TREATMENT", 79, 94], ["roots", "ANATOMY", 112, 117]]], ["Another avermectin product, emamectin benzoate, a semi-synthetic product of avermectin has been shown to be very active as a nematocide in destroying root-knot nematodes when administered at the nursery bed of chili.", [["root", "ANATOMY", 150, 154], ["emamectin benzoate", "CHEMICAL", 28, 46], ["avermectin", "CHEMICAL", 76, 86], ["nematocide", "CHEMICAL", 125, 135], ["emamectin benzoate", "CHEMICAL", 28, 46], ["avermectin", "CHEMICAL", 76, 86], ["avermectin", "SIMPLE_CHEMICAL", 8, 18], ["emamectin benzoate", "SIMPLE_CHEMICAL", 28, 46], ["avermectin", "SIMPLE_CHEMICAL", 76, 86], ["nematocide", "SIMPLE_CHEMICAL", 125, 135], ["chili", "ORGANISM_SUBDIVISION", 210, 215], ["chili", "SPECIES", 210, 215], ["chili", "SPECIES", 210, 215], ["Another avermectin product", "TREATMENT", 0, 26], ["emamectin benzoate", "TREATMENT", 28, 46], ["a semi-synthetic product of avermectin", "TREATMENT", 48, 86]]], ["It significantly reduced the population of nematodes meloidogyne spp.) in a dose-dependent manner.", [["meloidogyne spp.", "ORGANISM", 53, 69], ["meloidogyne spp.", "SPECIES", 53, 69], ["nematodes meloidogyne spp.", "TREATMENT", 43, 69], ["significantly", "OBSERVATION_MODIFIER", 3, 16], ["reduced", "OBSERVATION_MODIFIER", 17, 24], ["population", "OBSERVATION_MODIFIER", 29, 39]]], ["Avermectin has been reported to be effective against other nematodes including: Hoplolaimus galeatus and Tylenchorynchus dubius [90] .", [["Avermectin", "CHEMICAL", 0, 10], ["Avermectin", "CHEMICAL", 0, 10], ["Avermectin", "SIMPLE_CHEMICAL", 0, 10], ["Hoplolaimus galeatus", "ORGANISM", 80, 100], ["Tylenchorynchus dubius", "ORGANISM", 105, 127], ["Hoplolaimus galeatus", "SPECIES", 80, 100], ["Tylenchorynchus dubius", "SPECIES", 105, 127], ["Hoplolaimus galeatus", "SPECIES", 80, 100], ["Tylenchorynchus dubius", "SPECIES", 105, 127], ["Avermectin", "TREATMENT", 0, 10], ["Hoplolaimus galeatus", "PROBLEM", 80, 100], ["Tylenchorynchus dubius", "PROBLEM", 105, 127], ["nematodes", "OBSERVATION", 59, 68]]], ["Several reports have confirmed the efficacy of avermectin as a nematocides against various nematodes that attack plants.", [["avermectin", "CHEMICAL", 47, 57], ["avermectin", "CHEMICAL", 47, 57], ["avermectin", "SIMPLE_CHEMICAL", 47, 57], ["nematocides", "SIMPLE_CHEMICAL", 63, 74], ["avermectin", "TREATMENT", 47, 57]]], ["Jayakumar et al. [90] reported the effectiveness of avermectin in the treatment of seed against reniform nematode, and Rotylenchulus reniformis used crude avermectin to treat seed.", [["seed", "ANATOMY", 83, 87], ["seed", "ANATOMY", 175, 179], ["avermectin", "CHEMICAL", 52, 62], ["avermectin", "CHEMICAL", 155, 165], ["avermectin", "CHEMICAL", 52, 62], ["avermectin", "SIMPLE_CHEMICAL", 52, 62], ["seed", "ORGANISM_SUBDIVISION", 83, 87], ["reniform nematode", "ORGANISM", 96, 113], ["Rotylenchulus reniformis", "ORGANISM", 119, 143], ["avermectin", "SIMPLE_CHEMICAL", 155, 165], ["seed", "ORGANISM_SUBDIVISION", 175, 179], ["Rotylenchulus reniformis", "SPECIES", 119, 143], ["Rotylenchulus reniformis", "SPECIES", 119, 143], ["avermectin", "TREATMENT", 52, 62], ["reniform nematode", "PROBLEM", 96, 113], ["Rotylenchulus reniformis", "TREATMENT", 119, 143], ["crude avermectin", "TREATMENT", 149, 165]]], ["Blackburn et al. [91] also reported the nematocide effect of avermectin B1 in reducing the population of H. galeatus and T. dubius.", [["avermectin B1", "CHEMICAL", 61, 74], ["avermectin B1", "CHEMICAL", 61, 74], ["avermectin B1", "SIMPLE_CHEMICAL", 61, 74], ["H. galeatus", "ORGANISM", 105, 116], ["T. dubius", "ORGANISM", 121, 130], ["H. galeatus", "SPECIES", 105, 116], ["T. dubius", "SPECIES", 121, 130], ["H. galeatus", "SPECIES", 105, 116], ["T. dubius", "SPECIES", 121, 130], ["avermectin B1", "TREATMENT", 61, 74], ["H. galeatus", "PROBLEM", 105, 116], ["T. dubius", "PROBLEM", 121, 130], ["H. galeatus", "ANATOMY", 105, 116], ["dubius", "ANATOMY", 124, 130]]], ["In an experiment conducted by Das et al. [92] , the efficacy of emamectin benzoate as a nematocide in the reduction of root-knot nematode (Meloidogyne spp.) populations was reported when used in the nursery bed of chili.Antibacterial ActionAn observed non-prescriptive activity of avermectins is its antibacterial activity.", [["root", "ANATOMY", 119, 123], ["chili", "ANATOMY", 214, 219], ["emamectin benzoate", "CHEMICAL", 64, 82], ["nematocide", "CHEMICAL", 88, 98], ["avermectins", "CHEMICAL", 281, 292], ["emamectin benzoate", "CHEMICAL", 64, 82], ["nematocide", "CHEMICAL", 88, 98], ["avermectins", "CHEMICAL", 281, 292], ["emamectin benzoate", "SIMPLE_CHEMICAL", 64, 82], ["nematocide", "SIMPLE_CHEMICAL", 88, 98], ["nematode", "ORGANISM", 129, 137], ["Meloidogyne spp.", "ORGANISM", 139, 155], ["chili", "ORGANISM_SUBDIVISION", 214, 219], ["avermectins", "SIMPLE_CHEMICAL", 281, 292], ["Meloidogyne spp.", "SPECIES", 139, 155], ["chili", "SPECIES", 214, 219], ["Meloidogyne spp.", "SPECIES", 139, 155], ["chili", "SPECIES", 214, 219], ["emamectin benzoate", "TREATMENT", 64, 82], ["a nematocide", "TREATMENT", 86, 98], ["Antibacterial", "TREATMENT", 220, 233], ["avermectins", "TREATMENT", 281, 292], ["antibacterial activity", "OBSERVATION", 300, 322]]], ["The primary pharmacological activity of avermectins is its use as insecticides, nematocides, antihelminthic and arachnicides [93] .", [["avermectins", "CHEMICAL", 40, 51], ["nematocides", "CHEMICAL", 80, 91], ["arachnicides", "CHEMICAL", 112, 124], ["avermectins", "CHEMICAL", 40, 51], ["nematocides", "CHEMICAL", 80, 91], ["arachnicides", "CHEMICAL", 112, 124], ["avermectins", "SIMPLE_CHEMICAL", 40, 51], ["nematocides", "SIMPLE_CHEMICAL", 80, 91], ["antihelminthic", "SIMPLE_CHEMICAL", 93, 107], ["arachnicides", "SIMPLE_CHEMICAL", 112, 124], ["avermectins", "TREATMENT", 40, 51], ["nematocides", "TREATMENT", 80, 91], ["antihelminthic", "TREATMENT", 93, 107], ["arachnicides", "TREATMENT", 112, 124]]], ["However, recent studies have shown that avermectin is not effective against broad spectrum bacteria, others have shown it is effective against some bacteria species [93] .", [["avermectin", "CHEMICAL", 40, 50], ["avermectin", "CHEMICAL", 40, 50], ["avermectin", "SIMPLE_CHEMICAL", 40, 50], ["recent studies", "TEST", 9, 23], ["avermectin", "TREATMENT", 40, 50], ["broad spectrum bacteria", "PROBLEM", 76, 99], ["some bacteria species", "PROBLEM", 143, 164], ["bacteria", "OBSERVATION", 91, 99]]], ["Some avermectins have been evaluated for antibacterial activities include ivermectin, selamectin, doramectin, and moxidectin.", [["avermectins", "CHEMICAL", 5, 16], ["ivermectin", "CHEMICAL", 74, 84], ["selamectin", "CHEMICAL", 86, 96], ["doramectin", "CHEMICAL", 98, 108], ["moxidectin", "CHEMICAL", 114, 124], ["avermectins", "CHEMICAL", 5, 16], ["ivermectin", "CHEMICAL", 74, 84], ["selamectin", "CHEMICAL", 86, 96], ["doramectin", "CHEMICAL", 98, 108], ["moxidectin", "CHEMICAL", 114, 124], ["avermectins", "SIMPLE_CHEMICAL", 5, 16], ["ivermectin", "SIMPLE_CHEMICAL", 74, 84], ["selamectin", "SIMPLE_CHEMICAL", 86, 96], ["doramectin", "SIMPLE_CHEMICAL", 98, 108], ["moxidectin", "SIMPLE_CHEMICAL", 114, 124], ["Some avermectins", "TREATMENT", 0, 16], ["antibacterial activities", "TREATMENT", 41, 65], ["ivermectin", "TREATMENT", 74, 84], ["selamectin", "TREATMENT", 86, 96], ["doramectin", "TREATMENT", 98, 108], ["moxidectin", "TREATMENT", 114, 124]]], ["Using the approved standard methods based on the gold standard proportion, glycerol reuptake or nitrate reductase, resazurin of viable colony forming unit after exposure [94] .", [["colony", "ANATOMY", 135, 141], ["glycerol reuptake", "CHEMICAL", 75, 92], ["nitrate", "CHEMICAL", 96, 103], ["resazurin", "CHEMICAL", 115, 124], ["glycerol", "CHEMICAL", 75, 83], ["nitrate", "CHEMICAL", 96, 103], ["resazurin", "CHEMICAL", 115, 124], ["glycerol", "SIMPLE_CHEMICAL", 75, 83], ["nitrate reductase", "GENE_OR_GENE_PRODUCT", 96, 113], ["resazurin", "SIMPLE_CHEMICAL", 115, 124], ["nitrate reductase", "PROTEIN", 96, 113], ["the approved standard methods", "TREATMENT", 6, 35], ["the gold standard proportion", "TREATMENT", 45, 73], ["glycerol reuptake", "TREATMENT", 75, 92], ["nitrate reductase", "TREATMENT", 96, 113], ["resazurin", "TREATMENT", 115, 124]]], ["The 3 (4, 5-dimethylthiazol-2-yl) 2, 5 diphenyl tetrazolium bromide (MTT) assay method was used to test the antibacterial activity of four different avermectins in different Mycobacterium species.", [["3 (4, 5-dimethylthiazol-2-yl) 2, 5 diphenyl tetrazolium bromide", "CHEMICAL", 4, 67], ["avermectins", "CHEMICAL", 149, 160], ["3 (4, 5-dimethylthiazol-2-yl) 2, 5 diphenyl tetrazolium bromide", "CHEMICAL", 4, 67], ["MTT", "CHEMICAL", 69, 72], ["avermectins", "CHEMICAL", 149, 160], ["3 (4, 5-dimethylthiazol-2-yl) 2, 5 diphenyl tetrazolium bromide", "SIMPLE_CHEMICAL", 4, 67], ["MTT", "SIMPLE_CHEMICAL", 69, 72], ["avermectins", "SIMPLE_CHEMICAL", 149, 160], ["dimethylthiazol", "TREATMENT", 12, 27], ["5 diphenyl tetrazolium bromide (MTT) assay method", "TREATMENT", 37, 86], ["different Mycobacterium species", "PROBLEM", 164, 195], ["Mycobacterium species", "OBSERVATION", 174, 195]]], ["All four were effective against both Mycobacterium bovis and M. tuberculosis laboratory strains (H37Rv, CDC 1551, and Erdman) in a concentration-dependent manner.", [["Mycobacterium bovis", "ORGANISM", 37, 56], ["M. tuberculosis", "ORGANISM", 61, 76], ["Mycobacterium bovis", "SPECIES", 37, 56], ["M. tuberculosis", "SPECIES", 61, 76], ["Mycobacterium bovis", "SPECIES", 37, 56], ["M. tuberculosis", "SPECIES", 61, 76], ["H37Rv", "SPECIES", 97, 102], ["both Mycobacterium bovis", "PROBLEM", 32, 56], ["M. tuberculosis laboratory strains", "PROBLEM", 61, 95], ["CDC", "TEST", 104, 107], ["Mycobacterium bovis", "OBSERVATION", 37, 56], ["tuberculosis", "OBSERVATION_MODIFIER", 64, 76]]], ["While all of them were effective against M. smegmatis apart from doramectin.", [["doramectin", "CHEMICAL", 65, 75], ["doramectin", "CHEMICAL", 65, 75], ["M. smegmatis", "ORGANISM", 41, 53], ["doramectin", "SIMPLE_CHEMICAL", 65, 75], ["M. smegmatis", "SPECIES", 41, 53], ["M. smegmatis", "SPECIES", 41, 53], ["M. smegmatis", "PROBLEM", 41, 53], ["doramectin", "TREATMENT", 65, 75], ["smegmatis", "OBSERVATION", 44, 53]]], ["They showed a lower inhibitory effect against M. avium [95] .", [["M. avium", "ORGANISM", 46, 54], ["M. avium", "SPECIES", 46, 54], ["M. avium", "SPECIES", 46, 54], ["a lower inhibitory effect", "PROBLEM", 12, 37], ["lower inhibitory", "OBSERVATION_MODIFIER", 14, 30]]], ["With a recent study showing that the presence of glycerol in the assay medium plays an important role in the antibacterial activity of some drugs on some mycobacterium species, the inhibitory activities of selamectin, moxidectin, and ivermectin were only slightly affected in the absence of glycerol in the assay medium [93, 96, 97] .", [["glycerol", "CHEMICAL", 49, 57], ["selamectin", "CHEMICAL", 206, 216], ["moxidectin", "CHEMICAL", 218, 228], ["ivermectin", "CHEMICAL", 234, 244], ["glycerol", "CHEMICAL", 291, 299], ["glycerol", "CHEMICAL", 49, 57], ["selamectin", "CHEMICAL", 206, 216], ["moxidectin", "CHEMICAL", 218, 228], ["ivermectin", "CHEMICAL", 234, 244], ["glycerol", "CHEMICAL", 291, 299], ["glycerol", "SIMPLE_CHEMICAL", 49, 57], ["selamectin", "SIMPLE_CHEMICAL", 206, 216], ["moxidectin", "SIMPLE_CHEMICAL", 218, 228], ["ivermectin", "SIMPLE_CHEMICAL", 234, 244], ["glycerol", "SIMPLE_CHEMICAL", 291, 299], ["a recent study", "TEST", 5, 19], ["glycerol in the assay medium", "TREATMENT", 49, 77], ["some drugs", "TREATMENT", 135, 145], ["some mycobacterium species", "PROBLEM", 149, 175], ["selamectin", "TREATMENT", 206, 216], ["moxidectin", "TREATMENT", 218, 228], ["ivermectin", "TREATMENT", 234, 244], ["slightly affected", "PROBLEM", 255, 272], ["glycerol", "TREATMENT", 291, 299], ["antibacterial activity", "OBSERVATION_MODIFIER", 109, 131], ["mycobacterium species", "OBSERVATION", 154, 175]]], ["Lim et al. [93] also tested the antibacterial activity of avermectins on some M. tuberculosis that are resistant to drugs (multidrug-resistance [MDR] and extensive drug-resistance [XDR] .", [["avermectins", "CHEMICAL", 58, 69], ["tuberculosis", "DISEASE", 81, 93], ["XDR", "DISEASE", 181, 184], ["avermectins", "CHEMICAL", 58, 69], ["avermectins", "SIMPLE_CHEMICAL", 58, 69], ["M. tuberculosis", "ORGANISM", 78, 93], ["M. tuberculosis", "SPECIES", 78, 93], ["M. tuberculosis", "SPECIES", 78, 93], ["the antibacterial activity of avermectins", "TREATMENT", 28, 69], ["some M. tuberculosis", "PROBLEM", 73, 93], ["drugs", "TREATMENT", 116, 121], ["tuberculosis", "OBSERVATION", 81, 93]]], ["Twenty-seven MDR and XDR isolated from different geographical location have been confirmed to be resistant to anti-TB drugs such as kanamycin, ethambol, rifampin, ethionamide, rifabutin, isoniazid, p-aminosalicyclate (PAS), streptomycin and pyrazinamide.", [["kanamycin", "CHEMICAL", 132, 141], ["ethambol", "CHEMICAL", 143, 151], ["rifampin", "CHEMICAL", 153, 161], ["ethionamide", "CHEMICAL", 163, 174], ["rifabutin", "CHEMICAL", 176, 185], ["isoniazid", "CHEMICAL", 187, 196], ["p-aminosalicyclate", "CHEMICAL", 198, 216], ["PAS", "CHEMICAL", 218, 221], ["streptomycin", "CHEMICAL", 224, 236], ["pyrazinamide", "CHEMICAL", 241, 253], ["kanamycin", "CHEMICAL", 132, 141], ["ethambol", "CHEMICAL", 143, 151], ["rifampin", "CHEMICAL", 153, 161], ["ethionamide", "CHEMICAL", 163, 174], ["rifabutin", "CHEMICAL", 176, 185], ["isoniazid", "CHEMICAL", 187, 196], ["p-aminosalicyclate", "CHEMICAL", 198, 216], ["PAS", "CHEMICAL", 218, 221], ["streptomycin", "CHEMICAL", 224, 236], ["pyrazinamide", "CHEMICAL", 241, 253], ["kanamycin", "SIMPLE_CHEMICAL", 132, 141], ["ethambol", "SIMPLE_CHEMICAL", 143, 151], ["rifampin", "SIMPLE_CHEMICAL", 153, 161], ["ethionamide", "SIMPLE_CHEMICAL", 163, 174], ["rifabutin", "SIMPLE_CHEMICAL", 176, 185], ["isoniazid", "SIMPLE_CHEMICAL", 187, 196], ["p-aminosalicyclate", "SIMPLE_CHEMICAL", 198, 216], ["PAS", "SIMPLE_CHEMICAL", 218, 221], ["streptomycin", "SIMPLE_CHEMICAL", 224, 236], ["pyrazinamide", "SIMPLE_CHEMICAL", 241, 253], ["XDR", "PROBLEM", 21, 24], ["anti-TB drugs", "TREATMENT", 110, 123], ["kanamycin", "TREATMENT", 132, 141], ["ethambol", "TREATMENT", 143, 151], ["rifampin", "TREATMENT", 153, 161], ["ethionamide", "TREATMENT", 163, 174], ["rifabutin", "TREATMENT", 176, 185], ["isoniazid", "TREATMENT", 187, 196], ["p-aminosalicyclate (PAS)", "TREATMENT", 198, 222], ["streptomycin", "TREATMENT", 224, 236], ["pyrazinamide", "TREATMENT", 241, 253], ["seven MDR", "OBSERVATION_MODIFIER", 7, 16]]], ["All were sensitive to MIC activity of avermectins except three MDR and two drug susceptibility.", [["MIC", "CHEMICAL", 22, 25], ["avermectins", "CHEMICAL", 38, 49], ["avermectins", "CHEMICAL", 38, 49], ["avermectins", "SIMPLE_CHEMICAL", 38, 49], ["MIC activity of avermectins", "TREATMENT", 22, 49], ["drug susceptibility", "OBSERVATION", 75, 94]]], ["Clinical trials of selamectin, moxidectin, and ivermectin have shown that their antibacterial activity is bactericidal against M. tuberculosis strain H37Rv and mc 2 587.", [["selamectin", "CHEMICAL", 19, 29], ["moxidectin", "CHEMICAL", 31, 41], ["ivermectin", "CHEMICAL", 47, 57], ["tuberculosis", "DISEASE", 130, 142], ["mc 2 587", "CHEMICAL", 160, 168], ["selamectin", "CHEMICAL", 19, 29], ["moxidectin", "CHEMICAL", 31, 41], ["ivermectin", "CHEMICAL", 47, 57], ["selamectin", "SIMPLE_CHEMICAL", 19, 29], ["moxidectin", "SIMPLE_CHEMICAL", 31, 41], ["ivermectin", "SIMPLE_CHEMICAL", 47, 57], ["M. tuberculosis strain", "ORGANISM", 127, 149], ["H37Rv", "ORGANISM", 150, 155], ["M. tuberculosis", "SPECIES", 127, 142], ["M. tuberculosis strain H37Rv", "SPECIES", 127, 155], ["selamectin", "TREATMENT", 19, 29], ["moxidectin", "TREATMENT", 31, 41], ["ivermectin", "TREATMENT", 47, 57]]], ["They all reduce the number of the initial bacteria viability up to six orders of magnitude [93] .", [["the initial bacteria viability", "PROBLEM", 30, 60], ["magnitude", "TEST", 81, 90]]], ["Selamectin is the most potent with respect to bactericidal activity, while ivermectin was the most potent bactericidal avermectin against MDR strain.", [["Selamectin", "CHEMICAL", 0, 10], ["ivermectin", "CHEMICAL", 75, 85], ["avermectin", "CHEMICAL", 119, 129], ["Selamectin", "CHEMICAL", 0, 10], ["ivermectin", "CHEMICAL", 75, 85], ["avermectin", "CHEMICAL", 119, 129], ["Selamectin", "SIMPLE_CHEMICAL", 0, 10], ["ivermectin", "SIMPLE_CHEMICAL", 75, 85], ["avermectin", "SIMPLE_CHEMICAL", 119, 129], ["MDR strain", "ORGANISM", 138, 148], ["Selamectin", "TREATMENT", 0, 10], ["bactericidal activity", "TREATMENT", 46, 67], ["ivermectin", "TREATMENT", 75, 85], ["MDR strain", "PROBLEM", 138, 148], ["most potent", "OBSERVATION_MODIFIER", 18, 29], ["bactericidal activity", "OBSERVATION", 46, 67]]], ["The sensitivity of Mycobacterium spp. to avermectin as compared to other bacteria might be linked to the nature and complexity of their cell wall envelope [98] .", [["cell wall", "ANATOMY", 136, 145], ["avermectin", "CHEMICAL", 41, 51], ["avermectin", "CHEMICAL", 41, 51], ["Mycobacterium spp", "ORGANISM", 19, 36], ["avermectin", "GENE_OR_GENE_PRODUCT", 41, 51], ["cell wall", "CELLULAR_COMPONENT", 136, 145], ["Mycobacterium", "SPECIES", 19, 32], ["Mycobacterium spp", "PROBLEM", 19, 36], ["avermectin", "TREATMENT", 41, 51], ["other bacteria", "PROBLEM", 67, 81], ["their cell wall envelope", "TEST", 130, 154], ["Mycobacterium spp", "OBSERVATION", 19, 36], ["cell", "OBSERVATION", 136, 140], ["wall", "ANATOMY_MODIFIER", 141, 145]]], ["As stated earlier by Wolstenholme and Rogers [99] , avermectin causes paralysis and fecundity by binding to glutamate-gated chloride channels on the muscles and nerves of the parasite, which does not occur in humans due to the lack of different channels that bind to avermectins.", [["muscles", "ANATOMY", 149, 156], ["nerves", "ANATOMY", 161, 167], ["avermectin", "CHEMICAL", 52, 62], ["paralysis", "DISEASE", 70, 79], ["glutamate", "CHEMICAL", 108, 117], ["chloride", "CHEMICAL", 124, 132], ["avermectins", "CHEMICAL", 267, 278], ["avermectin", "CHEMICAL", 52, 62], ["glutamate", "CHEMICAL", 108, 117], ["chloride", "CHEMICAL", 124, 132], ["avermectins", "CHEMICAL", 267, 278], ["avermectin", "GENE_OR_GENE_PRODUCT", 52, 62], ["glutamate", "SIMPLE_CHEMICAL", 108, 117], ["chloride", "SIMPLE_CHEMICAL", 124, 132], ["muscles", "ORGAN", 149, 156], ["nerves", "MULTI-TISSUE_STRUCTURE", 161, 167], ["humans", "ORGANISM", 209, 215], ["avermectins", "GENE_OR_GENE_PRODUCT", 267, 278], ["glutamate-gated chloride channels", "PROTEIN", 108, 141], ["humans", "SPECIES", 209, 215], ["humans", "SPECIES", 209, 215], ["avermectin", "TREATMENT", 52, 62], ["paralysis", "PROBLEM", 70, 79], ["fecundity", "PROBLEM", 84, 93], ["glutamate", "TEST", 108, 117], ["paralysis", "OBSERVATION", 70, 79], ["muscles", "ANATOMY", 149, 156], ["nerves", "ANATOMY", 161, 167], ["parasite", "OBSERVATION", 175, 183]]], ["Observations that selamectin and moxidectin, majorly used as an antiparasitic drugs in animals with a report of no toxic effect, showed a strong activity against M. bacterium.", [["selamectin", "CHEMICAL", 18, 28], ["moxidectin", "CHEMICAL", 33, 43], ["selamectin", "CHEMICAL", 18, 28], ["moxidectin", "CHEMICAL", 33, 43], ["selamectin", "SIMPLE_CHEMICAL", 18, 28], ["moxidectin", "SIMPLE_CHEMICAL", 33, 43], ["M. bacterium", "ORGANISM", 162, 174], ["M. bacterium", "SPECIES", 162, 174], ["selamectin", "TREATMENT", 18, 28], ["moxidectin", "TREATMENT", 33, 43], ["an antiparasitic drugs", "TREATMENT", 61, 83], ["toxic effect", "PROBLEM", 115, 127], ["M. bacterium", "PROBLEM", 162, 174]]], ["This shows that avermectins, with their high specificity for some mycobacterium can be selected for some pathogens that are resistance to antibacterial drugs, without any concern for side effect on the intestinal gut flora when administered orally.", [["intestinal gut flora", "ANATOMY", 202, 222], ["avermectins", "CHEMICAL", 16, 27], ["mycobacterium", "DISEASE", 66, 79], ["avermectins", "CHEMICAL", 16, 27], ["avermectins", "SIMPLE_CHEMICAL", 16, 27], ["intestinal gut", "ORGANISM_SUBDIVISION", 202, 216], ["flora", "ORGANISM_SUBSTANCE", 217, 222], ["avermectins", "TREATMENT", 16, 27], ["some mycobacterium", "PROBLEM", 61, 79], ["some pathogens", "PROBLEM", 100, 114], ["antibacterial drugs", "TREATMENT", 138, 157], ["side effect", "PROBLEM", 183, 194], ["the intestinal gut flora", "PROBLEM", 198, 222], ["mycobacterium", "OBSERVATION", 66, 79], ["intestinal gut", "ANATOMY", 202, 216]]], ["The study also showed that ivermectin and moxidectin can also inhibit the growth of different strains of M. ulcerans at concentrations ranging from 4 to 8 \u00b5g/mL.", [["ivermectin", "CHEMICAL", 27, 37], ["moxidectin", "CHEMICAL", 42, 52], ["ivermectin", "CHEMICAL", 27, 37], ["moxidectin", "CHEMICAL", 42, 52], ["ivermectin", "SIMPLE_CHEMICAL", 27, 37], ["moxidectin", "SIMPLE_CHEMICAL", 42, 52], ["M. ulcerans", "ORGANISM", 105, 116], ["M. ulcerans", "SPECIES", 105, 116], ["M. ulcerans", "SPECIES", 105, 116], ["The study", "TEST", 0, 9], ["ivermectin", "TREATMENT", 27, 37], ["moxidectin", "TREATMENT", 42, 52], ["M. ulcerans", "PROBLEM", 105, 116], ["growth", "OBSERVATION_MODIFIER", 74, 80], ["ulcerans", "OBSERVATION", 108, 116]]], ["While they are not effective in M. marinum which shares similar features with M. ulcerans.", [["M. marinum", "ORGANISM", 32, 42], ["M. ulcerans", "ORGANISM", 78, 89], ["M. marinum", "SPECIES", 32, 42], ["M. ulcerans", "SPECIES", 78, 89], ["M. marinum", "SPECIES", 32, 42], ["M. ulcerans", "SPECIES", 78, 89], ["M. ulcerans", "PROBLEM", 78, 89], ["not", "UNCERTAINTY", 15, 18], ["effective", "OBSERVATION_MODIFIER", 19, 28], ["ulcerans", "OBSERVATION", 81, 89]]], ["They also found out that IVM performed better than the standard drug rifampicin at the administered MIC concentration.", [["rifampicin", "CHEMICAL", 69, 79], ["MIC", "CHEMICAL", 100, 103], ["IVM", "CHEMICAL", 25, 28], ["rifampicin", "CHEMICAL", 69, 79], ["rifampicin", "SIMPLE_CHEMICAL", 69, 79], ["MIC", "SIMPLE_CHEMICAL", 100, 103], ["IVM", "PROBLEM", 25, 28], ["the standard drug rifampicin", "TREATMENT", 51, 79], ["the administered MIC concentration", "TREATMENT", 83, 117]]], ["And when the two drugs were combined (IVM and rifampicin), a better activity was observed as compared to individual activity in eliminating the parasite [99] .", [["IVM", "CHEMICAL", 38, 41], ["rifampicin", "CHEMICAL", 46, 56], ["IVM", "CHEMICAL", 38, 41], ["rifampicin", "CHEMICAL", 46, 56], ["rifampicin", "SIMPLE_CHEMICAL", 46, 56], ["the two drugs", "TREATMENT", 9, 22], ["IVM", "TREATMENT", 38, 41], ["rifampicin", "TREATMENT", 46, 56]]], ["It was suggested that the induction of P-glycoprotein/ABCB1 in human by rifampicin may reduce the plasma concentration of IVM.", [["plasma", "ANATOMY", 98, 104], ["rifampicin", "CHEMICAL", 72, 82], ["rifampicin", "CHEMICAL", 72, 82], ["IVM", "CHEMICAL", 122, 125], ["P-glycoprotein", "GENE_OR_GENE_PRODUCT", 39, 53], ["ABCB1", "GENE_OR_GENE_PRODUCT", 54, 59], ["human", "ORGANISM", 63, 68], ["rifampicin", "SIMPLE_CHEMICAL", 72, 82], ["plasma", "ORGANISM_SUBSTANCE", 98, 104], ["P-glycoprotein", "PROTEIN", 39, 53], ["ABCB1", "PROTEIN", 54, 59], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["P-glycoprotein/ABCB1 in human", "TREATMENT", 39, 68], ["rifampicin", "TREATMENT", 72, 82], ["the plasma concentration of IVM", "TREATMENT", 94, 125]]], ["Of all the types of avermectin tested against M. ulcerus, that causes Buruli ulcer (BU) in vitro, selamectin and milbemycin were the most potent with MIC concentrations of 2 to 4 \u00b5g/mL and 2 to 8 \u00b5g/mL, respectively, while IVM and moxidectin were not significantly active (MIC > 32 \u00b5g/mL) overall, it was concluded that selamectin had the best potential in the treatment of BU.", [["avermectin", "CHEMICAL", 20, 30], ["Buruli ulcer", "DISEASE", 70, 82], ["BU", "DISEASE", 84, 86], ["selamectin", "CHEMICAL", 98, 108], ["milbemycin", "CHEMICAL", 113, 123], ["MIC", "CHEMICAL", 150, 153], ["IVM", "CHEMICAL", 223, 226], ["moxidectin", "CHEMICAL", 231, 241], ["selamectin", "CHEMICAL", 320, 330], ["BU", "DISEASE", 374, 376], ["avermectin", "CHEMICAL", 20, 30], ["selamectin", "CHEMICAL", 98, 108], ["milbemycin", "CHEMICAL", 113, 123], ["IVM", "CHEMICAL", 223, 226], ["moxidectin", "CHEMICAL", 231, 241], ["selamectin", "CHEMICAL", 320, 330], ["avermectin", "SIMPLE_CHEMICAL", 20, 30], ["M. ulcerus", "ORGANISM", 46, 56], ["Buruli ulcer", "PATHOLOGICAL_FORMATION", 70, 82], ["selamectin", "SIMPLE_CHEMICAL", 98, 108], ["milbemycin", "SIMPLE_CHEMICAL", 113, 123], ["MIC", "SIMPLE_CHEMICAL", 150, 153], ["IVM", "SIMPLE_CHEMICAL", 223, 226], ["moxidectin", "SIMPLE_CHEMICAL", 231, 241], ["selamectin", "SIMPLE_CHEMICAL", 320, 330], ["BU", "PATHOLOGICAL_FORMATION", 374, 376], ["M. ulcerus", "SPECIES", 46, 56], ["M. ulcerus", "SPECIES", 46, 56], ["avermectin", "TREATMENT", 20, 30], ["M. ulcerus", "PROBLEM", 46, 56], ["Buruli ulcer", "PROBLEM", 70, 82], ["selamectin", "TREATMENT", 98, 108], ["milbemycin", "TREATMENT", 113, 123], ["MIC concentrations", "TREATMENT", 150, 168], ["moxidectin", "TREATMENT", 231, 241], ["MIC", "TEST", 273, 276], ["Buruli", "OBSERVATION_MODIFIER", 70, 76], ["ulcer", "OBSERVATION", 77, 82]]], ["Besides, of all the tested isolates of Staphylococcus aureus (>20) using IVM, only 2 isolates were sensitive to IVM [94] .", [["Staphylococcus aureus", "DISEASE", 39, 60], ["IVM", "CHEMICAL", 112, 115], ["IVM", "CHEMICAL", 112, 115], ["Staphylococcus aureus", "ORGANISM", 39, 60], ["Staphylococcus aureus", "SPECIES", 39, 60], ["Staphylococcus aureus", "SPECIES", 39, 60], ["Staphylococcus aureus", "PROBLEM", 39, 60], ["IVM", "TREATMENT", 73, 76], ["2 isolates", "TREATMENT", 83, 93], ["Staphylococcus aureus", "OBSERVATION", 39, 60]]], ["The LD 50 of IVM in animals is 50 mg/kg, while the administered dose in animals and humans is 200 \u00b5g/kg and peaked at the concentration of 52 ng/mL in plasma.", [["plasma", "ANATOMY", 151, 157], ["IVM", "CHEMICAL", 13, 16], ["IVM", "CHEMICAL", 13, 16], ["humans", "ORGANISM", 84, 90], ["plasma", "ORGANISM_SUBSTANCE", 151, 157], ["humans", "SPECIES", 84, 90], ["humans", "SPECIES", 84, 90], ["IVM in animals", "TREATMENT", 13, 27]]], ["The potential of IVM in the treatment of methicillin-resistance and methicillin-sensitive S. aureus isolates can make IVM a good antibiotic in addition to its anti-helminthic properties [94] .Endectocides for Malaria ControlMalaria is one of the top diseases that cause death among infants, especially in India and Africa.", [["IVM", "CHEMICAL", 17, 20], ["methicillin", "CHEMICAL", 41, 52], ["methicillin", "CHEMICAL", 68, 79], ["Endectocides", "CHEMICAL", 192, 204], ["Malaria ControlMalaria", "DISEASE", 209, 231], ["death", "DISEASE", 270, 275], ["IVM", "CHEMICAL", 17, 20], ["methicillin", "CHEMICAL", 41, 52], ["methicillin", "CHEMICAL", 68, 79], ["IVM", "CHEMICAL", 118, 121], ["methicillin", "SIMPLE_CHEMICAL", 41, 52], ["methicillin", "SIMPLE_CHEMICAL", 68, 79], ["S. aureus", "ORGANISM", 90, 99], ["infants", "ORGANISM", 282, 289], ["S. aureus", "SPECIES", 90, 99], ["infants", "SPECIES", 282, 289], ["S. aureus", "SPECIES", 90, 99], ["IVM", "TREATMENT", 17, 20], ["methicillin-resistance", "TREATMENT", 41, 63], ["methicillin", "TREATMENT", 68, 79], ["sensitive S. aureus isolates", "PROBLEM", 80, 108], ["a good antibiotic", "TREATMENT", 122, 139], ["its anti-helminthic properties", "TREATMENT", 155, 185], ["Malaria ControlMalaria", "PROBLEM", 209, 231], ["the top diseases", "PROBLEM", 242, 258], ["death", "PROBLEM", 270, 275], ["Malaria", "OBSERVATION", 209, 216]]], ["It is caused by Plasmodium falciparum in Africa and transmitted to humans by female anopheles.", [["Plasmodium falciparum", "DISEASE", 16, 37], ["Plasmodium falciparum", "ORGANISM", 16, 37], ["humans", "ORGANISM", 67, 73], ["female anopheles", "ORGANISM", 77, 93], ["Plasmodium falciparum", "SPECIES", 16, 37], ["humans", "SPECIES", 67, 73], ["Plasmodium falciparum", "SPECIES", 16, 37], ["humans", "SPECIES", 67, 73], ["Plasmodium falciparum", "PROBLEM", 16, 37], ["Plasmodium falciparum", "OBSERVATION", 16, 37]]], ["Progress has been made in reducing malaria deaths since 2010 [100] .", [["malaria deaths", "DISEASE", 35, 49]]], ["However, recent data showed that there is substantial rise in the number of malaria deaths.", [["malaria", "DISEASE", 76, 83], ["deaths", "DISEASE", 84, 90], ["malaria deaths", "PROBLEM", 76, 90], ["substantial", "OBSERVATION_MODIFIER", 42, 53], ["rise", "OBSERVATION_MODIFIER", 54, 58], ["number", "OBSERVATION_MODIFIER", 66, 72], ["malaria deaths", "OBSERVATION", 76, 90]]], ["It was noticed that the major challenge in the management of malaria is the complexity in the life cycle of the parasite, which often develops resistance to various approved drugs [101] .", [["malaria", "DISEASE", 61, 68], ["malaria", "PROBLEM", 61, 68], ["major", "OBSERVATION_MODIFIER", 24, 29], ["malaria", "OBSERVATION", 61, 68]]], ["The insecticidal activity of ivermectin and its specific effect on Anopheles mosquito prompted an investigation into its antiplasmodial activity against the malaria parasite in order to use it for malaria treatment [102] .", [["ivermectin", "CHEMICAL", 29, 39], ["malaria parasite", "DISEASE", 157, 173], ["malaria", "DISEASE", 197, 204], ["ivermectin", "CHEMICAL", 29, 39], ["ivermectin", "SIMPLE_CHEMICAL", 29, 39], ["Anopheles mosquito", "ORGANISM", 67, 85], ["Anopheles mosquito", "SPECIES", 67, 85], ["ivermectin", "TREATMENT", 29, 39], ["Anopheles mosquito", "TREATMENT", 67, 85], ["an investigation", "TEST", 95, 111], ["the malaria parasite", "PROBLEM", 153, 173], ["malaria treatment", "TREATMENT", 197, 214], ["insecticidal", "OBSERVATION_MODIFIER", 4, 16], ["activity", "OBSERVATION_MODIFIER", 17, 25], ["malaria", "OBSERVATION", 157, 164]]], ["The antiplasmodial and insecticidal effects of ivermectin often depend on the concentration, route of administration, duration, species type, and experimental design [103] .", [["ivermectin", "CHEMICAL", 47, 57], ["ivermectin", "CHEMICAL", 47, 57], ["ivermectin", "SIMPLE_CHEMICAL", 47, 57], ["The antiplasmodial", "TREATMENT", 0, 18], ["ivermectin", "TREATMENT", 47, 57], ["antiplasmodial", "OBSERVATION_MODIFIER", 4, 18]]], ["Ivermectin was reported to inhibit the development of P. falciparum at the asexual stage with IC 50 in the range of 1-10 \u00b5g/mL, however, ivermectin had no effect at concentrations of 3.9-1000 ng/mL on P. vivax [104] .", [["Ivermectin", "CHEMICAL", 0, 10], ["P. falciparum", "DISEASE", 54, 67], ["ivermectin", "CHEMICAL", 137, 147], ["P. vivax", "DISEASE", 201, 209], ["Ivermectin", "CHEMICAL", 0, 10], ["ivermectin", "CHEMICAL", 137, 147], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["P. falciparum", "ORGANISM", 54, 67], ["ivermectin", "SIMPLE_CHEMICAL", 137, 147], ["P. falciparum", "SPECIES", 54, 67], ["P. vivax", "SPECIES", 201, 209], ["P. falciparum", "SPECIES", 54, 67], ["P. vivax", "SPECIES", 201, 209], ["Ivermectin", "TREATMENT", 0, 10], ["P. falciparum", "PROBLEM", 54, 67], ["IC", "TREATMENT", 94, 96], ["ivermectin", "TREATMENT", 137, 147], ["falciparum", "OBSERVATION", 57, 67]]], ["However, incubation of ivermectin with a different dilution of P. vivax with plasma from healthy individuals (4.28-34.24 ng/mL) for 4 h, ivermectin was able to inhibit the growth of P. vivax.", [["plasma", "ANATOMY", 77, 83], ["ivermectin", "CHEMICAL", 23, 33], ["P. vivax", "DISEASE", 63, 71], ["ivermectin", "CHEMICAL", 137, 147], ["P. vivax", "DISEASE", 182, 190], ["ivermectin", "CHEMICAL", 23, 33], ["ivermectin", "CHEMICAL", 137, 147], ["ivermectin", "SIMPLE_CHEMICAL", 23, 33], ["P. vivax", "ORGANISM", 63, 71], ["plasma", "ORGANISM_SUBSTANCE", 77, 83], ["ivermectin", "SIMPLE_CHEMICAL", 137, 147], ["P. vivax", "ORGANISM", 182, 190], ["P. vivax", "SPECIES", 63, 71], ["P. vivax", "SPECIES", 182, 190], ["P. vivax", "SPECIES", 63, 71], ["P. vivax", "SPECIES", 182, 190], ["ivermectin", "TREATMENT", 23, 33], ["a different dilution", "TREATMENT", 39, 59], ["ivermectin", "TREATMENT", 137, 147], ["vivax", "PROBLEM", 185, 190]]], ["It is reported that the metabolite of ivermectin may be responsible for the inhibitory activity of ivermectin at low concentration.", [["ivermectin", "CHEMICAL", 38, 48], ["ivermectin", "CHEMICAL", 99, 109], ["ivermectin", "CHEMICAL", 38, 48], ["ivermectin", "CHEMICAL", 99, 109], ["ivermectin", "SIMPLE_CHEMICAL", 38, 48], ["ivermectin", "SIMPLE_CHEMICAL", 99, 109], ["ivermectin", "TREATMENT", 38, 48], ["ivermectin at low concentration", "TREATMENT", 99, 130]]], ["The lack of ivermectin effect on P. falciparum in vitro might be due to the absence of the glutamate-gated chloride channel and GABA-gated chloride channels in P. falciparum where ivermectin binds to insects [104, 105] it was also reported that ivermectin has no significant effect on P. falciparum at the blood stage of development in vitro, while the possible mechanism of ivermectin in inhibiting the parasite at the blood stage might be by blocking nucleo-cytoplasmic shuttling of P. falciparum signal transduction particle (SRP) components [104] .", [["blood", "ANATOMY", 306, 311], ["blood", "ANATOMY", 420, 425], ["cytoplasmic", "ANATOMY", 460, 471], ["ivermectin", "CHEMICAL", 12, 22], ["P. falciparum", "DISEASE", 33, 46], ["glutamate", "CHEMICAL", 91, 100], ["chloride", "CHEMICAL", 107, 115], ["GABA", "CHEMICAL", 128, 132], ["chloride", "CHEMICAL", 139, 147], ["P. falciparum", "DISEASE", 160, 173], ["ivermectin", "CHEMICAL", 180, 190], ["ivermectin", "CHEMICAL", 245, 255], ["P. falciparum", "DISEASE", 285, 298], ["ivermectin", "CHEMICAL", 375, 385], ["ivermectin", "CHEMICAL", 12, 22], ["glutamate", "CHEMICAL", 91, 100], ["chloride", "CHEMICAL", 107, 115], ["GABA", "CHEMICAL", 128, 132], ["chloride", "CHEMICAL", 139, 147], ["ivermectin", "CHEMICAL", 180, 190], ["ivermectin", "CHEMICAL", 245, 255], ["ivermectin", "CHEMICAL", 375, 385], ["ivermectin", "SIMPLE_CHEMICAL", 12, 22], ["P. falciparum", "ORGANISM", 33, 46], ["glutamate", "SIMPLE_CHEMICAL", 91, 100], ["chloride", "SIMPLE_CHEMICAL", 107, 115], ["GABA", "SIMPLE_CHEMICAL", 128, 132], ["chloride", "SIMPLE_CHEMICAL", 139, 147], ["P. falciparum", "ORGANISM", 160, 173], ["ivermectin", "SIMPLE_CHEMICAL", 180, 190], ["ivermectin", "SIMPLE_CHEMICAL", 245, 255], ["P. falciparum", "ORGANISM", 285, 298], ["blood", "ORGANISM_SUBSTANCE", 306, 311], ["ivermectin", "SIMPLE_CHEMICAL", 375, 385], ["blood", "ORGANISM_SUBSTANCE", 420, 425], ["cytoplasmic", "ORGANISM_SUBSTANCE", 460, 471], ["P. falciparum signal transduction particle", "GENE_OR_GENE_PRODUCT", 485, 527], ["glutamate-gated chloride channel", "PROTEIN", 91, 123], ["GABA-gated chloride channels", "PROTEIN", 128, 156], ["P. falciparum signal transduction particle (SRP) components", "PROTEIN", 485, 544], ["P. falciparum", "SPECIES", 33, 46], ["P. falciparum", "SPECIES", 160, 173], ["P. falciparum", "SPECIES", 285, 298], ["P. falciparum", "SPECIES", 485, 498], ["P. falciparum", "SPECIES", 33, 46], ["P. falciparum", "SPECIES", 160, 173], ["P. falciparum", "SPECIES", 285, 298], ["P. falciparum", "SPECIES", 485, 498], ["ivermectin effect", "TREATMENT", 12, 29], ["P. falciparum", "PROBLEM", 33, 46], ["the glutamate", "TEST", 87, 100], ["gated chloride channel", "TREATMENT", 101, 123], ["GABA-gated chloride channels", "TREATMENT", 128, 156], ["P. falciparum", "PROBLEM", 160, 173], ["ivermectin binds", "TREATMENT", 180, 196], ["ivermectin", "TREATMENT", 245, 255], ["P. falciparum", "PROBLEM", 285, 298], ["ivermectin", "TREATMENT", 375, 385], ["the parasite", "PROBLEM", 400, 412], ["P. falciparum signal transduction particle", "TREATMENT", 485, 527]]], ["This process takes place through a cascade of events involving the induction of chloride dependent polarization of the Plasmodium nuclear membrane then altering the shuttling of importin \u03b1/\u03b2, which leads to the inhibition of SRP polypeptides [106] .", [["nuclear membrane", "ANATOMY", 130, 146], ["chloride", "CHEMICAL", 80, 88], ["chloride", "CHEMICAL", 80, 88], ["chloride", "SIMPLE_CHEMICAL", 80, 88], ["Plasmodium", "ORGANISM", 119, 129], ["nuclear membrane", "CELLULAR_COMPONENT", 130, 146], ["importin \u03b1", "GENE_OR_GENE_PRODUCT", 178, 188], ["\u03b2", "GENE_OR_GENE_PRODUCT", 189, 190], ["importin \u03b1", "PROTEIN", 178, 188], ["\u03b2", "PROTEIN", 189, 190], ["chloride dependent polarization", "TREATMENT", 80, 111], ["the Plasmodium nuclear membrane", "TREATMENT", 115, 146], ["SRP polypeptides", "TREATMENT", 225, 241], ["Plasmodium nuclear membrane", "OBSERVATION", 119, 146]]], ["It is believed that the importin \u03b1/\u03b2 might be karyophyrin \u03b1/\u03b2 as it is the only importin present in P. Falciparum.", [["importin \u03b1", "GENE_OR_GENE_PRODUCT", 24, 34], ["\u03b2", "GENE_OR_GENE_PRODUCT", 35, 36], ["karyophyrin \u03b1", "GENE_OR_GENE_PRODUCT", 46, 59], ["\u03b2", "GENE_OR_GENE_PRODUCT", 60, 61], ["importin", "GENE_OR_GENE_PRODUCT", 80, 88], ["P. Falciparum", "ORGANISM", 100, 113], ["importin \u03b1", "PROTEIN", 24, 34], ["\u03b2", "PROTEIN", 35, 36], ["karyophyrin \u03b1", "PROTEIN", 46, 59], ["\u03b2", "PROTEIN", 60, 61], ["importin", "PROTEIN", 80, 88], ["P. Falciparum", "SPECIES", 100, 113], ["P. Falciparum", "SPECIES", 100, 113], ["karyophyrin", "TREATMENT", 46, 57]]], ["A different observation on the process by which ivermectin inhibits the growth of mosquitoes when infected with P. falciparum [106] .", [["ivermectin", "CHEMICAL", 48, 58], ["P. falciparum", "DISEASE", 112, 125], ["ivermectin", "CHEMICAL", 48, 58], ["ivermectin", "SIMPLE_CHEMICAL", 48, 58], ["mosquitoes", "ORGANISM", 82, 92], ["P. falciparum", "ORGANISM", 112, 125], ["P. falciparum", "SPECIES", 112, 125], ["P. falciparum", "SPECIES", 112, 125], ["ivermectin", "TREATMENT", 48, 58], ["P. falciparum", "PROBLEM", 112, 125]]], ["Kobylinski et al. [103] reported that ivermectin decreased the intensity and prevalence of oocyst in different mosquitoes, while de Carvalho et al. and Perez-Garcia et al. [104, 107] reported a reduction in the prevalence of oocyst without affecting the intensity in mosquito infected with P. falciparum and P. vivax.", [["oocyst", "ANATOMY", 225, 231], ["ivermectin", "CHEMICAL", 38, 48], ["P. falciparum", "DISEASE", 290, 303], ["P. vivax", "DISEASE", 308, 316], ["ivermectin", "CHEMICAL", 38, 48], ["ivermectin", "SIMPLE_CHEMICAL", 38, 48], ["P. falciparum", "ORGANISM", 290, 303], ["P. vivax", "ORGANISM", 308, 316], ["P. falciparum", "SPECIES", 290, 303], ["P. vivax", "SPECIES", 308, 316], ["P. falciparum", "SPECIES", 290, 303], ["P. vivax", "SPECIES", 308, 316], ["ivermectin", "TREATMENT", 38, 48], ["oocyst", "PROBLEM", 225, 231], ["P. falciparum", "TREATMENT", 290, 303], ["P. vivax", "TREATMENT", 308, 316], ["oocyst", "OBSERVATION", 225, 231]]], ["Three different avermectins were also tested with respect to the hepatic effect of Plasmodium.", [["hepatic", "ANATOMY", 65, 72], ["avermectins", "CHEMICAL", 16, 27], ["avermectins", "SIMPLE_CHEMICAL", 16, 27], ["hepatic", "ORGAN", 65, 72], ["Plasmodium", "ORGANISM", 83, 93], ["Three different avermectins", "TREATMENT", 0, 27], ["Plasmodium", "PROBLEM", 83, 93], ["hepatic", "ANATOMY", 65, 72], ["Plasmodium", "OBSERVATION", 83, 93]]], ["Ivermectin, eprinomectin, emamectin were orally administered into mice at 10 mg/kg thrice, using soybean oil as a vehicle before infection with P. berghei 24 h later.", [["oil", "ANATOMY", 105, 108], ["Ivermectin", "CHEMICAL", 0, 10], ["eprinomectin", "CHEMICAL", 12, 24], ["emamectin", "CHEMICAL", 26, 35], ["infection with P. berghei", "DISEASE", 129, 154], ["Ivermectin", "CHEMICAL", 0, 10], ["eprinomectin", "CHEMICAL", 12, 24], ["emamectin", "CHEMICAL", 26, 35], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["eprinomectin", "SIMPLE_CHEMICAL", 12, 24], ["emamectin", "SIMPLE_CHEMICAL", 26, 35], ["mice", "ORGANISM", 66, 70], ["soybean", "ORGANISM", 97, 104], ["oil", "ORGANISM_SUBSTANCE", 105, 108], ["P. berghei", "ORGANISM", 144, 154], ["mice", "SPECIES", 66, 70], ["P. berghei", "SPECIES", 144, 154], ["mice", "SPECIES", 66, 70], ["soybean", "SPECIES", 97, 104], ["P. berghei", "SPECIES", 144, 154], ["Ivermectin", "TREATMENT", 0, 10], ["eprinomectin", "TREATMENT", 12, 24], ["emamectin", "TREATMENT", 26, 35]]], ["The parasite load was determined between 44-46 h post infections.", [["infections", "DISEASE", 54, 64], ["The parasite load", "TEST", 0, 17], ["infections", "PROBLEM", 54, 64], ["parasite load", "OBSERVATION", 4, 17], ["infections", "OBSERVATION", 54, 64]]], ["It has been found that ivermectin has been shown to be effective with approximately 88% protection against liver infection while the other two have been shown to be ineffective compared to primaquine, the standard drug [106] .", [["liver", "ANATOMY", 107, 112], ["ivermectin", "CHEMICAL", 23, 33], ["liver infection", "DISEASE", 107, 122], ["primaquine", "CHEMICAL", 189, 199], ["ivermectin", "CHEMICAL", 23, 33], ["primaquine", "CHEMICAL", 189, 199], ["ivermectin", "SIMPLE_CHEMICAL", 23, 33], ["liver", "ORGAN", 107, 112], ["primaquine", "SIMPLE_CHEMICAL", 189, 199], ["ivermectin", "TREATMENT", 23, 33], ["liver infection", "PROBLEM", 107, 122], ["primaquine", "TREATMENT", 189, 199], ["ivermectin", "OBSERVATION", 23, 33], ["shown to be", "UNCERTAINTY", 43, 54], ["effective", "OBSERVATION_MODIFIER", 55, 64], ["liver", "ANATOMY", 107, 112], ["infection", "OBSERVATION", 113, 122]]], ["Of note is the mild neurotoxicity of ivermectin in some of the mice treated.", [["neurotoxicity", "DISEASE", 20, 33], ["ivermectin", "CHEMICAL", 37, 47], ["ivermectin", "CHEMICAL", 37, 47], ["ivermectin", "SIMPLE_CHEMICAL", 37, 47], ["mice", "ORGANISM", 63, 67], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["the mild neurotoxicity", "PROBLEM", 11, 33], ["ivermectin", "TREATMENT", 37, 47], ["mild", "OBSERVATION_MODIFIER", 15, 19], ["neurotoxicity", "OBSERVATION", 20, 33]]], ["One of the major observation in a mouse-model of antimalarial activity of ivermectin showed mild neurotoxicity as impairment in infection and behavior were observed in the mice.", [["ivermectin", "CHEMICAL", 74, 84], ["neurotoxicity", "DISEASE", 97, 110], ["impairment in infection", "DISEASE", 114, 137], ["ivermectin", "CHEMICAL", 74, 84], ["mouse", "ORGANISM", 34, 39], ["ivermectin", "SIMPLE_CHEMICAL", 74, 84], ["mice", "ORGANISM", 172, 176], ["mouse", "SPECIES", 34, 39], ["mice", "SPECIES", 172, 176], ["mouse", "SPECIES", 34, 39], ["mice", "SPECIES", 172, 176], ["ivermectin", "TREATMENT", 74, 84], ["mild neurotoxicity", "PROBLEM", 92, 110], ["impairment in infection", "PROBLEM", 114, 137], ["major", "OBSERVATION_MODIFIER", 11, 16], ["mild", "OBSERVATION_MODIFIER", 92, 96], ["neurotoxicity", "OBSERVATION", 97, 110], ["infection", "OBSERVATION", 128, 137]]], ["With the potent insecticidal activity of ivermectin against female Anopheles mosquitoes, it was concluded that the ability of ivermectin to prevent parasite invasion of the liver could be central to malaria treatment and prevention as it decreases the level of Plasmodium in the blood and other tissues [108] .", [["liver", "ANATOMY", 173, 178], ["blood", "ANATOMY", 279, 284], ["tissues", "ANATOMY", 295, 302], ["ivermectin", "CHEMICAL", 41, 51], ["ivermectin", "CHEMICAL", 126, 136], ["invasion of the liver", "DISEASE", 157, 178], ["malaria", "DISEASE", 199, 206], ["ivermectin", "CHEMICAL", 41, 51], ["ivermectin", "CHEMICAL", 126, 136], ["ivermectin", "SIMPLE_CHEMICAL", 41, 51], ["female Anopheles mosquitoes", "ORGANISM", 60, 87], ["ivermectin", "SIMPLE_CHEMICAL", 126, 136], ["liver", "ORGAN", 173, 178], ["Plasmodium", "ORGANISM", 261, 271], ["blood", "ORGANISM_SUBSTANCE", 279, 284], ["tissues", "TISSUE", 295, 302], ["Anopheles mosquitoes", "SPECIES", 67, 87], ["ivermectin", "TREATMENT", 41, 51], ["ivermectin", "TREATMENT", 126, 136], ["parasite invasion of the liver", "PROBLEM", 148, 178], ["malaria treatment", "TREATMENT", 199, 216], ["prevention", "TREATMENT", 221, 231], ["Plasmodium in the blood and other tissues", "PROBLEM", 261, 302], ["parasite", "OBSERVATION_MODIFIER", 148, 156], ["invasion", "OBSERVATION", 157, 165], ["liver", "ANATOMY", 173, 178], ["malaria", "OBSERVATION", 199, 206], ["Plasmodium", "OBSERVATION", 261, 271], ["blood", "ANATOMY", 279, 284]]], ["A study by Mekuriaw et al. [109] showed that ivermectin has anti-plasmodial activity in humans infected with An.", [["ivermectin", "CHEMICAL", 45, 55], ["ivermectin", "CHEMICAL", 45, 55], ["ivermectin", "SIMPLE_CHEMICAL", 45, 55], ["humans", "ORGANISM", 88, 94], ["humans", "SPECIES", 88, 94], ["humans", "SPECIES", 88, 94], ["A study", "TEST", 0, 7], ["ivermectin", "TREATMENT", 45, 55], ["anti-plasmodial activity", "OBSERVATION", 60, 84], ["infected", "OBSERVATION", 95, 103]]], ["Arabiensis which might be linked to the delay effect on fecundity.", [["Arabiensis", "CHEMICAL", 0, 10], ["Arabiensis", "TREATMENT", 0, 10]]], ["More experiments still need to be conducted on the efficacy of ivermectin in treating malaria.Anti-Inflammatory Effect of AvermectinNew discovery on the pharmacological activity of ivermectin is its potential usage as an anti-inflammatory drug.", [["ivermectin", "CHEMICAL", 63, 73], ["malaria", "DISEASE", 86, 93], ["AvermectinNew", "CHEMICAL", 122, 135], ["ivermectin", "CHEMICAL", 181, 191], ["ivermectin", "CHEMICAL", 63, 73], ["ivermectin", "CHEMICAL", 181, 191], ["ivermectin", "SIMPLE_CHEMICAL", 63, 73], ["AvermectinNew", "SIMPLE_CHEMICAL", 122, 135], ["ivermectin", "SIMPLE_CHEMICAL", 181, 191], ["ivermectin", "TREATMENT", 63, 73], ["malaria", "PROBLEM", 86, 93], ["ivermectin", "TREATMENT", 181, 191], ["an anti-inflammatory drug", "TREATMENT", 218, 243], ["malaria", "OBSERVATION", 86, 93], ["anti-inflammatory drug", "OBSERVATION", 221, 243]]], ["Ivermectin has been reported to modulate immune activity in mast cells and macrophages that are important in T-cell mediated skin inflammation through the following process: (1) priming of T cell through skin emigration of allergen-loaded DC [110] .", [["mast cells", "ANATOMY", 60, 70], ["macrophages", "ANATOMY", 75, 86], ["T-cell", "ANATOMY", 109, 115], ["skin", "ANATOMY", 125, 129], ["T cell", "ANATOMY", 189, 195], ["skin", "ANATOMY", 204, 208], ["DC", "ANATOMY", 239, 241], ["Ivermectin", "CHEMICAL", 0, 10], ["inflammation", "DISEASE", 130, 142], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["mast cells", "CELL", 60, 70], ["macrophages", "CELL", 75, 86], ["T-cell", "CELL", 109, 115], ["skin", "ORGAN", 125, 129], ["T cell", "CELL", 189, 195], ["skin", "ORGAN", 204, 208], ["mast cells", "CELL_TYPE", 60, 70], ["macrophages", "CELL_TYPE", 75, 86], ["T cell", "CELL_TYPE", 189, 195], ["DC", "CELL_TYPE", 239, 241], ["Ivermectin", "TREATMENT", 0, 10], ["mast cells", "PROBLEM", 60, 70], ["macrophages", "PROBLEM", 75, 86], ["skin inflammation", "PROBLEM", 125, 142], ["T cell through skin emigration of allergen", "TREATMENT", 189, 231], ["immune activity", "OBSERVATION", 41, 56], ["mast cells", "OBSERVATION", 60, 70], ["macrophages", "OBSERVATION", 75, 86], ["skin", "ANATOMY", 125, 129], ["inflammation", "OBSERVATION", 130, 142], ["skin", "ANATOMY", 204, 208]]], ["(2) Recruitment of effector T cells by the skin, and (3) generating a cluster of T-cell/DC through macrophage, this is important in dermal skin inflammation [111] .", [["effector T cells", "ANATOMY", 19, 35], ["skin", "ANATOMY", 43, 47], ["T-cell", "ANATOMY", 81, 87], ["DC", "ANATOMY", 88, 90], ["macrophage", "ANATOMY", 99, 109], ["dermal skin", "ANATOMY", 132, 143], ["inflammation", "DISEASE", 144, 156], ["effector T cells", "CELL", 19, 35], ["skin", "ORGAN", 43, 47], ["T-cell", "CELL", 81, 87], ["DC", "CELL", 88, 90], ["macrophage", "CELL", 99, 109], ["dermal skin", "TISSUE", 132, 143], ["effector T cells", "CELL_TYPE", 19, 35], ["T-cell", "CELL_TYPE", 81, 87], ["DC", "CELL_TYPE", 88, 90], ["macrophage", "CELL_TYPE", 99, 109], ["effector T cells", "TREATMENT", 19, 35], ["T-cell/DC through macrophage", "TREATMENT", 81, 109], ["dermal skin inflammation", "PROBLEM", 132, 156], ["skin", "ANATOMY", 43, 47], ["skin", "ANATOMY", 139, 143], ["inflammation", "OBSERVATION", 144, 156]]], ["Ventre et al. [112] , using murine, showed that application of ivermectin topically delays skin inflammation as a result of allergy prompted by regular contact with Dermatophagoides farina (an allergen), slowing the synthesis of inflammatory cytokines, priming and activation of allergen-specific T-cells.", [["skin", "ANATOMY", 91, 95], ["T-cells", "ANATOMY", 297, 304], ["ivermectin", "CHEMICAL", 63, 73], ["skin inflammation", "DISEASE", 91, 108], ["allergy", "DISEASE", 124, 131], ["ivermectin", "CHEMICAL", 63, 73], ["murine", "ORGANISM", 28, 34], ["ivermectin", "SIMPLE_CHEMICAL", 63, 73], ["skin", "ORGAN", 91, 95], ["Dermatophagoides farina", "ORGANISM", 165, 188], ["T-cells", "CELL", 297, 304], ["inflammatory cytokines", "PROTEIN", 229, 251], ["allergen-specific T-cells", "CELL_TYPE", 279, 304], ["murine", "SPECIES", 28, 34], ["Dermatophagoides farina", "SPECIES", 165, 188], ["Dermatophagoides farina", "SPECIES", 165, 188], ["ivermectin", "TREATMENT", 63, 73], ["skin inflammation", "PROBLEM", 91, 108], ["allergy", "PROBLEM", 124, 131], ["inflammatory cytokines", "PROBLEM", 229, 251], ["allergen", "TEST", 279, 287], ["skin", "ANATOMY", 91, 95], ["inflammation", "OBSERVATION", 96, 108], ["inflammatory cytokines", "OBSERVATION", 229, 251]]], ["They also showed that ivermectin did not have a significant effect on dendritic cells functions, either in an in vivo or in vitro, but caused impairment in the activation of T-cells, production and proliferation of cytokines by stimulating antigen-specificity and polyclonal activity.", [["dendritic cells", "ANATOMY", 70, 85], ["T-cells", "ANATOMY", 174, 181], ["ivermectin", "CHEMICAL", 22, 32], ["ivermectin", "CHEMICAL", 22, 32], ["ivermectin", "SIMPLE_CHEMICAL", 22, 32], ["dendritic cells", "CELL", 70, 85], ["T-cells", "CELL", 174, 181], ["dendritic cells", "CELL_TYPE", 70, 85], ["T-cells", "CELL_TYPE", 174, 181], ["cytokines", "PROTEIN", 215, 224], ["ivermectin", "TREATMENT", 22, 32], ["dendritic cells functions", "PROBLEM", 70, 95], ["T-cells", "PROBLEM", 174, 181], ["proliferation of cytokines", "PROBLEM", 198, 224], ["stimulating antigen", "TEST", 228, 247], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["dendritic cells", "OBSERVATION", 70, 85], ["polyclonal activity", "OBSERVATION", 264, 283]]], ["N\u00f6renberg et al. [113] and Wareham et al. [114] showed that ivermectin possess immunomodulatory activity in mast cells and macrophages in various in vitro models.", [["mast cells", "ANATOMY", 108, 118], ["macrophages", "ANATOMY", 123, 134], ["ivermectin", "CHEMICAL", 60, 70], ["ivermectin", "CHEMICAL", 60, 70], ["ivermectin", "SIMPLE_CHEMICAL", 60, 70], ["mast cells", "CELL", 108, 118], ["macrophages", "CELL", 123, 134], ["mast cells", "CELL_TYPE", 108, 118], ["macrophages", "CELL_TYPE", 123, 134], ["ivermectin", "TREATMENT", 60, 70], ["immunomodulatory activity in mast cells", "PROBLEM", 79, 118], ["macrophages", "PROBLEM", 123, 134], ["immunomodulatory activity", "OBSERVATION", 79, 104], ["mast cells", "OBSERVATION", 108, 118], ["macrophages", "OBSERVATION", 123, 134]]], ["Thus, the anti-inflammatory effect of ivermectin can be linked to its regulatory effect in T-cells, skin mast cells and macrophages.", [["T-cells", "ANATOMY", 91, 98], ["skin mast cells", "ANATOMY", 100, 115], ["macrophages", "ANATOMY", 120, 131], ["ivermectin", "CHEMICAL", 38, 48], ["ivermectin", "CHEMICAL", 38, 48], ["ivermectin", "SIMPLE_CHEMICAL", 38, 48], ["T-cells", "CELL", 91, 98], ["skin mast cells", "CELL", 100, 115], ["macrophages", "CELL", 120, 131], ["T-cells", "CELL_TYPE", 91, 98], ["skin mast cells", "CELL_TYPE", 100, 115], ["macrophages", "CELL_TYPE", 120, 131], ["ivermectin", "TREATMENT", 38, 48], ["skin", "ANATOMY", 100, 104], ["mast cells", "OBSERVATION", 105, 115], ["macrophages", "ANATOMY", 120, 131]]], ["Leyva-Castillo et al. [115] also showed that ivermectin -induced modulation of T-cells does not involve some target expressed by T cells such as P2XR4 (involved in the regulation of Ca 2+ metabolism) and FXR (a receptor for which ivermectin has a strong affinity for).", [["T-cells", "ANATOMY", 79, 86], ["T cells", "ANATOMY", 129, 136], ["ivermectin", "CHEMICAL", 45, 55], ["Ca", "CHEMICAL", 182, 184], ["ivermectin", "CHEMICAL", 230, 240], ["ivermectin", "CHEMICAL", 45, 55], ["Ca 2+", "CHEMICAL", 182, 187], ["ivermectin", "CHEMICAL", 230, 240], ["ivermectin", "SIMPLE_CHEMICAL", 45, 55], ["T-cells", "CELL", 79, 86], ["T cells", "CELL", 129, 136], ["P2XR4", "GENE_OR_GENE_PRODUCT", 145, 150], ["Ca 2+", "GENE_OR_GENE_PRODUCT", 182, 187], ["FXR", "GENE_OR_GENE_PRODUCT", 204, 207], ["ivermectin", "SIMPLE_CHEMICAL", 230, 240], ["T-cells", "CELL_TYPE", 79, 86], ["T cells", "CELL_TYPE", 129, 136], ["P2XR4", "PROTEIN", 145, 150], ["Ca 2", "PROTEIN", 182, 186], ["FXR", "PROTEIN", 204, 207], ["Leyva", "TEST", 0, 5], ["ivermectin", "TREATMENT", 45, 55], ["T-cells", "PROBLEM", 79, 86], ["Ca", "TEST", 182, 184], ["FXR", "PROBLEM", 204, 207], ["ivermectin", "TREATMENT", 230, 240], ["FXR", "ANATOMY", 204, 207]]], ["However, other receptors involved in T-cell proliferation and screened in vitro showed that they were also not involved in IVM-immunomodulatory effect on T-cell.", [["T-cell", "ANATOMY", 37, 43], ["T-cell", "ANATOMY", 154, 160], ["IVM", "CHEMICAL", 123, 126], ["T-cell", "CELL", 37, 43], ["IVM", "SIMPLE_CHEMICAL", 123, 126], ["T-cell", "CELL", 154, 160], ["T-cell", "CELL_TYPE", 154, 160], ["cell proliferation", "OBSERVATION", 39, 57]]], ["Some of these receptors include Ryanodine receptors (RyRs), gamma aminobutyric acid (GABA A Rs) type A receptors, type 3, 5-hydroxytryptamine receptors (5-HT3Rs) [116] .", [["Ryanodine", "CHEMICAL", 32, 41], ["gamma aminobutyric acid", "CHEMICAL", 60, 83], ["GABA", "CHEMICAL", 85, 89], ["5-hydroxytryptamine", "CHEMICAL", 122, 141], ["5-HT3Rs", "CHEMICAL", 153, 160], ["Ryanodine", "CHEMICAL", 32, 41], ["gamma aminobutyric acid", "CHEMICAL", 60, 83], ["GABA", "CHEMICAL", 85, 89], ["5-hydroxytryptamine", "CHEMICAL", 122, 141], ["5-HT3Rs", "CHEMICAL", 153, 160], ["Ryanodine receptors", "GENE_OR_GENE_PRODUCT", 32, 51], ["RyRs", "SIMPLE_CHEMICAL", 53, 57], ["gamma aminobutyric acid", "SIMPLE_CHEMICAL", 60, 83], ["GABA A Rs) type A receptors", "GENE_OR_GENE_PRODUCT", 85, 112], ["type 3", "GENE_OR_GENE_PRODUCT", 114, 120], ["5-hydroxytryptamine receptors", "SIMPLE_CHEMICAL", 122, 151], ["5-HT3Rs", "SIMPLE_CHEMICAL", 153, 160], ["Ryanodine receptors", "PROTEIN", 32, 51], ["RyRs", "PROTEIN", 53, 57], ["gamma aminobutyric acid (GABA A Rs) type A receptors", "PROTEIN", 60, 112], ["type 3, 5-hydroxytryptamine receptors", "PROTEIN", 114, 151], ["HT3Rs", "PROTEIN", 155, 160], ["Ryanodine receptors", "TREATMENT", 32, 51], ["RyRs", "TEST", 53, 57], ["gamma aminobutyric acid", "TEST", 60, 83], ["hydroxytryptamine receptors", "TREATMENT", 124, 151]]], ["In addition, Ci et al. [117] showed that the mechanism of anti-inflammatory activity of avermectin might involve a reduction in the pathway of mitogen-activated protein kinase (MAPK) and nuclear transcription factor kappa B (NFkB).AnticancerAnother non-prescription discovery for ivermectin is as an anticancer drugs.", [["anticancer", "ANATOMY", 300, 310], ["avermectin", "CHEMICAL", 88, 98], ["ivermectin", "CHEMICAL", 280, 290], ["avermectin", "CHEMICAL", 88, 98], ["ivermectin", "CHEMICAL", 280, 290], ["avermectin", "SIMPLE_CHEMICAL", 88, 98], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 143, 175], ["MAPK", "GENE_OR_GENE_PRODUCT", 177, 181], ["nuclear transcription factor kappa B", "GENE_OR_GENE_PRODUCT", 187, 223], ["NFkB", "GENE_OR_GENE_PRODUCT", 225, 229], ["ivermectin", "SIMPLE_CHEMICAL", 280, 290], ["anticancer", "CANCER", 300, 310], ["mitogen-activated protein kinase", "PROTEIN", 143, 175], ["MAPK", "PROTEIN", 177, 181], ["nuclear transcription factor kappa B", "PROTEIN", 187, 223], ["NFkB", "PROTEIN", 225, 229], ["Ci et al.", "TEST", 13, 22], ["avermectin", "TREATMENT", 88, 98], ["a reduction", "TREATMENT", 113, 124], ["mitogen", "TEST", 143, 150], ["ivermectin", "TREATMENT", 280, 290], ["an anticancer drugs", "TREATMENT", 297, 316], ["anti-inflammatory activity", "OBSERVATION", 58, 84]]], ["The ability of ivermectin to stimulate the intracellular influx of chloride ion in cells from a leukemia patient and induction of oxidative stress leading to the death of the leukemia cells without having any effect on normal cells [43] .", [["intracellular", "ANATOMY", 43, 56], ["cells", "ANATOMY", 83, 88], ["leukemia", "ANATOMY", 96, 104], ["leukemia cells", "ANATOMY", 175, 189], ["cells", "ANATOMY", 226, 231], ["ivermectin", "CHEMICAL", 15, 25], ["chloride", "CHEMICAL", 67, 75], ["leukemia", "DISEASE", 96, 104], ["death", "DISEASE", 162, 167], ["leukemia", "DISEASE", 175, 183], ["ivermectin", "CHEMICAL", 15, 25], ["chloride", "CHEMICAL", 67, 75], ["ivermectin", "SIMPLE_CHEMICAL", 15, 25], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 56], ["chloride", "SIMPLE_CHEMICAL", 67, 75], ["cells", "CELL", 83, 88], ["leukemia", "CANCER", 96, 104], ["patient", "ORGANISM", 105, 112], ["leukemia cells", "CELL", 175, 189], ["cells", "CELL", 226, 231], ["leukemia cells", "CELL_TYPE", 175, 189], ["normal cells", "CELL_TYPE", 219, 231], ["patient", "SPECIES", 105, 112], ["ivermectin", "TREATMENT", 15, 25], ["chloride ion in cells", "TREATMENT", 67, 88], ["a leukemia patient", "PROBLEM", 94, 112], ["oxidative stress", "PROBLEM", 130, 146], ["the leukemia cells", "PROBLEM", 171, 189], ["leukemia", "OBSERVATION", 96, 104], ["leukemia cells", "OBSERVATION", 175, 189]]], ["The anticancer effect of ivermectin against leukemia was also tested in mice using three different models, all of which demonstrated the ability of ivermectin to inhibit or slow the growth of tumor cells.", [["anticancer", "ANATOMY", 4, 14], ["leukemia", "ANATOMY", 44, 52], ["tumor cells", "ANATOMY", 192, 203], ["ivermectin", "CHEMICAL", 25, 35], ["leukemia", "DISEASE", 44, 52], ["ivermectin", "CHEMICAL", 148, 158], ["tumor", "DISEASE", 192, 197], ["ivermectin", "CHEMICAL", 25, 35], ["ivermectin", "CHEMICAL", 148, 158], ["anticancer", "CANCER", 4, 14], ["ivermectin", "SIMPLE_CHEMICAL", 25, 35], ["leukemia", "CANCER", 44, 52], ["mice", "ORGANISM", 72, 76], ["ivermectin", "SIMPLE_CHEMICAL", 148, 158], ["tumor cells", "CELL", 192, 203], ["tumor cells", "CELL_TYPE", 192, 203], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["ivermectin", "TREATMENT", 25, 35], ["leukemia", "PROBLEM", 44, 52], ["ivermectin", "TREATMENT", 148, 158], ["slow the growth of tumor cells", "PROBLEM", 173, 203], ["growth", "OBSERVATION_MODIFIER", 182, 188], ["tumor cells", "OBSERVATION", 192, 203]]], ["Most tissue cancers in human have a deregulated WNT-TCF (WNT-T cell factors) signaling pathway.", [["tissue cancers", "ANATOMY", 5, 19], ["cancers", "DISEASE", 12, 19], ["tissue cancers", "CANCER", 5, 19], ["human", "ORGANISM", 23, 28], ["WNT", "GENE_OR_GENE_PRODUCT", 48, 51], ["TCF", "GENE_OR_GENE_PRODUCT", 52, 55], ["WNT-T cell factors", "GENE_OR_GENE_PRODUCT", 57, 75], ["WNT", "PROTEIN", 48, 51], ["TCF", "PROTEIN", 52, 55], ["WNT-T cell factors", "PROTEIN", 57, 75], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["Most tissue cancers in human", "PROBLEM", 0, 28], ["a deregulated WNT", "PROBLEM", 34, 51], ["TCF (WNT-T cell factors", "TREATMENT", 52, 75], ["signaling pathway", "PROBLEM", 77, 94], ["cancers", "OBSERVATION", 12, 19]]], ["This pathway regulates cell proliferation and metastasis.", [["cell", "ANATOMY", 23, 27], ["cell", "CELL", 23, 27], ["This pathway regulates cell proliferation", "PROBLEM", 0, 41], ["metastasis", "PROBLEM", 46, 56], ["regulates cell proliferation", "OBSERVATION", 13, 41], ["metastasis", "OBSERVATION", 46, 56]]], ["The antitumor effect of ivermectin in human colon cancer and lung carcinoma xenograft is dependent on WNT-TCF signaling pathway, it is effective if the cancer is WNT-TCF-dependent and ineffective if it is not [118] .", [["antitumor", "ANATOMY", 4, 13], ["colon cancer", "ANATOMY", 44, 56], ["lung carcinoma xenograft", "ANATOMY", 61, 85], ["cancer", "ANATOMY", 152, 158], ["ivermectin", "CHEMICAL", 24, 34], ["colon cancer", "DISEASE", 44, 56], ["lung carcinoma", "DISEASE", 61, 75], ["cancer", "DISEASE", 152, 158], ["ivermectin", "CHEMICAL", 24, 34], ["antitumor", "CANCER", 4, 13], ["ivermectin", "SIMPLE_CHEMICAL", 24, 34], ["human", "ORGANISM", 38, 43], ["colon cancer", "CANCER", 44, 56], ["lung carcinoma xenograft", "CANCER", 61, 85], ["WNT", "GENE_OR_GENE_PRODUCT", 102, 105], ["TCF", "GENE_OR_GENE_PRODUCT", 106, 109], ["cancer", "CANCER", 152, 158], ["WNT", "GENE_OR_GENE_PRODUCT", 162, 165], ["TCF", "GENE_OR_GENE_PRODUCT", 166, 169], ["WNT", "PROTEIN", 102, 105], ["TCF", "PROTEIN", 106, 109], ["WNT", "PROTEIN", 162, 165], ["TCF", "PROTEIN", 166, 169], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["ivermectin", "TREATMENT", 24, 34], ["human colon cancer", "PROBLEM", 38, 56], ["lung carcinoma xenograft", "PROBLEM", 61, 85], ["the cancer", "PROBLEM", 148, 158], ["colon", "ANATOMY", 44, 49], ["cancer", "OBSERVATION", 50, 56], ["lung", "ANATOMY", 61, 65], ["carcinoma xenograft", "OBSERVATION", 66, 85], ["cancer", "OBSERVATION", 152, 158]]], ["The potency of ivermectin as an anticancer in a glioma xenograft is also observed by inhibiting DEAD-vox RNA helicase DDX23 [119] .", [["anticancer", "ANATOMY", 32, 42], ["glioma xenograft", "ANATOMY", 48, 64], ["ivermectin", "CHEMICAL", 15, 25], ["glioma", "DISEASE", 48, 54], ["ivermectin", "CHEMICAL", 15, 25], ["ivermectin", "SIMPLE_CHEMICAL", 15, 25], ["anticancer", "CANCER", 32, 42], ["glioma xenograft", "CANCER", 48, 64], ["DEAD-vox", "GENE_OR_GENE_PRODUCT", 96, 104], ["DEAD-vox RNA helicase", "PROTEIN", 96, 117], ["ivermectin", "TREATMENT", 15, 25], ["an anticancer", "TREATMENT", 29, 42], ["a glioma xenograft", "TREATMENT", 46, 64], ["glioma xenograft", "OBSERVATION", 48, 64]]], ["This type of helicase is linked to miR-21 processing, a microRNA associated with glioma the proliferation and metastasis of glioma cells.", [["glioma", "ANATOMY", 81, 87], ["glioma cells", "ANATOMY", 124, 136], ["glioma", "DISEASE", 81, 87], ["glioma", "DISEASE", 124, 130], ["miR-21", "GENE_OR_GENE_PRODUCT", 35, 41], ["glioma", "CANCER", 81, 87], ["glioma cells", "CELL", 124, 136], ["helicase", "PROTEIN", 13, 21], ["miR-21", "DNA", 35, 41], ["glioma cells", "CELL_TYPE", 124, 136], ["a microRNA", "PROBLEM", 54, 64], ["glioma the proliferation", "PROBLEM", 81, 105], ["metastasis of glioma cells", "PROBLEM", 110, 136], ["helicase", "OBSERVATION", 13, 21], ["microRNA", "ANATOMY", 56, 64], ["associated with", "UNCERTAINTY", 65, 80], ["glioma", "OBSERVATION", 81, 87], ["proliferation", "OBSERVATION_MODIFIER", 92, 105], ["metastasis", "OBSERVATION", 110, 120], ["glioma cells", "OBSERVATION", 124, 136]]], ["One of the key pathways in colon cancer is the inhibition of TGF\u03b2-R2 (a WNT-TCF repressor) by miR-21, leading to the overexpression of WNT-TCF [120] .", [["colon cancer", "ANATOMY", 27, 39], ["colon cancer", "DISEASE", 27, 39], ["colon cancer", "CANCER", 27, 39], ["TGF\u03b2-R2", "GENE_OR_GENE_PRODUCT", 61, 68], ["WNT-TCF", "GENE_OR_GENE_PRODUCT", 72, 79], ["miR-21", "GENE_OR_GENE_PRODUCT", 94, 100], ["WNT-TCF", "GENE_OR_GENE_PRODUCT", 135, 142], ["TGF\u03b2-R2", "PROTEIN", 61, 68], ["WNT", "PROTEIN", 72, 75], ["TCF repressor", "PROTEIN", 76, 89], ["miR-21", "DNA", 94, 100], ["WNT", "PROTEIN", 135, 138], ["TCF", "PROTEIN", 139, 142], ["colon cancer", "PROBLEM", 27, 39], ["TGF", "TEST", 61, 64], ["a WNT-TCF repressor", "TREATMENT", 70, 89], ["the overexpression of WNT", "PROBLEM", 113, 138], ["colon", "ANATOMY", 27, 32], ["cancer", "OBSERVATION", 33, 39]]], ["This shows that ivermectin can play a dual role in preventing tumor growth and metastasis.", [["tumor", "ANATOMY", 62, 67], ["ivermectin", "CHEMICAL", 16, 26], ["tumor", "DISEASE", 62, 67], ["ivermectin", "CHEMICAL", 16, 26], ["ivermectin", "SIMPLE_CHEMICAL", 16, 26], ["tumor", "CANCER", 62, 67], ["ivermectin", "TREATMENT", 16, 26], ["tumor growth", "PROBLEM", 62, 74], ["metastasis", "PROBLEM", 79, 89], ["preventing", "UNCERTAINTY", 51, 61], ["tumor", "OBSERVATION", 62, 67], ["growth", "OBSERVATION_MODIFIER", 68, 74], ["metastasis", "OBSERVATION", 79, 89]]], ["Ivermectin can also inhibit the depolymerization of microtubules, thus preventing mitosis in tumor cells as well as increasing the polymerization of microtubules [121] .Metabolic Effect of IVMIvermectin has also been reported to affect lipid and carbohydrate metabolism in mammals by targeting farnesoid X receptor (FXR), a nuclear hormone receptor that is involved in glucose, cholesterol, and bile control.", [["microtubules", "ANATOMY", 52, 64], ["tumor cells", "ANATOMY", 93, 104], ["microtubules", "ANATOMY", 149, 161], ["nuclear", "ANATOMY", 324, 331], ["bile", "ANATOMY", 395, 399], ["Ivermectin", "CHEMICAL", 0, 10], ["tumor", "DISEASE", 93, 98], ["IVMIvermectin", "CHEMICAL", 189, 202], ["glucose", "CHEMICAL", 369, 376], ["cholesterol", "CHEMICAL", 378, 389], ["Ivermectin", "CHEMICAL", 0, 10], ["IVMIvermectin", "CHEMICAL", 189, 202], ["carbohydrate", "CHEMICAL", 246, 258], ["glucose", "CHEMICAL", 369, 376], ["cholesterol", "CHEMICAL", 378, 389], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["microtubules", "CELLULAR_COMPONENT", 52, 64], ["tumor cells", "CELL", 93, 104], ["IVMIvermectin", "SIMPLE_CHEMICAL", 189, 202], ["lipid", "SIMPLE_CHEMICAL", 236, 241], ["carbohydrate", "SIMPLE_CHEMICAL", 246, 258], ["farnesoid X receptor", "GENE_OR_GENE_PRODUCT", 294, 314], ["FXR", "GENE_OR_GENE_PRODUCT", 316, 319], ["nuclear hormone receptor", "GENE_OR_GENE_PRODUCT", 324, 348], ["glucose", "SIMPLE_CHEMICAL", 369, 376], ["cholesterol", "SIMPLE_CHEMICAL", 378, 389], ["bile", "SIMPLE_CHEMICAL", 395, 399], ["microtubules", "PROTEIN", 52, 64], ["tumor cells", "CELL_TYPE", 93, 104], ["farnesoid X receptor", "PROTEIN", 294, 314], ["FXR", "PROTEIN", 316, 319], ["nuclear hormone receptor", "PROTEIN", 324, 348], ["Ivermectin", "TREATMENT", 0, 10], ["the depolymerization of microtubules", "TREATMENT", 28, 64], ["mitosis in tumor cells", "PROBLEM", 82, 104], ["IVMIvermectin", "TREATMENT", 189, 202], ["a nuclear hormone receptor", "TEST", 322, 348], ["glucose", "TEST", 369, 376], ["cholesterol", "TEST", 378, 389], ["bile control", "TREATMENT", 395, 407], ["tumor cells", "OBSERVATION", 93, 104], ["increasing", "OBSERVATION_MODIFIER", 116, 126], ["FXR", "ANATOMY", 316, 319], ["bile", "ANATOMY", 395, 399]]], ["Ivermectin binds to FXR to initiate its transcriptional function and the recruitment of other metabolic regulators.", [["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["FXR", "GENE_OR_GENE_PRODUCT", 20, 23], ["FXR", "PROTEIN", 20, 23], ["metabolic regulators", "PROTEIN", 94, 114], ["Ivermectin binds", "TREATMENT", 0, 16], ["FXR", "TEST", 20, 23], ["FXR", "ANATOMY", 20, 23]]], ["An experimental model of diabetes using mice shows that ivermectin significantly reduced serum glucose and cholesterol concentrations and enhanced the sensitivity of insulin, however, ivermectin had no effect in FXR-null mice [122] .", [["serum", "ANATOMY", 89, 94], ["diabetes", "DISEASE", 25, 33], ["ivermectin", "CHEMICAL", 56, 66], ["glucose", "CHEMICAL", 95, 102], ["cholesterol", "CHEMICAL", 107, 118], ["ivermectin", "CHEMICAL", 184, 194], ["ivermectin", "CHEMICAL", 56, 66], ["glucose", "CHEMICAL", 95, 102], ["cholesterol", "CHEMICAL", 107, 118], ["ivermectin", "CHEMICAL", 184, 194], ["mice", "ORGANISM", 40, 44], ["ivermectin", "SIMPLE_CHEMICAL", 56, 66], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["cholesterol", "SIMPLE_CHEMICAL", 107, 118], ["insulin", "GENE_OR_GENE_PRODUCT", 166, 173], ["ivermectin", "SIMPLE_CHEMICAL", 184, 194], ["FXR", "GENE_OR_GENE_PRODUCT", 212, 215], ["insulin", "PROTEIN", 166, 173], ["FXR", "PROTEIN", 212, 215], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 221, 225], ["mice", "SPECIES", 40, 44], ["diabetes", "PROBLEM", 25, 33], ["ivermectin", "TREATMENT", 56, 66], ["serum glucose", "TEST", 89, 102], ["cholesterol concentrations", "TEST", 107, 133], ["insulin", "TREATMENT", 166, 173], ["ivermectin", "TREATMENT", 184, 194], ["FXR", "TEST", 212, 215], ["diabetes", "OBSERVATION", 25, 33]]], ["C. elegans, a nematode in which ivermectin is active against, possesses a DAF-12 (a nuclear hormone receptor that regulates its life cycle), that shares almost similar homologue with FXR [123] .", [["nuclear", "ANATOMY", 84, 91], ["ivermectin", "CHEMICAL", 32, 42], ["ivermectin", "CHEMICAL", 32, 42], ["C. elegans", "ORGANISM", 0, 10], ["ivermectin", "SIMPLE_CHEMICAL", 32, 42], ["DAF-12", "GENE_OR_GENE_PRODUCT", 74, 80], ["nuclear hormone receptor", "GENE_OR_GENE_PRODUCT", 84, 108], ["FXR [123]", "GENE_OR_GENE_PRODUCT", 183, 192], ["DAF-12", "PROTEIN", 74, 80], ["nuclear hormone receptor", "PROTEIN", 84, 108], ["FXR", "PROTEIN", 183, 186], ["C. elegans", "SPECIES", 0, 10], ["C. elegans", "SPECIES", 0, 10], ["C. elegans", "PROBLEM", 0, 10], ["a nematode", "PROBLEM", 12, 22], ["a DAF", "TEST", 72, 77], ["a nuclear hormone receptor", "TREATMENT", 82, 108], ["FXR", "ANATOMY", 183, 186]]], ["However, there is no proof if ivermectin elicits its nematocidal activity through this receptor.Anti-Alcohol TherapiesFour different types of AVM were tested for their potential as anti-alcohol therapy, namely selamectin (SEL), abamectin (ABM), ivermectin (IVM) and moxidectin (MOX).", [["ivermectin", "CHEMICAL", 30, 40], ["Anti-Alcohol", "CHEMICAL", 96, 108], ["AVM", "DISEASE", 142, 145], ["anti-alcohol", "CHEMICAL", 181, 193], ["selamectin", "CHEMICAL", 210, 220], ["SEL", "CHEMICAL", 222, 225], ["abamectin", "CHEMICAL", 228, 237], ["ABM", "CHEMICAL", 239, 242], ["ivermectin", "CHEMICAL", 245, 255], ["IVM", "CHEMICAL", 257, 260], ["moxidectin", "CHEMICAL", 266, 276], ["MOX", "CHEMICAL", 278, 281], ["ivermectin", "CHEMICAL", 30, 40], ["Anti-Alcohol", "CHEMICAL", 96, 108], ["selamectin", "CHEMICAL", 210, 220], ["abamectin", "CHEMICAL", 228, 237], ["ivermectin", "CHEMICAL", 245, 255], ["IVM", "CHEMICAL", 257, 260], ["moxidectin", "CHEMICAL", 266, 276], ["MOX", "CHEMICAL", 278, 281], ["ivermectin", "SIMPLE_CHEMICAL", 30, 40], ["Anti-Alcohol", "SIMPLE_CHEMICAL", 96, 108], ["AVM", "CANCER", 142, 145], ["anti-alcohol", "SIMPLE_CHEMICAL", 181, 193], ["selamectin", "SIMPLE_CHEMICAL", 210, 220], ["SEL", "SIMPLE_CHEMICAL", 222, 225], ["abamectin", "SIMPLE_CHEMICAL", 228, 237], ["ABM", "SIMPLE_CHEMICAL", 239, 242], ["ivermectin", "SIMPLE_CHEMICAL", 245, 255], ["IVM", "SIMPLE_CHEMICAL", 257, 260], ["moxidectin", "SIMPLE_CHEMICAL", 266, 276], ["MOX", "SIMPLE_CHEMICAL", 278, 281], ["ivermectin", "TREATMENT", 30, 40], ["this receptor", "TREATMENT", 82, 95], ["Anti-Alcohol Therapies", "TREATMENT", 96, 118], ["AVM", "PROBLEM", 142, 145], ["anti-alcohol therapy", "TREATMENT", 181, 201], ["selamectin (SEL)", "TREATMENT", 210, 226], ["abamectin (ABM)", "TREATMENT", 228, 243], ["ivermectin (IVM)", "TREATMENT", 245, 261], ["moxidectin (MOX)", "TREATMENT", 266, 282], ["no proof", "UNCERTAINTY", 18, 26], ["AVM", "OBSERVATION", 142, 145]]], ["IVM modulates the action of ethanol on P2X4Rs in an in vivo study, which may be associated with a decrease in alcohol intake [124] .", [["ethanol", "CHEMICAL", 28, 35], ["alcohol", "CHEMICAL", 110, 117], ["IVM", "CHEMICAL", 0, 3], ["ethanol", "CHEMICAL", 28, 35], ["alcohol", "CHEMICAL", 110, 117], ["ethanol", "SIMPLE_CHEMICAL", 28, 35], ["P2X4Rs", "SIMPLE_CHEMICAL", 39, 45], ["alcohol", "SIMPLE_CHEMICAL", 110, 117], ["IVM", "TREATMENT", 0, 3], ["P2X4Rs", "TREATMENT", 39, 45], ["a decrease in alcohol intake", "PROBLEM", 96, 124], ["decrease", "OBSERVATION_MODIFIER", 98, 106]]], ["Also in both male and female mice of the C57BL/6J strain.", [["mice", "ORGANISM", 29, 33], ["C57BL/6J strain", "ORGANISM", 41, 56], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["C57BL/6J", "SPECIES", 41, 49], ["the C57BL/6J strain", "PROBLEM", 37, 56]]], ["IVM at a dose between 1.25-10 mg/kg reduces alcohol intake in various models mimicking different types of alcohol intake in human such as binge drinking, social drinking, and alcohol-induced behaviour [125, 126] .", [["IVM", "CHEMICAL", 0, 3], ["alcohol", "CHEMICAL", 44, 51], ["alcohol", "CHEMICAL", 106, 113], ["alcohol", "CHEMICAL", 175, 182], ["IVM", "CHEMICAL", 0, 3], ["alcohol", "CHEMICAL", 44, 51], ["alcohol", "CHEMICAL", 106, 113], ["alcohol", "CHEMICAL", 175, 182], ["alcohol", "SIMPLE_CHEMICAL", 44, 51], ["alcohol", "SIMPLE_CHEMICAL", 106, 113], ["human", "ORGANISM", 124, 129], ["alcohol", "SIMPLE_CHEMICAL", 175, 182], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 124, 129], ["IVM", "TREATMENT", 0, 3]]], ["IVM elicits its anti-alcohol effectively at 9 h post-administration, a time that us close to the half-life of IVM in the plasma [127] .", [["plasma", "ANATOMY", 121, 127], ["IVM", "CHEMICAL", 0, 3], ["IVM", "CHEMICAL", 0, 3], ["IVM", "CHEMICAL", 110, 113], ["anti-alcohol", "SIMPLE_CHEMICAL", 16, 28], ["plasma", "ORGANISM_SUBSTANCE", 121, 127], ["IVM", "TREATMENT", 0, 3]]], ["It also showed that the least effective dose of IVM (2.5 mg/kg) is in proximity to the level of IVM in the brain, which is 0.28 ng/h/mg tissue.", [["brain", "ANATOMY", 107, 112], ["tissue", "ANATOMY", 136, 142], ["IVM", "CHEMICAL", 48, 51], ["IVM", "CHEMICAL", 48, 51], ["IVM", "CHEMICAL", 96, 99], ["IVM", "SIMPLE_CHEMICAL", 48, 51], ["brain", "ORGAN", 107, 112], ["tissue", "TISSUE", 136, 142], ["IVM", "TREATMENT", 48, 51], ["least", "OBSERVATION_MODIFIER", 24, 29], ["effective", "OBSERVATION_MODIFIER", 30, 39], ["brain", "ANATOMY", 107, 112]]], ["This shows the decrease in alcohol intake can be linked to the administration of IVM.", [["alcohol", "CHEMICAL", 27, 34], ["alcohol", "CHEMICAL", 27, 34], ["IVM", "CHEMICAL", 81, 84], ["alcohol", "SIMPLE_CHEMICAL", 27, 34], ["IVM", "TREATMENT", 81, 84], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["alcohol intake", "OBSERVATION", 27, 41]]], ["IVM does not have any significant effect on water and food intake as well as weight change and general physiology of the mice.", [["IVM", "CHEMICAL", 0, 3], ["water", "SIMPLE_CHEMICAL", 44, 49], ["food", "ORGANISM_SUBDIVISION", 54, 58], ["mice", "ORGANISM", 121, 125], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 121, 125], ["IVM", "TREATMENT", 0, 3], ["weight change", "PROBLEM", 77, 90], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["effect", "OBSERVATION", 34, 40]]], ["Using a self-operant chamber technique designed by Yardley et al. [127] , IVM also caused a reduction in preference for alcohol bottle and appetite for alcohol consumption.", [["alcohol", "CHEMICAL", 120, 127], ["alcohol", "CHEMICAL", 152, 159], ["IVM", "CHEMICAL", 74, 77], ["alcohol", "CHEMICAL", 120, 127], ["alcohol", "CHEMICAL", 152, 159], ["alcohol", "SIMPLE_CHEMICAL", 152, 159], ["a self-operant chamber technique", "TREATMENT", 6, 38], ["IVM", "TREATMENT", 74, 77]]], ["This same observation was reflected in another experiment using both male and female rats of HAD-1 and HAD-2 strains [128] .", [["rats", "ORGANISM", 85, 89], ["HAD-1", "ORGANISM", 93, 98], ["HAD-2 strains", "ORGANISM", 103, 116], ["rats", "SPECIES", 85, 89]]], ["Proving that IVM can be effective as an anti-alcohol therapy in different animal models of alcohol intake.", [["IVM", "CHEMICAL", 13, 16], ["alcohol", "CHEMICAL", 91, 98], ["IVM", "CHEMICAL", 13, 16], ["alcohol", "CHEMICAL", 91, 98], ["anti-alcohol", "SIMPLE_CHEMICAL", 40, 52], ["alcohol", "SIMPLE_CHEMICAL", 91, 98], ["an anti-alcohol therapy", "TREATMENT", 37, 60]]], ["Another model representing the long-term exposure of IVM to alcohol intake was conducted by [127, 129] .", [["alcohol", "CHEMICAL", 60, 67], ["IVM", "CHEMICAL", 53, 56], ["alcohol", "CHEMICAL", 60, 67], ["alcohol", "SIMPLE_CHEMICAL", 60, 67], ["long-term", "OBSERVATION_MODIFIER", 31, 40]]], ["IVM was administered intraperitoneally to female C57BL/6J mice strain at a dose of 2.5 mg/kg for seven consecutive days and resulted in a substantial decrease in alcohol intake as well as the option to drink alcohol bottle or another bottle, the mice preference reduced with respect to alcohol bottle [127] .", [["IVM", "CHEMICAL", 0, 3], ["alcohol", "CHEMICAL", 162, 169], ["alcohol", "CHEMICAL", 208, 215], ["alcohol", "CHEMICAL", 286, 293], ["IVM", "CHEMICAL", 0, 3], ["alcohol", "CHEMICAL", 162, 169], ["alcohol", "CHEMICAL", 208, 215], ["alcohol", "CHEMICAL", 286, 293], ["C57BL/6J mice", "ORGANISM", 49, 62], ["alcohol", "SIMPLE_CHEMICAL", 162, 169], ["alcohol", "SIMPLE_CHEMICAL", 208, 215], ["mice", "ORGANISM", 246, 250], ["alcohol", "SIMPLE_CHEMICAL", 286, 293], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 246, 250], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 246, 250], ["IVM", "TREATMENT", 0, 3], ["substantial", "OBSERVATION_MODIFIER", 138, 149], ["decrease", "OBSERVATION_MODIFIER", 150, 158], ["alcohol intake", "OBSERVATION", 162, 176]]], ["Yardley et al. [129] using the same female mice strain as Yardley et al. [127] , also administered IVM at 3 mg/kg for 10 consecutive days and also reported a reduction in alcohol intake without affecting fluid intake or body weight.", [["fluid", "ANATOMY", 204, 209], ["body", "ANATOMY", 220, 224], ["IVM", "CHEMICAL", 99, 102], ["alcohol", "CHEMICAL", 171, 178], ["IVM", "CHEMICAL", 99, 102], ["alcohol", "CHEMICAL", 171, 178], ["mice", "ORGANISM", 43, 47], ["alcohol", "SIMPLE_CHEMICAL", 171, 178], ["fluid", "ORGANISM_SUBSTANCE", 204, 209], ["body", "ORGANISM_SUBDIVISION", 220, 224], ["mice", "SPECIES", 43, 47], ["IVM", "TREATMENT", 99, 102], ["body weight", "TEST", 220, 231], ["reduction", "OBSERVATION_MODIFIER", 158, 167]]], ["The various models used a dose extrapolated from the approved pharmacology dose for humans.", [["humans", "ORGANISM", 84, 90], ["humans", "SPECIES", 84, 90], ["humans", "SPECIES", 84, 90]]], ["Another experiment to see whether modifying the route of administration of IVM would still produce the same anti-alcohol effect of IVM was conducted by [126] .", [["IVM", "CHEMICAL", 75, 78], ["IVM", "CHEMICAL", 131, 134], ["IVM", "CHEMICAL", 75, 78], ["IVM", "CHEMICAL", 131, 134], ["IVM", "TREATMENT", 75, 78], ["IVM", "TREATMENT", 131, 134]]], ["The oral administration of IVM for 30 days also shows similar findings with i.p administration.", [["oral", "ANATOMY", 4, 8], ["IVM", "CHEMICAL", 27, 30], ["IVM", "CHEMICAL", 27, 30], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["IVM", "TREATMENT", 27, 30], ["i.p administration", "TREATMENT", 76, 94]]], ["They also show that IVM did not cause any histological changes in the kidney, liver, and brain tissues of the animals.", [["kidney", "ANATOMY", 70, 76], ["liver", "ANATOMY", 78, 83], ["brain tissues", "ANATOMY", 89, 102], ["IVM", "CHEMICAL", 20, 23], ["kidney", "ORGAN", 70, 76], ["liver", "ORGAN", 78, 83], ["brain tissues", "TISSUE", 89, 102], ["any histological changes in the kidney, liver, and brain tissues of the animals", "PROBLEM", 38, 117], ["histological", "OBSERVATION", 42, 54], ["kidney", "ANATOMY", 70, 76], ["liver", "ANATOMY", 78, 83], ["brain tissues", "ANATOMY", 89, 102]]], ["Neurobehavioral effect of IVM has also shown that the drug does not have any neurological deficits, such as perceptual, cognitive, and emotional functions, however, mild anxiolytic activity was observed, which is likely linked to the GABA A Rs potentiation [130] .", [["neurological", "ANATOMY", 77, 89], ["IVM", "CHEMICAL", 26, 29], ["neurological deficits, such as perceptual, cognitive, and emotional functions", "DISEASE", 77, 154], ["GABA", "CHEMICAL", 234, 238], ["IVM", "CHEMICAL", 26, 29], ["GABA", "CHEMICAL", 234, 238], ["GABA A Rs", "GENE_OR_GENE_PRODUCT", 234, 243], ["IVM", "TREATMENT", 26, 29], ["any neurological deficits", "PROBLEM", 73, 98], ["perceptual, cognitive, and emotional functions", "PROBLEM", 108, 154], ["mild anxiolytic activity", "PROBLEM", 165, 189], ["mild", "OBSERVATION_MODIFIER", 165, 169]]], ["A clinical study involving administration of 120 mg of IVM to humans did not induce any adverse reaction or toxicity [131] .", [["IVM", "CHEMICAL", 55, 58], ["toxicity", "DISEASE", 108, 116], ["IVM", "CHEMICAL", 55, 58], ["humans", "ORGANISM", 62, 68], ["humans", "SPECIES", 62, 68], ["humans", "SPECIES", 62, 68], ["A clinical study", "TEST", 0, 16], ["IVM", "TREATMENT", 55, 58], ["any adverse reaction", "PROBLEM", 84, 104], ["toxicity", "PROBLEM", 108, 116]]], ["In summary, IVM has shown a great potential to be used as an anti-alcohol drug with minimal adverse effects.", [["IVM", "CHEMICAL", 12, 15], ["IVM", "CHEMICAL", 12, 15], ["an anti-alcohol drug", "TREATMENT", 58, 78], ["minimal adverse effects", "PROBLEM", 84, 107]]], ["To study the mechanism by which IVM can act as an anti-alcohol drug, Natsuaki et al. [111] conducted various in vitro and in vivo experiments.", [["IVM", "CHEMICAL", 32, 35], ["IVM", "CHEMICAL", 32, 35], ["IVM", "SIMPLE_CHEMICAL", 32, 35], ["anti-alcohol", "SIMPLE_CHEMICAL", 50, 62], ["an anti-alcohol drug", "TREATMENT", 47, 67]]], ["It has been discovered the rate of alcohol consumption significantly reduced in male P2X4R knock-out mice, hypothesizing that the anti-alcohol potential of IVM may be related to the potentiation of P2X4R.", [["alcohol", "CHEMICAL", 35, 42], ["IVM", "CHEMICAL", 156, 159], ["alcohol", "CHEMICAL", 35, 42], ["IVM", "CHEMICAL", 156, 159], ["alcohol", "SIMPLE_CHEMICAL", 35, 42], ["P2X4R", "GENE_OR_GENE_PRODUCT", 85, 90], ["mice", "ORGANISM", 101, 105], ["P2X4R", "GENE_OR_GENE_PRODUCT", 198, 203], ["P2X4R", "PROTEIN", 85, 90], ["P2X4R", "PROTEIN", 198, 203], ["mice", "SPECIES", 101, 105], ["IVM", "PROBLEM", 156, 159], ["P2X4R", "TREATMENT", 198, 203]]], ["Jin et al. [132] showed that ethanol addiction can be linked to its ability to inhibit pre-synaptic P2XRs in the synaptic terminals that releases GABA in the VTA, preventing the release of GABA into the DA neurons, which inadvertently lead to an increased firing of VTA and DA neurons, suggesting that the addictive effect of ethanol can be countered by DA system inhibition.", [["pre-synaptic P2XRs", "ANATOMY", 87, 105], ["synaptic terminals", "ANATOMY", 113, 131], ["VTA", "ANATOMY", 158, 161], ["DA neurons", "ANATOMY", 203, 213], ["DA neurons", "ANATOMY", 274, 284], ["ethanol", "CHEMICAL", 29, 36], ["GABA", "CHEMICAL", 146, 150], ["GABA", "CHEMICAL", 189, 193], ["DA", "CHEMICAL", 203, 205], ["DA", "CHEMICAL", 274, 276], ["ethanol", "CHEMICAL", 326, 333], ["DA", "CHEMICAL", 354, 356], ["ethanol", "CHEMICAL", 29, 36], ["GABA", "CHEMICAL", 146, 150], ["GABA", "CHEMICAL", 189, 193], ["ethanol", "CHEMICAL", 326, 333], ["ethanol", "SIMPLE_CHEMICAL", 29, 36], ["P2XRs", "GENE_OR_GENE_PRODUCT", 100, 105], ["synaptic terminals", "CELLULAR_COMPONENT", 113, 131], ["GABA", "SIMPLE_CHEMICAL", 146, 150], ["VTA", "SIMPLE_CHEMICAL", 158, 161], ["GABA", "SIMPLE_CHEMICAL", 189, 193], ["DA neurons", "CELL", 203, 213], ["VTA", "SIMPLE_CHEMICAL", 266, 269], ["DA neurons", "CELL", 274, 284], ["ethanol", "SIMPLE_CHEMICAL", 326, 333], ["DA", "SIMPLE_CHEMICAL", 354, 356], ["P2XRs", "PROTEIN", 100, 105], ["DA neurons", "CELL_TYPE", 203, 213], ["DA neurons", "CELL_TYPE", 274, 284], ["an increased firing of VTA and DA neurons", "PROBLEM", 243, 284], ["ethanol", "TREATMENT", 326, 333]]], ["Khoja et al. [133] also provided more evidence of a link between DA system and IVM.", [["DA", "CHEMICAL", 65, 67], ["IVM", "CHEMICAL", 79, 82], ["DA", "SIMPLE_CHEMICAL", 65, 67], ["DA system", "TREATMENT", 65, 74], ["IVM", "TREATMENT", 79, 82]]], ["Their findings showed that IVM can play a role in the phosphorylation of cAMP response element binding protein (CREB) and DARP-32 (a 32 KDa phosphoprotein) as well as dopamine in the ventral striatum though P2X4R potentiation.", [["ventral striatum", "ANATOMY", 183, 199], ["IVM", "CHEMICAL", 27, 30], ["cAMP", "CHEMICAL", 73, 77], ["dopamine", "CHEMICAL", 167, 175], ["IVM", "CHEMICAL", 27, 30], ["cAMP", "CHEMICAL", 73, 77], ["dopamine", "CHEMICAL", 167, 175], ["IVM", "SIMPLE_CHEMICAL", 27, 30], ["cAMP response element binding protein", "GENE_OR_GENE_PRODUCT", 73, 110], ["CREB", "GENE_OR_GENE_PRODUCT", 112, 116], ["DARP-32", "GENE_OR_GENE_PRODUCT", 122, 129], ["dopamine", "SIMPLE_CHEMICAL", 167, 175], ["ventral striatum", "MULTI-TISSUE_STRUCTURE", 183, 199], ["P2X4R", "GENE_OR_GENE_PRODUCT", 207, 212], ["cAMP response element binding protein", "PROTEIN", 73, 110], ["CREB", "PROTEIN", 112, 116], ["DARP-32", "PROTEIN", 122, 129], ["32 KDa phosphoprotein", "PROTEIN", 133, 154], ["P2X4R", "PROTEIN", 207, 212], ["cAMP response element binding protein", "TEST", 73, 110], ["CREB", "TEST", 112, 116], ["DARP", "TEST", 122, 126], ["a 32 KDa phosphoprotein", "TREATMENT", 131, 154], ["dopamine", "TREATMENT", 167, 175], ["P2X4R potentiation", "PROBLEM", 207, 225], ["ventral striatum", "ANATOMY", 183, 199]]], ["Based on a previous study by [134, 135] that reported a link between coordination of ethanol-linked behavior and phosphorylation of CREB and DARPP-32, Khoja et al. [133] concluded that the mechanism by which IVM acts as an anti-alcohol effect of IVM might be by controlling steps linked to dopamine signaling in the brain area involved in drug reward circuitry.", [["brain area", "ANATOMY", 316, 326], ["ethanol", "CHEMICAL", 85, 92], ["IVM", "CHEMICAL", 246, 249], ["dopamine", "CHEMICAL", 290, 298], ["ethanol", "CHEMICAL", 85, 92], ["IVM", "CHEMICAL", 208, 211], ["IVM", "CHEMICAL", 246, 249], ["dopamine", "CHEMICAL", 290, 298], ["ethanol", "SIMPLE_CHEMICAL", 85, 92], ["CREB", "GENE_OR_GENE_PRODUCT", 132, 136], ["DARPP-32", "GENE_OR_GENE_PRODUCT", 141, 149], ["dopamine", "SIMPLE_CHEMICAL", 290, 298], ["brain area", "MULTI-TISSUE_STRUCTURE", 316, 326], ["CREB", "PROTEIN", 132, 136], ["DARPP", "PROTEIN", 141, 146], ["a previous study", "TEST", 9, 25], ["phosphorylation of CREB", "TREATMENT", 113, 136], ["DARPP", "TEST", 141, 146], ["an anti-alcohol effect of IVM", "TREATMENT", 220, 249], ["brain", "ANATOMY", 316, 321]]], ["Abamectin, another type of AVM, shares similar structure with IVM, the difference being the presence of a double bond between the carbon atom at positions 22 and 23 of the spiroketal unit.", [["Abamectin", "CHEMICAL", 0, 9], ["AVM", "DISEASE", 27, 30], ["IVM", "CHEMICAL", 62, 65], ["Abamectin", "CHEMICAL", 0, 9], ["IVM", "CHEMICAL", 62, 65], ["carbon", "CHEMICAL", 130, 136], ["spiroketal", "CHEMICAL", 172, 182], ["Abamectin", "SIMPLE_CHEMICAL", 0, 9], ["carbon atom", "SIMPLE_CHEMICAL", 130, 141], ["Abamectin", "TREATMENT", 0, 9], ["AVM", "PROBLEM", 27, 30], ["a double bond between the carbon atom", "TREATMENT", 104, 141], ["AVM", "OBSERVATION", 27, 30], ["carbon atom", "OBSERVATION", 130, 141]]], ["Asatryan et al. [125] showed that ABM had similar effect on Xenopus oocytes as observed with IVM.", [["Xenopus oocytes", "ANATOMY", 60, 75], ["ABM", "CHEMICAL", 34, 37], ["IVM", "CHEMICAL", 93, 96], ["ABM", "SIMPLE_CHEMICAL", 34, 37], ["Xenopus", "ORGANISM", 60, 67], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 68, 75], ["ABM", "PROBLEM", 34, 37], ["Xenopus oocytes", "TREATMENT", 60, 75], ["IVM", "TREATMENT", 93, 96], ["Xenopus oocytes", "OBSERVATION", 60, 75]]], ["They also find out that ABM enhanced P2X4R potentiation more than IVM at higher concentrations and acting as a direct agonist in P2X4R potentiation in comparison with IVM, as it enhances P2X4R activity in the absence of ATP.", [["ATP", "CHEMICAL", 220, 223], ["IVM", "CHEMICAL", 66, 69], ["IVM", "CHEMICAL", 167, 170], ["ATP", "CHEMICAL", 220, 223], ["ABM", "SIMPLE_CHEMICAL", 24, 27], ["P2X4R", "GENE_OR_GENE_PRODUCT", 37, 42], ["P2X4R", "SIMPLE_CHEMICAL", 129, 134], ["P2X4R", "GENE_OR_GENE_PRODUCT", 187, 192], ["ATP", "SIMPLE_CHEMICAL", 220, 223], ["P2X4R", "PROTEIN", 37, 42], ["P2X4R", "PROTEIN", 129, 134], ["P2X4R", "PROTEIN", 187, 192], ["ABM enhanced P2X4R potentiation", "PROBLEM", 24, 55], ["a direct agonist in P2X4R potentiation", "TREATMENT", 109, 147], ["IVM", "TREATMENT", 167, 170], ["ATP", "PROBLEM", 220, 223]]], ["There was no difference in the potentiation of GABAARs-mediated current between ABM and IVM, however, the potency reduced with increased concentration when compared to IVM.", [["IVM", "CHEMICAL", 88, 91], ["IVM", "CHEMICAL", 168, 171], ["GABAARs", "SIMPLE_CHEMICAL", 47, 54], ["GABAARs", "PROTEIN", 47, 54], ["the potentiation of GABAARs", "PROBLEM", 27, 54], ["ABM", "TREATMENT", 80, 83], ["IVM", "TREATMENT", 88, 91], ["increased concentration", "PROBLEM", 127, 150], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["Their results also showed that ABM reverses the inhibition of ATP-activated current by ethanol, decreased ethanol intake and enhanced water intake.", [["ABM", "CHEMICAL", 31, 34], ["ATP", "CHEMICAL", 62, 65], ["ethanol", "CHEMICAL", 87, 94], ["ethanol", "CHEMICAL", 106, 113], ["ATP", "CHEMICAL", 62, 65], ["ethanol", "CHEMICAL", 87, 94], ["ethanol", "CHEMICAL", 106, 113], ["ABM", "SIMPLE_CHEMICAL", 31, 34], ["ATP", "SIMPLE_CHEMICAL", 62, 65], ["ethanol", "SIMPLE_CHEMICAL", 87, 94], ["ethanol", "SIMPLE_CHEMICAL", 106, 113], ["water", "SIMPLE_CHEMICAL", 134, 139], ["ABM", "PROBLEM", 31, 34], ["ATP", "PROBLEM", 62, 65]]], ["The variance between the anti-alcohol effects of ABM and IVM was not well explained, suggesting more research on their mechanism.", [["IVM", "CHEMICAL", 57, 60], ["ABM", "PROBLEM", 49, 52], ["IVM", "TREATMENT", 57, 60]]], ["SEL, another type of AVM showed low ow P2X4R potency and reversed ethanol inhibitory activity compared to IVM and ABM.", [["AVM", "ANATOMY", 21, 24], ["SEL", "DISEASE", 0, 3], ["AVM", "DISEASE", 21, 24], ["ethanol", "CHEMICAL", 66, 73], ["ethanol", "CHEMICAL", 66, 73], ["IVM", "CHEMICAL", 106, 109], ["AVM", "CANCER", 21, 24], ["P2X4R", "GENE_OR_GENE_PRODUCT", 39, 44], ["ethanol", "SIMPLE_CHEMICAL", 66, 73], ["P2X4R", "PROTEIN", 39, 44], ["AVM", "PROBLEM", 21, 24], ["low ow P2X4R potency", "PROBLEM", 32, 52], ["ABM", "PROBLEM", 114, 117], ["AVM", "OBSERVATION", 21, 24], ["low ow", "OBSERVATION_MODIFIER", 32, 38]]], ["Lespine et al. [136] reported that the poor activity of SEL can be linked to its structural variation.", [["SEL", "DISEASE", 56, 59], ["SEL", "GENE_OR_GENE_PRODUCT", 56, 59], ["SEL", "PROTEIN", 56, 59]]], ["SEL contains only one saccharide group, which is believed to limit its affinity for p-glycoprotein [136] .", [["SEL", "CHEMICAL", 0, 3], ["saccharide", "CHEMICAL", 22, 32], ["one saccharide group", "OBSERVATION_MODIFIER", 18, 38]]], ["Apart from this, other differences between SEL and IVM includes, replacing the isobutyl and alicyclic hydroxyl groups in IVM with a cyclohexyl ring and an unsaturated ketoxime group in SEL respectively.", [["SEL", "DISEASE", 43, 46], ["isobutyl", "CHEMICAL", 79, 87], ["hydroxyl", "CHEMICAL", 102, 110], ["cyclohexyl", "CHEMICAL", 132, 142], ["ketoxime", "CHEMICAL", 167, 175], ["IVM", "CHEMICAL", 51, 54], ["isobutyl", "CHEMICAL", 79, 87], ["alicyclic hydroxyl", "CHEMICAL", 92, 110], ["IVM", "CHEMICAL", 121, 124], ["cyclohexyl", "CHEMICAL", 132, 142], ["unsaturated ketoxime", "CHEMICAL", 155, 175], ["isobutyl", "SIMPLE_CHEMICAL", 79, 87], ["alicyclic hydroxyl", "SIMPLE_CHEMICAL", 92, 110], ["IVM", "SIMPLE_CHEMICAL", 121, 124], ["cyclohexyl ring", "SIMPLE_CHEMICAL", 132, 147], ["ketoxime", "SIMPLE_CHEMICAL", 167, 175], ["the isobutyl and alicyclic hydroxyl groups", "TREATMENT", 75, 117], ["a cyclohexyl ring", "TREATMENT", 130, 147], ["an unsaturated ketoxime group", "TREATMENT", 152, 181]]], ["Asatryan et al. [125] reported that very high amount of SEL (10 \u00b5M) was required to potentiate P2X4R as compared to IVM (0.5 \u00b5M), a weaker action on GABAARs as compared to IVM and ABM, leading to its inability to antagonized the inhibitory effect of ethanol on P2X4Rs.", [["SEL", "CHEMICAL", 56, 59], ["IVM", "CHEMICAL", 116, 119], ["ethanol", "CHEMICAL", 250, 257], ["IVM", "CHEMICAL", 116, 119], ["IVM", "CHEMICAL", 172, 175], ["ethanol", "CHEMICAL", 250, 257], ["P2X4R", "GENE_OR_GENE_PRODUCT", 95, 100], ["GABAARs", "GENE_OR_GENE_PRODUCT", 149, 156], ["ethanol", "SIMPLE_CHEMICAL", 250, 257], ["P2X4Rs", "GENE_OR_GENE_PRODUCT", 261, 267], ["P2X4R", "PROTEIN", 95, 100], ["GABAARs", "PROTEIN", 149, 156], ["P2X4Rs", "PROTEIN", 261, 267], ["IVM", "TEST", 116, 119], ["a weaker action on GABAARs", "PROBLEM", 130, 156], ["ABM", "PROBLEM", 180, 183], ["ethanol on P2X4Rs", "TREATMENT", 250, 267]]], ["They also reported the inability of SEL to affect appetite or preference for ethanol intake.", [["ethanol", "CHEMICAL", 77, 84], ["ethanol", "CHEMICAL", 77, 84], ["ethanol", "SIMPLE_CHEMICAL", 77, 84]]], ["MOX is a type of AVM that is structurally different from IVM [137] .", [["AVM", "ANATOMY", 17, 20], ["MOX", "CHEMICAL", 0, 3], ["AVM", "DISEASE", 17, 20], ["IVM", "CHEMICAL", 57, 60], ["MOX", "SIMPLE_CHEMICAL", 0, 3], ["AVM", "CANCER", 17, 20], ["AVM", "PROBLEM", 17, 20], ["AVM", "OBSERVATION", 17, 20]]], ["The isopropyl group in IVM is substituted by dimethyl butyl group and MOX contains a methoxime group from which its name was derived.", [["isopropyl", "CHEMICAL", 4, 13], ["IVM", "CHEMICAL", 23, 26], ["dimethyl butyl", "CHEMICAL", 45, 59], ["MOX", "CHEMICAL", 70, 73], ["methoxime", "CHEMICAL", 85, 94], ["isopropyl", "CHEMICAL", 4, 13], ["IVM", "CHEMICAL", 23, 26], ["dimethyl butyl", "CHEMICAL", 45, 59], ["MOX", "CHEMICAL", 70, 73], ["methoxime", "CHEMICAL", 85, 94], ["isopropyl", "SIMPLE_CHEMICAL", 4, 13], ["IVM", "SIMPLE_CHEMICAL", 23, 26], ["dimethyl butyl", "SIMPLE_CHEMICAL", 45, 59], ["MOX", "SIMPLE_CHEMICAL", 70, 73], ["methoxime", "SIMPLE_CHEMICAL", 85, 94], ["The isopropyl group in IVM", "TREATMENT", 0, 26], ["a methoxime group", "TREATMENT", 83, 100]]], ["These features are believed to enhance its lipophilicity and might increase its ability to cross the blood brain barrier (BBB).", [["blood brain barrier", "ANATOMY", 101, 120], ["BBB", "ANATOMY", 122, 125], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 101, 120], ["BBB", "MULTI-TISSUE_STRUCTURE", 122, 125]]], ["Another difference between MOX and IVM is that P-gp has low affinity for MOX, which means that MOX does not allow P-gp to be extracted from the brain.", [["brain", "ANATOMY", 144, 149], ["MOX", "CHEMICAL", 27, 30], ["MOX", "CHEMICAL", 73, 76], ["MOX", "CHEMICAL", 95, 98], ["MOX", "CHEMICAL", 27, 30], ["IVM", "CHEMICAL", 35, 38], ["MOX", "CHEMICAL", 73, 76], ["MOX", "CHEMICAL", 95, 98], ["MOX", "SIMPLE_CHEMICAL", 27, 30], ["P-gp", "GENE_OR_GENE_PRODUCT", 47, 51], ["MOX", "SIMPLE_CHEMICAL", 73, 76], ["MOX", "SIMPLE_CHEMICAL", 95, 98], ["P-gp", "GENE_OR_GENE_PRODUCT", 114, 118], ["brain", "ORGAN", 144, 149], ["P-gp", "PROTEIN", 47, 51], ["P-gp", "PROTEIN", 114, 118], ["brain", "ANATOMY", 144, 149]]], ["In addition, it also does not have a significant effect on GABAARs [138, 139] .", [["GABAARs", "PROTEIN", 59, 66], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["effect", "OBSERVATION", 49, 55]]], ["The advantage of these differences is that it reduces the potential toxicity as a result of accumulation from long-term usage in brain deficient in P-gp and effect that IVM has on the brain and interaction of MOX with other drugs that stimulate GABAARs which might lead to depression and coma.", [["brain", "ANATOMY", 129, 134], ["brain", "ANATOMY", 184, 189], ["toxicity", "DISEASE", 68, 76], ["IVM", "CHEMICAL", 169, 172], ["MOX", "CHEMICAL", 209, 212], ["depression", "DISEASE", 273, 283], ["coma", "DISEASE", 288, 292], ["IVM", "CHEMICAL", 169, 172], ["MOX", "CHEMICAL", 209, 212], ["brain", "ORGAN", 129, 134], ["brain", "ORGAN", 184, 189], ["MOX", "SIMPLE_CHEMICAL", 209, 212], ["GABAARs", "GENE_OR_GENE_PRODUCT", 245, 252], ["P-gp", "PROTEIN", 148, 152], ["GABAARs", "PROTEIN", 245, 252], ["the potential toxicity", "PROBLEM", 54, 76], ["accumulation", "PROBLEM", 92, 104], ["long-term usage in brain deficient", "PROBLEM", 110, 144], ["IVM", "PROBLEM", 169, 172], ["other drugs", "TREATMENT", 218, 229], ["depression", "PROBLEM", 273, 283], ["coma", "PROBLEM", 288, 292], ["long-term usage", "OBSERVATION_MODIFIER", 110, 125], ["brain", "ANATOMY", 129, 134], ["deficient", "OBSERVATION", 135, 144], ["brain", "ANATOMY", 184, 189]]], ["Result also showed that MOX at varying concentration induces currents in Xenopus oocytes via the potentiation of P2X4Rs significantly and reverse the inhibitory effect of ethanol at low concentration but had no effect at high concentrations [139] .", [["Xenopus oocytes", "ANATOMY", 73, 88], ["MOX", "CHEMICAL", 24, 27], ["ethanol", "CHEMICAL", 171, 178], ["MOX", "CHEMICAL", 24, 27], ["ethanol", "CHEMICAL", 171, 178], ["MOX", "SIMPLE_CHEMICAL", 24, 27], ["Xenopus", "ORGANISM", 73, 80], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 81, 88], ["P2X4Rs", "GENE_OR_GENE_PRODUCT", 113, 119], ["ethanol", "SIMPLE_CHEMICAL", 171, 178], ["P2X4Rs", "PROTEIN", 113, 119], ["MOX at varying concentration", "PROBLEM", 24, 52], ["Xenopus oocytes", "TREATMENT", 73, 88], ["the potentiation of P2X4Rs", "TREATMENT", 93, 119], ["ethanol at low concentration", "TREATMENT", 171, 199], ["Xenopus oocytes", "OBSERVATION", 73, 88]]], ["In vivo study also showed that MOX reduced the desire for ethanol consumption in C57BL/6J mice of both sexes in different models of alcohol intake [139] .", [["MOX", "CHEMICAL", 31, 34], ["ethanol", "CHEMICAL", 58, 65], ["alcohol", "CHEMICAL", 132, 139], ["MOX", "CHEMICAL", 31, 34], ["ethanol", "CHEMICAL", 58, 65], ["alcohol", "CHEMICAL", 132, 139], ["MOX", "SIMPLE_CHEMICAL", 31, 34], ["ethanol", "SIMPLE_CHEMICAL", 58, 65], ["C57BL/6J mice", "ORGANISM", 81, 94], ["alcohol", "SIMPLE_CHEMICAL", 132, 139], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["vivo study", "TEST", 3, 13], ["ethanol consumption", "TREATMENT", 58, 77]]], ["Comparing the various doses used for IVM, it has been shown that MOX was more efficient on reducing ethanol consumption as it takes 4 h for MOX to reduce ethanol intake, while IVM takes a longer period to exert similar effect.Antitumor Effect of AvermectinsDrinyaev et al. [140] were the first to confirm the antitumor activity of AVM.", [["antitumor", "ANATOMY", 309, 318], ["MOX", "CHEMICAL", 65, 68], ["ethanol", "CHEMICAL", 100, 107], ["MOX", "CHEMICAL", 140, 143], ["ethanol", "CHEMICAL", 154, 161], ["IVM", "CHEMICAL", 176, 179], ["AVM", "DISEASE", 331, 334], ["IVM", "CHEMICAL", 37, 40], ["MOX", "CHEMICAL", 65, 68], ["ethanol", "CHEMICAL", 100, 107], ["MOX", "CHEMICAL", 140, 143], ["ethanol", "CHEMICAL", 154, 161], ["IVM", "CHEMICAL", 176, 179], ["MOX", "SIMPLE_CHEMICAL", 65, 68], ["ethanol", "SIMPLE_CHEMICAL", 100, 107], ["MOX", "SIMPLE_CHEMICAL", 140, 143], ["ethanol", "SIMPLE_CHEMICAL", 154, 161], ["Antitumor", "CANCER", 226, 235], ["antitumor", "CANCER", 309, 318], ["AVM", "CANCER", 331, 334], ["IVM", "TREATMENT", 37, 40], ["Avermectins", "TREATMENT", 246, 257], ["AVM", "PROBLEM", 331, 334], ["AVM", "OBSERVATION", 331, 334]]], ["They tested the combination effect of AVM C and AVM B on tumor growth using experimental mice.", [["tumor", "ANATOMY", 57, 62], ["AVM B", "CHEMICAL", 48, 53], ["tumor", "DISEASE", 57, 62], ["AVM B", "CHEMICAL", 48, 53], ["AVM C", "SIMPLE_CHEMICAL", 38, 43], ["AVM B", "CELL", 48, 53], ["tumor", "CANCER", 57, 62], ["mice", "ORGANISM", 89, 93], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["AVM C", "PROBLEM", 38, 43], ["AVM B on tumor growth", "PROBLEM", 48, 69], ["experimental mice", "TREATMENT", 76, 93], ["AVM", "OBSERVATION", 38, 41], ["AVM", "OBSERVATION", 48, 51]]], ["It inhibits the growth of 755, ascites Ehrlich and solid Ehrlich carcinoma and P388 lympholeukemia, and the highest inhibition of tumor growth (70-80%) observed when administered intraperitoneally.", [["ascites Ehrlich", "ANATOMY", 31, 46], ["solid Ehrlich carcinoma", "ANATOMY", 51, 74], ["P388 lympholeukemia", "ANATOMY", 79, 98], ["tumor", "ANATOMY", 130, 135], ["ascites Ehrlich and solid Ehrlich carcinoma", "DISEASE", 31, 74], ["tumor", "DISEASE", 130, 135], ["ascites Ehrlich", "CANCER", 31, 46], ["solid Ehrlich carcinoma", "CANCER", 51, 74], ["P388 lympholeukemia", "CANCER", 79, 98], ["tumor", "CANCER", 130, 135], ["ascites Ehrlich", "PROBLEM", 31, 46], ["solid Ehrlich carcinoma", "PROBLEM", 51, 74], ["P388 lympholeukemia", "PROBLEM", 79, 98], ["tumor growth", "PROBLEM", 130, 142], ["growth", "OBSERVATION_MODIFIER", 16, 22], ["ascites", "OBSERVATION", 31, 38], ["solid", "OBSERVATION_MODIFIER", 51, 56], ["Ehrlich carcinoma", "OBSERVATION", 57, 74], ["P388 lympholeukemia", "OBSERVATION", 79, 98], ["highest", "OBSERVATION_MODIFIER", 108, 115], ["inhibition", "OBSERVATION_MODIFIER", 116, 126], ["tumor", "OBSERVATION", 130, 135], ["growth", "OBSERVATION_MODIFIER", 136, 142]]], ["AVM have also been shown to improve some anticancer drugs (e.g., vincristine) as they synergistically increase the suppression of the growth of EC, P388 lympholeukemia, and melanoma B16 when administered after vincristine injection.", [["anticancer", "ANATOMY", 41, 51], ["EC", "ANATOMY", 144, 146], ["P388 lympholeukemia", "ANATOMY", 148, 167], ["melanoma B16", "ANATOMY", 173, 185], ["AVM", "DISEASE", 0, 3], ["vincristine", "CHEMICAL", 65, 76], ["melanoma", "DISEASE", 173, 181], ["vincristine", "CHEMICAL", 210, 221], ["vincristine", "CHEMICAL", 65, 76], ["vincristine", "CHEMICAL", 210, 221], ["anticancer", "CANCER", 41, 51], ["vincristine", "SIMPLE_CHEMICAL", 65, 76], ["EC", "CELL", 144, 146], ["P388 lympholeukemia", "CELL", 148, 167], ["melanoma B16", "CELL", 173, 185], ["vincristine", "SIMPLE_CHEMICAL", 210, 221], ["EC", "CELL_TYPE", 144, 146], ["melanoma B16", "CELL_LINE", 173, 185], ["AVM", "PROBLEM", 0, 3], ["some anticancer drugs", "TREATMENT", 36, 57], ["vincristine", "TREATMENT", 65, 76], ["P388 lympholeukemia", "PROBLEM", 148, 167], ["melanoma B16", "TREATMENT", 173, 185], ["vincristine injection", "TREATMENT", 210, 231]]], ["IVM has been identified as one of the avermectin group of drugs that has the potential to treat leukemia cells [43] .", [["leukemia cells", "ANATOMY", 96, 110], ["IVM", "CHEMICAL", 0, 3], ["leukemia", "DISEASE", 96, 104], ["IVM", "CHEMICAL", 0, 3], ["avermectin", "SIMPLE_CHEMICAL", 38, 48], ["leukemia cells", "CELL", 96, 110], ["leukemia cells", "CELL_TYPE", 96, 110], ["IVM", "TREATMENT", 0, 3], ["the avermectin group of drugs", "TREATMENT", 34, 63], ["leukemia cells", "PROBLEM", 96, 110], ["leukemia cells", "OBSERVATION", 96, 110]]], ["IVM was reported to be effective in cell death induction of myeloid leukemia at low concentration without affecting normal hematopoietic cells.", [["cell", "ANATOMY", 36, 40], ["myeloid leukemia", "ANATOMY", 60, 76], ["hematopoietic cells", "ANATOMY", 123, 142], ["IVM", "CHEMICAL", 0, 3], ["death", "DISEASE", 41, 46], ["myeloid leukemia", "DISEASE", 60, 76], ["IVM", "CHEMICAL", 0, 3], ["cell", "CELL", 36, 40], ["myeloid leukemia", "CANCER", 60, 76], ["hematopoietic cells", "CELL", 123, 142], ["normal hematopoietic cells", "CELL_TYPE", 116, 142], ["IVM", "TREATMENT", 0, 3], ["myeloid leukemia", "PROBLEM", 60, 76], ["effective", "OBSERVATION_MODIFIER", 23, 32], ["cell death", "OBSERVATION", 36, 46], ["myeloid leukemia", "OBSERVATION", 60, 76], ["normal hematopoietic cells", "OBSERVATION", 116, 142]]], ["In three independent experiments involving the induction of leukemia in mice, IVM slows the growth of tumor cells at a dosage that seems replicable in humans.", [["leukemia", "ANATOMY", 60, 68], ["tumor cells", "ANATOMY", 102, 113], ["leukemia", "DISEASE", 60, 68], ["IVM", "CHEMICAL", 78, 81], ["tumor", "DISEASE", 102, 107], ["IVM", "CHEMICAL", 78, 81], ["leukemia", "CANCER", 60, 68], ["mice", "ORGANISM", 72, 76], ["tumor cells", "CELL", 102, 113], ["humans", "ORGANISM", 151, 157], ["tumor cells", "CELL_TYPE", 102, 113], ["mice", "SPECIES", 72, 76], ["humans", "SPECIES", 151, 157], ["mice", "SPECIES", 72, 76], ["humans", "SPECIES", 151, 157], ["leukemia", "PROBLEM", 60, 68], ["IVM", "TREATMENT", 78, 81], ["tumor cells", "PROBLEM", 102, 113], ["leukemia", "OBSERVATION", 60, 68], ["growth", "OBSERVATION_MODIFIER", 92, 98], ["tumor cells", "OBSERVATION", 102, 113]]], ["This antitumor activity is believed to be linked to the established ability of IVM to increase chloride influx in parasite and nematodes, as IVM increased the concentration of chloride ion and cell polarization in leukemic cells.", [["antitumor", "ANATOMY", 5, 14], ["cell", "ANATOMY", 193, 197], ["leukemic cells", "ANATOMY", 214, 228], ["chloride", "CHEMICAL", 95, 103], ["IVM", "CHEMICAL", 141, 144], ["chloride", "CHEMICAL", 176, 184], ["IVM", "CHEMICAL", 79, 82], ["chloride", "CHEMICAL", 95, 103], ["IVM", "CHEMICAL", 141, 144], ["chloride", "CHEMICAL", 176, 184], ["antitumor", "CANCER", 5, 14], ["IVM", "SIMPLE_CHEMICAL", 79, 82], ["chloride", "SIMPLE_CHEMICAL", 95, 103], ["chloride", "SIMPLE_CHEMICAL", 176, 184], ["cell", "CELL", 193, 197], ["leukemic cells", "CELL", 214, 228], ["leukemic cells", "CELL_TYPE", 214, 228], ["IVM", "TREATMENT", 79, 82], ["chloride influx in parasite and nematodes", "PROBLEM", 95, 136], ["IVM", "TREATMENT", 141, 144], ["chloride ion and cell polarization in leukemic cells", "TREATMENT", 176, 228], ["cell polarization", "OBSERVATION", 193, 210], ["leukemic cells", "OBSERVATION", 214, 228]]], ["In addition, IVM increases reactive oxygen species (ROS) in leukemic cells, which may contribute to the cytotoxicity observed in leukemic cells [141] .", [["leukemic cells", "ANATOMY", 60, 74], ["leukemic cells", "ANATOMY", 129, 143], ["IVM", "CHEMICAL", 13, 16], ["oxygen", "CHEMICAL", 36, 42], ["ROS", "CHEMICAL", 52, 55], ["IVM", "CHEMICAL", 13, 16], ["oxygen", "CHEMICAL", 36, 42], ["IVM", "SIMPLE_CHEMICAL", 13, 16], ["reactive oxygen species", "SIMPLE_CHEMICAL", 27, 50], ["ROS", "SIMPLE_CHEMICAL", 52, 55], ["leukemic cells", "CELL", 60, 74], ["leukemic cells", "CELL", 129, 143], ["leukemic cells", "CELL_TYPE", 60, 74], ["leukemic cells", "CELL_TYPE", 129, 143], ["IVM", "PROBLEM", 13, 16], ["reactive oxygen species", "PROBLEM", 27, 50], ["leukemic cells", "PROBLEM", 60, 74], ["the cytotoxicity", "PROBLEM", 100, 116], ["leukemic cells", "PROBLEM", 129, 143], ["increases", "OBSERVATION_MODIFIER", 17, 26], ["reactive", "OBSERVATION_MODIFIER", 27, 35], ["oxygen species", "OBSERVATION", 36, 50], ["leukemic cells", "OBSERVATION", 60, 74], ["leukemic cells", "OBSERVATION", 129, 143]]], ["It was also reported that IVM enhances the antitumor effect of established drugs such as cytarabine and daunorubicin.", [["antitumor", "ANATOMY", 43, 52], ["IVM", "CHEMICAL", 26, 29], ["cytarabine", "CHEMICAL", 89, 99], ["daunorubicin", "CHEMICAL", 104, 116], ["IVM", "CHEMICAL", 26, 29], ["cytarabine", "CHEMICAL", 89, 99], ["daunorubicin", "CHEMICAL", 104, 116], ["IVM", "SIMPLE_CHEMICAL", 26, 29], ["antitumor", "CANCER", 43, 52], ["cytarabine", "SIMPLE_CHEMICAL", 89, 99], ["daunorubicin", "SIMPLE_CHEMICAL", 104, 116], ["established drugs", "TREATMENT", 63, 80], ["cytarabine", "TREATMENT", 89, 99], ["daunorubicin", "TREATMENT", 104, 116]]], ["A low concentration of IVM has been reported to alter the tumor growth through a constitutive mechanism involving direct activation of transcriptional activity of TCF, repressing the phosphorylation of \u03b2-catenin and cyclin D at the C-terminal [142] .", [["tumor", "ANATOMY", 58, 63], ["IVM", "CHEMICAL", 23, 26], ["tumor", "DISEASE", 58, 63], ["IVM", "CHEMICAL", 23, 26], ["IVM", "SIMPLE_CHEMICAL", 23, 26], ["tumor", "CANCER", 58, 63], ["TCF", "GENE_OR_GENE_PRODUCT", 163, 166], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 202, 211], ["cyclin D", "GENE_OR_GENE_PRODUCT", 216, 224], ["TCF", "PROTEIN", 163, 166], ["\u03b2-catenin", "PROTEIN", 202, 211], ["cyclin D", "PROTEIN", 216, 224], ["A low concentration of IVM", "TREATMENT", 0, 26], ["the tumor growth", "PROBLEM", 54, 70], ["a constitutive mechanism", "PROBLEM", 79, 103], ["transcriptional activity of TCF", "TREATMENT", 135, 166], ["the phosphorylation of \u03b2-catenin", "TREATMENT", 179, 211], ["cyclin D", "TREATMENT", 216, 224], ["low concentration", "OBSERVATION_MODIFIER", 2, 19], ["tumor", "OBSERVATION", 58, 63]]], ["IVM was also revealed to be active as an antitumor agent in human colon cancer xenograft and lung cancer in an in vivo experiment through inhibition of TCF and blocking of WNT-TCF pathway without any side effects [142] .", [["antitumor", "ANATOMY", 41, 50], ["colon cancer xenograft", "ANATOMY", 66, 88], ["lung cancer", "ANATOMY", 93, 104], ["IVM", "CHEMICAL", 0, 3], ["colon cancer", "DISEASE", 66, 78], ["lung cancer", "DISEASE", 93, 104], ["IVM", "CHEMICAL", 0, 3], ["antitumor", "CANCER", 41, 50], ["human", "ORGANISM", 60, 65], ["colon cancer xenograft", "CANCER", 66, 88], ["lung cancer", "CANCER", 93, 104], ["TCF", "GENE_OR_GENE_PRODUCT", 152, 155], ["WNT", "GENE_OR_GENE_PRODUCT", 172, 175], ["TCF", "GENE_OR_GENE_PRODUCT", 176, 179], ["TCF", "PROTEIN", 152, 155], ["WNT", "PROTEIN", 172, 175], ["TCF", "PROTEIN", 176, 179], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["IVM", "TREATMENT", 0, 3], ["an antitumor agent", "TREATMENT", 38, 56], ["human colon cancer xenograft", "PROBLEM", 60, 88], ["lung cancer", "PROBLEM", 93, 104], ["inhibition of TCF", "TREATMENT", 138, 155], ["blocking of WNT", "TREATMENT", 160, 175], ["TCF pathway", "TREATMENT", 176, 187], ["any side effects", "PROBLEM", 196, 212], ["active", "OBSERVATION_MODIFIER", 28, 34], ["colon", "ANATOMY", 66, 71], ["cancer xenograft", "OBSERVATION", 72, 88], ["lung", "ANATOMY", 93, 97], ["cancer", "OBSERVATION", 98, 104]]], ["There are reports that the mode of action of avermectin in tumor cells might be different from that of nematodes and parasites.", [["tumor cells", "ANATOMY", 59, 70], ["avermectin", "CHEMICAL", 45, 55], ["tumor", "DISEASE", 59, 64], ["avermectin", "CHEMICAL", 45, 55], ["avermectin", "SIMPLE_CHEMICAL", 45, 55], ["tumor cells", "CELL", 59, 70], ["tumor cells", "CELL_TYPE", 59, 70], ["avermectin in tumor cells", "TREATMENT", 45, 70], ["parasites", "PROBLEM", 117, 126], ["tumor cells", "OBSERVATION", 59, 70], ["nematodes", "OBSERVATION", 103, 112]]], ["As stated earlier, the antitumor activity of AVM drugs may be due to the transcription pathway of TCF, phosphorylation of cyclin D and \u03b2 catethin, whereas, in the parasite, it is through the chloride-gated ion channels.", [["antitumor", "ANATOMY", 23, 32], ["AVM", "DISEASE", 45, 48], ["chloride", "CHEMICAL", 191, 199], ["chloride", "CHEMICAL", 191, 199], ["antitumor", "CANCER", 23, 32], ["AVM drugs", "SIMPLE_CHEMICAL", 45, 54], ["TCF", "GENE_OR_GENE_PRODUCT", 98, 101], ["cyclin D", "GENE_OR_GENE_PRODUCT", 122, 130], ["\u03b2 catethin", "GENE_OR_GENE_PRODUCT", 135, 145], ["chloride", "SIMPLE_CHEMICAL", 191, 199], ["TCF", "PROTEIN", 98, 101], ["cyclin D", "PROTEIN", 122, 130], ["\u03b2 catethin", "PROTEIN", 135, 145], ["chloride-gated ion channels", "PROTEIN", 191, 218], ["AVM drugs", "TREATMENT", 45, 54], ["cyclin D and \u03b2 catethin", "TREATMENT", 122, 145], ["AVM", "OBSERVATION", 45, 48]]], ["Some AVM, such as moxidectin, have been reported to be ten times more active than IVM as nematocides, whereas this same moxidectin is less active or not active at all in human cancer cells.", [["AVM", "ANATOMY", 5, 8], ["cancer cells", "ANATOMY", 176, 188], ["AVM", "DISEASE", 5, 8], ["moxidectin", "CHEMICAL", 18, 28], ["moxidectin", "CHEMICAL", 120, 130], ["cancer", "DISEASE", 176, 182], ["moxidectin", "CHEMICAL", 18, 28], ["IVM", "CHEMICAL", 82, 85], ["nematocides", "CHEMICAL", 89, 100], ["moxidectin", "CHEMICAL", 120, 130], ["moxidectin", "SIMPLE_CHEMICAL", 18, 28], ["nematocides", "SIMPLE_CHEMICAL", 89, 100], ["moxidectin", "SIMPLE_CHEMICAL", 120, 130], ["human", "ORGANISM", 170, 175], ["cancer cells", "CELL", 176, 188], ["human cancer cells", "CELL_TYPE", 170, 188], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["Some AVM", "PROBLEM", 0, 8], ["moxidectin", "TREATMENT", 18, 28], ["AVM", "OBSERVATION", 5, 8], ["cancer cells", "OBSERVATION", 176, 188]]], ["A particular concentration to cause behavior is observed for each measurable effect of IVM.", [["IVM", "CHEMICAL", 87, 90], ["IVM", "TREATMENT", 87, 90]]], ["Cytotoxicity of tumor cells is achieved at a concentration above 10 \u00b5M or longer while for 48 h or longer if the concentration is above 5 \u00b5M.", [["tumor cells", "ANATOMY", 16, 27], ["tumor", "DISEASE", 16, 21], ["tumor cells", "CELL", 16, 27], ["tumor cells", "CELL_TYPE", 16, 27], ["Cytotoxicity of tumor cells", "PROBLEM", 0, 27], ["tumor cells", "OBSERVATION", 16, 27]]], ["For the inhibition of TCF transcription and cell death induction through apoptosis, the concentration is lower at different durations [43] .", [["cell", "ANATOMY", 44, 48], ["death", "DISEASE", 49, 54], ["TCF", "GENE_OR_GENE_PRODUCT", 22, 25], ["cell", "CELL", 44, 48], ["TCF", "PROTEIN", 22, 25], ["TCF transcription", "TREATMENT", 22, 39], ["cell death induction", "TREATMENT", 44, 64], ["apoptosis", "PROBLEM", 73, 82]]], ["With respect to a brain tumor, the use of IVM may require caution as the blood brain barrier features might have been lost, leading to the entry of IVM into the brain.", [["brain tumor", "ANATOMY", 18, 29], ["blood brain barrier", "ANATOMY", 73, 92], ["brain", "ANATOMY", 161, 166], ["brain tumor", "DISEASE", 18, 29], ["IVM", "CHEMICAL", 42, 45], ["IVM", "CHEMICAL", 148, 151], ["brain tumor", "CANCER", 18, 29], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 73, 92], ["brain", "ORGAN", 161, 166], ["a brain tumor", "PROBLEM", 16, 29], ["IVM", "TREATMENT", 42, 45], ["caution", "TREATMENT", 58, 65], ["the blood brain barrier features", "PROBLEM", 69, 101], ["IVM into the brain", "PROBLEM", 148, 166], ["brain", "ANATOMY", 18, 23], ["tumor", "OBSERVATION", 24, 29], ["brain", "ANATOMY", 161, 166]]], ["The brain contains the gated-chloride ion and GABA-channels that IVM binds to in nematodes, thus IVM might bind to them in the brain leading to brain injury and death in normal cells [143] .", [["brain", "ANATOMY", 4, 9], ["brain", "ANATOMY", 127, 132], ["brain", "ANATOMY", 144, 149], ["cells", "ANATOMY", 177, 182], ["GABA", "CHEMICAL", 46, 50], ["brain injury", "DISEASE", 144, 156], ["death", "DISEASE", 161, 166], ["chloride", "CHEMICAL", 29, 37], ["GABA", "CHEMICAL", 46, 50], ["IVM", "CHEMICAL", 65, 68], ["IVM", "CHEMICAL", 97, 100], ["brain", "ORGAN", 4, 9], ["GABA", "SIMPLE_CHEMICAL", 46, 50], ["IVM", "SIMPLE_CHEMICAL", 65, 68], ["brain", "ORGAN", 127, 132], ["brain", "ORGAN", 144, 149], ["cells", "CELL", 177, 182], ["normal cells", "CELL_TYPE", 170, 182], ["IVM binds", "PROBLEM", 65, 74], ["IVM", "TREATMENT", 97, 100], ["brain injury", "PROBLEM", 144, 156], ["death", "PROBLEM", 161, 166], ["brain", "ANATOMY", 4, 9], ["brain", "ANATOMY", 127, 132], ["brain", "ANATOMY", 144, 149], ["injury", "OBSERVATION", 150, 156], ["normal cells", "OBSERVATION", 170, 182]]], ["Melotti et al. [144] summarizes the mechanism of antitumor activity of AVM, such as ivermectin, selamectin, and other types as follows: detects the role of avermectin B1 in inhibiting the activation of WNT-TCF reporter activity by N-terminal mutant (APC-insensitive) \u03b2-CATENIN as detected in their screen; detects the ability of AVM B1, IVM, doramectin, MOX and SEL to parallel the modulation of WNT-TCF targets by dnTCF; the finding that the specific WNT-TCF response blockade by low doses of Ivermectin and Selamectin is reversed by constitutively active TCF; the repression of key C-terminal phospho-isoforms of \u03b2-CATENIN resulting in the repression of the TCF target and positive cell cycle regulator CYCLIN D1 by IVM and SEL; the specific inhibition of in vivo-TCF-dependent, but not in vivo-TCF-independent cancer cells by IVM in xenograft.", [["antitumor", "ANATOMY", 49, 58], ["cell", "ANATOMY", 684, 688], ["cancer cells", "ANATOMY", 813, 825], ["xenograft", "ANATOMY", 836, 845], ["AVM", "DISEASE", 71, 74], ["ivermectin", "CHEMICAL", 84, 94], ["selamectin", "CHEMICAL", 96, 106], ["avermectin B1", "CHEMICAL", 156, 169], ["doramectin", "CHEMICAL", 342, 352], ["MOX", "CHEMICAL", 354, 357], ["Ivermectin", "CHEMICAL", 494, 504], ["Selamectin", "CHEMICAL", 509, 519], ["cancer", "DISEASE", 813, 819], ["ivermectin", "CHEMICAL", 84, 94], ["selamectin", "CHEMICAL", 96, 106], ["avermectin B1", "CHEMICAL", 156, 169], ["N-", "CHEMICAL", 231, 233], ["AVM B1", "CHEMICAL", 329, 335], ["IVM", "CHEMICAL", 337, 340], ["doramectin", "CHEMICAL", 342, 352], ["MOX", "CHEMICAL", 354, 357], ["Ivermectin", "CHEMICAL", 494, 504], ["Selamectin", "CHEMICAL", 509, 519], ["C", "CHEMICAL", 584, 585], ["IVM", "CHEMICAL", 718, 721], ["IVM", "CHEMICAL", 829, 832], ["antitumor", "CANCER", 49, 58], ["AVM", "SIMPLE_CHEMICAL", 71, 74], ["ivermectin", "SIMPLE_CHEMICAL", 84, 94], ["selamectin", "SIMPLE_CHEMICAL", 96, 106], ["avermectin B1", "GENE_OR_GENE_PRODUCT", 156, 169], ["WNT", "GENE_OR_GENE_PRODUCT", 202, 205], ["TCF", "GENE_OR_GENE_PRODUCT", 206, 209], ["APC-insensitive) \u03b2-CATENIN", "GENE_OR_GENE_PRODUCT", 250, 276], ["AVM B1", "GENE_OR_GENE_PRODUCT", 329, 335], ["IVM", "SIMPLE_CHEMICAL", 337, 340], ["doramectin", "SIMPLE_CHEMICAL", 342, 352], ["MOX", "SIMPLE_CHEMICAL", 354, 357], ["SEL", "SIMPLE_CHEMICAL", 362, 365], ["WNT-TCF", "GENE_OR_GENE_PRODUCT", 396, 403], ["dnTCF", "GENE_OR_GENE_PRODUCT", 415, 420], ["WNT", "GENE_OR_GENE_PRODUCT", 452, 455], ["TCF", "GENE_OR_GENE_PRODUCT", 456, 459], ["Ivermectin", "SIMPLE_CHEMICAL", 494, 504], ["Selamectin", "SIMPLE_CHEMICAL", 509, 519], ["TCF", "GENE_OR_GENE_PRODUCT", 557, 560], ["\u03b2-CATENIN", "GENE_OR_GENE_PRODUCT", 615, 624], ["TCF", "GENE_OR_GENE_PRODUCT", 660, 663], ["cell", "CELL", 684, 688], ["CYCLIN D1", "GENE_OR_GENE_PRODUCT", 705, 714], ["TCF", "GENE_OR_GENE_PRODUCT", 766, 769], ["TCF", "GENE_OR_GENE_PRODUCT", 797, 800], ["cancer cells", "CELL", 813, 825], ["xenograft", "CANCER", 836, 845], ["avermectin B1", "PROTEIN", 156, 169], ["WNT", "PROTEIN", 202, 205], ["TCF", "PROTEIN", 206, 209], ["N-terminal mutant", "PROTEIN", 231, 248], ["APC-insensitive) \u03b2-CATENIN", "PROTEIN", 250, 276], ["WNT", "PROTEIN", 396, 399], ["TCF", "PROTEIN", 400, 403], ["dnTCF", "PROTEIN", 415, 420], ["WNT", "PROTEIN", 452, 455], ["TCF", "PROTEIN", 456, 459], ["TCF", "PROTEIN", 557, 560], ["C-terminal phospho-isoforms", "PROTEIN", 584, 611], ["\u03b2-CATENIN", "PROTEIN", 615, 624], ["TCF", "PROTEIN", 660, 663], ["positive cell cycle regulator", "PROTEIN", 675, 704], ["CYCLIN D1", "PROTEIN", 705, 714], ["TCF", "PROTEIN", 766, 769], ["TCF", "PROTEIN", 797, 800], ["cancer cells", "CELL_TYPE", 813, 825], ["AVM", "PROBLEM", 71, 74], ["ivermectin", "TREATMENT", 84, 94], ["avermectin B1", "TREATMENT", 156, 169], ["N-terminal mutant (APC-insensitive) \u03b2-CATENIN", "PROBLEM", 231, 276], ["AVM B1", "PROBLEM", 329, 335], ["doramectin", "TREATMENT", 342, 352], ["TCF targets", "TREATMENT", 400, 411], ["TCF response blockade", "TREATMENT", 456, 477], ["Ivermectin", "TREATMENT", 494, 504], ["Selamectin", "TREATMENT", 509, 519], ["constitutively active TCF", "PROBLEM", 535, 560], ["\u03b2-CATENIN", "TREATMENT", 615, 624], ["the TCF target", "PROBLEM", 656, 670], ["positive cell cycle regulator CYCLIN D1", "TREATMENT", 675, 714], ["independent cancer cells", "PROBLEM", 801, 825], ["IVM in xenograft", "TREATMENT", 829, 845], ["AVM", "OBSERVATION", 71, 74], ["cancer cells", "OBSERVATION", 813, 825]]], ["The study showed that the regulation of phosphorylation of \u03b2 catenin may be by a ser-552 or ser-675 on the catenin polypeptide chain.", [["ser", "CHEMICAL", 81, 84], ["ser", "CHEMICAL", 92, 95], ["\u03b2 catenin", "GENE_OR_GENE_PRODUCT", 59, 68], ["ser-675", "AMINO_ACID", 92, 99], ["catenin", "GENE_OR_GENE_PRODUCT", 107, 114], ["\u03b2 catenin", "PROTEIN", 59, 68], ["catenin polypeptide chain", "PROTEIN", 107, 132], ["The study", "TEST", 0, 9], ["phosphorylation of \u03b2 catenin", "TREATMENT", 40, 68]]], ["The PP2A/PP1 protein phosphatase-blocked situation may be used by IVM or selamectin to improve this step either directly or indirectly to dephosphorylate P-ser552 / P-ser675.", [["selamectin", "CHEMICAL", 73, 83], ["IVM", "CHEMICAL", 66, 69], ["selamectin", "CHEMICAL", 73, 83], ["PP2A", "GENE_OR_GENE_PRODUCT", 4, 8], ["PP1", "GENE_OR_GENE_PRODUCT", 9, 12], ["IVM", "SIMPLE_CHEMICAL", 66, 69], ["selamectin", "SIMPLE_CHEMICAL", 73, 83], ["P-ser675", "GENE_OR_GENE_PRODUCT", 165, 173], ["PP2A", "PROTEIN", 4, 8], ["PP1 protein phosphatase", "PROTEIN", 9, 32], ["P", "DNA", 154, 155], ["ser552", "PROTEIN", 156, 162], ["P", "DNA", 165, 166], ["ser675", "DNA", 167, 173], ["The PP2A/PP1 protein phosphatase", "TEST", 0, 32], ["blocked situation", "PROBLEM", 33, 50], ["selamectin", "TREATMENT", 73, 83], ["dephosphorylate P", "TEST", 138, 155]]], ["This can be further explained in the relationship between \u03b2-catenin and TCF factors as an important step in WNT signaling in human colon cancer cells [145] .", [["colon cancer cells", "ANATOMY", 131, 149], ["colon cancer", "DISEASE", 131, 143], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 58, 67], ["TCF factors", "GENE_OR_GENE_PRODUCT", 72, 83], ["WNT", "GENE_OR_GENE_PRODUCT", 108, 111], ["human", "ORGANISM", 125, 130], ["colon cancer cells [145]", "CELL", 131, 155], ["\u03b2-catenin", "PROTEIN", 58, 67], ["TCF factors", "PROTEIN", 72, 83], ["WNT", "PROTEIN", 108, 111], ["human colon cancer cells", "CELL_TYPE", 125, 149], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["\u03b2-catenin and TCF factors", "TREATMENT", 58, 83], ["human colon cancer cells", "PROBLEM", 125, 149], ["colon", "ANATOMY", 131, 136]]], ["The decrease in the concentration of phosphorylated \u03b2-catenin in colon cancer cells also requires the B\u03b1 (PR55\u03b1) subunit of PP2A [146] .", [["colon cancer cells", "ANATOMY", 65, 83], ["\u03b2-catenin", "CHEMICAL", 52, 61], ["colon cancer", "DISEASE", 65, 77], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 52, 61], ["colon cancer cells", "CELL", 65, 83], ["B\u03b1 (PR55\u03b1", "GENE_OR_GENE_PRODUCT", 102, 111], ["PP2A", "GENE_OR_GENE_PRODUCT", 124, 128], ["phosphorylated \u03b2-catenin", "PROTEIN", 37, 61], ["colon cancer cells", "CELL_TYPE", 65, 83], ["B\u03b1 (PR55\u03b1) subunit", "PROTEIN", 102, 120], ["PP2A", "PROTEIN", 124, 128], ["The decrease", "PROBLEM", 0, 12], ["phosphorylated \u03b2-catenin", "TREATMENT", 37, 61], ["colon cancer cells", "PROBLEM", 65, 83], ["the B\u03b1", "TEST", 98, 104], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["colon", "ANATOMY", 65, 70], ["cancer cells", "OBSERVATION", 71, 83]]], ["This shows the complex nature involved in the inhibition of \u03b2-catethin phosphorylation and a potential multiple targets of IVM as an anticancer agent in colon cancer [147] .", [["anticancer", "ANATOMY", 133, 143], ["colon cancer", "ANATOMY", 153, 165], ["IVM", "CHEMICAL", 123, 126], ["colon cancer", "DISEASE", 153, 165], ["\u03b2-catethin", "CHEMICAL", 60, 70], ["IVM", "CHEMICAL", 123, 126], ["\u03b2-catethin", "GENE_OR_GENE_PRODUCT", 60, 70], ["IVM", "SIMPLE_CHEMICAL", 123, 126], ["anticancer", "CANCER", 133, 143], ["colon cancer", "CANCER", 153, 165], ["\u03b2-catethin", "PROTEIN", 60, 70], ["\u03b2-catethin phosphorylation", "TREATMENT", 60, 86], ["IVM", "TREATMENT", 123, 126], ["an anticancer agent", "TREATMENT", 130, 149], ["colon cancer", "PROBLEM", 153, 165], ["complex", "OBSERVATION_MODIFIER", 15, 22], ["colon", "ANATOMY", 153, 158], ["cancer", "OBSERVATION", 159, 165]]], ["One of the important information from these findings is that the human colon cancer cell lines are TCF-dependent [148] .", [["colon cancer cell lines", "ANATOMY", 71, 94], ["colon cancer", "DISEASE", 71, 83], ["human", "ORGANISM", 65, 70], ["colon cancer cell lines", "CELL", 71, 94], ["TCF", "GENE_OR_GENE_PRODUCT", 99, 102], ["human colon cancer cell lines", "CELL_LINE", 65, 94], ["TCF", "PROTEIN", 99, 102], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["the human colon cancer", "PROBLEM", 61, 83], ["colon", "ANATOMY", 71, 76], ["cancer cell lines", "OBSERVATION", 77, 94]]], ["For cancer cells deficient in the APC destruction complex, it is predicted that the pathway involved in the IVM-induced enhancement of PP2A is silent.", [["cancer cells", "ANATOMY", 4, 16], ["cancer", "DISEASE", 4, 10], ["IVM", "CHEMICAL", 108, 111], ["IVM", "CHEMICAL", 108, 111], ["cancer cells", "CELL", 4, 16], ["APC", "GENE_OR_GENE_PRODUCT", 34, 37], ["PP2A", "GENE_OR_GENE_PRODUCT", 135, 139], ["cancer cells", "CELL_TYPE", 4, 16], ["APC destruction complex", "PROTEIN", 34, 57], ["PP2A", "PROTEIN", 135, 139], ["cancer cells deficient", "PROBLEM", 4, 26], ["the APC destruction complex", "PROBLEM", 30, 57], ["induced enhancement of PP2A", "PROBLEM", 112, 139], ["APC", "OBSERVATION_MODIFIER", 34, 37], ["destruction", "OBSERVATION", 38, 49], ["silent", "OBSERVATION_MODIFIER", 143, 149]]], ["IVM treatment is also reported to reduce some important markers of colon cancer cells, such as ASCL2 andLGR5 [149, 150] .", [["colon cancer cells", "ANATOMY", 67, 85], ["IVM", "CHEMICAL", 0, 3], ["colon cancer", "DISEASE", 67, 79], ["IVM", "CHEMICAL", 0, 3], ["colon cancer cells", "CELL", 67, 85], ["ASCL2", "GENE_OR_GENE_PRODUCT", 95, 100], ["LGR5", "GENE_OR_GENE_PRODUCT", 104, 108], ["colon cancer cells", "CELL_TYPE", 67, 85], ["ASCL2", "PROTEIN", 95, 100], ["IVM treatment", "TREATMENT", 0, 13], ["colon cancer cells", "PROBLEM", 67, 85], ["LGR5", "TEST", 104, 108], ["colon", "ANATOMY", 67, 72], ["cancer cells", "OBSERVATION", 73, 85]]], ["The dependent of cells on TCF also on the environment of the cell.", [["cells", "ANATOMY", 17, 22], ["cell", "ANATOMY", 61, 65], ["cells", "CELL", 17, 22], ["TCF", "GENE_OR_GENE_PRODUCT", 26, 29], ["cell", "CELL", 61, 65], ["TCF", "PROTEIN", 26, 29], ["The dependent of cells", "PROBLEM", 0, 22], ["TCF", "TREATMENT", 26, 29], ["dependent", "OBSERVATION_MODIFIER", 4, 13]]], ["For example, it was reported by [148] that Ls174T and primary CC1 4 cells are TCF-dependent in vitro, while in an in vivo condition, they turn to TCF-independent cells.", [["primary CC1 4 cells", "ANATOMY", 54, 73], ["cells", "ANATOMY", 162, 167], ["Ls174T", "SIMPLE_CHEMICAL", 43, 49], ["CC1 4 cells", "CELL", 62, 73], ["TCF", "GENE_OR_GENE_PRODUCT", 78, 81], ["TCF", "GENE_OR_GENE_PRODUCT", 146, 149], ["cells", "CELL", 162, 167], ["primary CC1 4 cells", "CELL_LINE", 54, 73], ["TCF", "PROTEIN", 78, 81], ["TCF", "PROTEIN", 146, 149]]], ["Although the mechanism involved is not yet understood, de Sousa et al. [151] reported the role of DNA methylation in the process involved in the switch over.", [["DNA", "CELLULAR_COMPONENT", 98, 101], ["DNA methylation", "TREATMENT", 98, 113]]], ["However, some colon cancer cells, such as DLD1 remain TCF-dependent either in vitro or in vivo [148] .", [["colon cancer cells", "ANATOMY", 14, 32], ["colon cancer", "DISEASE", 14, 26], ["colon cancer cells", "CELL", 14, 32], ["DLD1", "GENE_OR_GENE_PRODUCT", 42, 46], ["TCF", "GENE_OR_GENE_PRODUCT", 54, 57], ["colon cancer cells", "CELL_TYPE", 14, 32], ["DLD1", "PROTEIN", 42, 46], ["TCF", "PROTEIN", 54, 57], ["some colon cancer cells", "PROBLEM", 9, 32], ["colon", "ANATOMY", 14, 19], ["cancer cells", "OBSERVATION", 20, 32]]], ["This is one of the proofs of IVM safety as an anticancer drug, as it only targets TCF-sensitive cancerous cells in vivo and not normal cells at the administered dose.", [["anticancer", "ANATOMY", 46, 56], ["cancerous cells", "ANATOMY", 96, 111], ["cells", "ANATOMY", 135, 140], ["IVM", "CHEMICAL", 29, 32], ["anticancer", "CANCER", 46, 56], ["TCF", "GENE_OR_GENE_PRODUCT", 82, 85], ["cancerous cells", "CELL", 96, 111], ["cells", "CELL", 135, 140], ["TCF", "PROTEIN", 82, 85], ["cancerous cells", "CELL_TYPE", 96, 111], ["normal cells", "CELL_TYPE", 128, 140], ["IVM safety", "TREATMENT", 29, 39], ["an anticancer drug", "TREATMENT", 43, 61], ["TCF-sensitive cancerous cells", "PROBLEM", 82, 111], ["cancerous cells", "OBSERVATION", 96, 111]]], ["However, non-specific toxicity might be developed at higher dosages.", [["toxicity", "DISEASE", 22, 30], ["non-specific toxicity", "PROBLEM", 9, 30], ["non-specific", "OBSERVATION_MODIFIER", 9, 21], ["toxicity", "OBSERVATION", 22, 30]]], ["Apart from anticancer usage of IVM, it can also be used as a prophylactic drug against some TCF-dependent intestinal tumor and sporadic colon tumor in an aging population.Antiviral EffectsThe role of IVM in inhibiting RNA helicase has led to research on the potential of AVM in the treatment of viral-related diseases.", [["anticancer", "ANATOMY", 11, 21], ["intestinal tumor", "ANATOMY", 106, 122], ["colon tumor", "ANATOMY", 136, 147], ["IVM", "CHEMICAL", 31, 34], ["intestinal tumor", "DISEASE", 106, 122], ["colon tumor", "DISEASE", 136, 147], ["IVM", "CHEMICAL", 200, 203], ["AVM", "DISEASE", 271, 274], ["viral-related diseases", "DISEASE", 295, 317], ["IVM", "CHEMICAL", 31, 34], ["IVM", "CHEMICAL", 200, 203], ["anticancer", "CANCER", 11, 21], ["IVM", "SIMPLE_CHEMICAL", 31, 34], ["TCF", "GENE_OR_GENE_PRODUCT", 92, 95], ["intestinal tumor", "CANCER", 106, 122], ["colon tumor", "CANCER", 136, 147], ["IVM", "SIMPLE_CHEMICAL", 200, 203], ["AVM", "CANCER", 271, 274], ["TCF", "PROTEIN", 92, 95], ["RNA helicase", "PROTEIN", 218, 230], ["IVM", "TREATMENT", 31, 34], ["a prophylactic drug", "TREATMENT", 59, 78], ["some TCF-dependent intestinal tumor", "PROBLEM", 87, 122], ["sporadic colon tumor", "PROBLEM", 127, 147], ["Antiviral Effects", "TREATMENT", 171, 188], ["IVM in inhibiting RNA helicase", "TREATMENT", 200, 230], ["AVM", "PROBLEM", 271, 274], ["viral-related diseases", "PROBLEM", 295, 317], ["anticancer usage", "OBSERVATION", 11, 27], ["dependent", "OBSERVATION_MODIFIER", 96, 105], ["intestinal", "ANATOMY", 106, 116], ["tumor", "OBSERVATION", 117, 122], ["sporadic", "OBSERVATION_MODIFIER", 127, 135], ["colon", "ANATOMY", 136, 141], ["tumor", "OBSERVATION", 142, 147], ["AVM", "OBSERVATION", 271, 274], ["viral", "OBSERVATION", 295, 300]]], ["IVM has been reported to inhibit the replication of most flavivirus through blocking viral helicase [152] .", [["IVM", "CHEMICAL", 0, 3], ["flavivirus", "DISEASE", 57, 67], ["IVM", "CHEMICAL", 0, 3], ["viral helicase", "PROTEIN", 85, 99], ["IVM", "TREATMENT", 0, 3], ["most flavivirus", "PROBLEM", 52, 67], ["blocking viral helicase", "TREATMENT", 76, 99]]], ["Some of the diseases caused by flavivirus include dengue, yellow fever, tick-borne encephalitis, and West Nile virus.", [["flavivirus", "DISEASE", 31, 41], ["dengue", "DISEASE", 50, 56], ["yellow fever", "DISEASE", 58, 70], ["tick-borne encephalitis", "DISEASE", 72, 95], ["West Nile virus", "DISEASE", 101, 116], ["yellow fever", "ORGANISM", 58, 70], ["tick-borne encephalitis", "ORGANISM", 72, 95], ["West Nile virus", "ORGANISM", 101, 116], ["yellow fever", "SPECIES", 58, 70], ["tick-borne encephalitis", "SPECIES", 72, 95], ["West Nile virus", "SPECIES", 101, 116], ["yellow fever, tick-borne encephalitis", "SPECIES", 58, 95], ["West Nile virus", "SPECIES", 101, 116], ["the diseases", "PROBLEM", 8, 20], ["flavivirus", "PROBLEM", 31, 41], ["dengue", "PROBLEM", 50, 56], ["yellow fever", "PROBLEM", 58, 70], ["tick-borne encephalitis", "PROBLEM", 72, 95], ["West Nile virus", "PROBLEM", 101, 116], ["diseases", "OBSERVATION", 12, 20], ["flavivirus", "OBSERVATION", 31, 41], ["yellow fever", "OBSERVATION", 58, 70]]], ["This led to the submission of a patent application for IVM as an off-label for antiviral therapy in humans.", [["IVM", "CHEMICAL", 55, 58], ["humans", "ORGANISM", 100, 106], ["humans", "SPECIES", 100, 106], ["humans", "SPECIES", 100, 106], ["a patent application", "TREATMENT", 30, 50], ["IVM", "TREATMENT", 55, 58], ["antiviral therapy", "TREATMENT", 79, 96], ["patent", "OBSERVATION", 32, 38], ["antiviral therapy", "OBSERVATION", 79, 96]]], ["A study also showed that consistent passaging of IVM for a six months duration did not induce resistance in the yellow fever virus, suggesting that the helicase domain may not be able to undergo mutation [28] .", [["IVM", "CHEMICAL", 49, 52], ["yellow fever", "DISEASE", 112, 124], ["IVM", "CHEMICAL", 49, 52], ["yellow fever virus", "ORGANISM", 112, 130], ["helicase domain", "PROTEIN", 152, 167], ["yellow fever virus", "SPECIES", 112, 130], ["yellow fever virus", "SPECIES", 112, 130], ["A study", "TEST", 0, 7], ["IVM", "TREATMENT", 49, 52], ["resistance", "PROBLEM", 94, 104], ["the yellow fever virus", "PROBLEM", 108, 130], ["the helicase domain", "PROBLEM", 148, 167]]], ["In addition, the report revealed that IVM had no activity against other types of virus, though it inhibits the replication of HIV-1 and dengue virus at high concentrations of IVM (25-50 \u00b5M) in an in vitro experiment.", [["IVM", "CHEMICAL", 38, 41], ["dengue", "DISEASE", 136, 142], ["IVM", "CHEMICAL", 175, 178], ["IVM", "CHEMICAL", 38, 41], ["IVM", "CHEMICAL", 175, 178], ["HIV-1", "ORGANISM", 126, 131], ["dengue virus", "ORGANISM", 136, 148], ["IVM", "SIMPLE_CHEMICAL", 175, 178], ["HIV-1", "SPECIES", 126, 131], ["dengue virus", "SPECIES", 136, 148], ["HIV-1", "SPECIES", 126, 131], ["dengue virus", "SPECIES", 136, 148], ["IVM", "PROBLEM", 38, 41], ["virus", "PROBLEM", 81, 86], ["HIV", "PROBLEM", 126, 129], ["dengue virus", "PROBLEM", 136, 148], ["virus", "OBSERVATION", 81, 86]]], ["Nuclear import of viral proteins is critical to the life cycle of many viruses, including many RNA viruses that replicate exclusively in the cytoplasm such as DENV, respiratory syncytial virus, and rabies [153] [154] [155] [156] .", [["Nuclear", "ANATOMY", 0, 7], ["cytoplasm", "ANATOMY", 141, 150], ["respiratory syncytial virus", "DISEASE", 165, 192], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["cytoplasm", "ORGANISM_SUBSTANCE", 141, 150], ["DENV", "ORGANISM", 159, 163], ["respiratory syncytial virus", "ORGANISM", 165, 192], ["viral proteins", "PROTEIN", 18, 32], ["respiratory syncytial virus", "SPECIES", 165, 192], ["DENV", "SPECIES", 159, 163], ["respiratory syncytial virus", "SPECIES", 165, 192], ["viral proteins", "PROBLEM", 18, 32], ["many viruses", "PROBLEM", 66, 78], ["many RNA viruses", "PROBLEM", 90, 106], ["DENV", "PROBLEM", 159, 163], ["respiratory syncytial virus", "PROBLEM", 165, 192], ["viral proteins", "OBSERVATION", 18, 32], ["viruses", "OBSERVATION", 71, 78], ["respiratory syncytial", "ANATOMY", 165, 186]]], ["The mechanism of inhibition of viral replication is linked to its inhibition of importin \u03b1/\u03b2-mediated transport, leading to the alteration of the trafficking of viral protein between the host cell cytoplasm and the nucleus [157, 158] .", [["cell cytoplasm", "ANATOMY", 192, 206], ["nucleus", "ANATOMY", 215, 222], ["importin \u03b1", "GENE_OR_GENE_PRODUCT", 80, 90], ["\u03b2", "GENE_OR_GENE_PRODUCT", 91, 92], ["cell cytoplasm", "ORGANISM_SUBSTANCE", 192, 206], ["nucleus", "CELLULAR_COMPONENT", 215, 222], ["importin \u03b1", "PROTEIN", 80, 90], ["\u03b2", "PROTEIN", 91, 92], ["viral protein", "PROTEIN", 161, 174], ["viral replication", "PROBLEM", 31, 48], ["viral protein", "PROBLEM", 161, 174], ["viral replication", "OBSERVATION", 31, 48], ["viral protein", "OBSERVATION", 161, 174], ["host cell cytoplasm", "OBSERVATION", 187, 206], ["nucleus", "ANATOMY", 215, 222]]], ["Forwood and Jans.", [["Jans", "ANATOMY", 12, 16]]], ["[159] also discovered that IVM prevents the ability of SV40T-ag to recognize Imp\u03b1/\u03b21.,this observation led investigators to subject IVM to various nuclear-localizing proteins such as IN, T-ag, hCMV UL44, p54, Imp\u03b1/\u03b2-recognized protein, and Imp\u03b21-recognized proteins in HeLa cells and compared with a standard drug (mifepristone).", [["nuclear", "ANATOMY", 147, 154], ["HeLa cells", "ANATOMY", 269, 279], ["IVM", "CHEMICAL", 27, 30], ["mifepristone", "CHEMICAL", 315, 327], ["IVM", "CHEMICAL", 27, 30], ["IVM", "CHEMICAL", 132, 135], ["mifepristone", "CHEMICAL", 315, 327], ["IVM", "SIMPLE_CHEMICAL", 27, 30], ["SV40T", "GENE_OR_GENE_PRODUCT", 55, 60], ["Imp\u03b1/\u03b21", "GENE_OR_GENE_PRODUCT", 77, 84], ["IN", "GENE_OR_GENE_PRODUCT", 183, 185], ["T-ag", "GENE_OR_GENE_PRODUCT", 187, 191], ["hCMV", "GENE_OR_GENE_PRODUCT", 193, 197], ["UL44", "GENE_OR_GENE_PRODUCT", 198, 202], ["p54", "GENE_OR_GENE_PRODUCT", 204, 207], ["Imp\u03b1", "GENE_OR_GENE_PRODUCT", 209, 213], ["\u03b2-", "GENE_OR_GENE_PRODUCT", 214, 216], ["Imp\u03b21", "GENE_OR_GENE_PRODUCT", 240, 245], ["HeLa cells", "CELL", 269, 279], ["mifepristone", "SIMPLE_CHEMICAL", 315, 327], ["SV40T", "PROTEIN", 55, 60], ["Imp\u03b1", "PROTEIN", 77, 81], ["\u03b21", "PROTEIN", 82, 84], ["nuclear-localizing proteins", "PROTEIN", 147, 174], ["IN", "PROTEIN", 183, 185], ["T", "PROTEIN", 187, 188], ["ag", "PROTEIN", 189, 191], ["hCMV", "PROTEIN", 193, 197], ["UL44", "PROTEIN", 198, 202], ["p54", "PROTEIN", 204, 207], ["Imp\u03b1", "PROTEIN", 209, 213], ["\u03b2-recognized protein", "PROTEIN", 214, 234], ["Imp\u03b21", "PROTEIN", 240, 245], ["HeLa cells", "CELL_LINE", 269, 279], ["hCMV", "SPECIES", 193, 197], ["T", "TEST", 187, 188], ["hCMV UL44", "TEST", 193, 202], ["p54", "TEST", 204, 207], ["Imp\u03b1", "TEST", 209, 213], ["protein", "TEST", 227, 234], ["Imp\u03b21", "TEST", 240, 245], ["proteins in HeLa cells", "PROBLEM", 257, 279], ["a standard drug (mifepristone", "TREATMENT", 298, 327], ["HeLa cells", "OBSERVATION", 269, 279]]], ["The result showed that IVM inhibited the accumulation of IN nuclear and T-ag nuclear, while mifepristone inhibited the accumulation of IN nuclear only [160] .", [["nuclear", "ANATOMY", 60, 67], ["nuclear", "ANATOMY", 77, 84], ["nuclear", "ANATOMY", 138, 145], ["IVM", "CHEMICAL", 23, 26], ["mifepristone", "CHEMICAL", 92, 104], ["IVM", "CHEMICAL", 23, 26], ["mifepristone", "CHEMICAL", 92, 104], ["IVM", "SIMPLE_CHEMICAL", 23, 26], ["IN", "GENE_OR_GENE_PRODUCT", 57, 59], ["nuclear", "CELLULAR_COMPONENT", 60, 67], ["T-ag", "GENE_OR_GENE_PRODUCT", 72, 76], ["mifepristone", "SIMPLE_CHEMICAL", 92, 104], ["IN", "GENE_OR_GENE_PRODUCT", 135, 137], ["IVM", "PROBLEM", 23, 26], ["mifepristone", "TREATMENT", 92, 104], ["accumulation", "OBSERVATION_MODIFIER", 41, 53]]], ["They also showed that IVM only inhibits nuclear protein that contains Imp\u03b1/\u03b21-recognized, as it did not inhibit TRF1 SRY or PTHrP which are transported in the nucleus dependent of Imp\u03b1/\u03b21 [161, 162] .", [["nuclear", "ANATOMY", 40, 47], ["nucleus", "ANATOMY", 159, 166], ["IVM", "CHEMICAL", 22, 25], ["IVM", "CHEMICAL", 22, 25], ["IVM", "SIMPLE_CHEMICAL", 22, 25], ["nuclear", "CELLULAR_COMPONENT", 40, 47], ["Imp\u03b1", "GENE_OR_GENE_PRODUCT", 70, 74], ["\u03b21", "GENE_OR_GENE_PRODUCT", 75, 77], ["TRF1 SRY", "GENE_OR_GENE_PRODUCT", 112, 120], ["PTHrP", "GENE_OR_GENE_PRODUCT", 124, 129], ["nucleus", "CELLULAR_COMPONENT", 159, 166], ["Imp\u03b1", "GENE_OR_GENE_PRODUCT", 180, 184], ["\u03b21", "GENE_OR_GENE_PRODUCT", 185, 187], ["nuclear protein", "PROTEIN", 40, 55], ["Imp\u03b1", "PROTEIN", 70, 74], ["\u03b21", "PROTEIN", 75, 77], ["TRF1", "PROTEIN", 112, 116], ["SRY", "PROTEIN", 117, 120], ["PTHrP", "PROTEIN", 124, 129], ["Imp\u03b1", "PROTEIN", 180, 184], ["IVM", "PROBLEM", 22, 25], ["nuclear protein", "TEST", 40, 55], ["TRF1 SRY", "PROBLEM", 112, 120], ["PTHrP", "TEST", 124, 129], ["nucleus", "ANATOMY_MODIFIER", 159, 166]]], ["From their results, it can be suggested that IVM is specific for a particular type of Imp\u03b2-recognized nuclear import, called Imp\u03b1/\u03b21-recognized nuclear import cargoes, and has no effect on other nuclear import pathways.", [["nuclear", "ANATOMY", 102, 109], ["nuclear", "ANATOMY", 144, 151], ["nuclear", "ANATOMY", 195, 202], ["IVM", "CHEMICAL", 45, 48], ["Imp\u03b2-", "GENE_OR_GENE_PRODUCT", 86, 91], ["nuclear", "CELLULAR_COMPONENT", 102, 109], ["Imp\u03b1", "GENE_OR_GENE_PRODUCT", 125, 129], ["\u03b21", "GENE_OR_GENE_PRODUCT", 130, 132], ["nuclear", "CELLULAR_COMPONENT", 144, 151], ["nuclear", "CELLULAR_COMPONENT", 195, 202], ["Imp\u03b1", "PROTEIN", 125, 129], ["\u03b21", "PROTEIN", 130, 132], ["nuclear import cargoes", "PROTEIN", 144, 166]]], ["In addition to the above report, IVM does not affect histone H2B and SUMO-conjugating enzyme UBC9 which are both imported into the nucleus by multiple different Imp\u03b2 homologues and Imp13 respectively [163, 164] .", [["nucleus", "ANATOMY", 131, 138], ["IVM", "CHEMICAL", 33, 36], ["histone H2B", "GENE_OR_GENE_PRODUCT", 53, 64], ["SUMO", "GENE_OR_GENE_PRODUCT", 69, 73], ["UBC9", "GENE_OR_GENE_PRODUCT", 93, 97], ["nucleus", "CELLULAR_COMPONENT", 131, 138], ["Imp\u03b2", "GENE_OR_GENE_PRODUCT", 161, 165], ["Imp13", "GENE_OR_GENE_PRODUCT", 181, 186], ["histone H2B", "PROTEIN", 53, 64], ["SUMO-conjugating enzyme", "PROTEIN", 69, 92], ["UBC9", "PROTEIN", 93, 97], ["Imp\u03b2 homologues", "PROTEIN", 161, 176], ["Imp13", "PROTEIN", 181, 186], ["histone H2B", "TREATMENT", 53, 64], ["SUMO-conjugating enzyme UBC9", "TEST", 69, 97], ["nucleus", "ANATOMY_MODIFIER", 131, 138]]], ["The antiviral activity of IVM and ribavirin was also tested against Newcastle disease virus (NDV) using a 9-day old chicken [165] .", [["IVM", "CHEMICAL", 26, 29], ["ribavirin", "CHEMICAL", 34, 43], ["Newcastle disease virus", "DISEASE", 68, 91], ["IVM", "CHEMICAL", 26, 29], ["ribavirin", "CHEMICAL", 34, 43], ["IVM", "SIMPLE_CHEMICAL", 26, 29], ["ribavirin", "SIMPLE_CHEMICAL", 34, 43], ["Newcastle disease virus", "ORGANISM", 68, 91], ["NDV", "ORGANISM", 93, 96], ["chicken", "ORGANISM", 116, 123], ["chicken", "SPECIES", 116, 123], ["Newcastle disease virus", "SPECIES", 68, 91], ["NDV", "SPECIES", 93, 96], ["chicken", "SPECIES", 116, 123], ["The antiviral activity of IVM", "TREATMENT", 0, 29], ["ribavirin", "TREATMENT", 34, 43], ["Newcastle disease virus", "PROBLEM", 68, 91], ["antiviral activity", "OBSERVATION", 4, 22]]], ["They observed that IVM and ribavirin were cytotoxic at concentrations above 50 \u00b5g/mL and 12.5 \u00b5g/mL, respectively.", [["IVM", "CHEMICAL", 19, 22], ["ribavirin", "CHEMICAL", 27, 36], ["IVM", "CHEMICAL", 19, 22], ["ribavirin", "CHEMICAL", 27, 36], ["IVM", "SIMPLE_CHEMICAL", 19, 22], ["ribavirin", "SIMPLE_CHEMICAL", 27, 36], ["IVM", "TREATMENT", 19, 22], ["ribavirin", "TREATMENT", 27, 36]]], ["However, the most potent concentration of IVM to inhibit virus growth is from 100 \u00b5g/mL and above, while the antiviral activity of ribavirin was experienced at all concentrations (6.25-200 \u00b5g/mL).", [["IVM", "CHEMICAL", 42, 45], ["ribavirin", "CHEMICAL", 131, 140], ["IVM", "CHEMICAL", 42, 45], ["ribavirin", "CHEMICAL", 131, 140], ["IVM", "SIMPLE_CHEMICAL", 42, 45], ["ribavirin", "SIMPLE_CHEMICAL", 131, 140], ["IVM", "TREATMENT", 42, 45], ["virus growth", "PROBLEM", 57, 69], ["ribavirin", "TREATMENT", 131, 140], ["most potent", "OBSERVATION_MODIFIER", 13, 24]]], ["The antiviral activity of IVM against HIV is also linked to an importin (IN) protein.Antiviral EffectsHIV produces a complex called PIC (pre-integration complex), made up of a newly transcribed viral cDNA, IN, host proteins, and other HIV proteins.", [["IVM", "CHEMICAL", 26, 29], ["IVM", "CHEMICAL", 26, 29], ["IVM", "SIMPLE_CHEMICAL", 26, 29], ["HIV", "ORGANISM", 38, 41], ["importin", "GENE_OR_GENE_PRODUCT", 63, 71], ["IN", "GENE_OR_GENE_PRODUCT", 73, 75], ["PIC", "GENE_OR_GENE_PRODUCT", 132, 135], ["pre-integration complex", "GENE_OR_GENE_PRODUCT", 137, 160], ["IN", "GENE_OR_GENE_PRODUCT", 206, 208], ["importin (IN) protein", "PROTEIN", 63, 84], ["PIC", "PROTEIN", 132, 135], ["pre-integration complex", "PROTEIN", 137, 160], ["viral cDNA", "DNA", 194, 204], ["IN, host proteins", "PROTEIN", 206, 223], ["HIV proteins", "PROTEIN", 235, 247], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 102, 105], ["HIV", "SPECIES", 235, 238], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 102, 105], ["HIV", "SPECIES", 235, 238], ["The antiviral activity of IVM", "TREATMENT", 0, 29], ["HIV", "PROBLEM", 38, 41], ["Antiviral EffectsHIV", "PROBLEM", 85, 105], ["PIC (pre-integration complex", "TREATMENT", 132, 160], ["a newly transcribed viral cDNA", "PROBLEM", 174, 204], ["host proteins", "TEST", 210, 223], ["other HIV proteins", "PROBLEM", 229, 247], ["antiviral activity", "OBSERVATION", 4, 22], ["viral cDNA", "OBSERVATION", 194, 204]]], ["It is believed that the transportation of PIC requires the action of IN [166] , for the integration of viral cDNA into the host cell genome, an important step in HIV infection [167] .", [["cell", "ANATOMY", 128, 132], ["PIC", "CHEMICAL", 42, 45], ["HIV infection", "DISEASE", 162, 175], ["PIC", "CHEMICAL", 42, 45], ["PIC", "GENE_OR_GENE_PRODUCT", 42, 45], ["IN [166]", "GENE_OR_GENE_PRODUCT", 69, 77], ["host cell", "CELL", 123, 132], ["HIV", "ORGANISM", 162, 165], ["PIC", "PROTEIN", 42, 45], ["viral cDNA", "DNA", 103, 113], ["host cell genome", "DNA", 123, 139], ["HIV", "SPECIES", 162, 165], ["viral cDNA", "TREATMENT", 103, 113], ["the host cell genome", "TREATMENT", 119, 139], ["HIV infection", "PROBLEM", 162, 175], ["viral cDNA", "OBSERVATION", 103, 113], ["host cell genome", "OBSERVATION", 123, 139]]], ["The inhibitory activity of IVM on IN was tested and compared with mifepristone (a standard drug that works by inhibiting IN) using HeLa cells infected with VSV-G-pseudotyped NL4-3.Luc.R-E-HIV. IVM at 25 \u00b5M significantly inhibits the growth of the virus.", [["HeLa cells", "ANATOMY", 131, 141], ["IVM", "CHEMICAL", 27, 30], ["mifepristone", "CHEMICAL", 66, 78], ["IVM", "CHEMICAL", 193, 196], ["IVM", "CHEMICAL", 27, 30], ["mifepristone", "CHEMICAL", 66, 78], ["IVM", "CHEMICAL", 193, 196], ["IVM", "SIMPLE_CHEMICAL", 27, 30], ["IN", "SIMPLE_CHEMICAL", 34, 36], ["mifepristone", "SIMPLE_CHEMICAL", 66, 78], ["IN", "GENE_OR_GENE_PRODUCT", 121, 123], ["HeLa cells", "CELL", 131, 141], ["VSV-G-pseudotyped NL4-3", "ORGANISM", 156, 179], ["Luc", "GENE_OR_GENE_PRODUCT", 180, 183], ["R-E", "GENE_OR_GENE_PRODUCT", 184, 187], ["IN", "PROTEIN", 121, 123], ["HeLa cells", "CELL_LINE", 131, 141], ["HIV", "SPECIES", 188, 191], ["mifepristone", "TREATMENT", 66, 78], ["HeLa cells", "TEST", 131, 141], ["VSV", "TEST", 156, 159], ["HIV", "PROBLEM", 188, 191], ["IVM", "TREATMENT", 193, 196], ["the virus", "PROBLEM", 243, 252], ["growth", "OBSERVATION_MODIFIER", 233, 239]]], ["The inhibition of importin this is consistent with ivermectin being able to generally inhibit Imp\u03b1/\u03b21-mediated nuclear import, which is essential for HIV infection and the first demonstration that inhibitors of nuclear import can have potent antiviral activity.", [["nuclear", "ANATOMY", 111, 118], ["nuclear", "ANATOMY", 211, 218], ["ivermectin", "CHEMICAL", 51, 61], ["HIV infection", "DISEASE", 150, 163], ["ivermectin", "CHEMICAL", 51, 61], ["importin", "GENE_OR_GENE_PRODUCT", 18, 26], ["ivermectin", "SIMPLE_CHEMICAL", 51, 61], ["Imp\u03b1", "GENE_OR_GENE_PRODUCT", 94, 98], ["\u03b21", "GENE_OR_GENE_PRODUCT", 99, 101], ["nuclear", "CELLULAR_COMPONENT", 111, 118], ["HIV", "ORGANISM", 150, 153], ["nuclear", "CELLULAR_COMPONENT", 211, 218], ["importin", "PROTEIN", 18, 26], ["Imp\u03b1", "PROTEIN", 94, 98], ["\u03b21", "PROTEIN", 99, 101], ["HIV", "SPECIES", 150, 153], ["ivermectin", "TREATMENT", 51, 61], ["HIV infection", "PROBLEM", 150, 163], ["consistent with", "UNCERTAINTY", 35, 50], ["antiviral activity", "OBSERVATION", 242, 260]]], ["DENV NS5 protein is critical in the viral replication of DENV in the host cytoplasm.", [["cytoplasm", "ANATOMY", 74, 83], ["DENV", "ORGANISM", 0, 4], ["NS5", "GENE_OR_GENE_PRODUCT", 5, 8], ["DENV", "ORGANISM", 57, 61], ["cytoplasm", "ORGANISM_SUBSTANCE", 74, 83], ["DENV NS5 protein", "PROTEIN", 0, 16], ["DENV", "SPECIES", 0, 4], ["DENV", "SPECIES", 57, 61], ["DENV NS5 protein", "TEST", 0, 16], ["DENV", "PROBLEM", 57, 61], ["NS5 protein", "OBSERVATION", 5, 16], ["viral replication", "OBSERVATION", 36, 53], ["DENV", "OBSERVATION", 57, 61], ["host cytoplasm", "OBSERVATION", 69, 83]]], ["Most DENV Ns5 proteins are found in the nucleus at a specific stage of the life cycle of viral infection [154] .", [["nucleus", "ANATOMY", 40, 47], ["viral infection", "DISEASE", 89, 104], ["DENV", "ORGANISM", 5, 9], ["Ns5", "GENE_OR_GENE_PRODUCT", 10, 13], ["nucleus", "CELLULAR_COMPONENT", 40, 47], ["DENV Ns5 proteins", "PROTEIN", 5, 22], ["DENV", "SPECIES", 5, 9], ["Most DENV Ns5 proteins", "PROBLEM", 0, 22], ["viral infection", "PROBLEM", 89, 104], ["Ns5 proteins", "OBSERVATION", 10, 22], ["nucleus", "ANATOMY", 40, 47], ["viral infection", "OBSERVATION", 89, 104]]], ["NS5 contains another NLS recognized by Imp\u03b21 alone that is not important for the accumulation of NS5nuclear [154] .", [["NLS", "GENE_OR_GENE_PRODUCT", 21, 24], ["Imp\u03b21", "GENE_OR_GENE_PRODUCT", 39, 44], ["NS5", "PROTEIN", 0, 3], ["NLS", "PROTEIN", 21, 24], ["Imp\u03b21", "PROTEIN", 39, 44], ["NS5", "TREATMENT", 0, 3], ["another NLS", "TREATMENT", 13, 24]]], ["It was concluded that IVM significantly inhibits the binding of Imp\u03b1/\u03b21 to NS5 and not the binding of Imp\u03b21 to NS5, showing that the inhibitory activity of IVM was specific, a situation not observed with mifepristone.", [["IVM", "CHEMICAL", 22, 25], ["mifepristone", "CHEMICAL", 204, 216], ["IVM", "CHEMICAL", 22, 25], ["IVM", "CHEMICAL", 156, 159], ["mifepristone", "CHEMICAL", 204, 216], ["IVM", "SIMPLE_CHEMICAL", 22, 25], ["Imp\u03b1", "GENE_OR_GENE_PRODUCT", 64, 68], ["\u03b21", "GENE_OR_GENE_PRODUCT", 69, 71], ["NS5", "GENE_OR_GENE_PRODUCT", 75, 78], ["Imp\u03b21", "GENE_OR_GENE_PRODUCT", 102, 107], ["NS5", "GENE_OR_GENE_PRODUCT", 111, 114], ["IVM", "SIMPLE_CHEMICAL", 156, 159], ["mifepristone", "SIMPLE_CHEMICAL", 204, 216], ["Imp\u03b1", "PROTEIN", 64, 68], ["\u03b21", "PROTEIN", 69, 71], ["NS5", "PROTEIN", 75, 78], ["Imp\u03b21", "PROTEIN", 102, 107], ["NS5", "PROTEIN", 111, 114], ["IVM", "PROBLEM", 22, 25], ["Imp\u03b1/\u03b21 to NS5", "TREATMENT", 64, 78], ["NS5", "TREATMENT", 111, 114], ["mifepristone", "TREATMENT", 204, 216]]], ["With respect to dengue virus (DENV) infection, IVM was also studied on its antiviral status against DENV [153, 168] .", [["dengue virus (DENV) infection", "DISEASE", 16, 45], ["IVM", "CHEMICAL", 47, 50], ["dengue virus", "ORGANISM", 16, 28], ["DENV", "ORGANISM", 30, 34], ["DENV", "ORGANISM", 100, 104], ["dengue virus", "SPECIES", 16, 28], ["dengue virus", "SPECIES", 16, 28], ["DENV", "SPECIES", 30, 34], ["DENV", "SPECIES", 100, 104], ["dengue virus (DENV) infection", "PROBLEM", 16, 45], ["IVM", "TREATMENT", 47, 50], ["DENV", "PROBLEM", 100, 104], ["dengue virus", "OBSERVATION", 16, 28], ["infection", "OBSERVATION", 36, 45]]], ["Ivermectin can block the DENV 2 at any anatomical barrier, like midgut or salivary gland the transmission rate of the virus by a mosquito is usually lower than the infection.", [["midgut", "ANATOMY", 64, 70], ["salivary gland", "ANATOMY", 74, 88], ["Ivermectin", "CHEMICAL", 0, 10], ["infection", "DISEASE", 164, 173], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["DENV 2", "ORGANISM", 25, 31], ["barrier", "TISSUE", 50, 57], ["midgut", "ORGAN", 64, 70], ["salivary gland", "ORGAN", 74, 88], ["Ivermectin", "TREATMENT", 0, 10], ["the DENV", "PROBLEM", 21, 29], ["the virus", "PROBLEM", 114, 123], ["the infection", "PROBLEM", 160, 173], ["DENV", "OBSERVATION", 25, 29], ["salivary gland", "ANATOMY", 74, 88], ["infection", "OBSERVATION", 164, 173]]], ["It is believed that the transmission rate is low as it involves several anatomical barriers such as the midgut and glands.", [["midgut", "ANATOMY", 104, 110], ["glands", "ANATOMY", 115, 121], ["midgut", "ORGAN", 104, 110], ["glands", "ORGAN", 115, 121], ["the transmission rate", "TEST", 20, 41], ["midgut", "ANATOMY", 104, 110], ["glands", "ANATOMY", 115, 121]]], ["Thus, research is often conducted on the effect of IVM on infection status rather than transmission [169] .", [["IVM", "CHEMICAL", 51, 54], ["infection", "DISEASE", 58, 67], ["IVM", "CHEMICAL", 51, 54], ["infection status", "PROBLEM", 58, 74], ["infection", "OBSERVATION", 58, 67]]], ["They find out that IVM significantly reduced the DENV infection when the vector is pretreated with IVM.", [["IVM", "CHEMICAL", 19, 22], ["infection", "DISEASE", 54, 63], ["IVM", "CHEMICAL", 19, 22], ["IVM", "CHEMICAL", 99, 102], ["DENV", "ORGANISM", 49, 53], ["DENV", "SPECIES", 49, 53], ["IVM", "PROBLEM", 19, 22], ["the DENV infection", "PROBLEM", 45, 63], ["IVM", "TREATMENT", 99, 102], ["DENV", "OBSERVATION_MODIFIER", 49, 53], ["infection", "OBSERVATION", 54, 63]]], ["IVM could work either in preventing the transport of DENV to the salivary gland or reducing the number of mosquitoes that carry the virus [43] .", [["salivary gland", "ANATOMY", 65, 79], ["IVM", "CHEMICAL", 0, 3], ["DENV", "ORGANISM", 53, 57], ["salivary gland", "ORGAN", 65, 79], ["DENV", "SPECIES", 53, 57], ["IVM", "TREATMENT", 0, 3], ["DENV", "PROBLEM", 53, 57], ["salivary gland", "ANATOMY", 65, 79]]], ["This means that IVM could be a potential drug used to control DENV infection by acting as an insecticidal [170] in killing A. albopictus [171] , or as an antiviral drug for the treatment of dengue [169] .", [["IVM", "CHEMICAL", 16, 19], ["DENV infection", "DISEASE", 62, 76], ["dengue", "DISEASE", 190, 196], ["IVM", "CHEMICAL", 16, 19], ["IVM", "SIMPLE_CHEMICAL", 16, 19], ["DENV", "ORGANISM", 62, 66], ["A. albopictus", "ORGANISM", 123, 136], ["A. albopictus", "SPECIES", 123, 136], ["DENV", "SPECIES", 62, 66], ["A. albopictus", "SPECIES", 123, 136], ["IVM", "TREATMENT", 16, 19], ["a potential drug", "TREATMENT", 29, 45], ["DENV infection", "PROBLEM", 62, 76], ["an antiviral drug", "TREATMENT", 151, 168], ["dengue", "PROBLEM", 190, 196]]], ["IVM prevents the growth of the virus in Aedes albopictus as well as destroys several blood-sucking vectors.", [["blood", "ANATOMY", 85, 90], ["IVM", "CHEMICAL", 0, 3], ["IVM", "CHEMICAL", 0, 3], ["Aedes albopictus", "ORGANISM", 40, 56], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["Aedes albopictus", "SPECIES", 40, 56], ["Aedes albopictus", "SPECIES", 40, 56], ["IVM", "TREATMENT", 0, 3], ["the virus", "PROBLEM", 27, 36], ["growth", "OBSERVATION_MODIFIER", 17, 23]]], ["More research are still been done to decipher the mechanism involved in how IVM affects the transmission and infection rate of DEN through Aedes albopictus.", [["IVM", "CHEMICAL", 76, 79], ["infection", "DISEASE", 109, 118], ["DEN", "CHEMICAL", 127, 130], ["IVM", "CHEMICAL", 76, 79], ["DEN", "ORGANISM", 127, 130], ["Aedes albopictus", "ORGANISM", 139, 155], ["Aedes albopictus", "SPECIES", 139, 155], ["Aedes albopictus", "SPECIES", 139, 155], ["infection rate", "PROBLEM", 109, 123]]], ["One of the mechanisms that IVM might be probably linked to inhibiting the growth of DENV might be by preventing the interaction of NS5 and Imp\u03b1/\u03b21 [152] .", [["DENV", "DISEASE", 84, 88], ["IVM", "CHEMICAL", 27, 30], ["DENV", "ORGANISM", 84, 88], ["NS5", "GENE_OR_GENE_PRODUCT", 131, 134], ["Imp\u03b1", "GENE_OR_GENE_PRODUCT", 139, 143], ["\u03b21", "GENE_OR_GENE_PRODUCT", 144, 146], ["NS5", "PROTEIN", 131, 134], ["Imp\u03b1", "PROTEIN", 139, 143], ["\u03b21", "PROTEIN", 144, 146], ["DENV", "SPECIES", 84, 88], ["DENV", "PROBLEM", 84, 88], ["NS5", "TREATMENT", 131, 134], ["DENV", "OBSERVATION", 84, 88]]], ["On the basis of the available structures of DENV bound to ssRNA (PDB 2JLU) it is not possible to predict a plausible interaction site or a model of the ternary complex.", [["DENV", "ORGANISM", 44, 48], ["ssRNA", "DNA", 58, 63], ["PDB 2JLU", "PROTEIN", 65, 73], ["ternary complex", "PROTEIN", 152, 167], ["DENV", "PROBLEM", 44, 48], ["ssRNA (PDB 2JLU", "TREATMENT", 58, 73], ["a plausible interaction site", "PROBLEM", 105, 133], ["DENV", "OBSERVATION", 44, 48], ["not possible", "UNCERTAINTY", 81, 93]]], ["Reasonably, during activity the helicase/RNA complex changes its structure [172] , allowing ivermectin to interact with the identified amino acids to block dsRNA unwinding.", [["ivermectin", "CHEMICAL", 92, 102], ["amino acids", "CHEMICAL", 135, 146], ["ivermectin", "CHEMICAL", 92, 102], ["amino acids", "CHEMICAL", 135, 146], ["ivermectin", "SIMPLE_CHEMICAL", 92, 102], ["amino acids", "AMINO_ACID", 135, 146], ["helicase", "PROTEIN", 32, 40], ["RNA complex", "PROTEIN", 41, 52], ["the helicase/RNA complex changes", "PROBLEM", 28, 60], ["ivermectin", "TREATMENT", 92, 102], ["the identified amino acids", "TREATMENT", 120, 146], ["block dsRNA unwinding", "PROBLEM", 150, 171]]], ["IVM has also been reported to be effective against another flavivirus, the yellow fever virus (YFV) [173, 174] .Ivermectin and CoronavirusWith the global pandemic nature of COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-COV-2), there is an urgency for scientists to discover drugs or compounds to treat the disease.", [["IVM", "CHEMICAL", 0, 3], ["flavivirus", "DISEASE", 59, 69], ["yellow fever", "DISEASE", 75, 87], ["Ivermectin", "CHEMICAL", 112, 122], ["CoronavirusWith", "CHEMICAL", 127, 142], ["COVID-19", "CHEMICAL", 173, 181], ["acute respiratory syndrome coronavirus", "DISEASE", 200, 238], ["IVM", "CHEMICAL", 0, 3], ["Ivermectin", "CHEMICAL", 112, 122], ["yellow fever virus", "ORGANISM", 75, 93], ["YFV", "ORGANISM", 95, 98], ["Ivermectin", "SIMPLE_CHEMICAL", 112, 122], ["COVID-19", "ORGANISM", 173, 181], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 193, 238], ["SARS-COV-2", "ORGANISM", 242, 252], ["yellow fever virus", "SPECIES", 75, 93], ["yellow fever virus", "SPECIES", 75, 93], ["YFV", "SPECIES", 95, 98], ["COVID-19", "SPECIES", 173, 181], ["severe acute respiratory syndrome coronavirus", "SPECIES", 193, 238], ["IVM", "TREATMENT", 0, 3], ["another flavivirus", "PROBLEM", 51, 69], ["the yellow fever virus", "PROBLEM", 71, 93], ["Ivermectin", "TREATMENT", 112, 122], ["COVID", "TEST", 173, 178], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 193, 238], ["SARS-COV", "TEST", 242, 250], ["an urgency", "PROBLEM", 264, 274], ["drugs", "TREATMENT", 302, 307], ["the disease", "PROBLEM", 330, 341], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["acute", "OBSERVATION_MODIFIER", 200, 205], ["respiratory syndrome", "OBSERVATION", 206, 226], ["urgency", "OBSERVATION", 267, 274], ["disease", "OBSERVATION", 334, 341]]], ["The reported antiviral potential of IVM has made it a potential drug to be investigated for the treatment of COVID-19 [175] .", [["IVM", "CHEMICAL", 36, 39], ["COVID-19 [175", "CHEMICAL", 109, 122], ["IVM", "CHEMICAL", 36, 39], ["COVID-19", "CHEMICAL", 109, 117], ["IVM", "SIMPLE_CHEMICAL", 36, 39], ["COVID", "TEST", 109, 114]]], ["Caly et al. [176] earlier reported the potential of IVM to inhibit the replication of SARS-CoV-2 in an in vitro experiment.", [["IVM", "CHEMICAL", 52, 55], ["IVM", "CHEMICAL", 52, 55], ["IVM", "SIMPLE_CHEMICAL", 52, 55], ["SARS-CoV-2", "ORGANISM", 86, 96], ["SARS-CoV", "SPECIES", 86, 94], ["IVM", "PROBLEM", 52, 55], ["CoV", "TEST", 91, 94]]], ["Such findings were obtained by incubating 2.19 mg/mL of IVM with a Vero/hSLAM-cells infected with SAES-CoV-2.", [["Vero/hSLAM-cells", "ANATOMY", 67, 83], ["IVM", "CHEMICAL", 56, 59], ["hSLAM-cells", "CELL", 72, 83], ["SAES-CoV-2", "CELL", 98, 108], ["Vero/hSLAM-cells", "CELL_LINE", 67, 83], ["IVM", "TREATMENT", 56, 59], ["a Vero/hSLAM-cells", "TREATMENT", 65, 83]]], ["Extrapolating this dose into human models shows that this dose well exceeds tolerable dose for humans approved by the US food and Drug administration.", [["human", "ORGANISM", 29, 34], ["humans", "ORGANISM", 95, 101], ["Drug", "SIMPLE_CHEMICAL", 130, 134], ["human", "SPECIES", 29, 34], ["humans", "SPECIES", 95, 101], ["human", "SPECIES", 29, 34], ["humans", "SPECIES", 95, 101], ["Drug administration", "TREATMENT", 130, 149]]], ["However, Guzzo et al. [131] showed that administration of 120 mg of IVM to healthy humans was safe and well tolerated by volunteers.", [["IVM", "CHEMICAL", 68, 71], ["IVM", "CHEMICAL", 68, 71], ["humans", "ORGANISM", 83, 89], ["volunteers", "ORGANISM", 121, 131], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 83, 89], ["IVM", "TREATMENT", 68, 71]]], ["The results showed the peak plasma concentration of 250 ng/mL, which was just a bit lower than the effective concentration of IVM that inhibits replication of SARS-COV-2 in Vero/hSLAM cells.", [["plasma", "ANATOMY", 28, 34], ["Vero/hSLAM cells", "ANATOMY", 173, 189], ["IVM", "CHEMICAL", 126, 129], ["IVM", "CHEMICAL", 126, 129], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 159, 169], ["Vero/hSLAM cells", "CELL", 173, 189], ["Vero/hSLAM cells", "CELL_LINE", 173, 189], ["the peak plasma concentration", "TEST", 19, 48], ["IVM", "TREATMENT", 126, 129], ["SARS", "PROBLEM", 159, 163], ["COV", "TEST", 164, 167], ["Vero/hSLAM cells", "TREATMENT", 173, 189], ["hSLAM cells", "ANATOMY", 178, 189]]], ["The results might have been a setback in further clinical trial of IVM.", [["IVM", "CHEMICAL", 67, 70], ["a setback", "TREATMENT", 28, 37], ["IVM", "TREATMENT", 67, 70]]], ["With the respiratory destructive nature of SARS-CoV-2 and Lespine et al. [177] showing a higher concentration of IVM in the respiratory system as compared to the plasma, one week after administration of IVM, shows that all hope might not be lost in the investigation of IVM as a potential antiviral drug.", [["respiratory system", "ANATOMY", 124, 142], ["plasma", "ANATOMY", 162, 168], ["SARS", "DISEASE", 43, 47], ["IVM", "CHEMICAL", 113, 116], ["IVM", "CHEMICAL", 270, 273], ["IVM", "CHEMICAL", 113, 116], ["IVM", "CHEMICAL", 203, 206], ["IVM", "CHEMICAL", 270, 273], ["plasma", "ORGANISM_SUBSTANCE", 162, 168], ["the respiratory destructive nature", "PROBLEM", 5, 39], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["a higher concentration of IVM in the respiratory system", "PROBLEM", 87, 142], ["IVM", "TREATMENT", 203, 206], ["IVM", "TREATMENT", 270, 273], ["a potential antiviral drug", "TREATMENT", 277, 303], ["respiratory", "ANATOMY", 9, 20], ["destructive", "OBSERVATION_MODIFIER", 21, 32], ["respiratory system", "ANATOMY", 124, 142]]], ["However, some care must be considered before the continuity of the investigation.", [["the investigation", "TEST", 63, 80]]], ["Based on the reported neurotoxicity and metabolic pathway of IVM, caution should be taken to conduct clinical trial on its antiviral potentials.", [["neurotoxicity", "DISEASE", 22, 35], ["IVM", "CHEMICAL", 61, 64], ["IVM", "TREATMENT", 61, 64], ["caution", "TREATMENT", 66, 73]]], ["The GABA-gated chloride channels in the human nervous system might be a target for IVM, this is because the BBB in disease-patient might be a weakened as a result of inflammation and other destructive processes, allowing IVM to cross the BBB and gain access to the CNS where it can elicit its neurotoxic effect (II) IVM is metabolized by CYP3A4 enzyme that is repeatedly inhibited by ritonavir and cubocistat, two drugs used to treat COVID-19 patients.", [["nervous system", "ANATOMY", 46, 60], ["BBB", "ANATOMY", 108, 111], ["BBB", "ANATOMY", 238, 241], ["CNS", "ANATOMY", 265, 268], ["GABA", "CHEMICAL", 4, 8], ["chloride", "CHEMICAL", 15, 23], ["inflammation", "DISEASE", 166, 178], ["neurotoxic", "DISEASE", 293, 303], ["IVM", "CHEMICAL", 316, 319], ["ritonavir", "CHEMICAL", 384, 393], ["cubocistat", "CHEMICAL", 398, 408], ["COVID", "DISEASE", 434, 439], ["GABA", "CHEMICAL", 4, 8], ["chloride", "CHEMICAL", 15, 23], ["IVM", "CHEMICAL", 83, 86], ["IVM", "CHEMICAL", 221, 224], ["IVM", "CHEMICAL", 316, 319], ["ritonavir", "CHEMICAL", 384, 393], ["cubocistat", "CHEMICAL", 398, 408], ["GABA", "SIMPLE_CHEMICAL", 4, 8], ["chloride", "SIMPLE_CHEMICAL", 15, 23], ["human", "ORGANISM", 40, 45], ["nervous system", "ANATOMICAL_SYSTEM", 46, 60], ["BBB", "MULTI-TISSUE_STRUCTURE", 108, 111], ["patient", "ORGANISM", 123, 130], ["BBB", "MULTI-TISSUE_STRUCTURE", 238, 241], ["CNS", "ANATOMICAL_SYSTEM", 265, 268], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 338, 344], ["ritonavir", "SIMPLE_CHEMICAL", 384, 393], ["cubocistat", "SIMPLE_CHEMICAL", 398, 408], ["patients", "ORGANISM", 443, 451], ["GABA-gated chloride channels", "PROTEIN", 4, 32], ["CYP3A4 enzyme", "PROTEIN", 338, 351], ["human", "SPECIES", 40, 45], ["patient", "SPECIES", 123, 130], ["patients", "SPECIES", 443, 451], ["human", "SPECIES", 40, 45], ["The GABA-gated chloride channels", "TREATMENT", 0, 32], ["IVM", "TREATMENT", 83, 86], ["the BBB in disease", "PROBLEM", 104, 122], ["a weakened", "PROBLEM", 140, 150], ["inflammation", "PROBLEM", 166, 178], ["other destructive processes", "PROBLEM", 183, 210], ["IVM", "TREATMENT", 221, 224], ["CYP3A4 enzyme", "TEST", 338, 351], ["ritonavir", "TREATMENT", 384, 393], ["cubocistat", "TREATMENT", 398, 408], ["two drugs", "TREATMENT", 410, 419], ["COVID", "TEST", 434, 439], ["weakened", "OBSERVATION", 142, 150], ["inflammation", "OBSERVATION", 166, 178], ["destructive", "OBSERVATION_MODIFIER", 189, 200], ["CNS", "ANATOMY", 265, 268]]], ["Furthermore, the two drugs are also reported to impair BBB.", [["BBB", "ANATOMY", 55, 58], ["BBB", "MULTI-TISSUE_STRUCTURE", 55, 58]]], ["Thus care should be taken in the administration of IVM with antiviral drugs [178] .", [["IVM", "CHEMICAL", 51, 54], ["antiviral drugs", "TREATMENT", 60, 75]]], ["Data obtained from the WHO-supported International Drug Monitoring Program are essential in the combination therapy of IVM with other antiviral drugs.", [["IVM", "CHEMICAL", 119, 122], ["IVM", "TREATMENT", 119, 122], ["other antiviral drugs", "TREATMENT", 128, 149]]], ["They reported that out of 1688 data on co-administration of IVM as an antiviral drugs, only one is linked to its neurotoxicity.", [["IVM", "CHEMICAL", 60, 63], ["neurotoxicity", "DISEASE", 113, 126], ["IVM", "CHEMICAL", 60, 63], ["IVM", "TREATMENT", 60, 63], ["an antiviral drugs", "TREATMENT", 67, 85], ["its neurotoxicity", "PROBLEM", 109, 126]]], ["(III). the third point is based on the evidenced stated earlier that the potency of IVM to treat SARS-CoV-2 infection might require a dosage that might be toxic to humans [178] .Metabolic Effects of IvermectinThe role of IVM in regulating lipid and glucose level was investigated using a high-fat diet animal of two types-FXR wild type and FXR \u2212/\u2212 mice.", [["IVM", "CHEMICAL", 84, 87], ["SARS", "DISEASE", 97, 101], ["infection", "DISEASE", 108, 117], ["Ivermectin", "CHEMICAL", 199, 209], ["IVM", "CHEMICAL", 221, 224], ["glucose", "CHEMICAL", 249, 256], ["IVM", "CHEMICAL", 84, 87], ["Ivermectin", "CHEMICAL", 199, 209], ["IVM", "CHEMICAL", 221, 224], ["glucose", "CHEMICAL", 249, 256], ["SARS-CoV-2", "ORGANISM", 97, 107], ["humans", "ORGANISM", 164, 170], ["Ivermectin", "SIMPLE_CHEMICAL", 199, 209], ["IVM", "SIMPLE_CHEMICAL", 221, 224], ["lipid", "SIMPLE_CHEMICAL", 239, 244], ["glucose", "SIMPLE_CHEMICAL", 249, 256], ["FXR", "GENE_OR_GENE_PRODUCT", 322, 325], ["FXR", "GENE_OR_GENE_PRODUCT", 340, 343], ["FXR", "PROTEIN", 322, 325], ["FXR", "PROTEIN", 340, 343], ["humans", "SPECIES", 164, 170], ["mice", "SPECIES", 348, 352], ["SARS-CoV", "SPECIES", 97, 105], ["humans", "SPECIES", 164, 170], ["mice", "SPECIES", 348, 352], ["IVM", "TREATMENT", 84, 87], ["SARS", "PROBLEM", 97, 101], ["CoV", "PROBLEM", 102, 105], ["2 infection", "PROBLEM", 106, 117], ["a dosage", "TREATMENT", 132, 140], ["Ivermectin", "TREATMENT", 199, 209], ["IVM", "TREATMENT", 221, 224], ["glucose level", "TEST", 249, 262], ["a high-fat diet", "TREATMENT", 286, 301], ["FXR", "ANATOMY", 322, 325]]], ["Animals were administered IVM intraperitoneally daily for 14 days and concomitantly exposed to a high-fat diet.", [["intraperitoneally", "ANATOMY", 30, 47], ["IVM", "CHEMICAL", 26, 29], ["IVM", "CHEMICAL", 26, 29], ["Animals", "ORGANISM", 0, 7], ["a high-fat diet", "TREATMENT", 95, 110]]], ["All the markers of liver injury (aspartate aminotransferase and alanine transferase) along with tissue histology showed no toxicity of IVM [179] .", [["liver", "ANATOMY", 19, 24], ["tissue", "ANATOMY", 96, 102], ["liver injury", "DISEASE", 19, 31], ["aspartate", "CHEMICAL", 33, 42], ["alanine", "CHEMICAL", 64, 71], ["toxicity", "DISEASE", 123, 131], ["IVM", "CHEMICAL", 135, 138], ["aspartate", "CHEMICAL", 33, 42], ["alanine", "CHEMICAL", 64, 71], ["IVM", "CHEMICAL", 135, 138], ["liver", "ORGAN", 19, 24], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 33, 59], ["alanine transferase", "GENE_OR_GENE_PRODUCT", 64, 83], ["tissue", "TISSUE", 96, 102], ["aspartate aminotransferase", "PROTEIN", 33, 59], ["alanine transferase", "PROTEIN", 64, 83], ["liver injury", "PROBLEM", 19, 31], ["aspartate aminotransferase", "TEST", 33, 59], ["alanine transferase", "TEST", 64, 83], ["tissue histology", "TEST", 96, 112], ["toxicity of IVM", "PROBLEM", 123, 138], ["liver", "ANATOMY", 19, 24], ["injury", "OBSERVATION", 25, 31], ["no", "UNCERTAINTY", 120, 122]]], ["IVM significantly reduced the serum level of cholesterol, low-density cholesterol, very low-density cholesterol, and glucose only in FXR-wild type mice without any change in appetite and weight gained.", [["serum", "ANATOMY", 30, 35], ["IVM", "CHEMICAL", 0, 3], ["cholesterol", "CHEMICAL", 45, 56], ["cholesterol", "CHEMICAL", 70, 81], ["cholesterol", "CHEMICAL", 100, 111], ["glucose", "CHEMICAL", 117, 124], ["IVM", "CHEMICAL", 0, 3], ["cholesterol", "CHEMICAL", 45, 56], ["cholesterol", "CHEMICAL", 70, 81], ["cholesterol", "CHEMICAL", 100, 111], ["glucose", "CHEMICAL", 117, 124], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["cholesterol", "SIMPLE_CHEMICAL", 45, 56], ["cholesterol", "SIMPLE_CHEMICAL", 70, 81], ["cholesterol", "SIMPLE_CHEMICAL", 100, 111], ["glucose", "SIMPLE_CHEMICAL", 117, 124], ["FXR", "GENE_OR_GENE_PRODUCT", 133, 136], ["mice", "ORGANISM", 147, 151], ["FXR", "PROTEIN", 133, 136], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["IVM", "PROBLEM", 0, 3], ["the serum level", "TEST", 26, 41], ["cholesterol", "TEST", 45, 56], ["very low-density cholesterol", "PROBLEM", 83, 111], ["glucose", "TEST", 117, 124], ["FXR", "TEST", 133, 136], ["any change in appetite", "PROBLEM", 160, 182], ["weight", "TEST", 187, 193], ["reduced", "OBSERVATION_MODIFIER", 18, 25], ["low-", "OBSERVATION_MODIFIER", 88, 92], ["density cholesterol", "OBSERVATION", 92, 111], ["FXR", "ANATOMY", 133, 136]]], ["It is reported that IVM-induced glucose decrease might be due to increased insulin sensitivity to glucose [122] .", [["IVM", "CHEMICAL", 20, 23], ["glucose", "CHEMICAL", 32, 39], ["glucose", "CHEMICAL", 98, 105], ["IVM", "CHEMICAL", 20, 23], ["glucose", "CHEMICAL", 32, 39], ["glucose", "CHEMICAL", 98, 105], ["IVM", "SIMPLE_CHEMICAL", 20, 23], ["glucose", "SIMPLE_CHEMICAL", 32, 39], ["insulin", "GENE_OR_GENE_PRODUCT", 75, 82], ["glucose", "SIMPLE_CHEMICAL", 98, 105], ["induced glucose decrease", "PROBLEM", 24, 48], ["increased insulin sensitivity", "PROBLEM", 65, 94], ["glucose", "TEST", 98, 105]]], ["The role of IVM as an FXR ligand in metabolic regulations was further confirmed by its ability to regulate the expression of some genes that are targeted either directly or indirectly by FXR. mRNA that codes for the expression of SHP, CYP7A1 and CYP8B1.", [["IVM", "CHEMICAL", 12, 15], ["IVM", "SIMPLE_CHEMICAL", 12, 15], ["FXR ligand", "GENE_OR_GENE_PRODUCT", 22, 32], ["FXR", "GENE_OR_GENE_PRODUCT", 187, 190], ["SHP", "GENE_OR_GENE_PRODUCT", 230, 233], ["CYP7A1", "GENE_OR_GENE_PRODUCT", 235, 241], ["CYP8B1", "GENE_OR_GENE_PRODUCT", 246, 252], ["FXR", "PROTEIN", 22, 25], ["FXR", "PROTEIN", 187, 190], ["mRNA", "RNA", 192, 196], ["SHP", "PROTEIN", 230, 233], ["CYP7A1", "PROTEIN", 235, 241], ["CYP8B1", "PROTEIN", 246, 252], ["an FXR ligand", "TEST", 19, 32], ["CYP7A1", "TEST", 235, 241], ["CYP8B1", "TEST", 246, 252], ["FXR", "ANATOMY", 187, 190]]], ["IVM suppresses the expression of CYP7A1, and CYP8B1 mRNA but induces the expression of SHP mRNA.", [["IVM", "CHEMICAL", 0, 3], ["CYP7A1", "GENE_OR_GENE_PRODUCT", 33, 39], ["CYP8B1", "GENE_OR_GENE_PRODUCT", 45, 51], ["SHP", "GENE_OR_GENE_PRODUCT", 87, 90], ["CYP7A1, and CYP8B1 mRNA", "RNA", 33, 56], ["SHP mRNA", "RNA", 87, 95], ["IVM", "TREATMENT", 0, 3], ["CYP7A1", "TEST", 33, 39], ["CYP8B1 mRNA", "PROBLEM", 45, 56], ["SHP mRNA", "PROBLEM", 87, 95], ["SHP mRNA", "OBSERVATION", 87, 95]]], ["IVM also regulates some key regulatory enzymes in glucose synthesis such as G6Pase and PEPCK.", [["glucose", "CHEMICAL", 50, 57], ["IVM", "CHEMICAL", 0, 3], ["glucose", "CHEMICAL", 50, 57], ["glucose", "SIMPLE_CHEMICAL", 50, 57], ["G6Pase", "GENE_OR_GENE_PRODUCT", 76, 82], ["PEPCK", "GENE_OR_GENE_PRODUCT", 87, 92], ["regulatory enzymes", "PROTEIN", 28, 46], ["G6Pase", "PROTEIN", 76, 82], ["PEPCK", "PROTEIN", 87, 92], ["IVM", "TREATMENT", 0, 3], ["glucose synthesis", "TEST", 50, 67], ["PEPCK", "TEST", 87, 92]]], ["However IVM was only active in FXR wild mice when it was not effective in FXR\u2212/\u2212 mice.", [["IVM", "CHEMICAL", 8, 11], ["FXR", "GENE_OR_GENE_PRODUCT", 31, 34], ["mice", "ORGANISM", 40, 44], ["FXR", "GENE_OR_GENE_PRODUCT", 74, 77], ["FXR", "PROTEIN", 31, 34], ["FXR", "PROTEIN", 74, 77], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 81, 85], ["IVM", "PROBLEM", 8, 11], ["active", "OBSERVATION_MODIFIER", 21, 27]]], ["In this mice (FXR wild type), IVM suppresses the expression of genes involved in G6Pase and PEPCK synthesis, leading to their low concentration [180] .", [["IVM", "CHEMICAL", 30, 33], ["mice", "ORGANISM", 8, 12], ["FXR", "GENE_OR_GENE_PRODUCT", 14, 17], ["G6Pase", "GENE_OR_GENE_PRODUCT", 81, 87], ["PEPCK", "GENE_OR_GENE_PRODUCT", 92, 97], ["FXR", "PROTEIN", 14, 17], ["G6Pase", "PROTEIN", 81, 87], ["PEPCK", "PROTEIN", 92, 97], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["IVM", "TREATMENT", 30, 33], ["PEPCK synthesis", "TREATMENT", 92, 107]]], ["This also confirms the importance FXR in the metabolic activity of IVM.", [["IVM", "CHEMICAL", 67, 70], ["FXR", "GENE_OR_GENE_PRODUCT", 34, 37], ["FXR", "PROTEIN", 34, 37], ["FXR", "OBSERVATION", 34, 37], ["metabolic activity", "OBSERVATION", 45, 63]]], ["Duran-Sandoval et al. [181] also showed that IVM does not have any effect on the expression of L-PK mRNA levels as compared to GW4064 in hepatic cells and tissues.", [["hepatic cells", "ANATOMY", 137, 150], ["tissues", "ANATOMY", 155, 162], ["GW4064", "CHEMICAL", 127, 133], ["IVM", "CHEMICAL", 45, 48], ["GW4064", "CHEMICAL", 127, 133], ["L-PK", "GENE_OR_GENE_PRODUCT", 95, 99], ["GW4064", "SIMPLE_CHEMICAL", 127, 133], ["hepatic cells", "CELL", 137, 150], ["tissues", "TISSUE", 155, 162], ["L-PK mRNA", "RNA", 95, 104], ["hepatic cells", "CELL_TYPE", 137, 150], ["L-PK mRNA levels", "TEST", 95, 111], ["hepatic", "ANATOMY", 137, 144], ["tissues", "ANATOMY", 155, 162]]], ["Apart from regulating genes involved in glucose metabolism, IVM also affects genes involves in cholesterol metabolism.", [["glucose", "CHEMICAL", 40, 47], ["IVM", "CHEMICAL", 60, 63], ["cholesterol", "CHEMICAL", 95, 106], ["glucose", "CHEMICAL", 40, 47], ["IVM", "CHEMICAL", 60, 63], ["cholesterol", "CHEMICAL", 95, 106], ["glucose", "SIMPLE_CHEMICAL", 40, 47], ["IVM", "SIMPLE_CHEMICAL", 60, 63], ["cholesterol", "SIMPLE_CHEMICAL", 95, 106], ["glucose metabolism", "PROBLEM", 40, 58], ["regulating genes", "OBSERVATION", 11, 27], ["glucose metabolism", "OBSERVATION", 40, 58], ["cholesterol metabolism", "OBSERVATION", 95, 117]]], ["Important regulatory enzymes, such as mRNA that codes for hydroxymethylglutaryl CoA reductase and hydroxymethylglutaryl Coenzyme A synthase, are suppressed by IVM in an FXR-dependent pathway [182] .", [["IVM", "CHEMICAL", 159, 162], ["hydroxymethylglutaryl CoA", "CHEMICAL", 58, 83], ["hydroxymethylglutaryl Coenzyme A", "CHEMICAL", 98, 130], ["IVM", "CHEMICAL", 159, 162], ["hydroxymethylglutaryl CoA reductase", "GENE_OR_GENE_PRODUCT", 58, 93], ["hydroxymethylglutaryl Coenzyme A synthase", "GENE_OR_GENE_PRODUCT", 98, 139], ["FXR", "GENE_OR_GENE_PRODUCT", 169, 172], ["regulatory enzymes", "PROTEIN", 10, 28], ["mRNA", "RNA", 38, 42], ["hydroxymethylglutaryl CoA reductase", "PROTEIN", 58, 93], ["hydroxymethylglutaryl Coenzyme A synthase", "PROTEIN", 98, 139], ["FXR", "PROTEIN", 169, 172], ["Important regulatory enzymes", "TEST", 0, 28], ["hydroxymethylglutaryl CoA reductase", "TREATMENT", 58, 93], ["hydroxymethylglutaryl Coenzyme A synthase", "TREATMENT", 98, 139]]], ["In addition to these regulatory enzymes, IVM also induced the expression of mRNA that codes multidrug resistance genes, bile salt excretory pumps, and type I scavenger receptor.", [["IVM", "CHEMICAL", 41, 44], ["IVM", "CHEMICAL", 41, 44], ["bile salt", "CHEMICAL", 120, 129], ["IVM", "SIMPLE_CHEMICAL", 41, 44], ["bile salt", "SIMPLE_CHEMICAL", 120, 129], ["type I scavenger receptor", "GENE_OR_GENE_PRODUCT", 151, 176], ["regulatory enzymes", "PROTEIN", 21, 39], ["mRNA", "RNA", 76, 80], ["multidrug resistance genes", "DNA", 92, 118], ["type I scavenger receptor", "PROTEIN", 151, 176], ["these regulatory enzymes", "TEST", 15, 39], ["IVM", "TREATMENT", 41, 44], ["multidrug resistance genes", "PROBLEM", 92, 118], ["bile salt excretory pumps", "TREATMENT", 120, 145], ["type I scavenger receptor", "TREATMENT", 151, 176], ["multidrug resistance", "OBSERVATION", 92, 112], ["bile", "ANATOMY", 120, 124], ["excretory pumps", "OBSERVATION", 130, 145]]], ["In another study, IVM caused a significant reduction in the serum cholesterol levels when administered to animal fed high-fat diet and a decrease in body weight was also observed despite the fact that Pharmaceuticals 2020, 13, 196 20 of 37 IVM did not influence the animal feed intake rate.", [["serum", "ANATOMY", 60, 65], ["body", "ANATOMY", 149, 153], ["IVM", "CHEMICAL", 18, 21], ["cholesterol", "CHEMICAL", 66, 77], ["IVM", "CHEMICAL", 18, 21], ["cholesterol", "CHEMICAL", 66, 77], ["IVM", "CHEMICAL", 240, 243], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["cholesterol", "SIMPLE_CHEMICAL", 66, 77], ["body", "ORGANISM_SUBDIVISION", 149, 153], ["another study", "TEST", 3, 16], ["IVM", "TREATMENT", 18, 21], ["a significant reduction in the serum cholesterol levels", "PROBLEM", 29, 84], ["animal fed high-fat diet", "TREATMENT", 106, 130], ["a decrease in body weight", "PROBLEM", 135, 160], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["reduction", "OBSERVATION_MODIFIER", 43, 52], ["decrease", "OBSERVATION_MODIFIER", 137, 145]]], ["IVM also regulates the level of glucose and insulin levels.", [["glucose", "CHEMICAL", 32, 39], ["IVM", "CHEMICAL", 0, 3], ["glucose", "CHEMICAL", 32, 39], ["glucose", "SIMPLE_CHEMICAL", 32, 39], ["insulin", "GENE_OR_GENE_PRODUCT", 44, 51], ["IVM", "TREATMENT", 0, 3], ["glucose", "TEST", 32, 39], ["insulin levels", "TEST", 44, 58]]], ["Their results also corroborated the reported hyperglycaemic and hyperlipidemic effects of IVM.", [["hyperglycaemic", "DISEASE", 45, 59], ["hyperlipidemic", "DISEASE", 64, 78], ["IVM", "CHEMICAL", 90, 93], ["IVM", "CHEMICAL", 90, 93], ["hyperglycaemic and hyperlipidemic effects of IVM", "PROBLEM", 45, 93], ["hyperglycaemic", "OBSERVATION_MODIFIER", 45, 59], ["hyperlipidemic", "OBSERVATION", 64, 78]]], ["In comparison to the above result, Jin et al. [122] using diabetic mice fed with a high-fat diet, showed that IVM had no significant effect on some regulatory enzymes involved in cholesterol metabolism.", [["diabetic", "DISEASE", 58, 66], ["IVM", "CHEMICAL", 110, 113], ["cholesterol", "CHEMICAL", 179, 190], ["IVM", "CHEMICAL", 110, 113], ["cholesterol", "CHEMICAL", 179, 190], ["mice", "ORGANISM", 67, 71], ["fat", "TISSUE", 88, 91], ["cholesterol", "SIMPLE_CHEMICAL", 179, 190], ["regulatory enzymes", "PROTEIN", 148, 166], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["diabetic mice fed", "TREATMENT", 58, 75], ["a high-fat diet", "TREATMENT", 81, 96], ["significant effect", "PROBLEM", 121, 139], ["some regulatory enzymes", "PROBLEM", 143, 166], ["cholesterol metabolism", "OBSERVATION", 179, 201]]], ["That is the mRNA gene that codes for FDFT1 (farnesyl-diphosphate farnesyltransferase 1), hydroxymethylglutaryl coenzyme A synthase, LDL receptor, and hydroxymethylglutaryl coenzyme A reductase were not affected.", [["farnesyl-diphosphate", "CHEMICAL", 44, 64], ["farnesyl-diphosphate", "CHEMICAL", 44, 64], ["hydroxymethylglutaryl", "CHEMICAL", 89, 110], ["hydroxymethylglutaryl coenzyme A", "CHEMICAL", 150, 182], ["FDFT1", "GENE_OR_GENE_PRODUCT", 37, 42], ["farnesyl-diphosphate farnesyltransferase 1", "GENE_OR_GENE_PRODUCT", 44, 86], ["hydroxymethylglutaryl coenzyme A synthase", "GENE_OR_GENE_PRODUCT", 89, 130], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 132, 144], ["hydroxymethylglutaryl coenzyme A reductase", "GENE_OR_GENE_PRODUCT", 150, 192], ["mRNA gene", "DNA", 12, 21], ["FDFT1", "PROTEIN", 37, 42], ["farnesyl-diphosphate farnesyltransferase 1", "PROTEIN", 44, 86], ["hydroxymethylglutaryl coenzyme A synthase", "PROTEIN", 89, 130], ["LDL receptor", "PROTEIN", 132, 144], ["hydroxymethylglutaryl coenzyme A reductase", "PROTEIN", 150, 192], ["FDFT1 (farnesyl-diphosphate farnesyltransferase", "TREATMENT", 37, 84], ["hydroxymethylglutaryl coenzyme A synthase", "TREATMENT", 89, 130], ["LDL receptor", "TREATMENT", 132, 144], ["hydroxymethylglutaryl coenzyme", "TREATMENT", 150, 180]]], ["However IVM alters the mRNA expression of key glucose synthesis enzymes (G6Pase and PEPCK).", [["IVM", "CHEMICAL", 8, 11], ["glucose", "CHEMICAL", 46, 53], ["IVM", "CHEMICAL", 8, 11], ["glucose", "CHEMICAL", 46, 53], ["glucose", "SIMPLE_CHEMICAL", 46, 53], ["G6Pase", "GENE_OR_GENE_PRODUCT", 73, 79], ["PEPCK", "GENE_OR_GENE_PRODUCT", 84, 89], ["glucose synthesis enzymes", "PROTEIN", 46, 71], ["G6Pase", "PROTEIN", 73, 79], ["PEPCK", "PROTEIN", 84, 89], ["key glucose synthesis enzymes", "TEST", 42, 71], ["G6Pase", "TEST", 73, 79], ["PEPCK", "TEST", 84, 89]]], ["The summary of pharmacological activities of avermectins are shown in Table 3 .PharmacokineticsThere are several factors that determine the pharmacokinetics of ivermectin.", [["avermectins", "CHEMICAL", 45, 56], ["ivermectin", "CHEMICAL", 160, 170], ["avermectins", "CHEMICAL", 45, 56], ["ivermectin", "CHEMICAL", 160, 170], ["avermectins", "SIMPLE_CHEMICAL", 45, 56], ["ivermectin", "SIMPLE_CHEMICAL", 160, 170], ["avermectins", "TREATMENT", 45, 56], ["Pharmacokinetics", "TREATMENT", 79, 95], ["ivermectin", "TREATMENT", 160, 170]]], ["Some of the factors include species, weight, body physiology, nutrition, vehicles used in drug preparation and administration route in the animals [183] .", [["body", "ANATOMY", 45, 49], ["body", "ORGANISM_SUBDIVISION", 45, 49], ["species", "PROBLEM", 28, 35], ["weight", "TEST", 37, 43], ["vehicles", "TREATMENT", 73, 81], ["drug preparation", "TREATMENT", 90, 106]]], ["However, the administration route and vehicle used in drug preparation are the major factors determining the bioavailability and half-life of the drug [184] .", [["the administration route", "TREATMENT", 9, 33], ["vehicle", "TREATMENT", 38, 45], ["drug preparation", "TREATMENT", 54, 70]]], ["Finally, ivermectin (150 \u00b5g/kg) was administered to 16 individuals with water or orange juice (750 mL).", [["orange juice", "ANATOMY", 81, 93], ["ivermectin", "CHEMICAL", 9, 19], ["ivermectin", "CHEMICAL", 9, 19], ["ivermectin", "SIMPLE_CHEMICAL", 9, 19], ["water", "SIMPLE_CHEMICAL", 72, 77], ["juice", "ORGANISM_SUBSTANCE", 88, 93], ["ivermectin", "TREATMENT", 9, 19]]], ["Chen et al. [185] reported that orange juice reduced the area under the curve (AUC) of 15.7 ng/d/mL and average maximum plasma concentration (C max ) of 20.7 ng/mL (water: 33.8 ng/mL; 24.3 ng/d/mL), likely because fruit juices and components are potent inhibitors of other drug carriers.", [["orange juice", "ANATOMY", 32, 44], ["plasma", "ANATOMY", 120, 126], ["fruit juices", "ANATOMY", 214, 226], ["orange", "ORGANISM_SUBSTANCE", 32, 38], ["juice", "ORGANISM_SUBSTANCE", 39, 44], ["plasma", "ORGANISM_SUBSTANCE", 120, 126], ["juices", "ORGANISM_SUBSTANCE", 220, 226], ["orange juice", "PROBLEM", 32, 44], ["AUC", "TEST", 79, 82], ["average maximum plasma concentration (C max )", "TREATMENT", 104, 149], ["fruit juices", "OBSERVATION", 214, 226]]], ["The pharmacokinetics (PK) of orally administered ivermectin was tested in 12 healthy male volunteers between 18 and 50 years.", [["ivermectin", "CHEMICAL", 49, 59], ["ivermectin", "CHEMICAL", 49, 59], ["ivermectin", "SIMPLE_CHEMICAL", 49, 59], ["volunteers", "ORGANISM", 90, 100], ["orally administered ivermectin", "TREATMENT", 29, 59]]], ["A single dose of 12 mg/kg as a tablet resulted in an average maximum plasma concentration peak time of (T max ) 3.6 h, an average maximum plasma concentration of 46 ng/mL and C max of 880 ng/h/mL without showing any clinical side effects [186] .", [["plasma", "ANATOMY", 69, 75], ["plasma", "ANATOMY", 138, 144], ["plasma", "ORGANISM_SUBSTANCE", 69, 75], ["plasma", "ORGANISM_SUBSTANCE", 138, 144], ["an average maximum plasma concentration", "TEST", 119, 158], ["C max", "TEST", 175, 180], ["any clinical side effects", "PROBLEM", 212, 237]]], ["Moreover, Schulz et al. [187] documented that administration of ascending doses of ivermectin resulted in an increase in C max and AUC of 23 ng/mL and 350 ng\u00b7h/mL in pre-school-aged children (PSAC) and school-aged children (SAC), respectively.", [["ivermectin", "CHEMICAL", 83, 93], ["ivermectin", "CHEMICAL", 83, 93], ["ivermectin", "SIMPLE_CHEMICAL", 83, 93], ["children", "ORGANISM", 182, 190], ["children", "ORGANISM", 214, 222], ["children", "SPECIES", 182, 190], ["children", "SPECIES", 214, 222], ["ascending doses of ivermectin", "TREATMENT", 64, 93], ["an increase in C max", "PROBLEM", 106, 126], ["AUC", "TEST", 131, 134], ["increase", "OBSERVATION_MODIFIER", 109, 117]]], ["They found that PSAC with lower BMI was correlated with substantially higher AUCs and these findings were two-times lower in children relative to previously studied parameters in adults.", [["PSAC", "SIMPLE_CHEMICAL", 16, 20], ["children", "ORGANISM", 125, 133], ["children", "SPECIES", 125, 133], ["PSAC with lower BMI", "PROBLEM", 16, 35], ["substantially higher AUCs", "PROBLEM", 56, 81], ["PSAC", "OBSERVATION", 16, 20]]], ["For PSAC treated with 100 and 200 \u00b5g/kg ivermectin, C max increased with median values of 15.5 and 24.4 ng/mL, respectively, while for SAC treated with 200, 400 and 600 \u00b5g/kg ivermectin, C max increased with 21.9, 40.7 and 66.1 ng/mL, respectively.", [["PSAC", "ANATOMY", 4, 8], ["PSAC", "CHEMICAL", 4, 8], ["ivermectin", "CHEMICAL", 40, 50], ["ivermectin", "CHEMICAL", 175, 185], ["ivermectin", "CHEMICAL", 40, 50], ["SAC", "CHEMICAL", 135, 138], ["ivermectin", "CHEMICAL", 175, 185], ["PSAC", "SIMPLE_CHEMICAL", 4, 8], ["ivermectin", "SIMPLE_CHEMICAL", 40, 50], ["C max", "SIMPLE_CHEMICAL", 52, 57], ["ivermectin", "SIMPLE_CHEMICAL", 175, 185], ["C max", "SIMPLE_CHEMICAL", 187, 192], ["PSAC", "TREATMENT", 4, 8], ["ivermectin", "TREATMENT", 40, 50], ["C max", "TEST", 52, 57], ["median values", "TEST", 73, 86], ["ivermectin", "TREATMENT", 175, 185], ["C max", "TEST", 187, 192], ["SAC", "ANATOMY", 135, 138]]], ["In addition, AUC 0-72 increased with ascending doses from 331 to 880 to 1636 ng\u00b7h/mL in SAC and from 169 to 369 ng\u00b7h/mL in PSAC treated groups.", [["PSAC", "ANATOMY", 123, 127], ["AUC", "TEST", 13, 16], ["ascending doses", "TEST", 37, 52], ["PSAC treated groups", "TREATMENT", 123, 142], ["SAC", "ANATOMY", 88, 91]]], ["Half-life (t 1/2 ), T max , V/F and mean residence time (MRT INF ) values of 18 h, 6 h, 8 L/kg, and 28 h, respectively were similar in all treated groups and therefore independent in dose and age [187] .", [["mean residence time", "TEST", 36, 55], ["MRT INF", "TEST", 57, 64]]], ["Schulz et al. [188] reported that C max of ivermectin was 51.6 and 40.1 ng/mL for plasma and dried blood spot samples, respectively and observed a slow clearance and a long t 1/2 (26 and 32 h, respectively) in plasma and dried blood spot samples.", [["plasma", "ANATOMY", 82, 88], ["blood spot samples", "ANATOMY", 99, 117], ["plasma", "ANATOMY", 210, 216], ["blood spot samples", "ANATOMY", 227, 245], ["ivermectin", "CHEMICAL", 43, 53], ["ivermectin", "CHEMICAL", 43, 53], ["C max", "SIMPLE_CHEMICAL", 34, 39], ["ivermectin", "SIMPLE_CHEMICAL", 43, 53], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["blood spot samples", "ORGANISM_SUBSTANCE", 99, 117], ["plasma", "ORGANISM_SUBSTANCE", 210, 216], ["blood spot samples", "ORGANISM_SUBSTANCE", 227, 245], ["C max of ivermectin", "TEST", 34, 53], ["plasma", "TEST", 82, 88], ["dried blood spot samples", "TEST", 93, 117], ["a slow clearance", "PROBLEM", 145, 161], ["plasma", "TEST", 210, 216], ["dried blood spot samples", "TEST", 221, 245]]], ["AUC values were 987 and 810 ng/mL/h for plasma and dried blood spot samples.", [["plasma", "ANATOMY", 40, 46], ["blood spot samples", "ANATOMY", 57, 75], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["blood spot samples", "ORGANISM_SUBSTANCE", 57, 75], ["AUC values", "TEST", 0, 10], ["plasma", "TEST", 40, 46], ["dried blood spot samples", "TEST", 51, 75]]], ["Ivermectin is well circulated within the blood, where it binds plasma protein, the largest amount is found in the liver, while the lowest amount is found in the brain due to restriction by the blood-brain barrier.", [["blood", "ANATOMY", 41, 46], ["plasma", "ANATOMY", 63, 69], ["liver", "ANATOMY", 114, 119], ["brain", "ANATOMY", 161, 166], ["blood", "ANATOMY", 193, 198], ["brain", "ANATOMY", 199, 204], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["liver", "ORGAN", 114, 119], ["brain", "ORGAN", 161, 166], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 199, 212], ["plasma protein", "PROTEIN", 63, 77], ["Ivermectin", "TREATMENT", 0, 10], ["plasma protein", "TEST", 63, 77], ["the blood-brain barrier", "TREATMENT", 189, 212], ["blood", "ANATOMY", 41, 46], ["largest", "OBSERVATION_MODIFIER", 83, 90], ["amount", "OBSERVATION_MODIFIER", 91, 97], ["liver", "ANATOMY", 114, 119], ["lowest", "OBSERVATION_MODIFIER", 131, 137], ["amount", "OBSERVATION_MODIFIER", 138, 144], ["brain", "ANATOMY", 161, 166], ["restriction", "OBSERVATION", 174, 185], ["brain", "ANATOMY", 199, 204]]], ["It is metabolized by the cytochrome P450 system in the liver, and excreted almost entirely in feces [189] .", [["liver", "ANATOMY", 55, 60], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 25, 40], ["liver", "ORGAN", 55, 60], ["cytochrome P450", "PROTEIN", 25, 40], ["the cytochrome P450 system", "TEST", 21, 47], ["cytochrome P450", "OBSERVATION", 25, 40], ["liver", "ANATOMY", 55, 60]]], ["The uneven distribution among different organs is a major factor determining the varying toxicity of ivermectin between invertebrates and their mammalian hosts.", [["organs", "ANATOMY", 40, 46], ["toxicity", "DISEASE", 89, 97], ["ivermectin", "CHEMICAL", 101, 111], ["ivermectin", "CHEMICAL", 101, 111], ["organs", "ORGAN", 40, 46], ["ivermectin", "SIMPLE_CHEMICAL", 101, 111], ["ivermectin", "TREATMENT", 101, 111], ["uneven", "OBSERVATION_MODIFIER", 4, 10], ["distribution", "OBSERVATION_MODIFIER", 11, 23], ["mammalian hosts", "OBSERVATION", 144, 159]]], ["Recent studies to determine the concentration of the drugs that bind to nerve tissues isolated from insects, nematodes, and rat brain, propose that avermectin can elicit its effect at a picomolar or nanomolar concentrations.", [["nerve tissues", "ANATOMY", 72, 85], ["nematodes", "ANATOMY", 109, 118], ["brain", "ANATOMY", 128, 133], ["avermectin", "CHEMICAL", 148, 158], ["avermectin", "CHEMICAL", 148, 158], ["nerve tissues", "TISSUE", 72, 85], ["rat", "ORGANISM", 124, 127], ["brain", "ORGAN", 128, 133], ["avermectin", "SIMPLE_CHEMICAL", 148, 158], ["rat", "SPECIES", 124, 127], ["rat", "SPECIES", 124, 127], ["Recent studies", "TEST", 0, 14], ["the drugs", "TREATMENT", 49, 58], ["nerve tissues", "PROBLEM", 72, 85], ["avermectin", "TREATMENT", 148, 158], ["a picomolar or nanomolar concentrations", "TREATMENT", 184, 223], ["nerve tissues", "ANATOMY", 72, 85]]], ["Using free-living C. elegans that is sensitive to avermectin, have been identified as a binding site specific to avermectin from its crude membrane preparation having a dissociation constant (Kd) of 0.26 nM, the Kd for rat brain was found to be 22 nM, and a 100 fold decrease affinity for avermectin.", [["membrane preparation", "ANATOMY", 139, 159], ["brain", "ANATOMY", 223, 228], ["avermectin", "CHEMICAL", 50, 60], ["avermectin", "CHEMICAL", 113, 123], ["avermectin", "CHEMICAL", 289, 299], ["avermectin", "CHEMICAL", 50, 60], ["avermectin", "CHEMICAL", 113, 123], ["avermectin", "CHEMICAL", 289, 299], ["C. elegans", "ORGANISM", 18, 28], ["avermectin", "SIMPLE_CHEMICAL", 50, 60], ["avermectin", "SIMPLE_CHEMICAL", 113, 123], ["rat", "ORGANISM", 219, 222], ["brain", "ORGAN", 223, 228], ["avermectin", "SIMPLE_CHEMICAL", 289, 299], ["C. elegans", "SPECIES", 18, 28], ["rat", "SPECIES", 219, 222], ["C. elegans", "SPECIES", 18, 28], ["rat", "SPECIES", 219, 222], ["free-living C. elegans", "TREATMENT", 6, 28], ["avermectin", "TREATMENT", 50, 60], ["a binding site", "PROBLEM", 86, 100], ["the Kd for rat brain", "TEST", 208, 228], ["avermectin", "TREATMENT", 289, 299]]], ["Avermectin is easily absorbed and metabolized by the liver and 98% in the excreta and 1% in the urine, when administered orally on an empty stomach [190] .", [["liver", "ANATOMY", 53, 58], ["excreta", "ANATOMY", 74, 81], ["urine", "ANATOMY", 96, 101], ["stomach", "ANATOMY", 140, 147], ["Avermectin", "CHEMICAL", 0, 10], ["Avermectin", "CHEMICAL", 0, 10], ["Avermectin", "SIMPLE_CHEMICAL", 0, 10], ["liver", "ORGAN", 53, 58], ["excreta", "ORGANISM_SUBSTANCE", 74, 81], ["urine", "ORGANISM_SUBSTANCE", 96, 101], ["stomach", "ORGAN", 140, 147], ["Avermectin", "TREATMENT", 0, 10], ["liver", "ANATOMY", 53, 58], ["stomach", "ANATOMY", 140, 147]]], ["A trace amount of the drug has been noticed in human milk.", [["milk", "ANATOMY", 53, 57], ["human", "ORGANISM", 47, 52], ["milk", "ORGANISM_SUBSTANCE", 53, 57], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["trace", "OBSERVATION_MODIFIER", 2, 7], ["amount", "OBSERVATION_MODIFIER", 8, 14]]], ["After 4 h of ivermectin administration, the drug concentration peaks at 30-46 ng/mL in the blood, which slowly decreases with time.", [["blood", "ANATOMY", 91, 96], ["ivermectin", "CHEMICAL", 13, 23], ["ivermectin", "CHEMICAL", 13, 23], ["ivermectin", "SIMPLE_CHEMICAL", 13, 23], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["ivermectin administration", "TREATMENT", 13, 38], ["the drug concentration peaks", "TEST", 40, 68], ["the blood", "TEST", 87, 96], ["blood", "ANATOMY", 91, 96], ["slowly", "OBSERVATION_MODIFIER", 104, 110], ["decreases", "OBSERVATION_MODIFIER", 111, 120]]], ["The concentration of metabolites increases in the blood for a longer period of time compared to the parent compound, which may be due to heterohepatic recycling.", [["blood", "ANATOMY", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["the blood", "PROBLEM", 46, 55], ["heterohepatic recycling", "PROBLEM", 137, 160], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["metabolites", "OBSERVATION_MODIFIER", 21, 32], ["increases", "OBSERVATION_MODIFIER", 33, 42], ["may be due to", "UNCERTAINTY", 123, 136], ["heterohepatic recycling", "OBSERVATION", 137, 160]]], ["Ivermectin has been identified in the nodules, skin fat, and subcutaneous fascia [192] .", [["nodules", "ANATOMY", 38, 45], ["skin fat", "ANATOMY", 47, 55], ["subcutaneous fascia", "ANATOMY", 61, 80], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["nodules", "TISSUE", 38, 45], ["skin fat", "TISSUE", 47, 55], ["subcutaneous fascia", "TISSUE", 61, 80], ["Ivermectin", "TREATMENT", 0, 10], ["the nodules", "PROBLEM", 34, 45], ["nodules", "OBSERVATION", 38, 45], ["skin fat", "ANATOMY", 47, 55], ["subcutaneous fascia", "ANATOMY", 61, 80]]], ["A single 12 mg oral administration of the drug, peaks at 8 h in the antihenar, sebum, squames, and forehead and begin to reduce after 24 h [183] .Environmental Effects of the Usage of Avermectins in LivestockAbamectin (avermectin B1) and ivermectin (22, 23-dihydroavermectin B1) are high molecular weight hydrophobic compounds that are active against a variety of animal parasites and insects [193] .", [["oral", "ANATOMY", 15, 19], ["sebum", "ANATOMY", 79, 84], ["squames", "ANATOMY", 86, 93], ["forehead", "ANATOMY", 99, 107], ["Avermectins", "CHEMICAL", 184, 195], ["LivestockAbamectin", "CHEMICAL", 199, 217], ["avermectin B1", "CHEMICAL", 219, 232], ["ivermectin", "CHEMICAL", 238, 248], ["22, 23-dihydroavermectin B1", "CHEMICAL", 250, 277], ["Avermectins", "CHEMICAL", 184, 195], ["LivestockAbamectin", "CHEMICAL", 199, 217], ["avermectin B1", "CHEMICAL", 219, 232], ["ivermectin", "CHEMICAL", 238, 248], ["22, 23-dihydroavermectin B1", "CHEMICAL", 250, 277], ["oral", "ORGANISM_SUBDIVISION", 15, 19], ["sebum", "TISSUE", 79, 84], ["forehead", "ORGAN", 99, 107], ["Avermectins", "SIMPLE_CHEMICAL", 184, 195], ["LivestockAbamectin", "SIMPLE_CHEMICAL", 199, 217], ["avermectin B1", "SIMPLE_CHEMICAL", 219, 232], ["ivermectin", "SIMPLE_CHEMICAL", 238, 248], ["22, 23-dihydroavermectin B1", "SIMPLE_CHEMICAL", 250, 277], ["the drug", "TREATMENT", 38, 46], ["Avermectins", "TREATMENT", 184, 195], ["LivestockAbamectin (avermectin B1", "TREATMENT", 199, 232], ["ivermectin", "TREATMENT", 238, 248], ["high molecular weight hydrophobic compounds", "PROBLEM", 283, 326], ["sebum", "ANATOMY", 79, 84], ["forehead", "ANATOMY", 99, 107], ["active", "OBSERVATION_MODIFIER", 336, 342]]], ["Numerous environmental fate and effects studies have been carried out in the development of these two compounds as antiparasitic agents and for abamectin as a crop protection chemical.", [["abamectin", "CHEMICAL", 144, 153], ["abamectin", "CHEMICAL", 144, 153], ["abamectin", "SIMPLE_CHEMICAL", 144, 153], ["effects studies", "TEST", 32, 47], ["antiparasitic agents", "TREATMENT", 115, 135], ["abamectin", "TREATMENT", 144, 153], ["a crop protection chemical", "TREATMENT", 157, 183], ["environmental fate", "OBSERVATION", 9, 27]]], ["Two essential AVM drugs, abamectin (avermectin B1) and ivermectin (22, 23-dihydroavermectin B1) , have been subjected to numerous environmental studies as they are widely used for crop protection and pest control.", [["abamectin", "CHEMICAL", 25, 34], ["avermectin B1", "CHEMICAL", 36, 49], ["ivermectin", "CHEMICAL", 55, 65], ["22, 23-dihydroavermectin B1", "CHEMICAL", 67, 94], ["abamectin", "CHEMICAL", 25, 34], ["avermectin B1", "CHEMICAL", 36, 49], ["ivermectin", "CHEMICAL", 55, 65], ["22, 23-dihydroavermectin B1", "CHEMICAL", 67, 94], ["AVM drugs", "SIMPLE_CHEMICAL", 14, 23], ["abamectin", "SIMPLE_CHEMICAL", 25, 34], ["avermectin B1", "SIMPLE_CHEMICAL", 36, 49], ["ivermectin", "SIMPLE_CHEMICAL", 55, 65], ["22, 23-dihydroavermectin B1", "SIMPLE_CHEMICAL", 67, 94], ["Two essential AVM drugs", "TREATMENT", 0, 23], ["abamectin (avermectin B1", "TREATMENT", 25, 49], ["ivermectin", "TREATMENT", 55, 65], ["crop protection", "TREATMENT", 180, 195], ["pest control", "TREATMENT", 200, 212], ["essential", "OBSERVATION_MODIFIER", 4, 13], ["AVM", "OBSERVATION", 14, 17]]], ["Their high molecular weight makes them immobile in soil (Koc > or4000), easily degraded in soil under aerobic conditions, t 1/2 of 2-8 weeks for abamectin in soil and 7-14 days for IVM in soil/faeces, in water the (t 1/2 ) for degradation was less than 12 h and less than 24 h as thin films on surfaces to less bioactive compounds.", [["faeces", "ANATOMY", 193, 199], ["abamectin", "CHEMICAL", 145, 154], ["IVM", "CHEMICAL", 181, 184], ["abamectin", "CHEMICAL", 145, 154], ["IVM", "CHEMICAL", 181, 184], ["abamectin", "SIMPLE_CHEMICAL", 145, 154], ["faeces", "ORGANISM_SUBSTANCE", 193, 199], ["abamectin", "TREATMENT", 145, 154], ["thin films", "TEST", 280, 290]]], ["Plants cannot absorb abamectin from the soil, nor is it bio accumulated in fish.", [["abamectin", "CHEMICAL", 21, 30], ["abamectin", "CHEMICAL", 21, 30], ["abamectin", "SIMPLE_CHEMICAL", 21, 30], ["fish", "ORGANISM_SUBDIVISION", 75, 79]]], ["A study showed that Daphnia magna is the most sensitive water species to abamectin and IVM with an LC 50 values of 0.34 ppb and 0.025 ppb, respectively, while fishes are the least sensitive with LC 50 values of 3.2 ppb and 3.0 ppb, respectively.", [["Daphnia magna", "DISEASE", 20, 33], ["abamectin", "CHEMICAL", 73, 82], ["IVM", "CHEMICAL", 87, 90], ["abamectin", "CHEMICAL", 73, 82], ["IVM", "CHEMICAL", 87, 90], ["Daphnia magna", "ORGANISM", 20, 33], ["abamectin", "SIMPLE_CHEMICAL", 73, 82], ["Daphnia magna", "SPECIES", 20, 33], ["Daphnia magna", "SPECIES", 20, 33], ["A study", "TEST", 0, 7], ["Daphnia magna", "PROBLEM", 20, 33], ["abamectin", "TREATMENT", 73, 82], ["an LC", "TEST", 96, 101], ["LC", "TEST", 195, 197], ["ppb", "TEST", 215, 218], ["Daphnia magna", "OBSERVATION", 20, 33]]], ["Sediments and other particles present in water that can degrade AVM and abamectin often reduce their toxicity in Daphnia.", [["AVM", "DISEASE", 64, 67], ["abamectin", "CHEMICAL", 72, 81], ["toxicity", "DISEASE", 101, 109], ["abamectin", "CHEMICAL", 72, 81], ["AVM", "SIMPLE_CHEMICAL", 64, 67], ["abamectin", "SIMPLE_CHEMICAL", 72, 81], ["AVM", "PROBLEM", 64, 67], ["abamectin", "TREATMENT", 72, 81], ["their toxicity in Daphnia", "PROBLEM", 95, 120], ["particles", "OBSERVATION_MODIFIER", 20, 29], ["AVM", "OBSERVATION", 64, 67]]], ["They have a little toxic effect on avian, for example, abamectin has an LC 50 values of 3102 ppm and 383 ppm for bobwhite quail and mallard duck, respectively, while in the earthworm, IVM and abamectin has LC 50 value of 315 ppm and 28 ppm, respectively.", [["abamectin", "CHEMICAL", 55, 64], ["IVM", "CHEMICAL", 184, 187], ["abamectin", "CHEMICAL", 192, 201], ["abamectin", "CHEMICAL", 55, 64], ["IVM", "CHEMICAL", 184, 187], ["abamectin", "CHEMICAL", 192, 201], ["avian", "ORGANISM", 35, 40], ["abamectin", "SIMPLE_CHEMICAL", 55, 64], ["quail", "ORGANISM", 122, 127], ["mallard duck", "ORGANISM", 132, 144], ["abamectin", "SIMPLE_CHEMICAL", 192, 201], ["quail", "SPECIES", 122, 127], ["mallard duck", "SPECIES", 132, 144], ["bobwhite quail", "SPECIES", 113, 127], ["mallard duck", "SPECIES", 132, 144], ["abamectin", "TEST", 192, 201], ["LC", "TEST", 206, 208], ["little", "OBSERVATION_MODIFIER", 12, 18], ["toxic", "OBSERVATION_MODIFIER", 19, 24], ["mallard duck", "ANATOMY", 132, 144]]], ["Residues of avermectin in livestock feces have been reported to affect the larval form of some dung-associated insects.", [["avermectin", "CHEMICAL", 12, 22], ["avermectin", "CHEMICAL", 12, 22], ["avermectin", "GENE_OR_GENE_PRODUCT", 12, 22], ["feces", "ORGANISM_SUBSTANCE", 36, 41], ["dung", "ORGANISM_SUBDIVISION", 95, 99], ["some dung", "PROBLEM", 90, 99], ["avermectin", "OBSERVATION_MODIFIER", 12, 22], ["livestock feces", "OBSERVATION", 26, 41], ["some", "OBSERVATION_MODIFIER", 90, 94], ["dung", "OBSERVATION", 95, 99]]], ["However, usage pattern of the drugs can limit their effects on dung-associated insects depending on the availability of dung without the drugs and mobility of the insects.", [["dung", "ORGANISM_SUBDIVISION", 63, 67], ["the drugs", "TREATMENT", 26, 35], ["the drugs", "TREATMENT", 133, 142]]], ["The above properties of IVM and abamectin concerning biodegradation often limit their bioaccumulation and translocation in the environment and minimize exposure to non-target organisms or location.Clinical Trials of AvermectinsOver 20 years, ivermectin has been used for in the treatment of human onchocerciasis and lymphatic filariasis [75] .", [["lymphatic", "ANATOMY", 316, 325], ["IVM", "CHEMICAL", 24, 27], ["abamectin", "CHEMICAL", 32, 41], ["Avermectins", "CHEMICAL", 216, 227], ["ivermectin", "CHEMICAL", 242, 252], ["onchocerciasis", "DISEASE", 297, 311], ["lymphatic filariasis", "DISEASE", 316, 336], ["IVM", "CHEMICAL", 24, 27], ["abamectin", "CHEMICAL", 32, 41], ["Avermectins", "CHEMICAL", 216, 227], ["ivermectin", "CHEMICAL", 242, 252], ["IVM", "SIMPLE_CHEMICAL", 24, 27], ["abamectin", "SIMPLE_CHEMICAL", 32, 41], ["Avermectins", "SIMPLE_CHEMICAL", 216, 227], ["ivermectin", "SIMPLE_CHEMICAL", 242, 252], ["human", "ORGANISM", 291, 296], ["human", "SPECIES", 291, 296], ["human", "SPECIES", 291, 296], ["IVM", "TREATMENT", 24, 27], ["abamectin", "TREATMENT", 32, 41], ["biodegradation", "TREATMENT", 53, 67], ["non-target organisms", "PROBLEM", 164, 184], ["Avermectins", "TREATMENT", 216, 227], ["ivermectin", "TREATMENT", 242, 252], ["human onchocerciasis", "PROBLEM", 291, 311], ["lymphatic filariasis", "PROBLEM", 316, 336], ["onchocerciasis", "OBSERVATION", 297, 311], ["lymphatic", "ANATOMY", 316, 325], ["filariasis", "OBSERVATION", 326, 336]]], ["Recent studies concerning ivermectin warrant the swift implementation of controlled clinical trials to evaluate its effectiveness against SARS-CoV-2 that can open up a new field of study on the prospective use of avermectin [178] .", [["ivermectin", "CHEMICAL", 26, 36], ["SARS", "DISEASE", 138, 142], ["avermectin", "CHEMICAL", 213, 223], ["ivermectin", "CHEMICAL", 26, 36], ["avermectin", "CHEMICAL", 213, 223], ["ivermectin", "SIMPLE_CHEMICAL", 26, 36], ["CoV-2", "ORGANISM", 143, 148], ["avermectin", "SIMPLE_CHEMICAL", 213, 223], ["SARS-CoV", "SPECIES", 138, 146], ["Recent studies", "TEST", 0, 14], ["ivermectin", "TREATMENT", 26, 36], ["SARS", "PROBLEM", 138, 142], ["avermectin", "TREATMENT", 213, 223]]], ["Moreover, a recent stage III clinical trial in dengue patients in Thailand showed that daily administration of 400 \u00b5g/kg for 3 days showed a modest effect against dengue virus [194] .", [["dengue", "DISEASE", 47, 53], ["dengue", "DISEASE", 163, 169], ["patients", "ORGANISM", 54, 62], ["dengue virus", "ORGANISM", 163, 175], ["patients", "SPECIES", 54, 62], ["dengue virus", "SPECIES", 163, 175], ["dengue", "SPECIES", 47, 53], ["dengue virus", "SPECIES", 163, 175], ["dengue virus", "PROBLEM", 163, 175], ["stage III", "OBSERVATION_MODIFIER", 19, 28]]], ["Another clinical trial was conducted at six health facilities in western Kenya and requires a sample size of 141 participants to detect the pharmacokinetics, efficacy and safety of ivermectin to provide a promising new malaria elimination tool [195] .", [["ivermectin", "CHEMICAL", 181, 191], ["malaria", "DISEASE", 219, 226], ["ivermectin", "CHEMICAL", 181, 191], ["ivermectin", "SIMPLE_CHEMICAL", 181, 191], ["participants", "SPECIES", 113, 125], ["ivermectin", "TREATMENT", 181, 191], ["a promising new malaria elimination tool", "PROBLEM", 203, 243]]], ["Three in vivo studies evaluated the long-term effect of ivermectin on the survival of mosquitoes by feeding at least seven days after ivermectin administration [196] [197] [198] .", [["ivermectin", "CHEMICAL", 56, 66], ["ivermectin", "CHEMICAL", 134, 144], ["ivermectin", "CHEMICAL", 56, 66], ["ivermectin", "CHEMICAL", 134, 144], ["ivermectin", "SIMPLE_CHEMICAL", 56, 66], ["mosquitoes", "ORGANISM", 86, 96], ["ivermectin", "SIMPLE_CHEMICAL", 134, 144], ["vivo studies", "TEST", 9, 21], ["ivermectin", "TREATMENT", 56, 66], ["ivermectin administration", "TREATMENT", 134, 159], ["long-term effect", "OBSERVATION_MODIFIER", 36, 52]]], ["Chaccour et al. [196] revealed that the administration of single low dose of 200 \u00b5g/kg ivermectin increased mosquito mortality by 1.33-fold when they fed on blood taken from humans received ivermectin one day earlier, however, no effect was observed when mosquitoes were fed on blood taken on day 14 post-treatment.", [["blood", "ANATOMY", 157, 162], ["blood", "ANATOMY", 278, 283], ["ivermectin", "CHEMICAL", 87, 97], ["ivermectin", "CHEMICAL", 190, 200], ["ivermectin", "CHEMICAL", 87, 97], ["ivermectin", "CHEMICAL", 190, 200], ["ivermectin", "SIMPLE_CHEMICAL", 87, 97], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["humans", "ORGANISM", 174, 180], ["ivermectin", "SIMPLE_CHEMICAL", 190, 200], ["blood", "ORGANISM_SUBSTANCE", 278, 283], ["humans", "SPECIES", 174, 180], ["humans", "SPECIES", 174, 180], ["single low dose", "TREATMENT", 58, 73], ["ivermectin", "TREATMENT", 190, 200], ["treatment", "TREATMENT", 305, 314]]], ["Bastiaens et al. [198] recorded that a repeated dose of 200 \u00b5g/kg administered on days zero and two had a modest effect on decreased survival seven days after treatment, while Bryan et al. [197] reported that administering 250 \u00b5g/kg to a single human volunteer had a significant impact for at least two weeks after treatment.", [["human", "ORGANISM", 245, 250], ["human", "SPECIES", 245, 250], ["human", "SPECIES", 245, 250], ["treatment", "TREATMENT", 159, 168], ["treatment", "TREATMENT", 315, 324]]], ["Other avermectins such as moxidectin, selamectin, and doramectin, used to control nematodes in livestock and pets in veterinary medicine are identified to be safe and well-accepted [75] .", [["moxidectin", "CHEMICAL", 26, 36], ["selamectin", "CHEMICAL", 38, 48], ["doramectin", "CHEMICAL", 54, 64], ["moxidectin", "CHEMICAL", 26, 36], ["selamectin", "CHEMICAL", 38, 48], ["doramectin", "CHEMICAL", 54, 64], ["avermectins", "SIMPLE_CHEMICAL", 6, 17], ["moxidectin", "SIMPLE_CHEMICAL", 26, 36], ["selamectin", "SIMPLE_CHEMICAL", 38, 48], ["doramectin", "SIMPLE_CHEMICAL", 54, 64], ["Other avermectins", "TREATMENT", 0, 17], ["moxidectin", "TREATMENT", 26, 36], ["selamectin", "TREATMENT", 38, 48], ["doramectin", "TREATMENT", 54, 64]]], ["A Phase III study was conducted to compare the efficacy, tolerability and safety of 2, 4, and 8 mg of moxidectin and ivermectin oral administration in individuals with Onchocerca volvulus infection, the parasite causing river blindness.", [["oral", "ANATOMY", 128, 132], ["moxidectin", "CHEMICAL", 102, 112], ["ivermectin", "CHEMICAL", 117, 127], ["Onchocerca volvulus infection", "DISEASE", 168, 197], ["river blindness", "DISEASE", 220, 235], ["moxidectin", "CHEMICAL", 102, 112], ["ivermectin", "CHEMICAL", 117, 127], ["moxidectin", "SIMPLE_CHEMICAL", 102, 112], ["ivermectin", "SIMPLE_CHEMICAL", 117, 127], ["oral", "ORGANISM_SUBDIVISION", 128, 132], ["Onchocerca volvulus", "ORGANISM", 168, 187], ["Onchocerca volvulus", "SPECIES", 168, 187], ["Onchocerca volvulus", "SPECIES", 168, 187], ["Phase III study", "TEST", 2, 17], ["moxidectin", "TREATMENT", 102, 112], ["ivermectin oral administration", "TREATMENT", 117, 147], ["Onchocerca volvulus infection", "PROBLEM", 168, 197], ["the parasite", "PROBLEM", 199, 211], ["river blindness", "PROBLEM", 220, 235], ["volvulus infection", "OBSERVATION", 179, 197], ["river blindness", "OBSERVATION", 220, 235]]], ["The 8 mg dose of moxidectin was found to be safe to human, confirming its ability to monitor onchocerciasis elimination [199] .", [["moxidectin", "CHEMICAL", 17, 27], ["onchocerciasis", "DISEASE", 93, 107], ["moxidectin", "CHEMICAL", 17, 27], ["moxidectin", "SIMPLE_CHEMICAL", 17, 27], ["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["The 8 mg dose of moxidectin", "TREATMENT", 0, 27], ["onchocerciasis elimination", "PROBLEM", 93, 119]]], ["Selamectin can be administered orally, topically, or subcutaneously in the veterinary medicine for the treatment of various ecto-and endoparasites in cats and dogs, but is not currently approved for human use [200] .", [["subcutaneously", "ANATOMY", 53, 67], ["Selamectin", "CHEMICAL", 0, 10], ["Selamectin", "CHEMICAL", 0, 10], ["Selamectin", "SIMPLE_CHEMICAL", 0, 10], ["cats", "ORGANISM", 150, 154], ["dogs", "ORGANISM", 159, 163], ["human", "ORGANISM", 199, 204], ["cats", "SPECIES", 150, 154], ["dogs", "SPECIES", 159, 163], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["Selamectin", "TREATMENT", 0, 10], ["the treatment", "TREATMENT", 99, 112]]], ["The summary the current clinical trials/human on avermectins are shown in Table 4 .", [["human", "ORGANISM", 40, 45], ["avermectins", "SIMPLE_CHEMICAL", 49, 60], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["human on avermectins", "TREATMENT", 40, 60]]], ["Summary of the current clinical trials/human on avermectins.DerivativeClinical Trial Ref.IvermectinPhase III clinical trial in dengue patient in Thailand shows it is safe but of no clinical benefit [194] Moxidectin Undergoing phase III clinical trial to treat patient Onchocerca volvulus infection [199] Selamectin Not approved for human use [200]Toxicity and Side EffectsAs with most drugs, avermectin also has unwanted effects or reactions, especially when administered indiscriminately [201] .", [["dengue", "DISEASE", 127, 133], ["Moxidectin", "CHEMICAL", 204, 214], ["Onchocerca volvulus infection", "DISEASE", 268, 297], ["Selamectin", "CHEMICAL", 304, 314], ["Toxicity", "DISEASE", 347, 355], ["avermectin", "CHEMICAL", 392, 402], ["[194] Moxidectin", "CHEMICAL", 198, 214], ["avermectin", "CHEMICAL", 392, 402], ["human", "ORGANISM", 39, 44], ["avermectins", "SIMPLE_CHEMICAL", 48, 59], ["patient", "ORGANISM", 134, 141], ["patient", "ORGANISM", 260, 267], ["Onchocerca volvulus", "ORGANISM", 268, 287], ["[199] Selamectin", "SIMPLE_CHEMICAL", 298, 314], ["human", "ORGANISM", 332, 337], ["Side EffectsAs", "SIMPLE_CHEMICAL", 360, 374], ["avermectin", "SIMPLE_CHEMICAL", 392, 402], ["human", "SPECIES", 39, 44], ["patient", "SPECIES", 134, 141], ["patient", "SPECIES", 260, 267], ["Onchocerca volvulus", "SPECIES", 268, 287], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 39, 44], ["dengue", "SPECIES", 127, 133], ["Onchocerca volvulus", "SPECIES", 268, 287], ["human", "SPECIES", 332, 337], ["avermectins", "TREATMENT", 48, 59], ["DerivativeClinical Trial Ref", "TREATMENT", 60, 88], ["IvermectinPhase III clinical trial", "TREATMENT", 89, 123], ["Moxidectin Undergoing phase III clinical trial", "TREATMENT", 204, 250], ["Onchocerca volvulus infection", "PROBLEM", 268, 297], ["Selamectin", "TREATMENT", 304, 314], ["Side EffectsAs", "PROBLEM", 360, 374], ["most drugs", "TREATMENT", 380, 390], ["avermectin", "TREATMENT", 392, 402]]], ["The toxicity of different types of AVM has been reported either singly or in combinations [166] .", [["toxicity", "DISEASE", 4, 12], ["AVM", "DISEASE", 35, 38], ["AVM", "CANCER", 35, 38], ["AVM", "PROBLEM", 35, 38], ["different types", "OBSERVATION_MODIFIER", 16, 31], ["AVM", "OBSERVATION", 35, 38]]], ["Some of the biochemical processes reported to be affected by AVM includes blocking of lipopolysaccharide (LPS) induced release of tumor necrosis factor (TNF), prostaglandin E2 (PGE2), nitric oxide (NO), and the increase in the concentration of intracellular calcium ion (Ca 2+ ) [202] .", [["intracellular", "ANATOMY", 244, 257], ["AVM", "DISEASE", 61, 64], ["lipopolysaccharide", "CHEMICAL", 86, 104], ["LPS", "CHEMICAL", 106, 109], ["tumor", "DISEASE", 130, 135], ["necrosis", "DISEASE", 136, 144], ["prostaglandin E2", "CHEMICAL", 159, 175], ["PGE2", "CHEMICAL", 177, 181], ["nitric oxide", "CHEMICAL", 184, 196], ["NO", "CHEMICAL", 198, 200], ["calcium", "CHEMICAL", 258, 265], ["Ca", "CHEMICAL", 271, 273], ["prostaglandin E2", "CHEMICAL", 159, 175], ["PGE2", "CHEMICAL", 177, 181], ["nitric oxide", "CHEMICAL", 184, 196], ["NO", "CHEMICAL", 198, 200], ["calcium", "CHEMICAL", 258, 265], ["Ca 2+ )", "CHEMICAL", 271, 278], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 86, 104], ["LPS", "SIMPLE_CHEMICAL", 106, 109], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 130, 151], ["TNF", "GENE_OR_GENE_PRODUCT", 153, 156], ["prostaglandin E2", "SIMPLE_CHEMICAL", 159, 175], ["PGE2", "SIMPLE_CHEMICAL", 177, 181], ["nitric oxide", "SIMPLE_CHEMICAL", 184, 196], ["NO", "SIMPLE_CHEMICAL", 198, 200], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 244, 257], ["calcium", "SIMPLE_CHEMICAL", 258, 265], ["tumor necrosis factor", "PROTEIN", 130, 151], ["TNF", "PROTEIN", 153, 156], ["the biochemical processes", "PROBLEM", 8, 33], ["AVM", "PROBLEM", 61, 64], ["lipopolysaccharide (LPS)", "TREATMENT", 86, 110], ["tumor necrosis factor", "PROBLEM", 130, 151], ["TNF)", "TREATMENT", 153, 157], ["prostaglandin E2 (PGE2)", "TREATMENT", 159, 182], ["nitric oxide", "TREATMENT", 184, 196], ["intracellular calcium ion (Ca", "TEST", 244, 273], ["AVM", "OBSERVATION", 61, 64], ["tumor necrosis", "OBSERVATION", 130, 144], ["increase", "OBSERVATION_MODIFIER", 211, 219]]], ["Severe effects of AVM are often related to overdose intake, thus it is not a common experience and includes respiratory failure, hypotension, and coma.", [["respiratory", "ANATOMY", 108, 119], ["AVM", "DISEASE", 18, 21], ["overdose", "DISEASE", 43, 51], ["respiratory failure", "DISEASE", 108, 127], ["hypotension", "DISEASE", 129, 140], ["coma", "DISEASE", 146, 150], ["Severe effects of AVM", "PROBLEM", 0, 21], ["overdose intake", "PROBLEM", 43, 58], ["respiratory failure", "PROBLEM", 108, 127], ["hypotension", "PROBLEM", 129, 140], ["coma", "PROBLEM", 146, 150], ["AVM", "OBSERVATION", 18, 21], ["respiratory failure", "OBSERVATION", 108, 127], ["hypotension", "OBSERVATION", 129, 140]]], ["Unless it is not treated rapidly, it can lead to death.", [["death", "DISEASE", 49, 54], ["death", "PROBLEM", 49, 54]]], ["Though no specific treatment is available, the observed symptoms can be managed until condition stabilized [203] .", [["specific treatment", "TREATMENT", 10, 28], ["the observed symptoms", "PROBLEM", 43, 64]]], ["The mechanism of AVM by which they elicit their pharmacology and toxicology is similar, despite the differences in their structure, potency, and safety.", [["AVM", "DISEASE", 17, 20], ["AVM", "CANCER", 17, 20], ["AVM", "PROBLEM", 17, 20], ["AVM", "OBSERVATION", 17, 20]]], ["Such mechanisms also involved the glutamate-gated chloride channels and or GABA receptors in the nerve and muscle cells in the invertebrate, resulting in their paralysis and death.", [["nerve", "ANATOMY", 97, 102], ["muscle cells", "ANATOMY", 107, 119], ["glutamate", "CHEMICAL", 34, 43], ["chloride", "CHEMICAL", 50, 58], ["GABA", "CHEMICAL", 75, 79], ["paralysis", "DISEASE", 160, 169], ["death", "DISEASE", 174, 179], ["glutamate", "CHEMICAL", 34, 43], ["chloride", "CHEMICAL", 50, 58], ["GABA", "CHEMICAL", 75, 79], ["glutamate", "SIMPLE_CHEMICAL", 34, 43], ["chloride", "SIMPLE_CHEMICAL", 50, 58], ["GABA receptors", "GENE_OR_GENE_PRODUCT", 75, 89], ["nerve", "TISSUE", 97, 102], ["muscle cells", "CELL", 107, 119], ["glutamate-gated chloride channels", "PROTEIN", 34, 67], ["GABA receptors", "PROTEIN", 75, 89], ["nerve and muscle cells", "CELL_TYPE", 97, 119], ["the glutamate", "TEST", 30, 43], ["GABA receptors", "TEST", 75, 89], ["their paralysis", "PROBLEM", 154, 169], ["death", "PROBLEM", 174, 179], ["nerve", "ANATOMY", 97, 102], ["muscle", "ANATOMY", 107, 113], ["paralysis", "OBSERVATION", 160, 169]]], ["The intoxication process of AVM often begins with hyper excitability, uncontrolled, and uncoordinated movement of the muscle and body.", [["AVM", "ANATOMY", 28, 31], ["muscle", "ANATOMY", 118, 124], ["body", "ANATOMY", 129, 133], ["AVM", "DISEASE", 28, 31], ["AVM", "CANCER", 28, 31], ["muscle", "ORGAN", 118, 124], ["body", "ORGANISM_SUBDIVISION", 129, 133], ["The intoxication process", "PROBLEM", 0, 24], ["AVM", "PROBLEM", 28, 31], ["hyper excitability", "PROBLEM", 50, 68], ["intoxication", "OBSERVATION", 4, 16], ["AVM", "OBSERVATION", 28, 31], ["hyper excitability", "OBSERVATION", 50, 68], ["uncoordinated movement", "OBSERVATION", 88, 110], ["muscle", "ANATOMY", 118, 124], ["body", "ANATOMY", 129, 133]]], ["This then leads to ataxia and immobility like-coma.", [["ataxia", "DISEASE", 19, 25], ["coma", "DISEASE", 46, 50], ["ataxia", "PROBLEM", 19, 25], ["immobility", "PROBLEM", 30, 40], ["coma", "PROBLEM", 46, 50]]], ["The enhanced permeability of chloride ion across the membrane and GABAA agonist's mimicking-effect of AVM as stated earlier can add to the toxicity of AVM.", [["membrane", "ANATOMY", 53, 61], ["AVM", "ANATOMY", 102, 105], ["chloride", "CHEMICAL", 29, 37], ["GABAA", "CHEMICAL", 66, 71], ["AVM", "DISEASE", 102, 105], ["toxicity", "DISEASE", 139, 147], ["AVM", "DISEASE", 151, 154], ["chloride", "CHEMICAL", 29, 37], ["chloride ion", "SIMPLE_CHEMICAL", 29, 41], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["GABAA", "SIMPLE_CHEMICAL", 66, 71], ["AVM", "CANCER", 102, 105], ["AVM", "CANCER", 151, 154], ["AVM", "PROBLEM", 102, 105], ["AVM", "PROBLEM", 151, 154], ["enhanced", "OBSERVATION_MODIFIER", 4, 12], ["permeability", "OBSERVATION_MODIFIER", 13, 25], ["AVM", "OBSERVATION", 102, 105], ["AVM", "OBSERVATION", 151, 154]]], ["The toxicity of AVM is more pronounced in animals with a compromised p-glycoprotein.", [["toxicity", "DISEASE", 4, 12], ["AVM", "DISEASE", 16, 19], ["AVM", "CANCER", 16, 19], ["p-glycoprotein", "GENE_OR_GENE_PRODUCT", 69, 83], ["p-glycoprotein", "PROTEIN", 69, 83], ["The toxicity of AVM", "PROBLEM", 0, 19], ["a compromised p-glycoprotein", "PROBLEM", 55, 83], ["AVM", "OBSERVATION", 16, 19], ["more pronounced", "OBSERVATION_MODIFIER", 23, 38]]], ["Their results also showed that IVM is not genotoxic as various studies using different models to screen for defects in DNA synthesis, clastogenicity, and mutagenicity.", [["IVM", "CHEMICAL", 31, 34], ["IVM", "CHEMICAL", 31, 34], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["IVM", "PROBLEM", 31, 34], ["various studies", "TEST", 55, 70], ["different models", "TEST", 77, 93], ["defects in DNA synthesis", "PROBLEM", 108, 132]]], ["The first AVM to be released for the treatment of animal and human parasitic infections was ivermectin, based on its high efficacy and tolerability.", [["AVM", "ANATOMY", 10, 13], ["AVM", "DISEASE", 10, 13], ["parasitic infections", "DISEASE", 67, 87], ["ivermectin", "CHEMICAL", 92, 102], ["ivermectin", "CHEMICAL", 92, 102], ["AVM", "CANCER", 10, 13], ["human", "ORGANISM", 61, 66], ["ivermectin", "SIMPLE_CHEMICAL", 92, 102], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["The first AVM", "PROBLEM", 0, 13], ["the treatment", "TREATMENT", 33, 46], ["animal and human parasitic infections", "PROBLEM", 50, 87], ["ivermectin", "TREATMENT", 92, 102], ["AVM", "OBSERVATION", 10, 13], ["parasitic", "OBSERVATION_MODIFIER", 67, 76], ["infections", "OBSERVATION", 77, 87]]], ["It was later followed by the approval and commercialization of others, such as abamectin, emamectin, and moxidectin, as an acaricides or insecticides and parasiticides for crop protection and animal health, respectively.", [["abamectin", "CHEMICAL", 79, 88], ["emamectin", "CHEMICAL", 90, 99], ["moxidectin", "CHEMICAL", 105, 115], ["abamectin", "CHEMICAL", 79, 88], ["emamectin", "CHEMICAL", 90, 99], ["moxidectin", "CHEMICAL", 105, 115], ["abamectin", "SIMPLE_CHEMICAL", 79, 88], ["emamectin", "SIMPLE_CHEMICAL", 90, 99], ["moxidectin", "SIMPLE_CHEMICAL", 105, 115], ["abamectin", "TREATMENT", 79, 88], ["emamectin", "TREATMENT", 90, 99], ["moxidectin", "TREATMENT", 105, 115], ["an acaricides", "TREATMENT", 120, 133], ["insecticides", "TREATMENT", 137, 149], ["parasiticides", "TREATMENT", 154, 167], ["crop protection", "TREATMENT", 172, 187]]], ["It was reported that the toxicity of IVM use is rare and most side effects are often transient and mild to moderate.", [["toxicity", "DISEASE", 25, 33], ["IVM", "CHEMICAL", 37, 40], ["IVM", "CHEMICAL", 37, 40], ["mild", "OBSERVATION_MODIFIER", 99, 103], ["moderate", "OBSERVATION_MODIFIER", 107, 115]]], ["Most observed symptoms are generally treated by available measures.", [["Most observed symptoms", "PROBLEM", 0, 22]]], ["Some observable toxicity may also be caused by the use of avermectin for non-labelled purposes.", [["toxicity", "DISEASE", 16, 24], ["avermectin", "CHEMICAL", 58, 68], ["avermectin", "CHEMICAL", 58, 68], ["avermectin", "SIMPLE_CHEMICAL", 58, 68], ["Some observable toxicity", "PROBLEM", 0, 24], ["avermectin", "TREATMENT", 58, 68], ["non-labelled purposes", "TREATMENT", 73, 94], ["toxicity", "OBSERVATION", 16, 24], ["may also be", "UNCERTAINTY", 25, 36]]], ["However, overdose or uncontrolled administration can lead to the development of severe toxicity.", [["overdose", "DISEASE", 9, 17], ["toxicity", "DISEASE", 87, 95], ["overdose", "PROBLEM", 9, 17], ["uncontrolled administration", "TREATMENT", 21, 48], ["severe toxicity", "PROBLEM", 80, 95], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["toxicity", "OBSERVATION", 87, 95]]], ["To illustrate the role of species differences in the expression of efflux transporter, Stevens et al. [204] investigated the effect of the placenta-fetal barrier on the toxic effect of AVM using rodents.", [["placenta", "ANATOMY", 139, 147], ["fetal", "ANATOMY", 148, 153], ["AVM", "DISEASE", 185, 188], ["placenta-fetal barrier", "TISSUE", 139, 161], ["efflux transporter", "PROTEIN", 67, 85], ["the placenta-fetal barrier", "TREATMENT", 135, 161], ["AVM", "PROBLEM", 185, 188], ["placenta", "ANATOMY", 139, 147], ["AVM", "OBSERVATION", 185, 188]]], ["They concluded that the use of animal models in toxicological research and extrapolation to humans is necessary to note the variation in genetic makeup between organisms and between animals and humans.Neurotoxicology of IvermectinThe major toxic effects of IVM observed in the animal studies using rats are ataxia, sluggishness, and ptosis, while in dogs, hypersalivation, ataxia, blindness, coma, respiratory compromise, tremors, mydriasis, anorexia, and death [3] .", [["respiratory", "ANATOMY", 398, 409], ["Ivermectin", "CHEMICAL", 220, 230], ["IVM", "CHEMICAL", 257, 260], ["ataxia", "DISEASE", 307, 313], ["sluggishness", "DISEASE", 315, 327], ["ptosis", "DISEASE", 333, 339], ["hypersalivation", "DISEASE", 356, 371], ["ataxia", "DISEASE", 373, 379], ["blindness", "DISEASE", 381, 390], ["coma", "DISEASE", 392, 396], ["respiratory compromise", "DISEASE", 398, 420], ["tremors", "DISEASE", 422, 429], ["mydriasis", "DISEASE", 431, 440], ["anorexia", "DISEASE", 442, 450], ["death", "DISEASE", 456, 461], ["Ivermectin", "CHEMICAL", 220, 230], ["IVM", "CHEMICAL", 257, 260], ["humans", "ORGANISM", 92, 98], ["humans", "ORGANISM", 194, 200], ["Ivermectin", "SIMPLE_CHEMICAL", 220, 230], ["rats", "ORGANISM", 298, 302], ["humans", "SPECIES", 92, 98], ["humans", "SPECIES", 194, 200], ["rats", "SPECIES", 298, 302], ["dogs", "SPECIES", 350, 354], ["humans", "SPECIES", 92, 98], ["humans", "SPECIES", 194, 200], ["Ivermectin", "TREATMENT", 220, 230], ["IVM", "TREATMENT", 257, 260], ["the animal studies", "TEST", 273, 291], ["ataxia", "PROBLEM", 307, 313], ["sluggishness", "PROBLEM", 315, 327], ["ptosis", "PROBLEM", 333, 339], ["hypersalivation", "PROBLEM", 356, 371], ["ataxia", "PROBLEM", 373, 379], ["blindness", "PROBLEM", 381, 390], ["coma", "PROBLEM", 392, 396], ["respiratory compromise", "PROBLEM", 398, 420], ["tremors", "PROBLEM", 422, 429], ["mydriasis", "PROBLEM", 431, 440], ["anorexia", "PROBLEM", 442, 450], ["death", "PROBLEM", 456, 461], ["toxic", "OBSERVATION_MODIFIER", 240, 245], ["ptosis", "OBSERVATION", 333, 339], ["blindness", "OBSERVATION", 381, 390], ["respiratory compromise", "OBSERVATION", 398, 420], ["anorexia", "OBSERVATION", 442, 450]]], ["It was also noted that young rats are sensitive to IVM, as a high concentrations of IVM are found in the brain due to a tender BBB and lack of p-glycoprotein.", [["brain", "ANATOMY", 105, 110], ["tender BBB", "ANATOMY", 120, 130], ["IVM", "CHEMICAL", 84, 87], ["IVM", "CHEMICAL", 51, 54], ["IVM", "CHEMICAL", 84, 87], ["rats", "ORGANISM", 29, 33], ["IVM", "SIMPLE_CHEMICAL", 84, 87], ["brain", "ORGAN", 105, 110], ["BBB", "MULTI-TISSUE_STRUCTURE", 127, 130], ["p-glycoprotein", "GENE_OR_GENE_PRODUCT", 143, 157], ["p-glycoprotein", "PROTEIN", 143, 157], ["rats", "SPECIES", 29, 33], ["IVM", "TREATMENT", 51, 54], ["a high concentrations of IVM", "PROBLEM", 59, 87], ["a tender BBB", "PROBLEM", 118, 130], ["lack of p-glycoprotein", "PROBLEM", 135, 157], ["brain", "ANATOMY", 105, 110], ["tender", "OBSERVATION", 120, 126]]], ["Most dogs sensitive to IVM neurotoxicity are due to a mutation in MDR1 gene as a result of 4 -bp deletion.", [["IVM", "CHEMICAL", 23, 26], ["neurotoxicity", "DISEASE", 27, 40], ["IVM", "CHEMICAL", 23, 26], ["dogs", "ORGANISM", 5, 9], ["MDR1", "GENE_OR_GENE_PRODUCT", 66, 70], ["MDR1 gene", "DNA", 66, 75], ["4 -bp deletion", "DNA", 91, 105], ["dogs", "SPECIES", 5, 9], ["IVM neurotoxicity", "PROBLEM", 23, 40], ["a mutation in MDR1 gene", "PROBLEM", 52, 75], ["bp deletion", "PROBLEM", 94, 105]]], ["The role of P-glycoprotein (P-gp) is critical in the potential neurotoxicity of IVM.", [["neurotoxicity", "DISEASE", 63, 76], ["IVM", "CHEMICAL", 80, 83], ["P-glycoprotein", "GENE_OR_GENE_PRODUCT", 12, 26], ["P-gp", "GENE_OR_GENE_PRODUCT", 28, 32], ["P-glycoprotein (P-gp", "PROTEIN", 12, 32], ["P-glycoprotein (P-gp)", "TREATMENT", 12, 33]]], ["P-gp is part of the important component of the BBB and it is important in the process by which the BBB regulates the entry and exit of drugs into the brain.", [["BBB", "ANATOMY", 47, 50], ["BBB", "ANATOMY", 99, 102], ["brain", "ANATOMY", 150, 155], ["P-gp", "GENE_OR_GENE_PRODUCT", 0, 4], ["BBB", "MULTI-TISSUE_STRUCTURE", 47, 50], ["BBB", "GENE_OR_GENE_PRODUCT", 99, 102], ["brain", "ORGAN", 150, 155], ["P-gp", "PROTEIN", 0, 4], ["drugs into the brain", "PROBLEM", 135, 155], ["brain", "ANATOMY", 150, 155]]], ["Therefore, any activity that regulates the function of P-gp can affect the concentration of IVM in the brain, especially the efflux of IVM from the brain.", [["brain", "ANATOMY", 103, 108], ["brain", "ANATOMY", 148, 153], ["IVM", "CHEMICAL", 92, 95], ["IVM", "CHEMICAL", 135, 138], ["P-gp", "GENE_OR_GENE_PRODUCT", 55, 59], ["brain", "ORGAN", 103, 108], ["brain", "ORGAN", 148, 153], ["P-gp", "PROTEIN", 55, 59], ["IVM in the brain", "PROBLEM", 92, 108], ["brain", "ANATOMY", 103, 108], ["brain", "ANATOMY", 148, 153]]], ["Some of the processes that affect the function of P-gp include mutation and administration of drugs that inhibit its ability to transport drugs out of the brain.", [["brain", "ANATOMY", 155, 160], ["P-gp", "GENE_OR_GENE_PRODUCT", 50, 54], ["brain", "ORGAN", 155, 160], ["P-gp", "PROTEIN", 50, 54], ["mutation", "PROBLEM", 63, 71], ["drugs", "TREATMENT", 94, 99], ["brain", "ANATOMY", 155, 160]]], ["Some groups of mice that have a low levels of p-glycoprotein and another group that does not express p-glycoprotein, indicated with (\u2212/\u2212) [206] .", [["mice", "ORGANISM", 15, 19], ["p-glycoprotein", "GENE_OR_GENE_PRODUCT", 46, 60], ["p-glycoprotein", "GENE_OR_GENE_PRODUCT", 101, 115], ["p-glycoprotein", "PROTEIN", 46, 60], ["p-glycoprotein", "PROTEIN", 101, 115], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["a low levels of p-glycoprotein", "PROBLEM", 30, 60]]], ["The sensitivity of animals with deficient genotype or wild type (+/+) to neurotoxicity or teratotoxicity of IVM also depends on its concentration in the brain and fetus.", [["brain", "ANATOMY", 153, 158], ["fetus", "ANATOMY", 163, 168], ["neurotoxicity", "DISEASE", 73, 86], ["teratotoxicity", "DISEASE", 90, 104], ["IVM", "CHEMICAL", 108, 111], ["IVM", "CHEMICAL", 108, 111], ["animals", "ORGANISM", 19, 26], ["brain", "ORGAN", 153, 158], ["fetus", "ORGAN", 163, 168], ["deficient genotype", "PROBLEM", 32, 50], ["neurotoxicity", "PROBLEM", 73, 86], ["teratotoxicity of IVM", "PROBLEM", 90, 111], ["brain", "ANATOMY", 153, 158], ["fetus", "ANATOMY", 163, 168]]], ["It was showed that mice deficient in p-glycoprotein share the same phenotype with MDR1a and MDR1b knockout mice [143] .", [["mice", "ORGANISM", 19, 23], ["p-glycoprotein", "GENE_OR_GENE_PRODUCT", 37, 51], ["MDR1a", "GENE_OR_GENE_PRODUCT", 82, 87], ["MDR1b", "GENE_OR_GENE_PRODUCT", 92, 97], ["p-glycoprotein", "PROTEIN", 37, 51], ["MDR1a", "PROTEIN", 82, 87], ["MDR1b", "PROTEIN", 92, 97], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 19, 23], ["mice deficient in p-glycoprotein", "PROBLEM", 19, 51]]], ["These knockout mice were used to prove that the accumulation of IVM in the brain was due to differences in the tissue distribution and pharmacokinetics of IVM as compared to wild type mice [207] .", [["brain", "ANATOMY", 75, 80], ["tissue", "ANATOMY", 111, 117], ["IVM", "CHEMICAL", 64, 67], ["IVM", "CHEMICAL", 155, 158], ["IVM", "CHEMICAL", 64, 67], ["IVM", "CHEMICAL", 155, 158], ["mice", "ORGANISM", 15, 19], ["brain", "ORGAN", 75, 80], ["tissue", "TISSUE", 111, 117], ["mice", "ORGANISM", 184, 188], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 15, 19], ["the accumulation of IVM in the brain", "PROBLEM", 44, 80], ["pharmacokinetics of IVM", "TREATMENT", 135, 158], ["brain", "ANATOMY", 75, 80]]], ["To further establish the role of MDR1a transporter in bioavailability and brain uptake of IVM, cyclosporine, a substrate for p-glycoprotein and IVM absorption were enhanced in the (\u2212/\u2212) CF-1 mice strain without affecting the intravenous pharmacokinetics of either drugs [208] .", [["brain", "ANATOMY", 74, 79], ["intravenous", "ANATOMY", 225, 236], ["IVM", "CHEMICAL", 90, 93], ["cyclosporine", "CHEMICAL", 95, 107], ["IVM", "CHEMICAL", 90, 93], ["cyclosporine", "CHEMICAL", 95, 107], ["IVM", "CHEMICAL", 144, 147], ["MDR1a", "GENE_OR_GENE_PRODUCT", 33, 38], ["brain", "ORGAN", 74, 79], ["IVM", "SIMPLE_CHEMICAL", 90, 93], ["cyclosporine", "SIMPLE_CHEMICAL", 95, 107], ["p-glycoprotein", "SIMPLE_CHEMICAL", 125, 139], ["IVM", "SIMPLE_CHEMICAL", 144, 147], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 225, 236], ["MDR1a transporter", "PROTEIN", 33, 50], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 191, 195], ["MDR1a transporter", "TREATMENT", 33, 50], ["IVM", "TREATMENT", 90, 93], ["cyclosporine", "TREATMENT", 95, 107], ["p-glycoprotein and IVM absorption", "TREATMENT", 125, 158], ["CF", "TEST", 186, 188], ["1 mice strain", "PROBLEM", 189, 202], ["the intravenous pharmacokinetics of either drugs", "TREATMENT", 221, 269]]], ["This shows that metabolism of the drugs in the liver between the two strains ((\u2212/\u2212) and (+/+)) of animals is similar, whereas the concentration of cyclosporine A and ivermectin in the brain has increased relative to the wild form (+/+) of mice independent of oral or intravenous administration.", [["liver", "ANATOMY", 47, 52], ["brain", "ANATOMY", 184, 189], ["oral", "ANATOMY", 259, 263], ["intravenous", "ANATOMY", 267, 278], ["cyclosporine A", "CHEMICAL", 147, 161], ["ivermectin", "CHEMICAL", 166, 176], ["cyclosporine A", "CHEMICAL", 147, 161], ["ivermectin", "CHEMICAL", 166, 176], ["liver", "ORGAN", 47, 52], ["animals", "ORGANISM", 98, 105], ["cyclosporine A", "SIMPLE_CHEMICAL", 147, 161], ["ivermectin", "SIMPLE_CHEMICAL", 166, 176], ["brain", "ORGAN", 184, 189], ["mice", "ORGANISM", 239, 243], ["oral", "ORGANISM_SUBDIVISION", 259, 263], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 267, 278], ["mice", "SPECIES", 239, 243], ["mice", "SPECIES", 239, 243], ["the drugs in the liver", "PROBLEM", 30, 52], ["the two strains", "TEST", 61, 76], ["cyclosporine A", "TREATMENT", 147, 161], ["ivermectin in the brain", "PROBLEM", 166, 189], ["oral or intravenous administration", "TREATMENT", 259, 293], ["metabolism", "OBSERVATION_MODIFIER", 16, 26], ["drugs", "OBSERVATION", 34, 39], ["liver", "ANATOMY", 47, 52], ["brain", "ANATOMY", 184, 189], ["increased", "OBSERVATION_MODIFIER", 194, 203]]], ["This confirms that changes and sensitivity of animals to IVM is as a result of p-glycoprotein deficiency, not adjustment in drug metabolism [208] .", [["IVM", "CHEMICAL", 57, 60], ["IVM", "CHEMICAL", 57, 60], ["p-glycoprotein", "GENE_OR_GENE_PRODUCT", 79, 93], ["IVM", "TREATMENT", 57, 60], ["p-glycoprotein deficiency", "PROBLEM", 79, 104], ["p-glycoprotein deficiency", "OBSERVATION", 79, 104]]], ["HIV protease inhibitors are another drug that can increase the toxicity of IVM in the brain.", [["brain", "ANATOMY", 86, 91], ["toxicity", "DISEASE", 63, 71], ["IVM", "CHEMICAL", 75, 78], ["IVM", "CHEMICAL", 75, 78], ["brain", "ORGAN", 86, 91], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV protease inhibitors", "TREATMENT", 0, 23], ["the toxicity of IVM in the brain", "PROBLEM", 59, 91], ["brain", "ANATOMY", 86, 91]]], ["HIV protease inhibitors are a substrate for P-gp and might compete with IVM for its binding, leading to accumulation of IVM in the brain that might further increase its toxicity in the brain.", [["brain", "ANATOMY", 131, 136], ["brain", "ANATOMY", 185, 190], ["toxicity", "DISEASE", 169, 177], ["IVM", "CHEMICAL", 72, 75], ["IVM", "CHEMICAL", 120, 123], ["P-gp", "GENE_OR_GENE_PRODUCT", 44, 48], ["brain", "ORGAN", 131, 136], ["brain", "ORGAN", 185, 190], ["P-gp", "PROTEIN", 44, 48], ["HIV", "SPECIES", 0, 3], ["HIV protease inhibitors", "TREATMENT", 0, 23], ["IVM", "TREATMENT", 72, 75], ["its binding", "PROBLEM", 80, 91], ["IVM in the brain", "PROBLEM", 120, 136], ["its toxicity in the brain", "PROBLEM", 165, 190], ["brain", "ANATOMY", 131, 136], ["increase", "OBSERVATION_MODIFIER", 156, 164], ["brain", "ANATOMY", 185, 190]]], ["Both albendazole and IVM are metabolized by CYP3A4, a drug metabolizing enzymes that is abundant in the liver and small intestine [209] .", [["liver", "ANATOMY", 104, 109], ["small intestine", "ANATOMY", 114, 129], ["albendazole", "CHEMICAL", 5, 16], ["IVM", "CHEMICAL", 21, 24], ["albendazole", "CHEMICAL", 5, 16], ["IVM", "CHEMICAL", 21, 24], ["albendazole", "SIMPLE_CHEMICAL", 5, 16], ["IVM", "SIMPLE_CHEMICAL", 21, 24], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 44, 50], ["liver", "ORGAN", 104, 109], ["intestine", "ORGAN", 120, 129], ["CYP3A4", "PROTEIN", 44, 50], ["metabolizing enzymes", "PROTEIN", 59, 79], ["albendazole", "TREATMENT", 5, 16], ["IVM", "TREATMENT", 21, 24], ["a drug metabolizing enzymes", "TEST", 52, 79], ["abundant", "OBSERVATION_MODIFIER", 88, 96], ["liver", "ANATOMY", 104, 109], ["small intestine", "ANATOMY", 114, 129]]], ["With most studies conducted so far showing that albendazole is not a substrate for P-gp, it can be concluded that the effect of albendazole on the increased toxicity of IVM might be connected to its clearance from the liver [210] .", [["liver", "ANATOMY", 218, 223], ["albendazole", "CHEMICAL", 48, 59], ["albendazole", "CHEMICAL", 128, 139], ["toxicity", "DISEASE", 157, 165], ["IVM", "CHEMICAL", 169, 172], ["albendazole", "CHEMICAL", 48, 59], ["albendazole", "CHEMICAL", 128, 139], ["IVM", "CHEMICAL", 169, 172], ["albendazole", "SIMPLE_CHEMICAL", 48, 59], ["P-gp", "GENE_OR_GENE_PRODUCT", 83, 87], ["albendazole", "SIMPLE_CHEMICAL", 128, 139], ["IVM", "SIMPLE_CHEMICAL", 169, 172], ["liver", "ORGAN", 218, 223], ["P-gp", "PROTEIN", 83, 87], ["most studies", "TEST", 5, 17], ["albendazole", "TREATMENT", 48, 59], ["albendazole", "TREATMENT", 128, 139], ["the increased toxicity of IVM", "TREATMENT", 143, 172], ["liver", "ANATOMY", 218, 223]]], ["In finding an answer to whether IVM neurotoxicity is due to drug metabolizing enzymes or P-gp, Nobmann et al. [211] used an IVM labelled with a fluorescent compound (BODIPY) tagged BODIPY-labelled IVM.", [["IVM", "CHEMICAL", 32, 35], ["neurotoxicity", "DISEASE", 36, 49], ["BODIPY", "CHEMICAL", 181, 187], ["IVM", "CHEMICAL", 32, 35], ["IVM", "CHEMICAL", 124, 127], ["BODIPY", "CHEMICAL", 166, 172], ["BODIPY", "CHEMICAL", 181, 187], ["IVM", "CHEMICAL", 197, 200], ["BODIPY", "SIMPLE_CHEMICAL", 166, 172], ["BODIPY", "SIMPLE_CHEMICAL", 181, 187], ["IVM", "SIMPLE_CHEMICAL", 197, 200], ["drug metabolizing enzymes", "PROTEIN", 60, 85], ["P-gp", "PROTEIN", 89, 93], ["IVM neurotoxicity", "PROBLEM", 32, 49], ["drug metabolizing enzymes", "TEST", 60, 85], ["an IVM", "TREATMENT", 121, 127], ["tagged BODIPY-labelled IVM", "TREATMENT", 174, 200]]], ["They found out that the efflux of the drug is reduced by a substrate that binds to P-gp.", [["P-gp", "GENE_OR_GENE_PRODUCT", 83, 87], ["P-gp", "PROTEIN", 83, 87], ["efflux", "OBSERVATION", 24, 30]]], ["Further investigation showed that the dosage required for drug-drug interaction to be effective as a co-substrate for P-gp might not be possible [212] .", [["P-gp", "GENE_OR_GENE_PRODUCT", 118, 122], ["P", "DNA", 118, 119], ["gp", "PROTEIN", 120, 122], ["Further investigation", "TEST", 0, 21], ["drug-drug interaction", "TREATMENT", 58, 79]]], ["Based on the inability of some antipsychotic, antiemetic and Ca 2+ blocking agents could not replicate their inhibitory activity of P-gp as achieved in the systemic circulation using suitable concentrations.Toxic Effect of IvermectinIvermectin, the most widely used AVM has been reported to be widely safe by several authors, they concluded that most mammalian species respond very well to IVM exposure.", [["Ca", "CHEMICAL", 61, 63], ["IvermectinIvermectin", "CHEMICAL", 223, 243], ["AVM", "DISEASE", 266, 269], ["IVM", "CHEMICAL", 390, 393], ["Ca 2+", "CHEMICAL", 61, 66], ["IvermectinIvermectin", "CHEMICAL", 223, 243], ["IVM", "CHEMICAL", 390, 393], ["Ca 2+", "SIMPLE_CHEMICAL", 61, 66], ["P-gp", "GENE_OR_GENE_PRODUCT", 132, 136], ["IvermectinIvermectin", "SIMPLE_CHEMICAL", 223, 243], ["AVM", "CANCER", 266, 269], ["P-gp", "PROTEIN", 132, 136], ["some antipsychotic", "TREATMENT", 26, 44], ["antiemetic", "TREATMENT", 46, 56], ["Ca 2+ blocking agents", "TREATMENT", 61, 82], ["IvermectinIvermectin", "TREATMENT", 223, 243], ["AVM", "PROBLEM", 266, 269], ["most mammalian species", "PROBLEM", 346, 368], ["systemic circulation", "ANATOMY", 156, 176], ["AVM", "OBSERVATION", 266, 269]]], ["However, few animals show high sensitivity to IVM toxicity.", [["IVM", "CHEMICAL", 46, 49], ["toxicity", "DISEASE", 50, 58], ["IVM", "CHEMICAL", 46, 49], ["animals", "ORGANISM", 13, 20], ["high sensitivity", "PROBLEM", 26, 42], ["IVM toxicity", "PROBLEM", 46, 58], ["high sensitivity", "OBSERVATION_MODIFIER", 26, 42]]], ["Chhaiya et al. [190] reported that some patients with filarial infection developed transient to mild side effects when administered IVM.", [["filarial infection", "DISEASE", 54, 72], ["IVM", "CHEMICAL", 132, 135], ["patients", "ORGANISM", 40, 48], ["filarial", "ORGANISM", 54, 62], ["patients", "SPECIES", 40, 48], ["filarial infection", "PROBLEM", 54, 72], ["mild side effects", "PROBLEM", 96, 113], ["IVM", "TREATMENT", 132, 135], ["filarial", "ANATOMY", 54, 62], ["infection", "OBSERVATION", 63, 72], ["mild", "OBSERVATION_MODIFIER", 96, 100]]], ["Anorexia, headache, myalgia, arthralgia, fever, eosinophilia, and asthenia are some of the symptoms reported.", [["Anorexia", "DISEASE", 0, 8], ["headache", "DISEASE", 10, 18], ["myalgia", "DISEASE", 20, 27], ["arthralgia", "DISEASE", 29, 39], ["fever", "DISEASE", 41, 46], ["eosinophilia", "DISEASE", 48, 60], ["asthenia", "DISEASE", 66, 74], ["Anorexia", "PROBLEM", 0, 8], ["headache", "PROBLEM", 10, 18], ["myalgia", "PROBLEM", 20, 27], ["arthralgia", "PROBLEM", 29, 39], ["fever", "PROBLEM", 41, 46], ["eosinophilia", "PROBLEM", 48, 60], ["asthenia", "PROBLEM", 66, 74], ["the symptoms", "PROBLEM", 87, 99], ["headache", "OBSERVATION", 10, 18], ["myalgia", "OBSERVATION", 20, 27], ["arthralgia", "OBSERVATION", 29, 39], ["fever", "OBSERVATION", 41, 46], ["eosinophilia", "OBSERVATION", 48, 60]]], ["Metabolic products of the microfilaria released in filarial patients has been reported to cause Mazzotti reactions and sudden death.", [["microfilaria", "ANATOMY", 26, 38], ["sudden death", "DISEASE", 119, 131], ["microfilaria", "ORGANISM_SUBSTANCE", 26, 38], ["filarial", "ORGANISM", 51, 59], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["the microfilaria", "PROBLEM", 22, 38], ["Mazzotti reactions", "PROBLEM", 96, 114], ["sudden death", "PROBLEM", 119, 131], ["microfilaria", "OBSERVATION", 26, 38], ["filarial", "ANATOMY", 51, 59]]], ["Also, some scabies patient administered IVM developed popular rashes and pruritus (33%) 2 to 4 days later.", [["scabies", "DISEASE", 11, 18], ["IVM", "CHEMICAL", 40, 43], ["rashes", "DISEASE", 62, 68], ["pruritus", "DISEASE", 73, 81], ["IVM", "CHEMICAL", 40, 43], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["some scabies", "PROBLEM", 6, 18], ["IVM", "TREATMENT", 40, 43], ["popular rashes", "PROBLEM", 54, 68], ["pruritus", "PROBLEM", 73, 81], ["some", "OBSERVATION_MODIFIER", 6, 10], ["scabies", "OBSERVATION", 11, 18]]], ["Other symptoms observed in some of the patients administered IVM include hematomas, prolonged in blood prothrombin time, nausea, decrease in blood pressure, and flat T waves on ECG [213] .", [["blood", "ANATOMY", 97, 102], ["blood", "ANATOMY", 141, 146], ["hematomas", "DISEASE", 73, 82], ["nausea", "DISEASE", 121, 127], ["IVM", "CHEMICAL", 61, 64], ["patients", "ORGANISM", 39, 47], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["prothrombin", "GENE_OR_GENE_PRODUCT", 103, 114], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["prothrombin", "PROTEIN", 103, 114], ["patients", "SPECIES", 39, 47], ["Other symptoms", "PROBLEM", 0, 14], ["hematomas", "PROBLEM", 73, 82], ["prolonged in blood prothrombin time", "PROBLEM", 84, 119], ["nausea", "PROBLEM", 121, 127], ["decrease in blood pressure", "PROBLEM", 129, 155], ["flat T waves", "PROBLEM", 161, 173], ["ECG", "TEST", 177, 180], ["hematomas", "OBSERVATION", 73, 82]]], ["Neonatal mice, which have an immature blood brain barrier, and adult mice and dogs with defective P-glycoprotein are most at risk of ivermectin toxicity, even when given at doses as low as 0.4 mg/kg [214] [215] [216] .", [["blood brain barrier", "ANATOMY", 38, 57], ["ivermectin", "CHEMICAL", 133, 143], ["toxicity", "DISEASE", 144, 152], ["ivermectin", "CHEMICAL", 133, 143], ["mice", "ORGANISM", 9, 13], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 38, 57], ["mice", "ORGANISM", 69, 73], ["dogs", "ORGANISM", 78, 82], ["ivermectin", "SIMPLE_CHEMICAL", 133, 143], ["P-glycoprotein", "PROTEIN", 98, 112], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 69, 73], ["dogs", "SPECIES", 78, 82], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 69, 73], ["defective P-glycoprotein", "TREATMENT", 88, 112], ["ivermectin toxicity", "PROBLEM", 133, 152], ["immature", "OBSERVATION", 29, 37]]], ["In addition, typical therapeutic doses have been shown to cause adverse effects in various mouse strains or stocks, and dog breeds with normal levels of P-glycoprotein [217] .", [["mouse", "ORGANISM", 91, 96], ["dog", "ORGANISM", 120, 123], ["P", "PROTEIN", 153, 154], ["glycoprotein", "PROTEIN", 155, 167], ["mouse", "SPECIES", 91, 96], ["dog", "SPECIES", 120, 123], ["mouse", "SPECIES", 91, 96], ["dog", "SPECIES", 120, 123], ["typical therapeutic doses", "TREATMENT", 13, 38], ["adverse effects", "PROBLEM", 64, 79], ["various mouse strains", "PROBLEM", 83, 104]]], ["Also, ivermectin has been shown to alter aspects of behavior and immune function in mice to indicate that the immunostimulatory properties of ivermectin are associated with altered function of T lymphocytes, in particular, T-helper lymphocytes.", [["T lymphocytes", "ANATOMY", 193, 206], ["T-helper lymphocytes", "ANATOMY", 223, 243], ["ivermectin", "CHEMICAL", 6, 16], ["ivermectin", "CHEMICAL", 142, 152], ["ivermectin", "CHEMICAL", 6, 16], ["ivermectin", "CHEMICAL", 142, 152], ["ivermectin", "SIMPLE_CHEMICAL", 6, 16], ["mice", "ORGANISM", 84, 88], ["ivermectin", "SIMPLE_CHEMICAL", 142, 152], ["T lymphocytes", "CELL", 193, 206], ["T-helper lymphocytes", "CELL", 223, 243], ["T lymphocytes", "CELL_TYPE", 193, 206], ["T-helper lymphocytes", "CELL_TYPE", 223, 243], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["ivermectin", "TREATMENT", 6, 16], ["ivermectin", "TREATMENT", 142, 152], ["altered function of T lymphocytes", "PROBLEM", 173, 206]]], ["The immunomodulating effects of ivermectin may provide an alternative approach for the treatment of disease problems involving immunosuppression [218, 219] .", [["ivermectin", "CHEMICAL", 32, 42], ["ivermectin", "CHEMICAL", 32, 42], ["ivermectin", "SIMPLE_CHEMICAL", 32, 42], ["ivermectin", "TREATMENT", 32, 42], ["an alternative approach", "TREATMENT", 55, 78], ["disease problems", "PROBLEM", 100, 116], ["immunosuppression", "TREATMENT", 127, 144]]], ["Davis et al. [220] also find out that IVM has no significant effect on most parameters evaluated when used to treat mite-infected mice within a barrier facility.", [["IVM", "CHEMICAL", 38, 41], ["mite-infected", "DISEASE", 116, 129], ["IVM", "CHEMICAL", 38, 41], ["mite", "ORGANISM", 116, 120], ["mice", "ORGANISM", 130, 134], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 130, 134], ["IVM", "TREATMENT", 38, 41], ["significant effect", "PROBLEM", 49, 67], ["no", "UNCERTAINTY", 46, 48], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["effect", "OBSERVATION", 61, 67]]], ["Molinari et al. [221] concluded that while IVM and ABM did not cause gene mutations in various in vitro and in vivo models using bacteria or animal cell.", [["cell", "ANATOMY", 148, 152], ["IVM", "CHEMICAL", 43, 46], ["IVM", "CHEMICAL", 43, 46], ["cell", "CELL", 148, 152], ["ABM", "PROBLEM", 51, 54], ["gene mutations", "PROBLEM", 69, 83], ["bacteria", "PROBLEM", 129, 137], ["animal cell", "PROBLEM", 141, 152], ["animal cell", "OBSERVATION", 141, 152]]], ["Neither was there any significant proof of clastogenic effect induced on animal cells.", [["cells", "ANATOMY", 80, 85], ["cells", "CELL", 80, 85], ["animal cells", "CELL_TYPE", 73, 85], ["clastogenic effect", "PROBLEM", 43, 61], ["clastogenic effect", "OBSERVATION", 43, 61], ["animal cells", "OBSERVATION", 73, 85]]], ["The scarce information on claims of the drugs causing breaks in single strands DNA or inhibit cell growth either in an in vitro or in vivo bioassays.", [["cell", "ANATOMY", 94, 98], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["cell", "CELL", 94, 98], ["the drugs", "TREATMENT", 36, 45], ["single strands DNA", "PROBLEM", 64, 82], ["inhibit cell growth", "PROBLEM", 86, 105], ["inhibit cell", "OBSERVATION", 86, 98], ["growth", "OBSERVATION_MODIFIER", 99, 105]]], ["The claimed genotoxicity and cytotoxicity of the two drugs needs to be thoroughly investigated and evaluated for the hazard classification, especially ABM, which is classified as a class II toxicity pesticides by EPA.", [["ABM", "CHEMICAL", 151, 154], ["toxicity", "DISEASE", 190, 198], ["EPA", "CHEMICAL", 213, 216], ["EPA", "CHEMICAL", 213, 216], ["EPA", "SIMPLE_CHEMICAL", 213, 216], ["cytotoxicity", "PROBLEM", 29, 41], ["the two drugs", "TREATMENT", 45, 58], ["ABM", "PROBLEM", 151, 154], ["genotoxicity", "OBSERVATION", 12, 24]]], ["Previously published toxicology testing of ivermectin yielded conflicting results.", [["ivermectin", "CHEMICAL", 43, 53], ["ivermectin", "CHEMICAL", 43, 53], ["ivermectin", "SIMPLE_CHEMICAL", 43, 53], ["ivermectin", "TREATMENT", 43, 53]]], ["One study reported daily exposure of adult CD1 mice to doses as high as 12 mg/kg for as long as 94 day resulted in only a 29% decreased body weight and no other clinical signs [215] .", [["body", "ANATOMY", 136, 140], ["CD1", "ORGANISM", 43, 46], ["mice", "ORGANISM", 47, 51], ["body", "ORGANISM_SUBDIVISION", 136, 140], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["One study", "TEST", 0, 9], ["adult CD1 mice", "TREATMENT", 37, 51], ["a 29% decreased body weight", "PROBLEM", 120, 147]]], ["In another study, doses as low as 0.2 mg/kg resulted in mortality, convulsion, and coma in pregnant female mice and 0.4 mg/kg caused cleft palate in pups exposed in utero [222] .", [["cleft palate", "ANATOMY", 133, 145], ["convulsion", "DISEASE", 67, 77], ["coma", "DISEASE", 83, 87], ["cleft palate", "DISEASE", 133, 145], ["mice", "ORGANISM", 107, 111], ["palate", "ORGAN", 139, 145], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["another study", "TEST", 3, 16], ["convulsion", "PROBLEM", 67, 77], ["cleft palate", "PROBLEM", 133, 145], ["cleft palate", "ANATOMY", 133, 145]]], ["This finding established a no-effect level in mice at 0.1 mg/kg and the belief that mice are uniquely sensitive to ivermectin toxicity.", [["ivermectin", "CHEMICAL", 115, 125], ["toxicity", "DISEASE", 126, 134], ["ivermectin", "CHEMICAL", 115, 125], ["mice", "ORGANISM", 46, 50], ["mice", "ORGANISM", 84, 88], ["ivermectin", "SIMPLE_CHEMICAL", 115, 125], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 84, 88], ["ivermectin toxicity", "PROBLEM", 115, 134]]], ["As a comparison, no-effect levels in rats at 5 mg/kg [215] .", [["rats", "ORGANISM", 37, 41], ["rats", "SPECIES", 37, 41], ["no-effect levels", "TEST", 17, 33]]], ["However, oral ivermectin at doses as high as 2.0 mg/kg has been used to treat mice without adverse effects [223] .", [["oral", "ANATOMY", 9, 13], ["ivermectin", "CHEMICAL", 14, 24], ["ivermectin", "CHEMICAL", 14, 24], ["oral", "ORGANISM_SUBDIVISION", 9, 13], ["ivermectin", "SIMPLE_CHEMICAL", 14, 24], ["mice", "ORGANISM", 78, 82], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["oral ivermectin at doses", "TREATMENT", 9, 33], ["adverse effects", "PROBLEM", 91, 106]]], ["Most published treatment regimens for mice range from 1 to 1.9 mg/kg all of which are clearly above the 0.1-mg/kg no effect level cited [224] [225] [226] [227] [228] .", [["[224] [225] [226] [227] [228]", "CHEMICAL", 136, 165], ["mice", "ORGANISM", 38, 42], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["Most published treatment regimens", "TREATMENT", 0, 33]]], ["To maximize the probability of successfully eliminating fur mites from their large mouse colony, they used the highest dose tested that lacked adverse effects in their toxicity study.", [["colony", "ANATOMY", 89, 95], ["toxicity", "DISEASE", 168, 176], ["mouse", "ORGANISM", 83, 88], ["mouse", "SPECIES", 83, 88], ["mouse", "SPECIES", 83, 88], ["their large mouse colony", "PROBLEM", 71, 95], ["the highest dose", "TREATMENT", 107, 123], ["their toxicity study", "TEST", 162, 182], ["large", "OBSERVATION_MODIFIER", 77, 82], ["mouse colony", "OBSERVATION", 83, 95]]], ["Because most colonies in their vivarium are maintained on a C57BL/6 (B6) background, toxicity experiments were conducted on mice of this strain.", [["colonies", "ANATOMY", 13, 21], ["vivarium", "ANATOMY", 31, 39], ["toxicity", "DISEASE", 85, 93], ["vivarium", "CELL", 31, 39], ["C57BL/6 (B6)", "ORGANISM", 60, 72], ["mice", "ORGANISM", 124, 128], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["a C57BL/6 (B6) background", "TREATMENT", 58, 83], ["toxicity experiments", "PROBLEM", 85, 105], ["this strain", "PROBLEM", 132, 143]]], ["They found that adult B6 mice were relatively resistant to high doses of ivermectin; only 1 of 144 mice receiving 5.4 mg/kg ivermectin daily (48 ppm diet) demonstrated clinical signs.", [["ivermectin", "CHEMICAL", 73, 83], ["ivermectin", "CHEMICAL", 124, 134], ["ivermectin", "CHEMICAL", 73, 83], ["ivermectin", "CHEMICAL", 124, 134], ["B6 mice", "ORGANISM", 22, 29], ["ivermectin", "SIMPLE_CHEMICAL", 73, 83], ["mice", "ORGANISM", 99, 103], ["ivermectin", "SIMPLE_CHEMICAL", 124, 134], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 99, 103], ["adult B6 mice", "PROBLEM", 16, 29], ["ivermectin", "TREATMENT", 73, 83], ["clinical signs", "TEST", 168, 182]]], ["Although gross necropsy and histologic evaluation of tissues from this mouse were unremarkable, the nature of the clinical presentation (tremors, ataxia) and the timing (2 d after initiation of treatment) are suggestive of ivermectin toxicity.", [["tissues", "ANATOMY", 53, 60], ["tremors", "DISEASE", 137, 144], ["ataxia", "DISEASE", 146, 152], ["ivermectin", "CHEMICAL", 223, 233], ["toxicity", "DISEASE", 234, 242], ["ivermectin", "CHEMICAL", 223, 233], ["tissues", "TISSUE", 53, 60], ["mouse", "ORGANISM", 71, 76], ["ivermectin", "SIMPLE_CHEMICAL", 223, 233], ["mouse", "SPECIES", 71, 76], ["mouse", "SPECIES", 71, 76], ["gross necropsy", "TEST", 9, 23], ["histologic evaluation", "TEST", 28, 49], ["tremors", "PROBLEM", 137, 144], ["ataxia", "PROBLEM", 146, 152], ["treatment", "TREATMENT", 194, 203], ["ivermectin toxicity", "PROBLEM", 223, 242], ["gross", "OBSERVATION_MODIFIER", 9, 14], ["necropsy", "OBSERVATION", 15, 23], ["suggestive of", "UNCERTAINTY", 209, 222], ["ivermectin toxicity", "OBSERVATION", 223, 242]]], ["Most reports do not describe mortality at doses equivalent to 12-and 24-ppm feed (1.3 and 2.7 mg/kg), but one study reported that 2 of 22 129/SvSj mice died after receiving a dose of 1 to 2 mg/kg [229] .", [["SvSj mice", "ORGANISM", 142, 151], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["one study", "TEST", 106, 115]]], ["Pathology was not performed and clinical signs were not observed in the cited study; it is possible that the mice died of unrelated causes, especially because an additional 10 129/SvSj mice receiving 5 times the original dose did not demonstrate toxicity [230] .", [["toxicity", "DISEASE", 246, 254], ["mice", "ORGANISM", 109, 113], ["mice", "ORGANISM", 185, 189], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 185, 189], ["Pathology", "TEST", 0, 9], ["clinical signs", "TEST", 32, 46], ["the cited study", "TEST", 68, 83], ["toxicity", "PROBLEM", 246, 254]]], ["Furthermore, 129/SvEv mice treated with oral ivermectin in water for 8 weeks at doses between 1.2 and 1.9 mg/kg demonstrated no adverse effects [231] .", [["oral", "ANATOMY", 40, 44], ["ivermectin", "CHEMICAL", 45, 55], ["ivermectin", "CHEMICAL", 45, 55], ["mice", "ORGANISM", 22, 26], ["oral", "ORGANISM_SUBDIVISION", 40, 44], ["ivermectin", "SIMPLE_CHEMICAL", 45, 55], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["oral ivermectin in water", "TREATMENT", 40, 64], ["adverse effects", "PROBLEM", 128, 143]]], ["In their study, body weight gain among the P0 generation remained constant through the first 3 weeks of treatment in all groups [232] .", [["body", "ANATOMY", 16, 20], ["weight gain", "DISEASE", 21, 32], ["body", "ORGANISM_SUBDIVISION", 16, 20], ["their study", "TEST", 3, 14], ["body weight gain", "PROBLEM", 16, 32], ["treatment", "TREATMENT", 104, 113]]], ["Nine days after the cessation of treatment (day 65), mice receiving 5.4 mg/kg (48 ppm diet) ivermectin were smaller than control mice.", [["ivermectin", "CHEMICAL", 92, 102], ["ivermectin", "CHEMICAL", 92, 102], ["mice", "ORGANISM", 53, 57], ["ivermectin", "SIMPLE_CHEMICAL", 92, 102], ["mice", "ORGANISM", 129, 133], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 129, 133], ["treatment", "TREATMENT", 33, 42], ["ivermectin", "TREATMENT", 92, 102]]], ["Unfortunately, the day 43 weight for the 48-ppm group was not recorded, so these animals may have gained less weight during the second half of the treatment period than during the first half; however, at day 181, no weight differences were observed between groups.", [["animals", "ORGANISM", 81, 88], ["weight", "TEST", 26, 32], ["weight differences", "PROBLEM", 216, 234]]], ["Weight loss was the only adverse finding reported in the initial toxicology study of ivermectin in adult CD1 mice [214] .", [["Weight loss", "DISEASE", 0, 11], ["ivermectin", "CHEMICAL", 85, 95], ["ivermectin", "CHEMICAL", 85, 95], ["ivermectin", "SIMPLE_CHEMICAL", 85, 95], ["CD1 mice", "ORGANISM", 105, 113], ["mice", "SPECIES", 109, 113], ["Weight loss", "PROBLEM", 0, 11], ["ivermectin", "TREATMENT", 85, 95], ["loss", "OBSERVATION", 7, 11]]], ["Comparing body weight at 32 weeks of age among mice in the P0, F1 (control diet), and F2 (control and 12-ppm diets) generations revealed that F1 and F2 mice were significantly larger than their P0 counterparts.", [["body", "ANATOMY", 10, 14], ["body", "ORGANISM_SUBDIVISION", 10, 14], ["mice", "ORGANISM", 47, 51], ["F2 mice", "ORGANISM", 149, 156], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 152, 156], ["F2 (control and 12-ppm diets) generations", "TREATMENT", 86, 127]]], ["The P0 generation was obtained from Taconic Farms at six to eight weeks of age and had been fed NIH no. 31M Rodent Diet prior to their arrival.", [["P0", "DNA", 4, 6]]], ["This diet has a considerably lower fat content (5.3%) than does the Purina 5058 feed (9% crude fat content) used [233] .", [["fat", "ANATOMY", 35, 38], ["fat", "ANATOMY", 95, 98], ["fat", "TISSUE", 35, 38], ["fat", "TISSUE", 95, 98], ["Purina", "SPECIES", 68, 74], ["a considerably lower fat content", "PROBLEM", 14, 46]]], ["However, weight gain was not observed in the group that received 2.7 mg/kg ivermectin.", [["weight gain", "DISEASE", 9, 20], ["ivermectin", "CHEMICAL", 75, 85], ["ivermectin", "CHEMICAL", 75, 85], ["ivermectin", "SIMPLE_CHEMICAL", 75, 85], ["weight gain", "PROBLEM", 9, 20], ["ivermectin", "TREATMENT", 75, 85]]], ["There was no weight increase over subsequent generations, and the treated F1 mice were significantly smaller than those in the control F1 group.", [["mice", "ORGANISM", 77, 81], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["weight increase", "PROBLEM", 13, 28], ["no", "UNCERTAINTY", 10, 12], ["weight", "OBSERVATION_MODIFIER", 13, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["smaller", "OBSERVATION_MODIFIER", 101, 108]]], ["Exposure to ivermectin as neonates apparently can reduce the animals' adult weight, even after drug exposure had ceased.", [["ivermectin", "CHEMICAL", 12, 22], ["ivermectin", "CHEMICAL", 12, 22], ["ivermectin", "SIMPLE_CHEMICAL", 12, 22], ["adult", "DEVELOPING_ANATOMICAL_STRUCTURE", 70, 75], ["ivermectin", "TREATMENT", 12, 22]]], ["Interestingly, the average weaning weight of F1 mice born during ivermectin treatment was very similar between dosage groups and to the weaning weight of animals born after the end of treatment.", [["ivermectin", "CHEMICAL", 65, 75], ["ivermectin", "CHEMICAL", 65, 75], ["F1 mice", "ORGANISM", 45, 52], ["ivermectin", "SIMPLE_CHEMICAL", 65, 75], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["ivermectin treatment", "TREATMENT", 65, 85], ["treatment", "TREATMENT", 184, 193]]], ["During the preweaning period, all pups gained weight at the same rate regardless of ivermectin exposure.", [["ivermectin", "CHEMICAL", 84, 94], ["ivermectin", "CHEMICAL", 84, 94], ["pups", "ORGANISM_SUBDIVISION", 34, 38], ["ivermectin", "SIMPLE_CHEMICAL", 84, 94], ["ivermectin exposure", "TREATMENT", 84, 103], ["ivermectin exposure", "OBSERVATION", 84, 103]]], ["The preweaning growth rate most likely reflects the dam's milk production.", [["milk", "ANATOMY", 58, 62], ["milk", "ORGANISM_SUBSTANCE", 58, 62], ["The preweaning growth rate", "TEST", 0, 26], ["most likely reflects", "UNCERTAINTY", 27, 47]]], ["Despite identical weaning weights, the ability of these animals to gain weight throughout their adult lives may be impaired by neonatal ivermectin exposure.", [["ivermectin", "CHEMICAL", 136, 146], ["ivermectin", "CHEMICAL", 136, 146], ["ivermectin", "SIMPLE_CHEMICAL", 136, 146], ["identical weaning weights", "TREATMENT", 8, 33], ["neonatal ivermectin exposure", "TREATMENT", 127, 155]]], ["The main adverse effects of ivermectin in the original toxicology study were seen in pregnant dams, embryos, and neonatal pups [215] .", [["embryos", "ANATOMY", 100, 107], ["ivermectin", "CHEMICAL", 28, 38], ["ivermectin", "CHEMICAL", 28, 38], ["ivermectin", "SIMPLE_CHEMICAL", 28, 38], ["dams", "ORGANISM_SUBDIVISION", 94, 98], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 100, 107], ["ivermectin", "TREATMENT", 28, 38], ["the original toxicology study", "TEST", 42, 71], ["embryos", "PROBLEM", 100, 107], ["main", "OBSERVATION_MODIFIER", 4, 8], ["adverse", "OBSERVATION_MODIFIER", 9, 16], ["effects", "OBSERVATION_MODIFIER", 17, 24], ["ivermectin", "OBSERVATION_MODIFIER", 28, 38]]], ["None of the pregnant mice showed any clinical signs or mortality in any of the treatment groups.", [["mice", "ORGANISM", 21, 25], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["mortality", "PROBLEM", 55, 64]]], ["In addition, they also observed no teratogenic effects (for example, cleft palate) in any of the pups that had been exposed to ivermectin at any dose in utero.", [["cleft palate", "ANATOMY", 69, 81], ["cleft palate", "DISEASE", 69, 81], ["ivermectin", "CHEMICAL", 127, 137], ["ivermectin", "CHEMICAL", 127, 137], ["palate", "ORGAN", 75, 81], ["pups", "ORGANISM", 97, 101], ["ivermectin", "SIMPLE_CHEMICAL", 127, 137], ["teratogenic effects", "PROBLEM", 35, 54], ["cleft palate", "PROBLEM", 69, 81], ["ivermectin", "TREATMENT", 127, 137]]], ["Their results also showed no differences in the numbers of litters or pups born to dams of the various treatment groups.", [["the various treatment groups", "TREATMENT", 91, 119]]], ["In summary, their findings indicate that ivermectin at doses as high as 5.4 mg/kg does not affect the fertility of C57BL/6NTac mice.", [["ivermectin", "CHEMICAL", 41, 51], ["ivermectin", "CHEMICAL", 41, 51], ["ivermectin", "SIMPLE_CHEMICAL", 41, 51], ["C57BL/6NTac mice", "ORGANISM", 115, 131], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 127, 131], ["ivermectin at doses", "TREATMENT", 41, 60], ["C57BL/6NTac mice", "TREATMENT", 115, 131]]], ["Of importance, dose-dependent increases in the mortality rates were noticed in neonatal mice in the 2.7-and 5.4-mg/kg groups.", [["mice", "ORGANISM", 88, 92], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["dependent increases", "PROBLEM", 20, 39], ["the mortality rates", "TEST", 43, 62], ["dependent", "OBSERVATION_MODIFIER", 20, 29], ["increases", "OBSERVATION_MODIFIER", 30, 39]]], ["In the highest dose group, none of the pups survived past the fourth day.", [["pups", "ORGANISM", 39, 43]]], ["This effect was transient, and litters born in the 12-and 48-ppm groups after cessation of treatment had identical survival rates.", [["treatment", "TREATMENT", 91, 100], ["transient", "OBSERVATION_MODIFIER", 16, 25]]], ["Even pups born immediately after treatment ended and that therefore had been exposed to ivermectin in utero for most of the pregnancy survived.", [["ivermectin", "CHEMICAL", 88, 98], ["ivermectin", "CHEMICAL", 88, 98], ["pups", "ORGANISM", 5, 9], ["ivermectin", "SIMPLE_CHEMICAL", 88, 98], ["treatment", "TREATMENT", 33, 42], ["ivermectin", "TREATMENT", 88, 98]]], ["This finding indicates no measurable intrauterine effect of ivermectin on the pups.", [["intrauterine", "ANATOMY", 37, 49], ["pups", "ANATOMY", 78, 82], ["ivermectin", "CHEMICAL", 60, 70], ["ivermectin", "CHEMICAL", 60, 70], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 49], ["ivermectin", "SIMPLE_CHEMICAL", 60, 70], ["pups", "ORGANISM_SUBDIVISION", 78, 82], ["measurable intrauterine effect", "PROBLEM", 26, 56], ["ivermectin", "TREATMENT", 60, 70], ["no", "UNCERTAINTY", 23, 25], ["measurable", "OBSERVATION_MODIFIER", 26, 36], ["intrauterine", "OBSERVATION", 37, 49], ["ivermectin", "OBSERVATION", 60, 70]]], ["The increased mortality in neonates in the higher dose groups is most likely due to two processes.", [["neonates", "ORGANISM", 27, 35], ["The increased mortality in neonates", "PROBLEM", 0, 35], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["mortality", "OBSERVATION_MODIFIER", 14, 23], ["most likely due to", "UNCERTAINTY", 65, 83]]], ["Nursing pups are exposed to ivermectin through milk.", [["milk", "ANATOMY", 47, 51], ["ivermectin", "CHEMICAL", 28, 38], ["ivermectin", "CHEMICAL", 28, 38], ["pups", "ORGANISM", 8, 12], ["ivermectin", "SIMPLE_CHEMICAL", 28, 38], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["ivermectin through milk", "TREATMENT", 28, 51]]], ["Because ivermectin is lipophilic, it concentrates in the milk, and the pups' oral exposure level is higher than that of the dam.", [["milk", "ANATOMY", 57, 61], ["oral", "ANATOMY", 77, 81], ["ivermectin", "CHEMICAL", 8, 18], ["ivermectin", "CHEMICAL", 8, 18], ["ivermectin", "SIMPLE_CHEMICAL", 8, 18], ["milk", "ORGANISM_SUBSTANCE", 57, 61], ["pups", "ORGANISM_SUBDIVISION", 71, 75], ["oral", "ORGANISM_SUBDIVISION", 77, 81], ["ivermectin", "TREATMENT", 8, 18], ["lipophilic", "OBSERVATION_MODIFIER", 22, 32], ["higher", "OBSERVATION_MODIFIER", 100, 106]]], ["In addition, the blood-brain barrier of rodents is not fully developed until approximately 10 d of age.", [["blood", "ANATOMY", 17, 22], ["brain", "ANATOMY", 23, 28], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 23, 36], ["rodents", "ORGANISM", 40, 47], ["the blood", "TEST", 13, 22], ["brain", "ANATOMY", 23, 28]]], ["One study reports similar findings in rats exposed to ivermectin and attributes neonatal mortality to the accumulation of ivermectin to toxic levels in the brain [234] .", [["brain", "ANATOMY", 156, 161], ["ivermectin", "CHEMICAL", 54, 64], ["ivermectin", "CHEMICAL", 122, 132], ["ivermectin", "CHEMICAL", 54, 64], ["ivermectin", "CHEMICAL", 122, 132], ["rats", "ORGANISM", 38, 42], ["ivermectin", "SIMPLE_CHEMICAL", 54, 64], ["ivermectin", "SIMPLE_CHEMICAL", 122, 132], ["brain", "ORGAN", 156, 161], ["rats", "SPECIES", 38, 42], ["One study", "TEST", 0, 9], ["ivermectin", "TREATMENT", 54, 64], ["ivermectin", "TREATMENT", 122, 132], ["toxic levels in the brain", "PROBLEM", 136, 161], ["brain", "ANATOMY", 156, 161]]], ["Although adult toxicity was studied in CD1 mice, reproductive toxicity was studied in CF1 mice.", [["toxicity", "DISEASE", 15, 23], ["toxicity", "DISEASE", 62, 70], ["CD1 mice", "ORGANISM", 39, 47], ["CF1 mice", "ORGANISM", 86, 94], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 90, 94], ["adult toxicity", "PROBLEM", 9, 23], ["reproductive toxicity", "PROBLEM", 49, 70], ["toxicity", "OBSERVATION", 15, 23]]], ["The CF1 stock later was found to have a high percentage of mice with a P-glycoprotein deficiency due to a natural mutation [214] .", [["CF1 stock", "ORGANISM", 4, 13], ["mice", "ORGANISM", 59, 63], ["glycoprotein", "PROTEIN", 73, 85], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["a P-glycoprotein deficiency", "PROBLEM", 69, 96], ["a natural mutation", "PROBLEM", 104, 122]]], ["This deficiency markedly increases the susceptibility of these mice to ivermectin toxicity.", [["ivermectin", "CHEMICAL", 71, 81], ["toxicity", "DISEASE", 82, 90], ["ivermectin", "CHEMICAL", 71, 81], ["mice", "ORGANISM", 63, 67], ["ivermectin", "SIMPLE_CHEMICAL", 71, 81], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["This deficiency", "PROBLEM", 0, 15], ["ivermectin toxicity", "PROBLEM", 71, 90], ["deficiency", "OBSERVATION", 5, 15], ["markedly", "OBSERVATION_MODIFIER", 16, 24], ["increases", "OBSERVATION_MODIFIER", 25, 34]]], ["The unfortunate use of this highly susceptible stock in the toxicity study gave rise to the idea that mice in general are highly susceptible to ivermectin toxicity.", [["toxicity", "DISEASE", 60, 68], ["ivermectin", "CHEMICAL", 144, 154], ["toxicity", "DISEASE", 155, 163], ["ivermectin", "CHEMICAL", 144, 154], ["mice", "ORGANISM", 102, 106], ["ivermectin", "SIMPLE_CHEMICAL", 144, 154], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 102, 106], ["the toxicity study", "TEST", 56, 74], ["ivermectin toxicity", "PROBLEM", 144, 163]]], ["Ricart et al. [232] did not observe any adverse effects of ivermectin exposure on the fertility or fecundity of offspring of C57BL/6NTac mice treated with ivermectin.", [["ivermectin", "CHEMICAL", 59, 69], ["ivermectin", "CHEMICAL", 155, 165], ["ivermectin", "CHEMICAL", 59, 69], ["ivermectin", "CHEMICAL", 155, 165], ["ivermectin", "SIMPLE_CHEMICAL", 59, 69], ["C57BL/6NTac mice", "ORGANISM", 125, 141], ["ivermectin", "SIMPLE_CHEMICAL", 155, 165], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 137, 141], ["ivermectin exposure", "TREATMENT", 59, 78], ["the fertility", "TREATMENT", 82, 95], ["C57BL/6NTac mice", "TREATMENT", 125, 141], ["ivermectin", "TREATMENT", 155, 165]]], ["In conclusion, their results suggest that ivermectin can be compounded in rodent feed and, although a decline in drug concentration occurs due to manufacturing, the remaining drug is stable for at least six months post-milling.", [["ivermectin", "CHEMICAL", 42, 52], ["ivermectin", "CHEMICAL", 42, 52], ["ivermectin", "SIMPLE_CHEMICAL", 42, 52], ["ivermectin", "TREATMENT", 42, 52], ["a decline in drug concentration", "PROBLEM", 100, 131], ["stable", "OBSERVATION_MODIFIER", 183, 189]]], ["Ivermectin can be safely administered to neonatal, juvenile, adult, and pregnant C57BL/6NTac mice at 1.3 mg/kg daily for an 8-wk period.", [["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["C57BL/6NTac mice", "ORGANISM", 81, 97], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["Ivermectin", "TREATMENT", 0, 10], ["pregnant C57BL/6NTac mice", "TREATMENT", 72, 97]]], ["Further studies should be conducted to assess safety in other strains of mice, including those known to be highly susceptible to ivermectin toxicity.", [["ivermectin", "CHEMICAL", 129, 139], ["toxicity", "DISEASE", 140, 148], ["ivermectin", "CHEMICAL", 129, 139], ["mice", "ORGANISM", 73, 77], ["ivermectin", "SIMPLE_CHEMICAL", 129, 139], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["Further studies", "TEST", 0, 15], ["ivermectin toxicity", "PROBLEM", 129, 148]]], ["Pregnant mice in their studies did not show any clinical signs, teratogenic effects, differences in the numbers of litters or pups born to dams of the various treatment groups or mortality in any of the treatment groups [232] .", [["mice", "ORGANISM", 9, 13], ["pups", "ORGANISM_SUBDIVISION", 126, 130], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["teratogenic effects", "PROBLEM", 64, 83], ["the various treatment groups", "TREATMENT", 147, 175]]], ["Together, these findings indicate that ivermectin at doses as high as 5.4 mg/kg has no effect on the fertility of C57BL/6NTac mice.ConclusionsThis review examines the medicinal and side effects of avermectins.", [["ivermectin", "CHEMICAL", 39, 49], ["avermectins", "CHEMICAL", 197, 208], ["ivermectin", "CHEMICAL", 39, 49], ["avermectins", "CHEMICAL", 197, 208], ["ivermectin", "SIMPLE_CHEMICAL", 39, 49], ["C57BL/6NTac mice", "ORGANISM", 114, 130], ["avermectins", "SIMPLE_CHEMICAL", 197, 208], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["ivermectin", "TREATMENT", 39, 49], ["C57BL/6NTac mice", "TREATMENT", 114, 130], ["avermectins", "TREATMENT", 197, 208]]], ["Avermectins are a remarkable compounds which were first isolated in 1978.", [["Avermectins", "CHEMICAL", 0, 11], ["Avermectins", "CHEMICAL", 0, 11], ["Avermectins", "SIMPLE_CHEMICAL", 0, 11], ["Avermectins", "TREATMENT", 0, 11]]], ["Avermectins are generally soluble in organic solvents, such as ethanol, chloroform, diethyl ether, ethyl acetate and have a high adsorption coefficient, which makes them less likely to accumulate in the water column.", [["Avermectins", "CHEMICAL", 0, 11], ["ethanol, chloroform, diethyl ether, ethyl acetate", "CHEMICAL", 63, 112], ["Avermectins", "CHEMICAL", 0, 11], ["ethanol", "CHEMICAL", 63, 70], ["chloroform", "CHEMICAL", 72, 82], ["diethyl ether", "CHEMICAL", 84, 97], ["ethyl acetate", "CHEMICAL", 99, 112], ["Avermectins", "SIMPLE_CHEMICAL", 0, 11], ["ethanol", "SIMPLE_CHEMICAL", 63, 70], ["chloroform", "SIMPLE_CHEMICAL", 72, 82], ["diethyl ether", "SIMPLE_CHEMICAL", 84, 97], ["ethyl acetate", "SIMPLE_CHEMICAL", 99, 112], ["Avermectins", "TREATMENT", 0, 11], ["organic solvents", "TREATMENT", 37, 53], ["ethanol, chloroform", "TREATMENT", 63, 82], ["diethyl ether", "TREATMENT", 84, 97], ["ethyl acetate", "TREATMENT", 99, 112], ["a high adsorption coefficient", "PROBLEM", 122, 151], ["generally", "OBSERVATION_MODIFIER", 16, 25], ["soluble", "OBSERVATION_MODIFIER", 26, 33], ["water column", "ANATOMY_MODIFIER", 203, 215]]], ["They are commonly used in oral, parenteral, topical, or spot topical (as in veterinary flea repellant \"drops\") form and show activity against a broad range of nematodes and arthropod parasites of domestic animals at doses of 300 \u00b5g/kg or less than 200 \u00b5g/kg.", [["oral", "ANATOMY", 26, 30], ["oral", "ORGANISM_SUBDIVISION", 26, 30], ["oral, parenteral, topical", "TREATMENT", 26, 51], ["spot topical", "TREATMENT", 56, 68]]], ["Ivermectin, the most widely used AVM has been reported to be widely safe for most mammalian species.", [["Ivermectin", "CHEMICAL", 0, 10], ["AVM", "DISEASE", 33, 36], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["AVM", "CANCER", 33, 36], ["Ivermectin", "TREATMENT", 0, 10], ["AVM", "PROBLEM", 33, 36], ["most mammalian species", "PROBLEM", 77, 99], ["AVM", "OBSERVATION", 33, 36]]], ["Several reports documented that administration of ascending doses of ivermectin resulted in an increase in C max , T max , t 1/2 and AUC in tested volunteers.", [["ivermectin", "CHEMICAL", 69, 79], ["ivermectin", "CHEMICAL", 69, 79], ["ivermectin", "SIMPLE_CHEMICAL", 69, 79], ["volunteers", "ORGANISM", 147, 157], ["ascending doses of ivermectin", "TREATMENT", 50, 79], ["C max", "TEST", 107, 112], ["T max", "TEST", 115, 120], ["AUC", "TEST", 133, 136], ["increase", "OBSERVATION_MODIFIER", 95, 103]]], ["Ivermectin is well circulated within the blood, where it binds plasma protein, the largest amount is found in the liver, while the lowest amount is found in the brain due to restriction by the blood-brain barrier.", [["blood", "ANATOMY", 41, 46], ["plasma", "ANATOMY", 63, 69], ["liver", "ANATOMY", 114, 119], ["brain", "ANATOMY", 161, 166], ["blood", "ANATOMY", 193, 198], ["brain", "ANATOMY", 199, 204], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "CHEMICAL", 0, 10], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["liver", "ORGAN", 114, 119], ["brain", "ORGAN", 161, 166], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 199, 212], ["plasma protein", "PROTEIN", 63, 77], ["Ivermectin", "TREATMENT", 0, 10], ["plasma protein", "TEST", 63, 77], ["the blood-brain barrier", "TREATMENT", 189, 212], ["blood", "ANATOMY", 41, 46], ["largest", "OBSERVATION_MODIFIER", 83, 90], ["amount", "OBSERVATION_MODIFIER", 91, 97], ["liver", "ANATOMY", 114, 119], ["lowest", "OBSERVATION_MODIFIER", 131, 137], ["amount", "OBSERVATION_MODIFIER", 138, 144], ["brain", "ANATOMY", 161, 166], ["restriction", "OBSERVATION", 174, 185], ["brain", "ANATOMY", 199, 204]]], ["It is metabolized by the cytochrome P450 system in the liver, and excreted almost entirely in feces.", [["liver", "ANATOMY", 55, 60], ["feces", "ANATOMY", 94, 99], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 25, 40], ["liver", "ORGAN", 55, 60], ["feces", "ORGANISM_SUBSTANCE", 94, 99], ["cytochrome P450", "PROTEIN", 25, 40], ["the cytochrome P450 system", "TREATMENT", 21, 47], ["cytochrome P450", "OBSERVATION", 25, 40], ["liver", "ANATOMY", 55, 60], ["feces", "OBSERVATION", 94, 99]]], ["IVM and abamectin concerned biodegradation that often limits their bioaccumulation and translocation in the environment and minimized their exposure to non-target organisms or location.", [["IVM", "CHEMICAL", 0, 3], ["abamectin", "CHEMICAL", 8, 17], ["IVM", "CHEMICAL", 0, 3], ["abamectin", "CHEMICAL", 8, 17], ["abamectin", "SIMPLE_CHEMICAL", 8, 17], ["IVM", "TREATMENT", 0, 3], ["abamectin", "TREATMENT", 8, 17]]], ["Over 20 years, ivermectin has been used for in the treatment of human onchocerciasis and lymphatic filariasis.", [["lymphatic", "ANATOMY", 89, 98], ["ivermectin", "CHEMICAL", 15, 25], ["onchocerciasis", "DISEASE", 70, 84], ["lymphatic filariasis", "DISEASE", 89, 109], ["ivermectin", "CHEMICAL", 15, 25], ["ivermectin", "SIMPLE_CHEMICAL", 15, 25], ["human", "ORGANISM", 64, 69], ["lymphatic filariasis", "CANCER", 89, 109], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["ivermectin", "TREATMENT", 15, 25], ["human onchocerciasis", "PROBLEM", 64, 84], ["lymphatic filariasis", "PROBLEM", 89, 109], ["onchocerciasis", "OBSERVATION", 70, 84], ["lymphatic", "ANATOMY", 89, 98], ["filariasis", "OBSERVATION", 99, 109]]], ["Recent studies concerning ivermectin warrant the swift implementation of controlled clinical trials to evaluate its effectiveness against SARS-CoV-2 that can open up a new field of study on the prospective use of avermectin.", [["ivermectin", "CHEMICAL", 26, 36], ["SARS", "DISEASE", 138, 142], ["avermectin", "CHEMICAL", 213, 223], ["ivermectin", "CHEMICAL", 26, 36], ["avermectin", "CHEMICAL", 213, 223], ["ivermectin", "SIMPLE_CHEMICAL", 26, 36], ["CoV-2", "ORGANISM", 143, 148], ["avermectin", "SIMPLE_CHEMICAL", 213, 223], ["SARS-CoV", "SPECIES", 138, 146], ["Recent studies", "TEST", 0, 14], ["ivermectin", "TREATMENT", 26, 36], ["SARS", "PROBLEM", 138, 142], ["avermectin", "TREATMENT", 213, 223]]], ["The major toxic effects of IVM observed in the animal studies using rats are ataxia, sluggishness, and ptosis, while in dogs, hypersalivation, ataxia, blindness, coma, respiratory distress, tremors, mydriasis, anorexia, and death.", [["respiratory", "ANATOMY", 168, 179], ["IVM", "CHEMICAL", 27, 30], ["ataxia", "DISEASE", 77, 83], ["sluggishness", "DISEASE", 85, 97], ["ptosis", "DISEASE", 103, 109], ["hypersalivation", "DISEASE", 126, 141], ["ataxia", "DISEASE", 143, 149], ["blindness", "DISEASE", 151, 160], ["coma", "DISEASE", 162, 166], ["respiratory distress", "DISEASE", 168, 188], ["tremors", "DISEASE", 190, 197], ["mydriasis", "DISEASE", 199, 208], ["anorexia", "DISEASE", 210, 218], ["death", "DISEASE", 224, 229], ["IVM", "CHEMICAL", 27, 30], ["rats", "ORGANISM", 68, 72], ["rats", "SPECIES", 68, 72], ["dogs", "SPECIES", 120, 124], ["IVM", "PROBLEM", 27, 30], ["the animal studies", "TEST", 43, 61], ["ataxia", "PROBLEM", 77, 83], ["sluggishness", "PROBLEM", 85, 97], ["ptosis", "PROBLEM", 103, 109], ["hypersalivation", "PROBLEM", 126, 141], ["ataxia", "PROBLEM", 143, 149], ["blindness", "PROBLEM", 151, 160], ["coma", "PROBLEM", 162, 166], ["respiratory distress", "PROBLEM", 168, 188], ["tremors", "PROBLEM", 190, 197], ["mydriasis", "PROBLEM", 199, 208], ["anorexia", "PROBLEM", 210, 218], ["death", "PROBLEM", 224, 229], ["major", "OBSERVATION_MODIFIER", 4, 9], ["toxic", "OBSERVATION_MODIFIER", 10, 15], ["ptosis", "OBSERVATION", 103, 109], ["blindness", "OBSERVATION", 151, 160], ["respiratory distress", "OBSERVATION", 168, 188], ["anorexia", "OBSERVATION", 210, 218]]]], "PMC7306211": [], "3c9d07cac8fdfacf5199e81f35aa6dd4dc7e49ab": [["IntroductionFeline immunodeficiency virus (FIV) is a Lentivirus, closely related to HIV and SIV, which infects members of Felidae family.", [["IntroductionFeline immunodeficiency virus (FIV)", "DISEASE", 0, 47], ["HIV and SIV", "DISEASE", 84, 95], ["IntroductionFeline immunodeficiency virus", "ORGANISM", 0, 41], ["FIV", "ORGANISM", 43, 46], ["Lentivirus", "ORGANISM", 53, 63], ["HIV", "ORGANISM", 84, 87], ["SIV", "ORGANISM", 92, 95], ["Felidae", "GENE_OR_GENE_PRODUCT", 122, 129], ["IntroductionFeline immunodeficiency virus", "SPECIES", 0, 41], ["HIV", "SPECIES", 84, 87], ["IntroductionFeline immunodeficiency virus", "SPECIES", 0, 41], ["FIV", "SPECIES", 43, 46], ["Lentivirus", "SPECIES", 53, 63], ["HIV", "SPECIES", 84, 87], ["SIV", "SPECIES", 92, 95], ["IntroductionFeline immunodeficiency virus", "PROBLEM", 0, 41], ["a Lentivirus", "PROBLEM", 51, 63], ["HIV", "PROBLEM", 84, 87]]], ["FIV is an important viral pathogen worldwide in the domestic cat (Felis catus), causes a slow progressive degeneration of immune functions that eventually leads to a disease.", [["FIV", "ORGANISM", 0, 3], ["cat", "ORGANISM", 61, 64], ["Felis catus", "ORGANISM", 66, 77], ["cat", "SPECIES", 61, 64], ["Felis catus", "SPECIES", 66, 77], ["FIV", "SPECIES", 0, 3], ["Felis catus", "SPECIES", 66, 77], ["an important viral pathogen", "PROBLEM", 7, 34], ["a slow progressive degeneration of immune functions", "PROBLEM", 87, 138], ["a disease", "PROBLEM", 164, 173], ["important", "OBSERVATION_MODIFIER", 10, 19], ["viral pathogen", "OBSERVATION", 20, 34], ["slow", "OBSERVATION_MODIFIER", 89, 93], ["progressive", "OBSERVATION_MODIFIER", 94, 105], ["degeneration", "OBSERVATION", 106, 118], ["immune functions", "OBSERVATION", 122, 138]]], ["FIV is unique among the nonprimate lentiviruses because in its natural host species it induces a disease similar to AIDS in humans infected with human immunodeficiency virus type 1 (HIV-1), characterized by a progressive depletion of CD4 + T lymphocytes [5, 28, 35, 48, 77] .", [["CD4 + T lymphocytes", "ANATOMY", 234, 253], ["AIDS", "DISEASE", 116, 120], ["human immunodeficiency virus", "DISEASE", 145, 173], ["FIV", "ORGANISM", 0, 3], ["lentiviruses", "ORGANISM", 35, 47], ["humans", "ORGANISM", 124, 130], ["human immunodeficiency virus type 1", "ORGANISM", 145, 180], ["HIV-1", "ORGANISM", 182, 187], ["CD4", "GENE_OR_GENE_PRODUCT", 234, 237], ["CD4", "PROTEIN", 234, 237], ["T lymphocytes", "CELL_TYPE", 240, 253], ["humans", "SPECIES", 124, 130], ["human immunodeficiency virus type 1", "SPECIES", 145, 180], ["HIV-1", "SPECIES", 182, 187], ["FIV", "SPECIES", 0, 3], ["humans", "SPECIES", 124, 130], ["human immunodeficiency virus type 1", "SPECIES", 145, 180], ["HIV-1", "SPECIES", 182, 187], ["the nonprimate lentiviruses", "PROBLEM", 20, 47], ["a disease", "PROBLEM", 95, 104], ["human immunodeficiency virus type", "PROBLEM", 145, 178], ["HIV", "TEST", 182, 185], ["a progressive depletion of CD4 + T lymphocytes", "PROBLEM", 207, 253], ["lentiviruses", "OBSERVATION", 35, 47], ["natural host species", "OBSERVATION", 63, 83], ["progressive", "OBSERVATION_MODIFIER", 209, 220], ["depletion", "OBSERVATION", 221, 230]]], ["Species-specific strains, related to domestic cat FIV, have been isolated from a variety of nondomestic Felidae [11, 43] .", [["cat FIV", "ORGANISM", 46, 53], ["cat FIV", "SPECIES", 46, 53], ["domestic cat FIV", "SPECIES", 37, 53], ["Species", "TEST", 0, 7], ["specific strains", "PROBLEM", 8, 24], ["domestic cat FIV", "PROBLEM", 37, 53], ["variety", "OBSERVATION_MODIFIER", 81, 88]]], ["Like HIV, FIV can be transmitted via mucosal exposure, blood transfer, and vertically either prenatally or postnatally [26] .", [["mucosal", "ANATOMY", 37, 44], ["blood", "ANATOMY", 55, 60], ["HIV", "ORGANISM", 5, 8], ["FIV", "ORGANISM", 10, 13], ["mucosal", "MULTI-TISSUE_STRUCTURE", 37, 44], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["HIV", "SPECIES", 5, 8], ["HIV", "SPECIES", 5, 8], ["FIV", "SPECIES", 10, 13], ["HIV", "PROBLEM", 5, 8], ["HIV", "OBSERVATION", 5, 8]]], ["For these reasons, FIV has been studied widely as both an important veterinary pathogen and an animal model for HIV/AIDS.", [["HIV/AIDS", "DISEASE", 112, 120], ["FIV", "ORGANISM", 19, 22], ["HIV", "ORGANISM", 112, 115], ["HIV", "SPECIES", 112, 115], ["FIV", "SPECIES", 19, 22], ["HIV", "SPECIES", 112, 115], ["FIV", "TREATMENT", 19, 22], ["HIV/AIDS", "PROBLEM", 112, 120]]], ["Although FIV was first recognized in 1993 in Brazil [23] and in 1994 in Argentina [65] , there are few data describing the prevalence, ecology, clinical aspects, or genetic analyses of FIV in South America ( Figure 1 ).", [["FIV", "DISEASE", 185, 188], ["FIV", "ORGANISM", 9, 12], ["FIV", "ORGANISM", 185, 188], ["FIV", "SPECIES", 9, 12], ["FIV", "SPECIES", 185, 188], ["FIV", "OBSERVATION", 9, 12]]], ["The prevalence of FIV within the continent is summarized in Table 1 .", [["FIV", "ORGANISM", 18, 21], ["FIV", "SPECIES", 18, 21], ["FIV", "TREATMENT", 18, 21], ["FIV", "OBSERVATION", 18, 21]]], ["A better characterization of FIV strains circulating within South America will be required to augment our understanding of the importance of this lentivirus in felids.", [["FIV strains", "ORGANISM", 29, 40], ["lentivirus", "ORGANISM", 146, 156], ["FIV", "SPECIES", 29, 32], ["FIV strains", "PROBLEM", 29, 40], ["this lentivirus in felids", "TREATMENT", 141, 166], ["FIV strains", "OBSERVATION", 29, 40]]], ["The data obtained allow a better understanding on FIV epidemiology and distribution.", [["FIV", "ORGANISM", 50, 53], ["FIV", "SPECIES", 50, 53], ["The data", "TEST", 0, 8]]], ["Efforts were made to gather and review all of the available information for each country.Felis CatusFIV infection, in domestic cats, causes a variable immunodeficiency syndrome characterized by recurrent gingivitis-stomatitis, cachexia, wasting, neurology, and an increased incidence of tumor development [1, 4, 48, 76] .", [["tumor", "ANATOMY", 287, 292], ["infection", "DISEASE", 104, 113], ["immunodeficiency syndrome", "DISEASE", 151, 176], ["gingivitis-stomatitis", "DISEASE", 204, 225], ["cachexia", "DISEASE", 227, 235], ["wasting", "DISEASE", 237, 244], ["tumor", "DISEASE", 287, 292], ["Felis CatusFIV", "ORGANISM", 89, 103], ["cats", "ORGANISM", 127, 131], ["tumor", "CANCER", 287, 292], ["cats", "SPECIES", 127, 131], ["Felis CatusFIV infection", "PROBLEM", 89, 113], ["a variable immunodeficiency syndrome", "PROBLEM", 140, 176], ["recurrent gingivitis", "PROBLEM", 194, 214], ["stomatitis", "PROBLEM", 215, 225], ["cachexia", "PROBLEM", 227, 235], ["tumor development", "PROBLEM", 287, 304], ["infection", "OBSERVATION", 104, 113], ["variable", "OBSERVATION_MODIFIER", 142, 150], ["immunodeficiency syndrome", "OBSERVATION", 151, 176], ["recurrent", "OBSERVATION_MODIFIER", 194, 203], ["gingivitis", "OBSERVATION", 204, 214], ["stomatitis", "OBSERVATION", 215, 225], ["cachexia", "OBSERVATION", 227, 235], ["increased", "OBSERVATION_MODIFIER", 264, 273], ["tumor", "OBSERVATION", 287, 292]]], ["In contrast, the ungulate lentiviruses cause diseases reminiscent of chronic inflammatory conditions while infection with the bovine lentivirus seems to be inapparent [71] .", [["infection", "DISEASE", 107, 116], ["lentiviruses", "ORGANISM", 26, 38], ["bovine", "ORGANISM", 126, 132], ["lentivirus", "ORGANISM", 133, 143], ["bovine", "SPECIES", 126, 132], ["bovine", "SPECIES", 126, 132], ["diseases", "PROBLEM", 45, 53], ["chronic inflammatory conditions", "PROBLEM", 69, 100], ["infection", "PROBLEM", 107, 116], ["the bovine lentivirus", "PROBLEM", 122, 143], ["ungulate lentiviruses", "OBSERVATION", 17, 38], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["inflammatory", "OBSERVATION", 77, 89], ["infection", "OBSERVATION", 107, 116], ["bovine lentivirus", "OBSERVATION", 126, 143]]], ["The rate of progression of the disease can depend on the genotype of the infecting FIV and is also likely influenced by undefined genetic determinants of the particular host [16] .", [["FIV", "DISEASE", 83, 86], ["FIV", "ORGANISM", 83, 86], ["FIV", "SPECIES", 83, 86], ["the disease", "PROBLEM", 27, 38], ["the infecting FIV", "PROBLEM", 69, 86], ["progression", "OBSERVATION_MODIFIER", 12, 23], ["disease", "OBSERVATION", 31, 38], ["infecting FIV", "OBSERVATION", 73, 86]]], ["FIV infection in domestic cats is associated with early robust humoral and cellular anti-viral immune responses, followed by a progressive immune suppression that results eventually in AIDS.", [["cellular", "ANATOMY", 75, 83], ["FIV infection", "DISEASE", 0, 13], ["AIDS", "DISEASE", 185, 189], ["FIV", "ORGANISM", 0, 3], ["cats", "ORGANISM", 26, 30], ["cellular", "CELL", 75, 83], ["cats", "SPECIES", 26, 30], ["FIV", "SPECIES", 0, 3], ["FIV infection in domestic cats", "PROBLEM", 0, 30], ["a progressive immune suppression", "PROBLEM", 125, 157], ["infection", "OBSERVATION", 4, 13], ["domestic cats", "OBSERVATION", 17, 30], ["associated with", "UNCERTAINTY", 34, 49], ["early", "OBSERVATION_MODIFIER", 50, 55], ["robust", "OBSERVATION_MODIFIER", 56, 62], ["humoral", "OBSERVATION", 63, 70], ["cellular anti-viral immune responses", "OBSERVATION", 75, 111]]], ["The outcome of infection depends on the balance between the viral destruction of the immune system and the ability of the remaining immune system to eliminate the virus.", [["immune system", "ANATOMY", 85, 98], ["immune system", "ANATOMY", 132, 145], ["infection", "DISEASE", 15, 24], ["infection", "PROBLEM", 15, 24], ["the viral destruction of the immune system", "PROBLEM", 56, 98], ["the virus", "PROBLEM", 159, 168], ["infection", "OBSERVATION", 15, 24], ["viral", "OBSERVATION_MODIFIER", 60, 65], ["destruction", "OBSERVATION", 66, 77], ["virus", "OBSERVATION", 163, 168]]], ["Although the decrease in numbers of CD4+ cells is the hallmark of FIV infection, the virus has been shown to infect a variety of cell types in their respective hosts including CD4 + and CD8 + lymphocytes, B lymphocytes, cells of neuronal lineage and monocyte/macrophage lineage [15, 17, 29] .", [["CD4+ cells", "ANATOMY", 36, 46], ["cell", "ANATOMY", 129, 133], ["CD4 + and CD8 + lymphocytes", "ANATOMY", 176, 203], ["B lymphocytes", "ANATOMY", 205, 218], ["cells", "ANATOMY", 220, 225], ["neuronal lineage", "ANATOMY", 229, 245], ["monocyte", "ANATOMY", 250, 258], ["macrophage lineage", "ANATOMY", 259, 277], ["FIV infection", "DISEASE", 66, 79], ["CD4", "GENE_OR_GENE_PRODUCT", 36, 39], ["FIV", "ORGANISM", 66, 69], ["cell", "CELL", 129, 133], ["hosts", "CELL", 160, 165], ["CD4", "GENE_OR_GENE_PRODUCT", 176, 179], ["CD8", "GENE_OR_GENE_PRODUCT", 186, 189], ["B lymphocytes", "CELL", 205, 218], ["cells", "CELL", 220, 225], ["neuronal lineage", "CELL", 229, 245], ["monocyte", "CELL", 250, 258], ["macrophage lineage", "CELL", 259, 277], ["CD4", "PROTEIN", 36, 39], ["CD4 + and CD8 + lymphocytes", "CELL_TYPE", 176, 203], ["B lymphocytes", "CELL_TYPE", 205, 218], ["neuronal lineage", "CELL_TYPE", 229, 245], ["monocyte/macrophage lineage", "CELL_TYPE", 250, 277], ["FIV", "SPECIES", 66, 69], ["the decrease", "PROBLEM", 9, 21], ["CD4+ cells", "PROBLEM", 36, 46], ["FIV infection", "PROBLEM", 66, 79], ["the virus", "PROBLEM", 81, 90], ["CD4", "TEST", 176, 179], ["CD8", "TEST", 186, 189], ["lymphocytes", "TEST", 192, 203], ["B lymphocytes", "TEST", 205, 218], ["neuronal lineage", "TEST", 229, 245], ["decrease", "OBSERVATION_MODIFIER", 13, 21], ["numbers", "OBSERVATION_MODIFIER", 25, 32], ["CD4+ cells", "OBSERVATION", 36, 46], ["hallmark of", "UNCERTAINTY", 54, 65], ["FIV infection", "OBSERVATION", 66, 79], ["variety", "OBSERVATION_MODIFIER", 118, 125], ["cell types", "OBSERVATION", 129, 139], ["lymphocytes", "ANATOMY", 192, 203], ["lymphocytes", "ANATOMY", 207, 218], ["neuronal lineage", "OBSERVATION", 229, 245], ["macrophage lineage", "OBSERVATION", 259, 277]]], ["Joshi et al. (2005) have characterized feline CD4 + CD25 + T regulatory cells that support FIV replication.", [["CD4 + CD25 + T regulatory cells", "ANATOMY", 46, 77], ["feline", "ORGANISM", 39, 45], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["CD25", "GENE_OR_GENE_PRODUCT", 52, 56], ["FIV", "ORGANISM", 91, 94], ["feline CD4 + CD25 + T regulatory cells", "CELL_TYPE", 39, 77], ["FIV", "SPECIES", 91, 94], ["T regulatory cells", "TREATMENT", 59, 77], ["FIV replication", "TREATMENT", 91, 106], ["FIV replication", "OBSERVATION", 91, 106]]], ["Recently, Reggeti, Ackerley and Bienzle (2008) have shown that feline dendritic cells express specific viral receptors and are infected productively by FIV [53] .", [["dendritic cells", "ANATOMY", 70, 85], ["feline", "ORGANISM", 63, 69], ["dendritic cells", "CELL", 70, 85], ["FIV [53", "ORGANISM", 152, 159], ["feline dendritic cells", "CELL_TYPE", 63, 85], ["viral receptors", "PROTEIN", 103, 118], ["FIV", "SPECIES", 152, 155], ["feline dendritic cells", "PROBLEM", 63, 85], ["specific viral receptors", "PROBLEM", 94, 118], ["dendritic cells", "OBSERVATION", 70, 85], ["viral receptors", "OBSERVATION", 103, 118]]], ["FIV shares a similar pattern of receptor usage to HIV-1; however, CD 134 rather than CD4 is the primary binding partner, and subsequent interaction with the secondary receptor CXCR4 permits cells entry [58, 72, 73] .", [["cells", "ANATOMY", 190, 195], ["FIV", "ORGANISM", 0, 3], ["HIV-1", "ORGANISM", 50, 55], ["CD 134", "GENE_OR_GENE_PRODUCT", 66, 72], ["CD4", "GENE_OR_GENE_PRODUCT", 85, 88], ["CXCR4", "GENE_OR_GENE_PRODUCT", 176, 181], ["cells", "CELL", 190, 195], ["CD4", "PROTEIN", 85, 88], ["CXCR4", "PROTEIN", 176, 181], ["HIV-1", "SPECIES", 50, 55], ["FIV", "SPECIES", 0, 3], ["HIV-1", "SPECIES", 50, 55], ["HIV", "PROBLEM", 50, 53]]], ["Differences in pathogenicity have been demonstrated among genetically distinct subtypes of FIV that circulate in domestic cats [14, 16, 49, 63, 68, 73] .", [["FIV", "ORGANISM", 91, 94], ["cats", "ORGANISM", 122, 126], ["FIV", "SPECIES", 91, 94], ["FIV", "OBSERVATION", 91, 94]]], ["On the basis of the analysis of envelope glycoprotein (Env), focusing on the third to fifth variable regions (V3-V5), FIV has been classified into five subtypes [30, 46, 60] a number that should be expected to increase as further studies reveal additional diversity.", [["envelope glycoprotein", "GENE_OR_GENE_PRODUCT", 32, 53], ["Env", "GENE_OR_GENE_PRODUCT", 55, 58], ["FIV", "ORGANISM", 118, 121], ["envelope glycoprotein", "PROTEIN", 32, 53], ["Env", "PROTEIN", 55, 58], ["V3", "PROTEIN", 110, 112], ["V5", "PROTEIN", 113, 115], ["FIV", "SPECIES", 118, 121], ["envelope glycoprotein", "PROBLEM", 32, 53], ["FIV", "PROBLEM", 118, 121], ["further studies", "TEST", 222, 237]]], ["Recent studies identified distinct groups of FIV isolates from the United States and New Zealand [24, 69] (Figure 2 ).Felis CatusData regarding FIV infection in domestic felids in South America are sparse and have not been well evaluated.", [["FIV infection", "DISEASE", 144, 157], ["FIV", "ORGANISM", 45, 48], ["Felis CatusData", "ORGANISM", 118, 133], ["FIV", "ORGANISM", 144, 147], ["FIV", "SPECIES", 45, 48], ["FIV", "SPECIES", 144, 147], ["Recent studies", "TEST", 0, 14], ["FIV infection", "PROBLEM", 144, 157], ["distinct", "OBSERVATION_MODIFIER", 26, 34], ["FIV isolates", "OBSERVATION", 45, 57], ["New", "OBSERVATION_MODIFIER", 85, 88], ["FIV", "OBSERVATION_MODIFIER", 144, 147], ["infection", "OBSERVATION", 148, 157], ["domestic felids", "OBSERVATION", 161, 176]]], ["Expanded surveys of South American isolates will be required to determine the FIV isolates in the continent since only few studies have been published.", [["FIV", "ORGANISM", 78, 81], ["FIV", "SPECIES", 78, 81], ["the FIV isolates", "PROBLEM", 74, 90]]], ["Although there are no doubts about the presence of FIV in South America, prevalence data obtained using different techniques cannot be compared amongst countries or studies (Table 1) .", [["FIV", "DISEASE", 51, 54], ["FIV", "ORGANISM", 51, 54], ["FIV", "SPECIES", 51, 54], ["different techniques", "TREATMENT", 104, 124], ["no", "UNCERTAINTY", 19, 21], ["FIV", "OBSERVATION", 51, 54]]], ["Knowing the prevalence and variability of FIV is important for designing and testing vaccines under field conditions [27, 77] .", [["FIV", "ORGANISM", 42, 45], ["FIV", "SPECIES", 42, 45]]], ["Also, identification of circulating subtypes is essential to develop strategies for molecular diagnosis, since the genetic diversity of this virus is high [44, 54] which may lead to false negative diagnoses if inappropriate primers are used.", [["circulating subtypes", "PROBLEM", 24, 44], ["molecular diagnosis", "TEST", 84, 103], ["this virus", "PROBLEM", 136, 146], ["false negative diagnoses", "PROBLEM", 182, 206], ["inappropriate primers", "PROBLEM", 210, 231]]], ["In South America, only subtype B and E viruses have been found.", [["B", "GENE_OR_GENE_PRODUCT", 31, 32], ["E viruses", "ORGANISM", 37, 46], ["E viruses", "SPECIES", 37, 46], ["subtype B and E viruses", "PROBLEM", 23, 46], ["viruses", "OBSERVATION", 39, 46]]], ["It is important to remember that subtype B viruses are distributed worldwide and that the subtype E viruses have been more consistently identified only in Argentina ( Figure 1 ).Felis CatusPreliminary studies suggested that FIV infection is widespread in the domestic cat population of Brazil [9, 12, 40, 52, 61, 64 ] .", [["FIV infection", "DISEASE", 224, 237], ["subtype B viruses", "ORGANISM", 33, 50], ["subtype E viruses", "ORGANISM", 90, 107], ["FIV", "ORGANISM", 224, 227], ["cat", "ORGANISM", 268, 271], ["B viruses", "SPECIES", 41, 50], ["E viruses", "SPECIES", 98, 107], ["FIV", "SPECIES", 224, 227], ["subtype B viruses", "PROBLEM", 33, 50], ["the subtype E viruses", "PROBLEM", 86, 107], ["Felis CatusPreliminary studies", "TEST", 178, 208], ["FIV infection", "PROBLEM", 224, 237], ["viruses", "OBSERVATION", 43, 50], ["FIV", "OBSERVATION_MODIFIER", 224, 227], ["infection", "OBSERVATION", 228, 237], ["widespread", "OBSERVATION_MODIFIER", 241, 251]]], ["A published review indicated that subtype E was the only prevalent in Brazil [77] .", [["A published review", "TEST", 0, 18]]], ["Nevertheless, all studies indentified B as the only subtype circulating in FIV positive animals in Brazil, [12, 32, 40, 62] .", [["B", "GENE_OR_GENE_PRODUCT", 38, 39], ["FIV", "ORGANISM", 75, 78], ["FIV", "SPECIES", 75, 78], ["all studies", "TEST", 14, 25]]], ["Here an analysis was conducted with 473 bp of sequence encoding 157 amino acids comprising the V3-V4 region of the envelope glycoprotein from different subtypes, including those reported previously from South America (Figure 2 ).", [["amino acids", "CHEMICAL", 68, 79], ["amino acids", "CHEMICAL", 68, 79], ["amino acids", "AMINO_ACID", 68, 79], ["V3-V4 region", "PROTEIN", 95, 107], ["envelope glycoprotein", "PROTEIN", 115, 136], ["an analysis", "TEST", 5, 16], ["amino acids", "TEST", 68, 79], ["the envelope glycoprotein", "PROBLEM", 111, 136], ["V4", "ANATOMY_MODIFIER", 98, 100], ["envelope glycoprotein", "OBSERVATION", 115, 136], ["different subtypes", "OBSERVATION", 142, 160]]], ["In this study we used this region of env in order to permit us to include more samples from South America.", [["this study", "TEST", 3, 13], ["this region of env", "TREATMENT", 22, 40]]], ["For this phylogenetic tree, the GenBank accession numbers, names, country and subtype for the FIV env sequences included were: M25381.", [["FIV", "ORGANISM", 94, 97], ["FIV env sequences", "DNA", 94, 111], ["the FIV env sequences", "TEST", 90, 111]]], ["It is important to state that all phylogenetic studies carried out in Brazil were performed in the same area, namely the south-east, and that Brazil is a huge country (Figure 1 ).", [["all phylogenetic studies", "TEST", 30, 54]]], ["More widespread surveys of Brazilian isolates are required to determine whether a single subtype of FIV predominates in Brazil.", [["FIV", "ORGANISM", 100, 103], ["FIV", "SPECIES", 100, 103], ["Brazilian isolates", "PROBLEM", 27, 45], ["FIV", "OBSERVATION", 100, 103]]], ["In Brazilian domestic cats, FIV infected cats have been observed over a prolonged period.", [["FIV infected", "DISEASE", 28, 40], ["cats", "ORGANISM", 22, 26], ["FIV", "ORGANISM", 28, 31], ["cats", "ORGANISM", 41, 45], ["cats", "SPECIES", 22, 26], ["cats", "SPECIES", 41, 45], ["FIV", "SPECIES", 28, 31], ["FIV infected cats", "PROBLEM", 28, 45], ["infected", "OBSERVATION_MODIFIER", 32, 40]]], ["During this time, few clinical signs were observed, although the virus was replicating and inducing changes in the immune system, leading to a progressive decline in immune function and the development later of overt clinical signs [51, 78, Hagiwara and Teixeira, unpublished data].", [["immune system", "ANATOMY", 115, 128], ["few clinical signs", "PROBLEM", 18, 36], ["the virus", "PROBLEM", 61, 70], ["inducing changes in the immune system", "PROBLEM", 91, 128], ["a progressive decline in immune function", "PROBLEM", 141, 181], ["overt clinical signs", "PROBLEM", 211, 231], ["progressive", "OBSERVATION_MODIFIER", 143, 154], ["decline", "OBSERVATION", 155, 162], ["immune function", "OBSERVATION", 166, 181]]], ["Previously, Brazilian studies established relationships between FIV infection and Toxoplasma gondii and Mycoplasma haemofelis [37, 39] .", [["FIV infection", "DISEASE", 64, 77], ["Toxoplasma gondii", "DISEASE", 82, 99], ["Mycoplasma haemofelis", "DISEASE", 104, 125], ["FIV", "ORGANISM", 64, 67], ["Toxoplasma gondii", "ORGANISM", 82, 99], ["Mycoplasma haemofelis", "ORGANISM", 104, 125], ["Toxoplasma gondii", "SPECIES", 82, 99], ["Mycoplasma haemofelis", "SPECIES", 104, 125], ["FIV", "SPECIES", 64, 67], ["Toxoplasma gondii", "SPECIES", 82, 99], ["Mycoplasma haemofelis", "SPECIES", 104, 125], ["Brazilian studies", "TEST", 12, 29], ["FIV infection", "PROBLEM", 64, 77], ["Toxoplasma gondii", "TEST", 82, 99], ["Mycoplasma haemofelis", "PROBLEM", 104, 125], ["FIV infection", "OBSERVATION", 64, 77]]], ["Otherwise, no association with disease has been recorded in cases of Brazilian FIV infection.", [["FIV infection", "DISEASE", 79, 92], ["FIV", "ORGANISM", 79, 82], ["FIV", "SPECIES", 79, 82], ["disease", "PROBLEM", 31, 38], ["Brazilian FIV infection", "PROBLEM", 69, 92], ["no association with", "UNCERTAINTY", 11, 30], ["disease", "OBSERVATION", 31, 38], ["Brazilian FIV infection", "OBSERVATION", 69, 92]]], ["It has been suggested that clade B viruses may be more ancient and relatively host adapted and thus may be less virulent [2, 50, 63] .Felis CatusPreliminary seroepidemiological studies carried out on clinical cases suggested that FIV infection is widespread in the domestic cat population of Argentina [65] .", [["FIV infection", "DISEASE", 230, 243], ["clade B viruses", "ORGANISM", 27, 42], ["FIV", "ORGANISM", 230, 233], ["cat", "ORGANISM", 274, 277], ["cat", "SPECIES", 274, 277], ["FIV", "SPECIES", 230, 233], ["clade B viruses", "PROBLEM", 27, 42], ["Felis CatusPreliminary seroepidemiological studies", "TEST", 134, 184], ["clinical cases", "TEST", 200, 214], ["FIV infection", "PROBLEM", 230, 243], ["FIV", "OBSERVATION_MODIFIER", 230, 233], ["infection", "OBSERVATION", 234, 243], ["widespread", "OBSERVATION_MODIFIER", 247, 257]]], ["The genetic diversity of FIV isolates from Argentine domestic cats has been well characterized [47, 75] .", [["FIV", "ORGANISM", 25, 28], ["cats", "ORGANISM", 62, 66], ["cats", "SPECIES", 62, 66], ["FIV", "SPECIES", 25, 28], ["FIV isolates", "TREATMENT", 25, 37], ["diversity", "OBSERVATION_MODIFIER", 12, 21], ["FIV isolates", "OBSERVATION", 25, 37]]], ["FIV isolates were isolated from peripheral blood mononuclear cells of four domestic cats.", [["peripheral blood mononuclear cells", "ANATOMY", 32, 66], ["FIV", "ORGANISM", 0, 3], ["peripheral blood mononuclear cells", "CELL", 32, 66], ["cats", "ORGANISM", 84, 88], ["peripheral blood mononuclear cells", "CELL_TYPE", 32, 66], ["cats", "SPECIES", 84, 88], ["FIV", "SPECIES", 0, 3], ["FIV isolates", "TREATMENT", 0, 12], ["peripheral blood mononuclear cells", "TREATMENT", 32, 66], ["peripheral", "ANATOMY_MODIFIER", 32, 42], ["blood", "ANATOMY", 43, 48], ["mononuclear cells", "OBSERVATION", 49, 66]]], ["Phylogenetic analysis revealed that one isolate clustered with subtype B and the others formed subtype E [47] , prototype sequence for this group (Figure 2) .Felis CatusIn the north of the continent a single study was performed in 52 domestic cats on Isabela Island, Galapagos, Ecuador's coast.", [["cats", "ORGANISM", 243, 247], ["cats", "SPECIES", 243, 247], ["Phylogenetic analysis", "TEST", 0, 21], ["subtype B", "PROBLEM", 63, 72], ["a single study", "TEST", 199, 213]]], ["It was demonstrated using serological methods that none of the tested animals was infected with FIV [36] .Nondomestic Felid SpeciesViruses related to domestic cat FIV occur also in nondomestic felids, indeed FIV strains have been present in the nondomestic cat population for longer than domestic cats [45] .", [["animals", "ORGANISM", 70, 77], ["FIV", "ORGANISM", 96, 99], ["Felid SpeciesViruses", "ORGANISM", 118, 138], ["cat FIV", "ORGANISM", 159, 166], ["nondomestic felids", "ORGANISM", 181, 199], ["FIV", "ORGANISM", 208, 211], ["cat", "ORGANISM", 257, 260], ["cat", "SPECIES", 159, 162], ["cat", "SPECIES", 257, 260], ["cats", "SPECIES", 297, 301], ["FIV", "SPECIES", 96, 99], ["domestic cat FIV", "SPECIES", 150, 166], ["FIV", "SPECIES", 208, 211], ["serological methods", "TEST", 26, 45], ["Nondomestic Felid SpeciesViruses", "PROBLEM", 106, 138], ["domestic cat FIV", "TREATMENT", 150, 166], ["FIV strains", "PROBLEM", 208, 219], ["FIV strains", "OBSERVATION", 208, 219]]], ["Carpenter et al. (1996) comment that members of at least eighteen of the 37 species in the family Felidae carry an FIV-related virus, as has been shown by the presence in their sera of antibodies which react with FIV antigens.", [["sera", "ANATOMY", 177, 181], ["Felidae", "GENE_OR_GENE_PRODUCT", 98, 105], ["FIV-related virus", "ORGANISM", 115, 132], ["sera", "ORGANISM_SUBSTANCE", 177, 181], ["FIV", "ORGANISM", 213, 216], ["antibodies", "PROTEIN", 185, 195], ["FIV antigens", "PROTEIN", 213, 225], ["FIV", "SPECIES", 213, 216], ["the 37 species", "PROBLEM", 69, 83], ["an FIV-related virus", "PROBLEM", 112, 132]]], ["A further twelve species were reported in another study that employed a three-antigen Western blot screening (cat, puma and lion FIV antigens) and a multigene PCR amplification of FIV genes [66] .", [["cat", "ORGANISM", 110, 113], ["puma", "ORGANISM", 115, 119], ["lion", "ORGANISM", 124, 128], ["FIV", "ORGANISM", 129, 132], ["FIV", "ORGANISM", 180, 183], ["cat, puma and lion FIV antigens", "PROTEIN", 110, 141], ["FIV genes", "DNA", 180, 189], ["cat", "SPECIES", 110, 113], ["lion FIV", "SPECIES", 124, 132], ["FIV", "SPECIES", 180, 183], ["A further twelve species", "PROBLEM", 0, 24], ["another study", "TEST", 42, 55], ["blot screening", "TEST", 94, 108], ["lion FIV antigens", "TREATMENT", 124, 141], ["a multigene PCR amplification of FIV genes", "TREATMENT", 147, 189]]], ["Lentiviruses in eight of these species have been detected in South America [6, 10, 19, 20, 33, 55, 66] .Nondomestic Felid SpeciesData regarding FIV infections in South American wild felids are sparse and studies have concentrated primarily on Brazil.", [["FIV infections", "DISEASE", 144, 158], ["FIV", "ORGANISM", 144, 147], ["FIV", "SPECIES", 144, 147], ["Lentiviruses", "TREATMENT", 0, 12], ["FIV infections", "PROBLEM", 144, 158], ["FIV infections", "OBSERVATION", 144, 158]]], ["The presence of antibodies against FIV in puma, detected by Western blotting, was found in Argentina (5 in 22, 23%), Bolivia (5 in 5, 100%), Brazil (2 in 13, 15%), Peru (1 in 5, 20%) and Venezuela (4 in 8, 50%) [10] .", [["FIV", "ORGANISM", 35, 38], ["puma", "CANCER", 42, 46], ["antibodies", "PROTEIN", 16, 26], ["FIV", "SPECIES", 35, 38], ["antibodies", "PROBLEM", 16, 26], ["FIV in puma", "PROBLEM", 35, 46]]], ["Further studies have reported antibodies recognizing FIV and the puma lentivirus (PLV in Brazilian free-ranging puma) [6, 19] .", [["FIV", "ORGANISM", 53, 56], ["puma lentivirus", "ORGANISM", 65, 80], ["antibodies", "PROTEIN", 30, 40], ["FIV", "SPECIES", 53, 56], ["Further studies", "TEST", 0, 15], ["antibodies recognizing FIV", "PROBLEM", 30, 56], ["the puma lentivirus", "PROBLEM", 61, 80], ["puma lentivirus", "OBSERVATION", 65, 80]]], ["Troyer et al. (2005) concluded that most of the South American felids maintain a low level of FIV infection throughout their population.", [["FIV infection", "DISEASE", 94, 107], ["felids", "ORGANISM", 63, 69], ["FIV", "ORGANISM", 94, 97], ["FIV", "SPECIES", 94, 97], ["FIV infection", "PROBLEM", 94, 107], ["low level", "OBSERVATION_MODIFIER", 81, 90], ["FIV", "OBSERVATION_MODIFIER", 94, 97], ["infection", "OBSERVATION", 98, 107]]], ["Within wild populations, the seroprevalence in South American felids varies from 5 to 28%.", [["South American felids", "SPECIES", 47, 68], ["populations", "OBSERVATION_MODIFIER", 12, 23]]], ["Unfortunately, the authors did not describe the regions of the continent where the samples originated.", [["samples", "ANATOMY", 83, 90], ["samples", "CANCER", 83, 90], ["the samples", "TEST", 79, 90], ["continent", "OBSERVATION", 63, 72]]], ["FIV pol genes from a Peruvian and a Brazilian zoo puma have been sequenced, the former being classified as subtype B and the latter as a distinct group, neither A nor B [10] .", [["FIV", "ORGANISM", 0, 3], ["pol", "GENE_OR_GENE_PRODUCT", 4, 7], ["FIV pol genes", "DNA", 0, 13], ["FIV", "SPECIES", 0, 3], ["Brazilian zoo puma", "SPECIES", 36, 54], ["pol genes", "OBSERVATION", 4, 13]]], ["Additionally, FIV provirus has been reported in Brazilian jaguars (Panthera onca), pumas, jaguarondis (Puma yagouaroundi), oncelots (Leopardus pardalis), margays (Leopardus wiedii), pampas cat (Leopardus colocolo), geoffroy's cat (Leopardus geoffroyi) and little spotted cats (Leopardus tigrinus) [20, 33, 55] .", [["pumas", "ANATOMY", 83, 88], ["FIV provirus", "DISEASE", 14, 26], ["FIV", "ORGANISM", 14, 17], ["Panthera onca", "ORGANISM", 67, 80], ["pumas", "ORGANISM", 83, 88], ["Puma yagouaroundi", "ORGANISM", 103, 120], ["Leopardus pardalis", "ORGANISM", 133, 151], ["margays", "ORGANISM", 154, 161], ["Leopardus wiedii", "ORGANISM", 163, 179], ["pampas cat", "ORGANISM", 182, 192], ["Leopardus colocolo", "ORGANISM", 194, 212], ["geoffroy's cat", "ORGANISM", 215, 229], ["Leopardus geoffroyi", "ORGANISM", 231, 250], ["cats", "ORGANISM", 271, 275], ["Leopardus tigrinus", "ORGANISM", 277, 295], ["Panthera onca", "SPECIES", 67, 80], ["pumas", "SPECIES", 83, 88], ["jaguarondis", "SPECIES", 90, 101], ["Puma yagouaroundi", "SPECIES", 103, 120], ["oncelots", "SPECIES", 123, 131], ["Leopardus pardalis", "SPECIES", 133, 151], ["margays", "SPECIES", 154, 161], ["Leopardus wiedii", "SPECIES", 163, 179], ["pampas", "SPECIES", 182, 188], ["cat", "SPECIES", 189, 192], ["Leopardus colocolo", "SPECIES", 194, 212], ["geoffroy", "SPECIES", 215, 223], ["cat", "SPECIES", 226, 229], ["Leopardus geoffroyi", "SPECIES", 231, 250], ["cats", "SPECIES", 271, 275], ["Leopardus tigrinus", "SPECIES", 277, 295], ["FIV", "SPECIES", 14, 17], ["Brazilian jaguars", "SPECIES", 48, 65], ["Panthera onca", "SPECIES", 67, 80], ["Puma yagouaroundi", "SPECIES", 103, 120], ["Leopardus pardalis", "SPECIES", 133, 151], ["Leopardus wiedii", "SPECIES", 163, 179], ["Leopardus colocolo", "SPECIES", 194, 212], ["Leopardus geoffroyi", "SPECIES", 231, 250], ["Leopardus tigrinus", "SPECIES", 277, 295], ["FIV provirus", "PROBLEM", 14, 26], ["oncelots (Leopardus pardalis", "TREATMENT", 123, 151], ["margays (Leopardus wiedii", "TREATMENT", 154, 179], ["pampas cat (Leopardus colocolo", "TREATMENT", 182, 212], ["little spotted cats", "PROBLEM", 256, 275], ["FIV provirus", "OBSERVATION", 14, 26], ["jaguarondis", "ANATOMY", 90, 101]]], ["The finding of these FIV infected species highlights the need for additional monitoring.", [["FIV infected", "DISEASE", 21, 33], ["FIV", "ORGANISM", 21, 24], ["FIV", "SPECIES", 21, 24], ["these FIV infected species", "PROBLEM", 15, 41], ["additional monitoring", "TEST", 66, 87], ["FIV", "OBSERVATION_MODIFIER", 21, 24], ["infected", "OBSERVATION", 25, 33]]], ["Although the implications of these infections for wild felid conservation are difficult to assess, it is generally accepted that monitoring these infections is an important component for the management of endangered populations [13] .Nondomestic Felid SpeciesIt is important to emphasize that FIV strains infecting 9 species of the Felidae have been at least partially sequenced and molecularly characterized [3, 10, 11, 25, 34, 38, 42, 43, 66] .", [["infections", "DISEASE", 35, 45], ["infections", "DISEASE", 146, 156], ["FIV strains", "ORGANISM", 293, 304], ["Felidae", "GENE_OR_GENE_PRODUCT", 332, 339], ["these infections", "PROBLEM", 29, 45], ["wild felid conservation", "PROBLEM", 50, 73], ["these infections", "PROBLEM", 140, 156], ["endangered populations", "PROBLEM", 205, 227], ["FIV strains infecting", "PROBLEM", 293, 314], ["Felid Species", "OBSERVATION", 246, 259]]], ["Genetic analysis indicates that different felid species are infected by different strains of FIV [8, 11] .", [["felid species", "ORGANISM", 42, 55], ["FIV", "ORGANISM", 93, 96], ["FIV", "SPECIES", 93, 96], ["Genetic analysis", "TEST", 0, 16], ["different felid species", "PROBLEM", 32, 55], ["different", "OBSERVATION_MODIFIER", 32, 41], ["felid species", "OBSERVATION", 42, 55]]], ["Analysis of pol gene sequence of FIV from lions (Panthera leo), pumas (Puma concolor) and domestic cats indicated that each species has a specific strain of FIV and that the strains are related but distinct [7, 43] .", [["pol", "GENE_OR_GENE_PRODUCT", 12, 15], ["FIV", "ORGANISM", 33, 36], ["lions", "ORGANISM", 42, 47], ["Panthera leo", "ORGANISM", 49, 61], ["pumas", "ORGANISM", 64, 69], ["Puma concolor", "ORGANISM", 71, 84], ["domestic cats", "ORGANISM", 90, 103], ["FIV", "ORGANISM", 157, 160], ["pol gene sequence", "DNA", 12, 29], ["Panthera leo", "SPECIES", 49, 61], ["pumas", "SPECIES", 64, 69], ["Puma concolor", "SPECIES", 71, 84], ["cats", "SPECIES", 99, 103], ["Panthera leo", "SPECIES", 49, 61], ["Puma concolor", "SPECIES", 71, 84], ["FIV", "SPECIES", 157, 160], ["Analysis", "TEST", 0, 8], ["pol gene sequence", "TEST", 12, 29], ["FIV", "PROBLEM", 33, 36], ["domestic cats", "TEST", 90, 103], ["a specific strain of FIV", "PROBLEM", 136, 160], ["the strains", "PROBLEM", 170, 181]]], ["Also, strains from African lions (subtype B and E) differ in their abilities to replicate in feline cell lines [59] , their sensitivity to receptor antagonists [71] , and their requirement for ectopic expression of CD134, the primary cellular receptor, for productive infection [41] .Nondomestic Felid SpeciesIt remains to be demonstrated that FIV-related viruses cause severe disease in species other than the domestic cat [6, 38] .", [["cell lines", "ANATOMY", 100, 110], ["cellular", "ANATOMY", 234, 242], ["infection", "DISEASE", 268, 277], ["African lions", "ORGANISM", 19, 32], ["subtype B", "CELL", 34, 43], ["E", "CELL", 48, 49], ["feline", "ORGANISM", 93, 99], ["cell lines", "CELL", 100, 110], ["CD134", "GENE_OR_GENE_PRODUCT", 215, 220], ["cellular", "CELL", 234, 242], ["FIV-related viruses", "ORGANISM", 344, 363], ["cat", "ORGANISM", 420, 423], ["feline cell lines", "CELL_LINE", 93, 110], ["CD134", "PROTEIN", 215, 220], ["primary cellular receptor", "PROTEIN", 226, 251], ["African lions", "SPECIES", 19, 32], ["receptor antagonists", "TEST", 139, 159], ["ectopic expression of CD134", "PROBLEM", 193, 220], ["productive infection", "PROBLEM", 257, 277], ["FIV-related viruses", "PROBLEM", 344, 363], ["severe disease in species", "PROBLEM", 370, 395], ["productive", "OBSERVATION_MODIFIER", 257, 267], ["infection", "OBSERVATION", 268, 277], ["Felid Species", "OBSERVATION", 296, 309], ["FIV", "OBSERVATION", 344, 347], ["severe", "OBSERVATION_MODIFIER", 370, 376], ["disease", "OBSERVATION", 377, 384]]], ["The apparent absence of clinical signs in pumas and lions may reflect a longer period of coevolution between virus and host in these species, whereas in the domestic cat, the virus and host have not yet had time to reach a similar state of nonpathogenic coexistence [6, 7, 57] .", [["pumas", "DISEASE", 42, 47], ["pumas", "CANCER", 42, 47], ["cat", "ORGANISM", 166, 169], ["cat", "SPECIES", 166, 169], ["clinical signs in pumas and lions", "PROBLEM", 24, 57], ["coevolution between virus", "PROBLEM", 89, 114]]], ["However, it is by no means certain that FIV does not cause disease in non-domestic cats.", [["FIV", "ORGANISM", 40, 43], ["cats", "ORGANISM", 83, 87], ["cats", "SPECIES", 83, 87], ["FIV", "SPECIES", 40, 43], ["disease in non-domestic cats", "PROBLEM", 59, 87]]], ["Not long ago, reports have shown immune depletion associated with FIV infection in lions and pumas [56, 57] and another recent study reported evidence of immune suppression in the Pallas' cat (Otocolobus manul), including histopatological changes [8] .", [["FIV infection", "DISEASE", 66, 79], ["FIV", "ORGANISM", 66, 69], ["Pallas' cat", "ORGANISM", 180, 191], ["Otocolobus manul", "ORGANISM", 193, 209], ["cat", "SPECIES", 188, 191], ["Otocolobus manul", "SPECIES", 193, 209], ["FIV", "SPECIES", 66, 69], ["Otocolobus manul", "SPECIES", 193, 209], ["immune depletion", "PROBLEM", 33, 49], ["FIV infection", "PROBLEM", 66, 79], ["another recent study", "TEST", 112, 132], ["immune suppression", "PROBLEM", 154, 172], ["histopatological changes", "PROBLEM", 222, 246], ["immune depletion", "OBSERVATION", 33, 49], ["FIV", "OBSERVATION_MODIFIER", 66, 69], ["infection", "OBSERVATION", 70, 79], ["evidence of", "UNCERTAINTY", 142, 153], ["immune suppression", "OBSERVATION", 154, 172]]], ["For example, a leopard cat (Felis bengalensis) was found to be infected with a domestic cat virus [42] and FIV infecting one puma was more characteristic of domestic cat FIV rather than puma FIV [10] .ConclusionsThe prevalence of FIV infection is South America has not been well evaluated and regional variations remain largely unexplored in domestic and wild cats.", [["FIV infection", "DISEASE", 230, 243], ["leopard cat", "ORGANISM", 15, 26], ["Felis bengalensis", "ORGANISM", 28, 45], ["domestic", "ORGANISM", 79, 87], ["cat virus", "ORGANISM", 88, 97], ["FIV", "ORGANISM", 107, 110], ["puma", "ORGANISM", 125, 129], ["cat FIV", "ORGANISM", 166, 173], ["puma FIV", "ORGANISM", 186, 194], ["FIV", "ORGANISM", 230, 233], ["cats", "ORGANISM", 360, 364], ["cat", "SPECIES", 23, 26], ["Felis bengalensis", "SPECIES", 28, 45], ["cat virus", "SPECIES", 88, 97], ["cat", "SPECIES", 166, 169], ["cats", "SPECIES", 360, 364], ["leopard cat", "SPECIES", 15, 26], ["Felis bengalensis", "SPECIES", 28, 45], ["domestic cat virus", "SPECIES", 79, 97], ["FIV", "SPECIES", 107, 110], ["domestic cat FIV", "SPECIES", 157, 173], ["puma FIV", "SPECIES", 186, 194], ["FIV", "SPECIES", 230, 233], ["a leopard cat (Felis bengalensis", "PROBLEM", 13, 45], ["a domestic cat virus", "TREATMENT", 77, 97], ["domestic cat FIV", "TREATMENT", 157, 173], ["FIV infection", "PROBLEM", 230, 243], ["infected", "OBSERVATION", 63, 71], ["FIV infection", "OBSERVATION", 230, 243]]], ["Considering that FIV has been detected in domestic cats in South America and that wild and domestic cats have overlapping territories in the communities and buffer zone, there is the potential for domestic felids to transmit this virus to naive wild felids in zoologic as well as free-range settings.", [["communities", "ANATOMY", 141, 152], ["FIV", "ORGANISM", 17, 20], ["cats", "ORGANISM", 51, 55], ["domestic cats", "ORGANISM", 91, 104], ["cats", "SPECIES", 51, 55], ["cats", "SPECIES", 100, 104], ["FIV", "SPECIES", 17, 20], ["domestic felids", "TREATMENT", 197, 212], ["this virus", "PROBLEM", 225, 235], ["FIV", "OBSERVATION", 17, 20]]], ["The isolation and molecular characterization of these pathogens, both in domestic and a variety of wild felines, would be helpful and may provide important baseline data to develop effective programs aimed at infectious disease prevention.", [["infectious disease", "DISEASE", 209, 227], ["The isolation", "TREATMENT", 0, 13], ["these pathogens", "PROBLEM", 48, 63], ["effective programs", "TREATMENT", 181, 199], ["infectious disease prevention", "TREATMENT", 209, 238], ["pathogens", "OBSERVATION", 54, 63]]], ["We believe that the feline population should be continually monitored for FIV infection and that clinical correlates to FIV infection should be further investigated.", [["FIV infection", "DISEASE", 74, 87], ["FIV infection", "DISEASE", 120, 133], ["feline", "ORGANISM", 20, 26], ["FIV", "ORGANISM", 74, 77], ["FIV", "ORGANISM", 120, 123], ["FIV", "SPECIES", 74, 77], ["FIV", "SPECIES", 120, 123], ["the feline population", "PROBLEM", 16, 37], ["FIV infection", "PROBLEM", 74, 87], ["FIV infection", "PROBLEM", 120, 133], ["infection", "OBSERVATION", 78, 87]]], ["As recently proposed [70] , researchers could consider early surveillance programs across defined populations and detailed, cohort studies of naturally infected animals to provide further insights.", [["cohort studies", "TEST", 124, 138], ["naturally infected animals", "PROBLEM", 142, 168]]], ["Such studies would provide an opportunity to track retrospectively the pattern and consequences of an ongoing epizootic.", [["Such studies", "TEST", 0, 12], ["an ongoing epizootic", "PROBLEM", 99, 119]]], ["There are technical reasons that hinder such studies, there is an urgent need for increased capacity in South American laboratories in order to conduct FIV screening and the apparent absence of FIV infection in some countries of the continent may merely reflect an absence of investigations.", [["FIV infection", "DISEASE", 194, 207], ["FIV", "ORGANISM", 152, 155], ["FIV", "ORGANISM", 194, 197], ["FIV", "SPECIES", 152, 155], ["FIV", "SPECIES", 194, 197], ["such studies", "TEST", 40, 52], ["increased capacity", "PROBLEM", 82, 100], ["FIV screening", "TEST", 152, 165], ["FIV infection", "PROBLEM", 194, 207], ["FIV", "OBSERVATION_MODIFIER", 194, 197], ["infection", "OBSERVATION", 198, 207]]], ["In addition, it is not easy to study FIV in wild cats as it is difficult to obtain samples from wild populations and only when these difficulties are overcome will it be possible to analyze and characterize FIV strains from the continent.", [["samples", "ANATOMY", 83, 90], ["FIV", "ORGANISM", 37, 40], ["cats", "ORGANISM", 49, 53], ["FIV", "ORGANISM", 207, 210], ["cats", "SPECIES", 49, 53], ["FIV", "SPECIES", 37, 40], ["FIV", "SPECIES", 207, 210], ["FIV strains", "PROBLEM", 207, 218]]]]}